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3Abstract
SCORE scale assesses the risk of fatal atherosclerotic cardiovascular disease (CVD),
based on traditional risk factor levels. The high-risk SCORE version is recommended
for Central & Eastern Europe/former Soviet Union (CEE/FSU). The aim of the thesis
was to evaluate SCORE performance in CEE/FSU, using evidence from two large
CEE/FSU studies.
These studies – MONICA and HAPIEE – include cohorts from CEE/FSU countries
which have relatively high but heterogeneous CVD mortality. MONICA subjects were
followed for 10 years from the mid-1980s. Ongoing HAPIEE follow-up (baseline
2002-2004) allowed preliminary assessment of SCORE performance in contemporary
CEE/FSU settings. The present study included Czech, Polish-Warsaw, Polish-
Tarnobrzeg, Lithuanian, and Russian MONICA samples (n=15,027), plus Czech,
Polish, and Russian HAPIEE samples (n=20,517). Predicted 10-year CVD mortality
was calculated with high-risk SCORE; observed mortality data came from local
registers.
While SCORE calibration was good in most MONICA samples (predicted to observed
(P/O) mortality ratios approached 1.0), mortality risk was under-estimated in Russian
men and women. In Cox regression analysis, SCORE 5% significantly predicted 10-
year CVD mortality: hazard ratios (HR) ranged from 1.7 to 6.3. The shorter HAPIEE
follow-up meant that P/O ratios exceeded 1.0. These ratios were 2-3 times higher in
Czech and Polish vs. Russian participants. Estimates of 10-year HAPIEE mortality
confirmed this gap between Czech and Polish vs. Russian samples. SCORE
significantly predicted CVD mortality in each HAPIEE sample (HR 2.6-10.5). Values
of Harrell’s C-statistic, a summary discrimination measure, reached 0.6-0.7 in
MONICA and HAPIEE. Adding socioeconomic parameters or alcohol consumption
characteristics to the SCORE model failed to improve its predictive performance.
High-risk SCORE discrimination was satisfactory in most MONICA and HAPIEE
samples, despite risk under-estimation in Russian MONICA. HAPIEE data suggest that
in contemporary Czech and Polish populations, high-risk SCORE might over-estimate
CVD risk. SCORE extension by additional predictors did not improve its performance.
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Chapter 1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality, morbidity, and
disability throughout the world.1-4 To prevent further increases in the CVD burden,
assessing present rates and monitoring population trends should be combined with
cardiovascular risk prediction and management, with a focus on individuals and groups
at higher risk, who are most likely to benefit from preventive measures.4-7 Multifactorial
concept of CVD infers that multiple risk factors should be considered in combination
when identifying individuals at increased total risk.8-16
There are numerous scores and algorithms to predict the future risk of cardiovascular
events in individuals who are currently free of clinical CVD. These scores are based on
established cardiovascular risk factors – core demographic (age and sex), behavioural
(smoking), physiological and clinical characteristics, such as blood pressure (BP), blood
lipids, and diabetes mellitus (DM). Multiple scales have been developed to predict
various fatal and/or non-fatal cardiovascular events over different time periods. All the
currently existing, prospective data-based risk scores have been derived from Western
European and North American cohorts, and differ by their prognostic accuracy when
applied to external populations.5;9;10;13;17;18
The best known and most widely used instruments are the Framingham risk model19 and
the SCORE (Systematic COronary Risk Evaluation) scale.20 The latter, based on
prospective data from 12 European cohorts, estimates 10-year risk of fatal CVD and
uses age, gender, blood lipids, BP, and smoking as risk predictors. SCORE exists in two
versions created specifically for high and low-risk countries of Europe. The European
Society of Cardiology (ESC) recommends applying the high-risk SCORE to all
populations of Central and Eastern Europe (CEE) and former Soviet Union (FSU),
although this version was derived without using any local data.
Of note, CEE/FSU countries have experienced a particularly heavy CVD burden, with
high rates of cardiovascular mortality and morbidity. While CVD mortality has declined
in most CEE states after the disintegration of the Soviet bloc in 1989, many FSU
countries continue to suffer from high rates of circulatory disease, and CVD remains an
important health problem throughout the region.21;22 Therefore, these populations
particularly need to have their cardiovascular risk assessed and managed by efficient,
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reliable, and relatively inexpensive tools, such as SCORE, which can be implemented in
healthcare systems with limited resources.17;23;24
However, the universal applicability of a single high-risk modification of SCORE to all
CEE/FSU populations appears questionable. It is not entirely clear how well SCORE
performs in CEE/FSU, since it has never been properly adjusted, or recalibrated, to
these populations. Importantly, CVD rates across CEE/FSU countries are
heterogeneous, with two to three-fold differences between areas with the highest and
lowest mortality, and it is possible that more than one risk score version is needed. As
classical risk factors only partly explain the differences in CVD rates between
populations, one would expect that the predictive ability of traditional risk determinants
captured by SCORE is also limited (for example, there may be over-estimation of risk
in countries with lower CVD rates, such as the Czech Republic and Poland, and risk
under-estimation in countries with higher rates, such as Russia). To my knowledge, no
prospective individual-level data have been used thus far to investigate the predictive
potential of SCORE in CEE/FSU settings.
In addition to and independently from risk factors included in existing, widely used
algorithms, such as Framingham or SCORE scales, numerous other parameters predict
cardiovascular risk. Recently, there have been ongoing attempts to improve the
performance of CVD scales by adding novel risk determinants, such as various
biological, genetic, or environmental characteristics (e.g.8;9;25-41). In the region of
interest, socioeconomic disadvantage and hazardous alcohol consumption appear to be
the most likely candidates for inclusion in the cardiovascular risk models, together with
conventional risk factors. These extended models might estimate CVD risk in CEE/FSU
populations more accurately than the original high-risk SCORE version.
Reflecting the current gaps in knowledge about CVD risk assessment in CEE/FSU, the
overall aim of this thesis is to assess the prognostic performance of the SCORE
instrument in the populations of interest. Specifically, it will examine (i) how reliably
SCORE predicts fatal cardiovascular events in CEE/FSU populations with different
levels of absolute risk (i.e. mortality levels); and (ii) whether inclusion of
socioeconomic parameters or alcohol consumption characteristics improves the
predictive performance of the SCORE instrument in these populations.
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This thesis uses individual-level data from four CEE/FSU countries: the Czech
Republic, Poland, Lithuania, and Russia. Although sharing some socioeconomic and
public health-related characteristics, these states are heterogeneous in terms of recent
CVD trends, socioeconomic trajectories, and alcohol consumption patterns. The data
come from two existing studies – MONICA and HAPIEE. The MONICA study
(MONitoring of trends and determinants in CArdiovascular disease) investigated the
dynamics of CVD rates and risk factors from the mid-1980s to at least the mid-1990s42,
while the ongoing HAPIEE (Health, Alcohol, and Psychosocial factors in Central and
Eastern Europe) project collects prospective data on cardiovascular outcomes.43 These
studies provide a unique opportunity to compare the predictive role of traditional,
SCORE-captured cardiovascular risk factors, as well as socioeconomic characteristics
and alcohol consumption parameters, across CEE/FSU populations and over time.
The thesis has been structured into ten chapters. Chapter 2 reviews the concept of total
cardiovascular risk prediction, the main characteristics of the existing risk scales, and
the major features of the CVD epidemic in CEE/FSU. The emphasis is on the widely
used SCORE model, as the instrument officially recommended for all European
countries, and on the SCORE applicability to CEE/FSU settings. The importance of
cardiovascular risk assessment in CEE/FSU populations facing high CVD rates, the
inadequate explanatory potential of classical risk determinants, and the role of other risk
predictors, such as socioeconomic parameters and alcohol consumption characteristics,
are also discussed. The research aims and objectives are presented in Chapter 3.
Chapter 4 describes the study methodology, including information about the study
population and samples, measurements of the main SCORE components and additional
risk determinants, and the overall strategy and specific steps of statistical analyses.
Chapters 5-9 present the study results. First, MONICA and HAPIEE samples are
described in terms of the levels of classical risk factors, additional risk determinants,
and atherosclerotic CVD mortality (Chapter 5). The prognostic performance of the
original, non-extended SCORE across MONICA and HAPIEE samples is then
evaluated (Chapter 6). Calibration and discrimination of the SCORE models extended
by additional risk determinants, namely socioeconomic characteristics or alcohol
consumption parameters, are also investigated (Chapters 7-8). Finally, the overall
strength of the association between SCORE and fatal CVD is assessed, employing the
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random effects meta-analysis technique for pooling the sample-specific effect estimates,
before and after adjustment for additional risk factors (Chapter 9).
In Chapter 10, the summary of the results is followed by a discussion of the
methodological limitations and strengths of the thesis. A critical review of the findings
and their comparison with the external evidence is also presented, focusing on the
predictive performance of the original SCORE and the cardiovascular risk models
extended by socioeconomic parameters or alcohol consumption characteristics. The
chapter then outlines the future directions of CVD risk assessment and reduction, such
as SCORE recalibration and further “evolution” as a prognostic model, the role of
socioeconomic measures and drinking parameters as CVD risk determinants, the
extension of risk models with novel predictors, and the importance of targeting lifestyle
risk factors for cardiovascular prevention. The research and policy implications,
together with the overall conclusions of the thesis, are presented in the final part of
Chapter 10.
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Chapter 2. Background
In this chapter, the concept of total cardiovascular risk assessment and the existing
instruments for cardiovascular risk prediction are reviewed, with an emphasis on the
SCORE model. The main features of CVD epidemic in CEE/FSU are described,
together with the importance and potential problems of total cardiovascular risk
evaluation in these populations. The predictive role of classical cardiovascular risk
factors, as well as non-conventional risk determinants, such as socioeconomic
characteristics and alcohol consumption parameters, is discussed. Finally, the possible
ways to optimise CVD risk prediction in CEE/FSU are considered.
2.1. Total cardiovascular risk assessment
In the following section, the current views on total CVD risk assessment are outlined,
including methodology and specific risk scales. Among numerous risk models, the
SCORE scale is described in more detail.
2.1.1. Total cardiovascular risk assessment: rationale, concept, benefits, and
methodology
Cardiovascular disease is a major public health problem and the leading cause of
mortality, morbidity, and disability throughout the world.1-4 The well-known Global
Burden of Disease project2 demonstrated that, in 2001, two major components of CVD,
coronary heart disease (CHD) and cerebrovascular disease, were, respectively, the first
and second leading causes of death. In combination, they were responsible for over 20%
of all deaths worldwide, where CHD accounted for 7.06 million lives lost, and
cerebrovascular disease claimed 5.39 million. Moreover, CHD and cerebrovascular
disease accounted, respectively, for 84.27 million and 72.02 million DALYs (disability-
adjusted life years) lost, and were, when combined, the primary cause of global disease
burden.
In Europe as a whole, CVD claims over 4.3 million lives every year, which is almost
one-half (48%) of all European deaths.22 Circulatory disease is the leading cause of
death among women in all European states and men in most European countries.
Specifically, CHD and stroke account for one half and one third of all CVD deaths, and
claim 1.92 and 1.24 million lives per year, respectively. In 2010, the latest year in the
WHO Health for All database with the all-European data available, age-standardised
death rates were 385.2 per 100,000 for CVD, 178.1 per 100,000 for CHD, and 102.2 per
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100,000 for cerebrovascular disease.21 Even though CVD incidence data for the entire
European region are unavailable, morbidity levels could be assessed indirectly, via
hospital discharge statistics. In 2010, the number of hospital discharges was as high as
2,505.0 per 100,000 for CVD, 800.5 per 100,000 for CHD and 441.9 per 100,000 for
cerebrovascular disease. Similar to other regions, in Europe CVD is not only the leading
cause of mortality and morbidity, but also the principal cause of years lost due to early
death. It is responsible for 23% (over 34 million) of DALYs lost annually.22
According to the WHO projections, the global death toll from non-communicable
causes, half of which will be related to CVD, might increase by 17% between 2006 and
2015.4 The global burden of CHD is expected to rise from approximately 47 million
DALYs in 1990 to 82 million in 2020, while the stroke burden is projected to increase
from 38 million to 61 million DALYs.3 The latest WHO estimates suggest that the
currently observed annual CVD mortality (approximately 17 million deaths in 2008)
will increase by 6 million in 2030.44
To prevent further increases in CVD mortality, morbidity, and disability, assessing
present rates and monitoring population trends should be combined with cardiovascular
risk prediction and management. Ideally, cardiovascular prevention should have
universal coverage, targeting whole populations as well as every individual, but in real-
world settings with limited healthcare resources, preventive measures need to be
focused on individuals and groups at higher risk, i.e. those most likely to benefit.5;6 This
targeted prevention approach aims to “save the greatest number of lives at lowest cost”.4
Therefore, over the last five decades, the general principles of total CVD risk
assessment have been developed, and numerous risk prediction instruments were
created. The former will be summarised in the rest of this section, while the latter will
be described in Sections 2.1.2 and 2.1.3.
The main principles of total CVD risk assessment were first formulated in the 1960-
1970s.45;46 Although these principles were introduced before obtaining the vast evidence
on strengths and benefits of total risk evaluation, they remain relevant half a century
later. Despite the tremendous progress of cardiology, epidemiology, and other
biomedical disciplines over the last decades, no single factor is yet known which would
either provide complete prevention from CVD, or inevitably lead to cardiovascular
pathology. In other words, no single factor can predict cardiovascular risk ideally.
Individual risk factors act as component causes, and clinical evidence shows that none
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of the currently known factors could qualify as a necessary component cause,
elimination of which would completely eradicate CVD. Multifactorial, or multicausal,
concept of CVD implies that various risk factors should be considered in combination
when identifying individuals at higher total risk.8-16 The exact impact of a specific risk
factor depends on the particular cardiovascular outcome of interest. However, these
factors are common enough, due to atherosclerosis parallelism in different vascular
territories, to create a single instrument assessing general CVD risk.47;48
The varied clinical course of CVD means that a substantial proportion of events are
registered in previously asymptomatic patients. This reflects a continuum of
cardiovascular risk in the population, with young, risk-free individuals and patients with
manifested CVD at the opposite ends of the spectrum, and people with predisposing risk
factors and asymptomatic atherosclerosis in the intermediate position.5;6 Therefore,
timely prevention and treatment implies identifying individuals at increased risk among
people currently free of symptomatic CVD and not receiving risk-lowering
interventions. Typically, risk prediction is based on combined levels of the core
demographic (age and sex), behavioural (smoking), physiological and clinical factors,
such as blood pressure (BP), blood lipids, and diabetes mellitus (DM). The same factors
also determine the level of total cardiovascular risk in patients with established and
symptomatic CVD, i.e. across the continuum of risk and atherosclerosis in the
population.5;17 According to the aims of the present research, its primary focus is
cardiovascular risk assessment in CVD-free individuals.
Cardiovascular risk factors are rarely observed in isolation. In fact, most people who
develop atherosclerotic CVD have several risk factors, which, when combined, produce
the total risk. In clinical practice, high cardiovascular risk more often results from a
combination of moderately elevated risk factors than from extremely high levels of
single factors. Moreover, the risk associated with any specific factor partly depends on
the amount of clustering.11;14;47;49 Even though the risk fraction attributable to a
particular factor may be of interest per se, the combined, total CVD risk appears to be
even more important, both clinically and epidemiologically.
The above-mentioned general principles of total cardiovascular risk assessment underlie
its multiple benefits. The main benefit is that risk groups are identified more effectively.
Under-treatment of high-risk people with multiple marginal risk factors is prevented,
and over-treatment of low-risk subjects with one isolated risk factor is avoided. In
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addition, as focusing on a single risk determinant would result in substantial over-
estimation of its population-attributable risk50, the multivariable approach also more
accurately evaluates population-level consequences of the risk factor distribution. As a
result, more efficient clinical decision-making allows a more targeted and cost-effective
allocation of limited healthcare resources, focusing on individuals and groups at the
highest risk.7;12;51;52 Moreover, since shared risk factors predict virtually all the
individual CVD outcomes, controlling these factors would prevent multiple outcomes,
although to a varying extent. For example, antihypertensive therapy not only reduces
BP, but also cuts the risks of CHD, stroke, and heart failure47;48, with the maximal
benefits among those at the highest baseline risk. Finally, more accurate prognostic
information improves risk communication and prevention/treatment compliance. Better
compliance, in turn, will further improve the effectiveness of cardiovascular risk-
reducing interventions.53;54
To utilise the above-mentioned benefits of total CVD risk assessment, the high accuracy
of risk scales is important. Otherwise, these instruments are no more efficient than
traditional, single risk factor-based approaches.14;55 The two main components of
predictive performance, namely calibration and discrimination, are briefly described
below (for details, see Section 4.5.3 in the Methods chapter).
The calibration ability of a risk score reflects how close predicted and observed risks
are, and is typically operationalized via the observed to predicted risk ratio, or via the
Hosmer-Lemeshow χ2 statistic.56-59 A model could be truly predictive only if
generalizable to external settings. Since CVD rates vary substantially across
populations60, any model will over- or under-predict risk in lower or higher-risk
populations, respectively.9;10;18;20 To some extent, the problem of generalizability could
be resolved by recalibration. Recalibration procedure adjusts existing scales to external
settings, by introducing population-specific event rates and risk factor means, while
keeping the original regression coefficients for risk factors.9;10 Relative risk estimates
are considered similar for both genders, across populations, and over time.20;23;61
Typically, the recalibrated models perform well in different populations (e.g.61-67; see
Section 2.1.3).
Another parameter of the model prognostic performance is discrimination – the ability
of a score to separate the participants who will experience events from those who will
remain event-free, over a defined time period.55;58;59;68 Threshold measures of
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discrimination include sensitivity (probability of high-risk score for people with
subsequent events), specificity (probability of low-risk score for people without
subsequent events), true to false positive ratio (likelihood ratio positive, LR+, or
sensitivity/1 - specificity), false to true negative ratio (likelihood ratio negative, LR-, or
(1-sensitivity)/specificity), positive predictive value (PPV, outcome probability in the
high-risk group), and negative predictive value (NPV, outcome probability in the low-
risk group). These measures are calculated for a certain cut-off point, which is typically
recommended as the drug treatment threshold in the clinical guidelines. However, these
threshold characteristics of discrimination are often inadequately described in the
recommendations and are assumed to be taken for granted by clinicians. Furthermore,
these thresholds differ between guidelines, are often selected arbitrarily, and fail to
reach a balance between sensitivity and specificity, which reflects the probability-based
nature of any risk scale. By contrast, summary discrimination measures are more useful
for comparing the overall predictive performance of different instruments, or for
assessing the impacts of different threshold values.58 An example of summary
discrimination measures is the area under the receiver operating characteristic
(AUROC) curve. This curve plots the proportion of true positives (sensitivity) versus
false positives (1 - specificity) across all risk thresholds. Therefore, AUROC, or the
Harrell’s C-statistic (AUROC equivalent for survival models), estimates the probability
that the scale assigns a higher risk to those developing the event than to those event-
free.10;58;69-71 A recently introduced discrimination measure for survival models is
Royston’s R2 index, which denotes the amount of the outcome variation accounted for
by risk predictors.72
Although the combination of traditional calibration and discrimination parameters
reflects statistical performance of the risk models better than either calibration or
discrimination alone, its usefulness for clinical decision making and, ultimately, for
clinical outcome improvement, is still limited.71;73 Moreover, the conventional
calibration and discrimination measures are relatively insensitive to adding new markers
to the model, unless independent, significant associations between new risk factors and
the outcome are exceptionally strong.39;71;74;75 Therefore, the use of novel model
performance measures was suggested for evaluating the new risk markers.34;39;68;71;76-79
The additional prognostic information, provided by extra risk predictors, could be
assessed by comparing the original and extended models and be operationalized via
25
such discrimination measures as likelihood ratio (LR) test p values and/or via risk
reclassification indices. In particular, Cook and colleagues proposed risk stratification
tables as a tool for assessing the benefit of adding a new marker to a pre-established set
of predictors.68;80;81 The risks calculated from models with and without the new
predictor are cross-tabulated, and the proportions of individuals stratified into high vs.
low-risk groups, or those in whom intervention is recommended or not, are presented.
The summary of the reclassification table is the net reclassification index (NRI), or the
net proportion of people who cross the risk threshold as a result of adding a new risk
predictor. In other words, it is the difference between the proportions of those moving
up and down the risk categories among people who develop events, plus the difference
between the proportions moving down and up among event-free participants.9;39;71;79
The NRI risk categories could be formed on clinically relevant thresholds. The
summary reclassification parameter – integrated discrimination improvement (IDI) – is
independent of risk thresholds and risk category numbers. IDI quantifies the separation
between the individuals who develop an event and those who do not, in terms of the
average predicted risks for these two groups, across all possible cut-offs. In other words,
IDI represents the extended model’s ability to improve average sensitivity without
affecting average specificity.39;71;79;82-85 Reclassification measures are considered the
most clinically relevant parameters of prognostic performance, since the adjustment of
risk levels, based on the additional risk determinants, could affect clinical decision
making, such as starting or withholding pharmacological treatment, and, hence,
influence clinical outcomes.70;73;84;86
Therefore, the heavy CVD burden is the main rationale for total cardiovascular risk
estimation. Assessing and controlling total risk levels could prevent future events more
effectively than a single risk factor approach. To achieve this aim, risk scales should
have adequate prognostic performance, i.e. acceptable calibration and discrimination.
The most widely used instruments for CVD risk prediction, including the SCORE scale
as the main risk algorithm of interest, will be described in the rest of Section 2.1.
2.1.2. Scales for predicting total cardiovascular risk
In the last 30 years, several instruments for total CVD risk assessment have been
developed. The characteristics of the most popular risk scales, including their predictive
performance, strengths and limitations, are discussed in this section. In particular, the
main features of the Framingham, PROCAM, ASSIGN, and QRISK/QRISK2 models
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are presented. The SCORE scale, officially recommended by the ESC for use in all
European populations, is the focus of Section 2.1.3.
Among the variety of currently available instruments for cardiovascular risk evaluation,
the oldest one is the Framingham risk function. The Framingham Heart Study (FHS),
which started in 1948, is an ongoing prospective, single-centre study of a community-
based adult cohort from Framingham, USA. The Framingham risk model, presented by
Anderson and colleagues in 199119, was derived from the 12-year follow-up of 5,573
FHS and Framingham Offspring Study participants – 30-74-year-old men and women,
free of CVD at baseline. The score estimated the five-year and 10-year risk of fatal and
non-fatal CHD, based on age, sex, levels of total cholesterol (TCH) and high-density
lipoprotein cholesterol (HDL-CH), systolic BP (SBP), current smoking, DM, and
electrocardiography signs of left ventricular hypertrophy. Absolute 10-year risk of
20% was recommended as an intervention threshold. A modification of this model
could be used to estimate the 4-12-year risk of six separate outcomes, namely
myocardial infarction (MI), CHD, CHD death, stroke, CVD, and CVD death87.
Wilson’s modification of the Framingham function is similar to that proposed by
Anderson and colleagues, but it uses TCH, low-density lipoprotein cholesterol (LDL-
CH), and SBP as categorical, rather than continuous variables.88
Later modifications of the Framingham risk function applied Cox proportional hazards
regression to the 12-year follow-up data on 8,491 Framingham study participants and
1,174 CVD events.48 The sex-specific risks of any first CVD event (CHD,
cerebrovascular or peripheral vascular disease, and heart failure) were predicted by age,
TCH, HDL-CH, SBP, treatment for AH, smoking, and DM. With simple adjustments,
the model could also be used for assessing the risks of each component of the general
CVD risk. Additionally, a total coronary risk score based only on non-laboratory
predictors was created. It included body mass index (BMI), instead of TCH and HDL-
CH, and performed reasonably well, when compared to the original risk function.48 The
recent version of the Framingham scale predicts 30-year risk of “hard” CVD (coronary
death, MI, or stroke), adjusting for competing risk of non-CVD death.89
The discriminative ability of Framingham models can be regarded as satisfactory. For
instance, the earliest Framingham risk score correctly identified 10% of the
asymptomatic population at the highest risk who accounted for approximately one-fifth
of CHD events and one-third of stroke and peripheral vascular events over the following
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eight years.90 The later models for coronary risk prediction demonstrated that in
Framingham men and women, AUROC was 0.76-0.79 and 0.79-0.83, respectively,
compared to 0.63-0.75 in men and 0.66-0.83 in women from six multi-ethnic American
studies.48;61 In non-American populations, the Framingham model discrimination was
also adequate. For example, in two German cohorts, namely MONICA Augsburg cohort
and PROCAM cohort, respective AUROC values were 0.78 and 0.73 for men and 0.88
and 0.77 for women.91 In Northern Irish and French men, the Framingham C-statistic
was 0.66 and 0.68, respectively92, while among the participants of the Chinese Multi-
provincial Cohort Study, it reached 0.71 for men and 0.74 for women.93
However, since the Framingham risk functions were developed in a white middle-class
sample, at the peak of CVD incidence in the USA, their generalizability was
problematic, especially for populations with lower background risk. Multiple studies
demonstrated that original, non-calibrated Framingham algorithms over-estimated
coronary risk not only in low-risk Mediterranean populations (e.g.62;94-96), but also in
Western and Northern Europe (for instance91;92;97-101), Native, Japanese or Hispanic
Americans61, and Asian populations93. A systematic review by Brindle and co-authors,
including 27 studies and 71,727 participants, demonstrated a substantial variability of
the original Framingham score calibration in different settings. Coronary risk was
under- or over-estimated in high and low-risk populations, respectively: predicted to
observed risk ratios varied from 0.43 to 2.87.18 Nonetheless, recalibrated Framingham
models typically performed well in different settings and populations
(e.g.23;61;62;65;93;94;102).
When used in European populations, the original Framingham model has been criticised
not only for risk over- or under-prediction, but also for its specific definitions of some
non-fatal end-points (incident effort angina and unstable angina), which were barely
applicable to other settings.20 These limitations stimulated the development of
alternative risk instruments, the most widely used of which are presented below.
The German PROCAM scale was derived from the PROspective CArdiovascular
Munster Study data (325 acute coronary events in 5,389 35-65-year-old men followed
for 10 years). This scale includes age, LDL-CH, HDL-CH, SBP, smoking, and DM, as
well as several additional risk factors, such as triglycerides and family history of
premature CHD. The instrument predicts 10-year probability of coronary death or first
MI in middle-aged men.103 The PROCAM scale showed good discrimination (AUROC
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0.82) and calibration (Hosmer-Lemeshow χ2 6.5) in the original dataset. However,
PROCAM demonstrated worse discrimination and inadequate calibration when applied
to external male populations. Among middle-aged men from Northern Ireland, France,
and England/Scotland, respective C-statistic values were 0.61, 0.64, and 0.63, and
predicted to observed event ratios were 1.78, 2.76, and 2.17.92;101 Another limitation of
the original PROCAM model is its impossibility to provide reliable coronary risk
predictions for women, since the proportion of women in the PROCAM cohort was
very low.
The Scottish ASSIGN score was derived from the Scottish Heart Health Extended
Cohort (SHHEC) study, with 6,540 men and 6,757 women, aged 30-74 years and free
from CVD at baseline, who were followed for fatal and non-fatal CVD over the next 10
years.104 ASSIGN includes not only conventional risk factors (sex, age, TCH, HDL-CH,
SBP, the number of cigarettes smoked daily, and DM), but also the area-based Scottish
Index of Multiple Deprivation (SIMD) and family history of premature CVD.
Demonstrating slightly better discrimination than the Framingham scale (respective
AUROC values were 0.73 vs. 0.72 for men, and 0.77 vs. 0.74 in women), the ASSIGN
score identified 20% of the population accounting for approximately 45% of CVD
events in the next 10 years. The ASSIGN predictions, lower on average than the
Framingham risk values, still over-estimated the risk, by 23% in men and 45% in
women. Despite its limited calibration potential, ASSIGN reflected the socioeconomic
gradient in CVD risk more effectively, compared to the Framingham score. This
approach, facilitating better fairness of cardiovascular risk evaluation and management,
will be discussed in more detail in Section 2.3.2.
The recently developed CVD risk instrument, QRISK, and its latest modification,
QRISK2, are based on the routinely collected data from contemporary UK general
practices, encompassing 2.3 million patients aged 35-74 years, over 16 million person-
years, and 140,000 incident CVD events.105 Risk factors included in the QRISK2 scale
are age, sex, ethnicity, TCH:HDL-CH ratio, SBP, smoking, BMI, family history of
premature CHD, Townsend deprivation score, treated AH, Type 2 DM, renal disease,
atrial fibrillation, and rheumatoid arthritis. Compared to the Framingham risk scale87,
QRISK2 demonstrated improved discrimination and calibration. Thus, out of the
112,156 patients classified as high-risk group (20% risk over 10 years) by the
Framingham score, 41.1% would be reclassified at low risk by QRISK2. Out of the
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78,024 patients classified at high risk by QRISK2 (20%), 15.3% would be categorised
into low-risk group by the Framingham score. Importantly, patients identified at high
risk by QRISK2 had higher observed rates of CVD events than patients classified as
high-risk by the Framingham scale. The AUROC values for QRISK2 were 0.79 in men
and 0.82 in women, compared to 0.78 and 0.80 for the Framingham scale.
The QRISK/QRISK2 instrument was also better calibrated than the Framingham model
and the ASSIGN scale. For instance, the predicted QRISK score was very close to the
observed risk in both male and female validation cohorts, while the Framingham score
was 47% and 18% higher than the actual risk in men and women, respectively, and
ASSIGN over-estimated the risk by 35% in men and 38% in women. Similarly, the
predicted to observed risk ratios were very close to 1.0 for the QRISK2 estimates, but
exceeded 1.0 (risk over-estimation) for the Framingham scale.105-107 In the independent
validation study, QRISK2 under-estimated the risk by 13% and 10% in male and female
UK patients from the THIN database (www.thin-uk.com), respectively, while the risk
over-prediction by the Framingham scale reached 32% and 10%. Moreover, AUROC
values were slightly higher for QRISK2 (0.76 in men and 0.78 in women) than for the
Framingham instrument (0.74 and 0.76, respectively).108 The latest QRISK modification
estimates lifetime risk of CVD, based on QRISK2 predictors and controlled for
competing risk of non-cardiovascular death.109
At present, the QRISK/QRISK2 instrument is the only risk scale developed using the
routinely collected data, which explains a greater size and lower selectivity of the
original sample. On the other hand, as the model validation was UK-based, involving a
one-third random sample of the original cohort and an alternative electronic primary
care practice system108, its international generalizability is unclear. Moreover, a
substantial amount of data was missing (for example, blood lipid measurements were
unavailable for 60-70% of the participants), and multiple imputation of the missing
values for TCH:HDL ratio, SBP, smoking, and BMI was performed. The risk
assessment validity and clinical decision potential of the data which were mostly
imputed, rather than recorded, might be regarded as questionable. The better
performance of QRISK/QRISK2, compared to that of the Framingham model, could be
partly explained by additional variables in the former scale (including a socioeconomic
parameter; for details, see Section 2.3.2). Other explanations may include the use of
data from contemporary UK populations, as well as the cohort-derived nature of the
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Framingham scale.110 Any instrument based on the data from treatment-naïve cohorts,
such as the Framingham score, will inevitably over-predict risk in the general
population, where treatment “contamination” effects are increasingly common.
However, this strength of the QRISK/QRISK2 also mirrors its limitation: this
population-derived instrument might inaccurately assess the risk in non-treated
individuals.
Less popular, but still worth mentioning are the scores such as PRECARD, derived
from the pooled Danish Glostrup Population Studies and the Copenhagen City Heart
Study data99;111, and FINRISK, based on the 10-year follow-up of the 1982 and 1987
cohorts from eastern and south-western Finland.112 Using the data from the UK Heart
Disease Prevention Project and the Scottish Heart Health Study, the Dundee risk
function measures modifiable coronary risk from TCH, BP, and smoking, by sex and
age.113 Based on the British Regional Heart Study (BRHS) results, the risk function by
Shaper and colleagues uses BP, smoking, self-reported CHD or DM, history of parental
death, and the presence of angina to predict the risk of acute MI or sudden ischemic
death in men only.114 The Reynolds score was developed using the follow-up data of
over 25,000 female American health professionals, to predict the 10-year composite risk
of MI, ischemic stroke, coronary revascularisation, and cardiovascular death, using age,
SBP, smoking, TCH, HDL-CH, high-sensitivity C-reactive protein (hsCRP), family
history of CVD, and glycated haemoglobin in diabetics.115 Later, an equivalent score
was developed for men.116 Most of these instruments performed adequately in the
original cohorts, but achieved relatively little international acceptance.
Therefore, numerous scores and algorithms have been developed for total
cardiovascular risk prediction in individuals currently free of manifested CVD, but
having various combinations of cardiovascular risk factors. Most of these scores are
based on traditional risk factors, such as age, gender, smoking, blood lipids, BP, and
DM. The risk assessment scales differ not only by risk determinants included in the
model, but also by outcomes and time-windows for predicted risk. All the currently
existing, prospective data-based scores have been derived from Western European and
North American populations, and vary by their discrimination and calibration ability
when applied externally. The SCORE model, created specifically for different types of
external populations and widely used across Europe, is described in the next section.
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2.1.3. SCORE model for fatal CVD risk assessment
The main reason for presenting the SCORE instrument in a separate section is its
advanced approach to generalizability of risk assessment functions, which resulted in
two versions of the original model. Moreover, SCORE is currently the risk scale
officially recommended by the European Society of Cardiology (ESC) for any European
country.17 This puts SCORE in a unique position of being the gold standard in
cardiovascular risk assessment for European populations and a current acme point in the
evolution of European clinical guidelines on CVD prevention.
Over the last few decades, separate guidelines on the management of specific risk
factors, such as AH or dyslipidemia, have been gradually replaced by more complex
cardiovascular prevention guidelines, incorporating various risk prediction scales.
Initially, European guidelines and recommendations on CVD/CHD prevention were
based on the Framingham risk model. In 1994, European recommendations presented
the Framingham risk function graphically, in a form of a Coronary Risk Chart – a table
containing absolute risk estimations for various levels of risk factors.117 In 1998, a
colourful version of these charts was introduced in the Joint European clinical
recommendations on CHD prevention.118 The current guidelines by the ESC and
collaborators contain the SCORE risk charts, based on the original European data from
the SCORE Project.17;119
Recommended for wide clinical use throughout Europe, these risk charts and the
underlying risk prediction algorithms are the main focus of Section 2.1.3. In particular,
after the general description of the SCORE scale, the evidence on calibration and
discrimination of the original, non-calibrated SCORE is presented. The limitations of
this instrument are summarised, and the prognostic performance of recalibrated SCORE
is described.
a) SCORE description
The SCORE (Systematic COronary Risk Evaluation) Project encompassed 12 European
cohorts with varying background risk, 205,178 individuals, over 2.7 million years of
follow-up, and 7,934 CVD deaths (including 5,652 CHD fatalities) as end-points.20 The
majority of SCORE cohorts were population-based; in addition, occupational cohorts
from France, Italy, and Spain were included to improve representation of low-risk
regions. To reflect different levels of background risk across Europe, two separate risk
charts were created – for high-risk countries, based on the data from Danish, Finnish,
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and Norwegian cohorts, and for low-risk countries, based on the cohorts from Belgium,
Italy, and Spain. These two charts predict the 10-year risk of fatal atherosclerotic CVD
in middle-aged people and include sex, smoking, SBP, and either TCH or TCH:HDL-
CH ratio (see Figure 2.1.1 for the SCORE chart recommended for high-risk countries).
Figure 2.1.1. SCORE chart: 10-year risk of fatal CVD in populations at high risk17;20
In the original Weibull risk model, age was defined as a hazard function, or a measure
of risk exposure time, rather than a risk factor in a traditional log-linear approach. As
the performance of the charts based on TCH and TCH:HDL-CH ratio is very similar
(concordance coefficients 0.99), they can be used interchangeably. People with pre-
existing atherosclerotic CVD are regarded as having increased risk, irrespective of their
risk factor levels. The SCORE model end-points include atherosclerotic cardiovascular
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fatal events (coronary and non-coronary), which better reflects the implications of total
CVD risk assessment at both individual and population levels. Non-coronary CVD
represents a substantial proportion of the total cardiovascular burden in the regions with
relatively low CHD rates; therefore, it is also included into the risk prediction algorithm.
The prognostic performance of the original SCORE instrument is discussed in the next
section.
b) Prognostic performance of original, non-calibrated SCORE
While no data on the SCORE calibration ability were presented in the original
publication, the discrimination potential of this scale in SCORE cohorts could be
regarded as satisfactory. Thus, the AUROC values in the SCORE Project cohorts not
used to derive the risk function were 0.70-0.72 and 0.71-0.84 for high and low-risk
cohorts, respectively.20 The SCORE threshold of 5% for fatal CVD risk over the next 10
years was associated with sensitivity of 59-83% and specificity of 46-73% in high-risk
cohorts, compared to 20-43% and 90-96%, respectively, in low-risk cohorts.
Although the prognostic performance of the original, non-calibrated SCORE was
satisfactory in the SCORE Project cohorts, it was not ideal in external populations. For
example, the performance of the non-calibrated high-risk SCORE instrument and the
Framingham scale was examined in the ethnically heterogeneous population of the
Newcastle Heart Project (684 South Asians and 825 Europeans), since South Asians
living in the UK are known to have a higher risk of CVD mortality than their peers of
European ethnicity. In all South Asian groups, the Framingham model mostly followed
the patterns expected from the national cause-specific mortality statistics for England
and Wales, while SCORE could under-predict CVD mortality risk by 17%, possibly due
to the non-inclusion of HDL-CH and DM as risk determinants.120 Both the Framingham
stroke model and the SCORE non-coronary CVD model predicted comparatively low
rates, in contrast to high national statistics-based figures: for instance, potential risk
under-prediction in South Asian men could reach 29% and 20%, respectively.
In the French virtual population, based on national demographic statistics and
representative observational studies (1,046,277 middle-aged men and women), the
baseline risk levels, assessed with the original low-risk SCORE version and the
Framingham scale, were compared to the cardiovascular mortality estimates from the
national vital statistics.121 As the individual-level record linkage was not performed, the
discrimination of CVD risk scales could not be evaluated. However, the indirect
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assessment of calibration showed that SCORE could slightly under-predict the risk (the
ratios of predicted to estimated risk were 0.94 in men and 0.85 in women), while the
Framingham scale might over-predict it (respective ratios were 1.48 and 1.27).
The performance of the non-calibrated low-risk SCORE model, the original
Framingham scale, and the local Framingham adaptation – REGICOR (REgistre GIroní
del COR) was investigated in the population of nine autonomous Spanish regions. The
study cohort included 5,732 35-74-year-old people, CVD-free at baseline and followed
for over five years.122 Sensitivity and specificity were similar for all risk scales, while
REGICOR demonstrated the highest PPV values. The percentage of participants
classified as high-risk was 7.5% for REGICOR (the closest to the observed CVD risk
level of 4.3%), compared to 16.6% and 8.4% for Framingham and SCORE scales,
respectively. However, as the 10-year mortality data were unavailable, it was not
possible to adequately assess SCORE calibration.
Among 40-65-year-old participants of the Austrian Vorarlberg Health Monitoring and
Promotion Programme (n=44,649), who were examined in 1985-1991 and followed for
10 years, the observed number of cardiovascular deaths was 371 in men and 116 in
women.123 The discriminative ability of the original low-risk SCORE was good and
similar in both genders (respective AUROC values 0.76 and 0.78). However, SCORE
over-predicted the risk in men (predicted to observed (P/O) risk ratio 1.20) and, to a
greater extent, in women (P/O ratio 1.91).
In Germany, the prognostic performance of the non-calibrated high and low-risk
SCORE versions and the Framingham scale were studied, using the nationally
representative data from the German National Health Interview and Examination
Survey 1998, as well as the national mortality statistics.124 In total, 1,811 men and 1,955
women, aged 30-69 years, with no previous history of CVD and no markedly elevated
levels of single risk factors, were included in the study. Since no follow-up data were
available for these participants, no direct calibration and/or discrimination assessment
was possible. However, the high-risk SCORE model could over-estimate CVD
mortality risk by 13% (87 events predicted vs. 77 estimated based on national mortality
statistics), while the Framingham and the low-risk SCORE scales might under-estimate
it by 20% and 39% (62 and 47 events predicted, respectively).
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Data from the prospective Reykjavik Study were used to investigate the SCORE
performance in Iceland – a country not included in the original SCORE database.63 In
the sample of 7,555 men and 8,277 women aged 36-64 years at baseline, median
observed 10-year risk of fatal CVD was 2.44% in men, compared to 1.97% and 3.93%
predicted by the low and high-risk SCORE, respectively; for women, these figures were
0.55%, 0.67%, and 1.14%, respectively. The discrimination ability of both SCORE
versions was adequate (AUROC 0.80). Therefore, despite the fact that the current
European recommendations on CVD prevention17 consider Iceland as a high-risk
country, the low-risk SCORE was better adjusted to Icelandic population, especially in
younger men and women of any age.
Both high and low-risk SCORE models were applied to the contemporary Norwegian
population – a nationally representative sample of 57,229 CVD-free individuals, aged
40-69 years at baseline (1985 and 1989). SCORE-predicted outcomes were compared to
the observed CVD mortality (718 and 226 observed cardiovascular deaths in men and
women, respectively).125 The high-risk SCORE calibration was rather modest, with
substantial risk over-prediction in Norwegian men of any age and older women.
Specifically, P/O ratios were 1.89, 1.89, and 2.22 in men aged 40-49, 50-59, and 60-69
years, respectively, and 1.67, 2.22, and 2.70 in women from the same age groups.
Discrimination of the high-risk SCORE was adequate, with AUROC values varying
from 0.65 to 0.72. However, these values were somewhat lower than those for the high-
risk cohorts in the original SCORE publication (0.70-0.72).20 The low-risk SCORE
function, even though officially not recommended for Norway17, was used as a
comparison and demonstrated better calibration: in the age groups of 40-49, 50-59, and
60-69 years, P/O ratios were 1.18, 1.09, and 1.27 for men and 1.12, 1.45, and 1.79 for
women, respectively, while the AUROC values were similar to the values for high-risk
SCORE and slightly lower than those for individual low-risk cohorts in the original
SCORE publication (0.71-0.84).20
The above-mentioned examples illustrate the restricted predictive ability of the non-
calibrated SCORE instrument across external populations. The underlying reasons for
this, as well as other SCORE limitations, are discussed below.
c) SCORE limitations
The limited prognostic performance of the original SCORE in external settings could be
explained by such factors as the variation of CVD risk between populations and over
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time; single assessment of risk factor levels resulting in regression dilution bias; and
real-world “contamination” of natural CVD clinical course, due to unaccounted risk-
reducing interventions such as antihypertensive therapy.58 Specifically, the so-called
background, baseline, or reference levels of cardiovascular risk, reflecting average
CVD-free survival, vary substantially across populations, due to their geographical,
cultural, social, behavioural, genetic, and other characteristics. This variation is only
partly explained by traditional risk factors included in the conventional risk models.126
In most industrialized countries, CVD and CHD incidence, mortality and case-fatality
have declined in the years following the SCORE data collection. As a result, SCORE
will be implicitly prone to risk over-estimation in contemporary settings.127;128 Since
both the scope and the speed of this decline are highly heterogeneous across countries
and regions (for details, see Section 2.2), using only two variants of the risk assessment
chart, which dichotomise Europe into “high” vs. “low” risk areas, might be inadequate.
The prevalence and distribution of classical risk factors also differ across populations,
explaining different absolute risks, despite similar relative risks, associated with a
specific factor.129-131 As risk factor levels in SCORE cohorts were measured only at
baseline, the regression dilution bias was introduced, resulting in the relative risk under-
estimation for factors with high intra-individual variability. For example, the magnitude
of this under-estimation for BP could be as large as one-third.132 Particularly inaccurate
prognosis is expected in individuals with extreme values of highly variable risk factors.
The SCORE investigators claimed that the impact of this potential bias was
“negligible”20, although did not provide any substantial evidence to support this
assumption.
Moreover, the SCORE chart does not include any indicator variables reflecting the
possible “contamination” of the natural, treatment-free clinical course of the disease by
various risk-reducing interventions, which are increasingly common in the real-world
clinical settings.133;134 For example, the benefits of antihypertensive therapy might go
far beyond BP reduction and not be fully reflected by the risk score. Ignoring this
contamination would over-estimate CVD risk when the SCORE instrument is applied to
general populations, rather than to “non-contaminated” cohorts.
In addition, due to the limited availability of international morbidity data and varying
definitions of non-fatal end-points, only fatal atherosclerotic CVD is regarded as an
outcome in the SCORE algorithm. Consequently, the substantial burden of
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cardiovascular morbidity and disability, experienced by individuals, populations,
healthcare services, and society in general, could be only indirectly assessed. Since
mortality risk is substantially lower than morbidity risk, this could also affect risk
communication between health professionals and patients.58
An extra SCORE limitation is its restricted age range (40-65 years), partly stemming
from the age limit compatibility of the original SCORE cohorts. From a clinical
perspective, the SCORE investigators’ assumption that “persons aged 30 are essentially
risk free within the next 10 years”20 seems rather unlikely, especially for the regions
where CVD is widely prevalent in younger age groups, such as many CEE/FSU
countries.22
The above-mentioned SCORE limitations affect the applicability of the non-calibrated
SCORE model to the contemporary external populations. For instance, Norway is
considered as one of the healthiest countries in the world. However, using the risk
threshold of 5%, including risk extrapolation to 60 years as recommended in the
European guidelines17, results in categorising a substantial proportion of Norwegians as
being at increased risk. Thus, among participants of the Nord-Tröndelag health study
1995-1997 (HUNT 2), medical treatment would be started in 22.5% of women and
85.9% of men aged 40 years. At 65 years, the respective figures would be as high as
84.0% and 91.6%, according to the Nordic Risk Group.135 Another research team also
demonstrated that the high-risk SCORE classifies a large proportion of asymptomatic
middle-aged and older Norwegians as having increased risk, which could lead to
unjustified medicalization of the general population.136 Of note, the SCORE Project
investigators themselves emphasised the absence of a single “perfect” level of absolute
risk that would define an optimal intervention threshold, regardless of the individual
characteristics.20
To overcome the problem of generalizability, common to both SCORE and other
existing cardiovascular risk charts, risk functions should be recalibrated, adapted and
updated, according to the contemporary local event rates and risk profiles. It is
particularly important when populations face rapid changes in CVD incidence, case
fatality, or risk factor distribution.58;137 The prognostic performance of recalibrated
SCORE in different populations is the focus of the following section.
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d) Prognostic performance of recalibrated SCORE
To facilitate the process of country-specific SCORE recalibration, the SCORE research
team initiated the HeartScore Project. HeartScore is an interactive web-based tool to
recalibrate the risk models and charts for individual countries, using current national
statistics on CVD mortality and risk factor distributions.11;138;139 Such country-specific
instruments have recently been developed for Cyprus, Germany, Greece, the
Netherlands, Spain, Sweden, and Switzerland, with recalibration in progress for several
other countries.
One of these recalibrated scales is SCORE-Germany, developed in 2005 and later
validated in two large population-based surveys: the Study of Health in Pomerania
(SHIP), Northeast Germany (n=1,956), and the Cooperative Health Research in the
Augsburg Region (KORA) study, South Germany (n=2,201).64 Among 40-65-year-old
CVD-free men and women examined in 1997-2001, the predicted 10-year risk of
cardiovascular death was compared to the risk extrapolated from the official CVD
mortality statistics. As individual-level data on observed CVD mortality were
unavailable, the direct assessment of SCORE calibration and discrimination was not
possible. Nonetheless, SCORE calibration was expected to be adequate: in accordance
with the estimated CVD rates, the model predicted higher risk in the SHIP cohort than
in the KORA cohort. The ratio of predicted to estimated mortality rates was close to 1.0
in both cohorts, although some potential risk over-prediction was registered in women.
In Switzerland, the predictive performance of the original low-risk and the country-
specific recalibrated SCORE was compared, using the data from a cross-sectional
population-based study of 5,773 men and women aged 35-74 years, together with the
national CVD mortality statistics for 2003.140 The original and recalibrated risk
functions classified 16.3% and 15.8% of men and 8.2% and 8.9% of women,
respectively, at increased risk. Both scales adequately estimated the number of CVD
deaths in 10 years: for men, 71 and 74 events were predicted by SCORE models,
compared to 73 events recorded in the national statistics data; for women, these figures
were 44 and 45 vs. 45, respectively. The recalibrated SCORE classified more women
and fewer men at increased risk than the original instrument, and also better estimated
risk in people aged over 65 years. Unfortunately, due to the cross-sectional nature of
this study, no prospective data were available for the direct assessment of SCORE
calibration and discrimination.
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By contrast, the performance of the Belgian SCORE version was assessed using
prospective individual-level data. Among 6,212 middle-aged men and women, CVD-
free at baseline (the early 1980s), 274 cardiovascular deaths were registered over 10
years. Good calibration ability of SCORE was confirmed by the P/O ratio of 0.96 and
the Hosmer-Lemeshow χ2 of 8.31. SCORE sensitivity, specificity, and Harrell’s C-
statistic were 77%, 72%, and 0.86, respectively, as an evidence of good
discrimination.66
Among 1,998 middle-aged Australians participating in the Blue Mountains Eye Study,
who were free from CVD or DM at baseline (1988) and developed 62 fatal CVD events
over the next 10 years, the recalibrated SCORE showed better prognostic performance,
compared to the original high and low-risk SCORE scales. Respective Hosmer-
Lemeshow χ2 values, reflecting the model’s calibration, were 2.32 vs. 32.78 and 4.40
for men and 7.43 vs. 27.25 and 12.92 for women.67 Discrimination of the local SCORE
was good and similar to that for the original high and low-risk instruments: C-statistic
values were 0.75-0.76 for men and 0.70-0.71 for women.
In the Netherlands, the predictive ability of the Framingham scale and the nationally
adapted SCORE instrument was compared for 39,719 20-59-year-old participants of the
Monitoring Project on Cardiovascular Disease Risk Factors (MP-CVDRF), who
developed 256 CVD deaths in 10 years.141 While the discriminative ability of both
models was adequate (AUROC 0.86 for Framingham and 0.85 for SCORE), their
calibration was poor, as the respective Hosmer-Lemeshow χ2 values were 64 and 35
(values under 20 are generally considered acceptable). Although the adapted SCORE
instrument was still better calibrated to the local settings than the non-calibrated
Framingham score, these findings suggest that the prognostic performance might be not
ideal even for recalibrated SCORE.
In the Dutch subsamples of the MP-CVDRF and MORGEN (Monitoring Project on
Chronic Disease Risk Factors) projects, 325 CVD deaths were observed among 32,885
37.5-62.5-year-old men and women over 10 years. Both locally adapted SCORE and the
original high-risk SCORE over-estimated the risk, while the low-risk SCORE version
demonstrated better calibration (respective P/O values 1.33, 1.85, and 0.90 in men, and
1.82, 1.79, and 1.05 in women).142 No findings on SCORE discrimination were
presented.
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Among 22,341 middle-aged men and women from North Sweden, who developed 229
fatal CVD events in 10 years following the baseline screening (1990-1994), the national
SCORE version demonstrated rather modest calibration, since it over-estimated the risk
of cardiovascular mortality (P/O ratio 1.57 for men and 1.55 for women); no data on
SCORE discrimination were reported.143 As the calibration of the original SCORE was
not analysed, it cannot be excluded that the local SCORE version still performed better
than the non-calibrated instrument.
Therefore, the above-cited evidence141-143 suggests that even for the locally adapted
SCORE versions, prognostic performance might decline over time. This re-emphasizes
the importance of SCORE recalibration as a continuous process of the model adjustment
to current event rates and risk factor levels.
To summarise, only two variants of the original SCORE scale may not fully reflect the
scope of background CVD risk and risk factor patterns in different European settings.
Up-to-date country-specific, recalibrated SCORE modifications typically predict risk
more accurately. Adequate risk assessment is particularly important for high-risk
populations, such as CEE/FSU countries. The problem of CVD burden and
cardiovascular risk prediction in CEE/FSU is discussed in the next section.
2.2. Cardiovascular disease in CEE/FSU
The current rates and time trends of CVD are summarised, using the data from the
European Health for All database and national studies. The role of traditional risk
factors as potential determinants of high CVD rates in CEE/FSU is examined. The
importance of cardiovascular risk prediction, the SCORE applicability to local settings,
and the opportunities for maximising its predictive potential are also discussed.
2.2.1. Cardiovascular mortality in CEE/FSU
The global burden of circulatory disease is not evenly distributed, and some countries,
such as CEE and FSU states, have experienced particularly high CVD rates. The main
focus of this section is on current rates and CVD trends across the CEE/FSU region, put
in the context by comparison with respective rates in Western Europe. Due to the
limited availability of the data on cardiovascular morbidity and disability for CEE/FSU,
the review will concentrate on fatal CVD rates in this region.
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Cardiovascular disease is considered the main determinant of the East-West life
expectancy gap: for example, in the mid-1990s, it accounted for over 50% of the six-
year difference in life expectancy between Eastern and Western Europe.144-146
Accordingly, the recent cross-sectional estimates of CVD mortality have demonstrated
the heterogeneity of Europe in terms of circulatory death rates. In particular, the Global
Burden of Disease 2000 and Comparative Risk Assessment studies showed that in 45-
59-year-old men from the CEE/FSU countries, the risk of cardiovascular death was
three to five times higher than in their peers from Western Europe. In women, relative
differences in fatal CVD were of similar magnitude.147
Analysing age-standardised national mortality rates for coronary and cerebrovascular
disease in 2000, Muller-Nordhorn and colleagues148 demonstrated the north-east to
south-west gradient in fatal CHD – in particular, the highest vs. lowest death rates in
CEE countries vs. France, Spain, or Portugal (Figure 2.2.1 shows the coronary
mortality rates in middle-aged men; the gradients for other age and gender groups were
similar).
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Figure 2.2.1. Age-standardised coronary mortality in European regions (45-74-year-old
men, 2000)148
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Cerebrovascular mortality was higher outside the “green” circle represented by Central
Western Europe – specifically, France, North Italy, and North Spain (Figure 2.2.2). The
cross-country patterns of coronary and cerebrovascular mortality were similar in both
genders. Therefore, men and women from the CEE region were at increased risk of not
only CHD, but also cerebrovascular death.148
Figure 2.2.2. Age-standardised cerebrovascular mortality in European regions (45-74-
year-old men, 2000)148
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In the late 2000s, according to the WHO statistics21, age-standardised CVD mortality
was the highest in the FSU republics, including Russia and Lithuania, lower in the non-
FSU countries such as the Czech Republic and Poland, and the lowest in the “old”
member states of the European Union (the members before May 2004, or EU-15), as
presented in Figure 2.2.3. The distribution of coronary and cerebrovascular mortality
across Europe (Figures 2.2.4 and 2.2.5, respectively) was similar to that for all
cardiovascular deaths. Even though CVD rates in the CEE/FSU region were generally
high, there were discrepancies between specific countries: for example, the relative
difference in cardiovascular mortality between Russia and Poland was two-fold. For
coronary and cerebrovascular mortality, the variation between CEE/FSU countries with
the highest and lowest rates was even greater, almost four-fold.
The rates of fatal circulatory disease are described in more detail for the Czech
Republic, Poland, Lithuania, and Russia, since this thesis is based on the existing
MONICA and HAPIEE studies. These international projects have collected the data on
CVD outcomes in Czech, Polish, Lithuanian, and Russian middle-aged population
samples.42;43 In particular, in 2009, the latest year for which official data are available,
age-standardised Czech and Polish CVD mortality rates (per 100,000) were similar,
being 1.4 times lower than the Lithuanian rates (357.0 and 356.3 vs. 496.8, respectively)
and 1.9 times lower than the Russian rates (683.0).21 To put the respective figures in the
context, they were 2.1, 2.0, 2.9, and 3.9 times higher than the rates in the “old” EU
states (Figure 2.2.3).
As shown in Figure 2.2.4, CHD mortality (per 100,000) in the Czech Republic (170.1)
was higher than in Poland (96.9), but still substantially lower than in Lithuania (305.1)
or Russia (351.7). Comparing these rates with coronary mortality in the EU-15 states
produced the 2.6, 1.5, 4.7, and 5.5-fold differences, respectively. In other words, the
coronary mortality gap between selected CEE/FSU countries and the EU-15 members
was generally larger than that for fatal CVD. In regard to cerebrovascular mortality,
Czech and Polish rates (79.1 and 72.4 per 100,000, respectively) were approximately
two-thirds and one-third of the corresponding Lithuanian and Russian figures (119.5
and 220.7 per 100,000, respectively). The rates of fatal cerebrovascular disease also
demonstrated marked differences between the CEE/FSU countries of interest and EU-
15: the respective gaps were 2.0, 1.8, 3.0, and 5.5-fold (Figure 2.2.5).
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Figure 2.2.3. Age-standardised CVD mortality across Europe (both genders, all ages
per 100,000; 2009 or latest available year)21
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Figure 2.2.4. Age-standardised CHD mortality across Europe (both genders, all ages
per 100,000; 2009 or latest available year)21
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Figure 2.2.5. Age-standardised cerebrovascular mortality across Europe (both genders, all
ages per 100,000; 2009 or latest available year)21
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Thus, the cross-sectional mortality estimates showed high, but not uniform rates of fatal
cardiovascular, coronary, and cerebrovascular disease across the CEE/FSU region. The
differences in CVD rates appeared relatively small between the non-FSU countries, but
were two to three-fold between former republics of the Soviet Union and non-FSU
states. These cross-sectional estimates are consistent with the recent time trends in
CVD, which are described below.
For specific countries of the CEE/FSU region, statistics on cardiovascular mortality has
been systematically collected from the 1950s, when fatal CVD rates were relatively
similar in CEE/FSU and Western populations. In the 1960-1970s, while cardiovascular
mortality in Western Europe remained stable or gradually declined, it approximately
doubled in CEE/FSU.149-153 According to the WHO statistics, the majority of CEE/FSU
countries demonstrated stagnation in cardiovascular mortality over the late 1970-1980s,
its gradual decline starting in the early to mid-1990s, and later divergence of
cardiovascular death rates. By contrast, CVD mortality in most Western European
countries – the EU-15 members – has been continuously declining over the last four-
five decades.21
The post-1989 heterogeneity of fatal CVD trends in CEE/FSU was mostly due to a
dramatic mortality increase in the former Soviet republics and a gradual mortality
decline in non-FSU states (e.g.144;149-151;154-157). For example, in the 1990s, coronary
mortality decreased by 40% in the Czech Republic and by 30% in Poland149, while this
decrease was less pronounced in Lithuania, and Russia did not achieve any substantial
reduction in CHD death rates.22 The trends in total cardiovascular, coronary, and
cerebrovascular mortality in these four countries could exemplify the general changes in
CVD rates across the CEE/FSU region.
In particular, according to the European Health for All database, CVD mortality in the
Czech Republic and Poland stagnated from the 1970s to the late 1980s and then
declined, particularly rapidly in the Czech population.21 Lithuanian trends in fatal CVD
were similar, although the mortality decline has decelerated since the early 2000s. In
Russia, a gradual increase in the early 1980s and a small decline in 1985-1987 were
followed by two peaks in the mid- and late 1990s, with some decrease in 1995-1997,
and a tendency towards a slow reduction starting from 2004. To compare, the EU-15
countries faced a steady decline in CVD mortality over the past 40 years (Figure 2.2.6).
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Similar trajectories were observed for coronary and cerebrovascular mortality (Figures
2.2.7-2.2.8).
Specifically, Czech and Polish rates of CHD and stroke death were relatively stable in
the 1970-1980s and then decreased – relatively fast and starting in the early 1990s in the
Czech Republic, slowly and starting from the late 1990s in Poland. An increase in
Polish rates of fatal CHD and stroke in the late 1990s, without a simultaneous elevation
in total CVD mortality, could be explained by the introduction of ICD (International
Classification of Disease) 10 in 1997.158 In Russia, some mortality decline in the late
1980s and early 1990s was followed by a sharp increase in the mid-1990s, a brief and
less pronounced reduction, and then another increase from the late 1990s to 2003. In
2004-2009, Russian coronary and cerebrovascular mortality levels remained high,
despite some decline. In Lithuania, CHD trends were closer to Russian ones, while
cerebrovascular mortality trajectories were similar to that in the Czech Republic and
Poland. By comparison, a continuous decline in fatal CHD and stroke was observed for
the EU-15 countries over the past four decades.
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Figure 2.2.6. Trends in age-standardised CVD mortality across Europe (both genders, all ages per 100,000; 1970-2009)21
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Figure 2.2.7. Trends in age-standardised CHD mortality across Europe (both genders, all ages per 100,000; 1970-2009)21
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Figure 2.2.8. Trends in age-standardised cerebrovascular mortality across Europe (both genders, all ages per 100,000; 1970-2009)21
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While several studies have investigated the recent dynamics of cardiovascular mortality
in the Czech Republic159-161, Poland162;163, and Lithuania164, the particularly dramatic
CVD mortality fluctuations in Russia have been addressed in more detail. Thus, Leon
and colleagues demonstrated that between 1984 and 1987, cardiovascular mortality in
20-69-year-old Russian men and women decreased, respectively, by 1,015 and 494 per
1,000,000.165 On the contrary, from 1987 to 1994, CVD mortality increased by 3,149
per 1,000,000 in men and by 1,314 per 1,000,000 in women. Even though absolute
differences in fatal CVD were greater in men, relative changes were of similar
magnitude in men and women, with the 1984-1987 decrease of 9% and 7% and the
1987-1994 increase of 29% and 17%, respectively. Changes in fatal CHD and stroke
rates, even though not presented in detail, followed the general pattern for
cardiovascular mortality.
Similar results for the period between 1990 and 1994 were obtained by Notzon and
colleagues, who additionally put the data in an international context. In particular, using
Russian national statistics for 1990-1994, the authors showed that increasing CVD
mortality accounted for 33.4% and 41.6% of the life expectancy decline in men (-6.1
years in total) and women (-3.2 years in total), respectively.166 Between 1990 and 1994,
mortality from heart disease rose by 31% in Russian men and by 17% in Russian
women. Over the same period, fatal heart disease rates in U.S. men and women
decreased by 8% and 6%. As a result, the ratio between heart disease mortality in
Russia vs. the USA rose from 1.4 to 2.0 in men, and from 1.3 to 1.7 in women.
Similarly, cerebrovascular mortality rose by 24% among Russian men and by 17% in
Russian women, while in their American peers, it decreased by 4%. The between-
country ratio for male and female cerebrovascular mortality increased, respectively,
from 5.3 to 6.8 and from 4.7 to 5.7.
In accordance with the above-cited studies, Shkolnikov and co-authors showed an
increase in adult Russian cardiovascular mortality between 1991 (the year of the Soviet
Union’s break-up) and 1994 (the year of minimal life expectancy). There was some
improvement from 1994 to 1998 (the year with the then-latest mortality data available),
even though the 1998 death rates remained higher than the 1991 levels.167 For instance,
CVD mortality rate ratios for 1994/1991, 1998/1994, and 1998/1991 reached,
respectively, 1.5, 0.8, and 1.2 in 15-74-year-old men, and 1.4, 0.8, and 1.2 in women of
the same age. The above-mentioned tendency of greater absolute differences in males,
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but similar relative changes in both genders was also observed for coronary and
cerebrovascular mortality.
Analysing more extensive national statistics data for 1991-2001, Men and colleagues
also demonstrated that in seven Russian regions, cardiovascular mortality was already
high in 1991 and rose further over the next 10 years, with a particularly sharp increase
after the 1998 economic crisis.168 For instance, in 35-69-year-olds, CVD mortality in
2001 was 24% higher for men and 18% higher for women than in 1998, while in 1994-
1998 fatal CVD rates decreased by 22-23%. The 1998-2001 increase in CHD mortality
was slightly smaller than the 1994-1998 decline: +21% vs. -26% in men, and +19% vs.
-27% in women. The increase in cerebrovascular mortality during 1998-2001 was
similar to the 1994-1998 drop for men (15-17%) and women (10-13%). A later analysis
of the national statistics data by the same research group demonstrated that in 35-60-
year-old Russian men, the rates of fatal CVD and CHD continued to increase from 2001
to 2003, remained relatively stable in 2003-2005, and in 2006 decreased to the level of
2003.169 Thus far, no studies extensively analysing the post-2006 CVD trends, based on
the Russian national data, have been published, to the best of my knowledge.
Importantly, the CEE/FSU region not only demonstrates high current CVD rates, but is
also expected to face an increasing CVD burden in the future. For instance, according to
the WHO estimates for 2020, coronary mortality in men and women from former
socialist economies, represented mostly by CEE/FSU countries, would increase to
712,000 and 702,000 deaths per year, respectively – by 52% and 26%, compared to the
1990 levels. An increase in cerebrovascular mortality is expected to be as large as 52%
in men (up to 364,000 deaths per year) and 24% in women (495,000 deaths per year).1
However considerable, these estimates could be regarded as conservative: they are
based only on expected population shifts (specifically, ageing) and do not take into
account potentially increasing risk factor levels in former socialist economies.
Therefore, not only are CVD rates in CEE/FSU higher than in EU-15, but there is also
marked heterogeneity in cardiovascular mortality across the CEE/FSU region. Although
circulatory death rates declined in most CEE populations since 1989, the FSU countries
still suffer from high CVD mortality. The extent to which the high rates of fatal CVD in
CEE/FSU are explained by conventional risk factors is discussed in the following
section.
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2.2.2. Traditional cardiovascular risk factors and fatal CVD in CEE/FSU
The simplest explanation of high CVD rates in the CEE/FSU populations would be a
higher prevalence of conventional cardiovascular risk factors. Classical risk factors are
considered as the principal determinants of total CVD risk and, hence, remain the basis
of the currently used scales and algorithms for cardiovascular risk assessment.
However, CVD has multicausal aetiology, and as yet, there is no single risk factor
acting as a necessary cause of circulatory disease (Section 2.1.1). Given the increasingly
large number of new factors that have been independently related to elevated
cardiovascular risk, it is possible that the role of traditional risk determinants, as the
explanation of high CVD mortality in CEE/FSU, is important, but not exclusive.
One of the best-known international epidemiological projects which allow the
comparison of conventional cardiovascular risk factors and CVD mortality across
populations is the WHO MONICA (MONitoring of trends and determinants in
CArdiovascular disease) initiative. In particular, this project monitored CVD events and
traditional risk factors in 38 middle-aged populations (men and women aged 35-64
years). In Europe, 29 populations from 16 countries were included in the project.42;130
Even though the MONICA follow-up took place from the mid-1980s to the mid-1990s,
this study remains one of the largest all-European sources of individual-level data on
CVD and cardiovascular risk factors.
In agreement with the WHO statistics presented in Section 2.2.1, the cross-sectional
MONICA data from the mid-1980s demonstrated that CVD rates in CEE/FSU countries
were higher than in Western Europe even before the collapse of the Soviet bloc. The
national age-standardized CVD and stroke mortality rates in 15 “communist” countries
participating in MONICA (including the Czech Republic, Poland, Lithuania, and
Russia) were on average twice as high as those in 25 “non-communist” countries.170
Although, in general, cardiovascular risk factors were more prevalent in Central/Eastern
European and Siberian centres, the East-West divide for these factors was less obvious
than for CVD rates. For example, while “communist” populations had a significantly
higher prevalence of AH and male smoking, the prevalence of hypercholesterolemia
was lower than in non-communist populations. A later ecological analysis demonstrated
that cross-sectional MONICA estimates of traditional risk factors (TCH, BP, and
smoking) inadequately reflected the between-population variation in cardiovascular,
coronary, and stroke mortality.126 Specifically, in men, these risk factors explained over
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39% of the stroke mortality variance, but less than 25% of the variance in fatal CVD
and CHD. In women, over 33% of the cardiovascular and stroke mortality variance was
explained by classical risk factors, while for coronary deaths this percentage was only
14%.
Using later MONICA data from the early 1990s, Bobak and Marmot showed that
contemporary levels of traditional cardiovascular risk factors explained 30% and 45%
of coronary mortality variation in men and women, respectively.149 These percentages
were higher than those obtained by Stewart and colleagues126, but still demonstrated that
over a half of between-population variation in fatal CHD remained unexplained by
conventional risk determinants. Similarly, the East-West differences in coronary
mortality were to some extent due to classical risk factors, but not explained away by
them. For instance, the age-adjusted rates of CHD mortality in Eastern European men
were 81% higher than in their Western peers; after adjustment for conventional
cardiovascular risk factors, this percentage reduced to 42%. For females, the respective
figures were 70% and 47%.
Importantly, the MONICA Project not only analysed cross-sectional data, but also
compared the international trends in CVD and cardiovascular risk factors over time. It
was shown that in populations with declining CHD mortality, two thirds and one third
of this decline were explained, respectively, by coronary event rates and case fatality.127
In turn, population-level trends in coronary event rates were partly explained by the
changes in conventional risk factors – by approximately 40% in men and 15% in
women.130 However, for the CEE/FSU populations, the risk factor trends did not fully
account for coronary mortality changes from the mid-1980s to the mid-1990s. In
general, the strength of the association between risk factors and mortality dynamics
depended on the selected statistical model, age group, and “exposure-disease” time
lag.130 Additionally, due to the ecological nature of data analysis, this association could
be confounded by various non-measured covariates, which were linked to both classical
risk factors and CHD. Precise estimation of the magnitude and direction of this complex
confounding effect is problematic, due to the understandably limited number of
potential confounders measured in MONICA populations.
The MONICA findings were confirmed in later studies from the CEE/FSU region,
focusing on the further follow-up of pre-established MONICA or other cohorts.
Specifically, in middle-aged men from Prague, followed for 20 years, CVD mortality
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was largely explained by AH, high TCH, and smoking.171 A marked decline in CHD
and stroke mortality in the Czech population over the period from 1985 to 2007-2008
was linked to a significant reduction in population levels of SBP and TCH, although the
magnitude of this impact was not reported.159;160 In Warsaw MONICA participants,
followed from 1984 for 10 years, the decline in fatal CVD by 25% in men and 33% in
women was mostly explained by reduced mean SBP levels and smoking prevalence.172
In Polish adult population, aged 25-74 years, CHD mortality halved from 1991 to 2005,
which was partly (54%) due to beneficial changes in classical risk factors, such as TCH,
SBP, and smoking.158 In general, it has been shown that traditional cardiovascular risk
factors demonstrate similar relative risks in CEE/FSU and Western populations.
Therefore, the evidence from local studies (predominantly from MONICA) is consistent
with the important role of classical risk factors in CVD and CHD mortality variation
and trends. However substantial, this impact is not exclusive; other, non-conventional
determinants of cardiovascular risk, described in more detail in Section 2.3, may also
play a role. Despite their limitations, classical risk factors remain the major risk
determinants incorporated in all CVD risk scales, including SCORE. The high-risk
SCORE version is officially recommended for CEE/FSU17, and its applicability to local
settings is discussed below.
2.2.3. SCORE applicability to CEE/FSU populations
The paradigm of total CVD risk assessment implies that the benefits of risk-lowering
interventions are the greatest in individuals, groups, and populations at the highest
background risk. This approach is particularly relevant to post-transitional CEE/FSU
countries, which face high and often increasing rates of CVD.22;173 These populations
particularly need to have their cardiovascular risk assessed and managed by efficient,
reliable, and inexpensive tools, which can be readily and easily implemented in
healthcare systems with limited resources.17;23;24 The scope of the CVD problem is too
substantial in CEE/FSU countries to postpone proactive risk assessment. For this
reason, the existing instruments, although not validated against country-specific risk
functions, are widely used – specifically, the high-risk SCORE model, recommended by
the ESC guidelines on CVD prevention.17 The SCORE strengths, limitations, and
potential ways to improve its performance in the CEE/FSU settings are outlined below.
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The obvious strength of the SCORE scale when applied to CEE/FSU populations is its
limited number of easily measured risk factors. All SCORE risk determinants are either
basic demographic characteristics (such as age and gender), or routinely measured
clinical parameters (BP, blood lipids, and self-reported smoking status). Therefore, no
additional resources are required for the total cardiovascular risk assessment with the
SCORE instrument. However, this parsimony and closeness to the real-world clinical
settings, together with the official endorsement of the SCORE use throughout Europe
by the ESC and national societies, should not mask a number of important SCORE
limitations.
The principal limitation is directly linked to SCORE simplicity: while classical risk
factors are important in cardiovascular risk prediction, they cannot explain this risk
completely (Section 2.2.2). Additionally, as mentioned in Section 2.2.1, CVD rates and
trends in the CEE/FSU region are heterogeneous. Nonetheless, according to the ESC
guidelines on CVD prevention, all CEE/FSU states, including the Czech Republic,
Poland, Lithuania, and Russia, are regarded as “high-risk” countries, without any further
differentiation.17 At the same time, only one Russian male cohort was included in the
original SCORE database.174 These data were obtained in the Soviet era, before the
dramatic changes in CVD mortality took place in the region. In the populations used for
the development of the high-risk SCORE version (Denmark, Finland, and Norway; no
CEE/FSU countries), the data were collected from the late 1970s to the early 1990s.20
Since then, CVD mortality has declined in some CEE/FSU countries, such as the Czech
Republic and Poland, and increased in the others, such as Russia, with particularly
striking fluctuations during the last three decades.
The risk estimates from the cohort studies which started more than 30 years ago are
likely to over-predict cardiovascular risk in some CEE/FSU states (such as the Czech
Republic and Poland) and under-predict it elsewhere (for example, Russia), since
contemporary Czech and Polish CVD mortality is lower and contemporary Russian
CVD mortality is higher than cardiovascular death rates in Scandinavian countries in the
late 1970s to the early 1990s.20;21 This could cause unnecessary medicalization of low-
risk individuals, as well as insufficient intervention for higher-risk people. Both
scenarios would result in human and economic losses and could further increase the
burden on the already struggling healthcare systems of CEE/FSU countries.
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As outlined in Section 2.1.3, adjusting, or recalibrating, the original SCORE scale for
specific countries makes the processes of risk prediction, reduction, and communication
more efficient. This approach is particularly relevant to CEE/FSU, due to its heavy
CVD burden. Recently, the country-specific SCORE models have been introduced in
the Czech Republic175 and Poland176, while in Lithuania and Russia, a non-specific
high-risk SCORE chart is widely used. To date, the Czech and Polish SCORE scales
lack a detailed description of recalibration procedure and/or comparison of their
predictive accuracy with the original instrument. Considering the above-mentioned
limitations of the non-calibrated SCORE, its performance might be far from ideal when
applied to CEE/FSU populations.
The nationally representative, updated information on event rates and risk factor
patterns, necessary for a proper SCORE recalibration, is not systematically collected in
CEE/FSU, since the coverage and the linkage between routine systems of health-related
and demographic data collection are inadequate.146 The approach based on the national
statistics, however attractive, cannot currently substitute for individual-level data
collection in cohort studies. Thus far, prospective individual-level studies, which could
form an evidence base for assessing the prognostic performance and potentially
recalibrating the existing CVD risk scales, have mostly been conducted outside
CEE/FSU. This enhances the importance of relevant local epidemiological projects in
CEE/FSU countries. In particular, MONICA and HAPIEE are among the largest
international studies on cardiovascular health and CVD in the region of interest. The
MONICA study investigated the dynamics of CVD and CHD rates and risk factors from
the mid-1980s to the mid-1990s42, while the ongoing HAPIEE (Health, Alcohol, and
Psychosocial factors in Eastern Europe) project collects prospective data on
cardiovascular outcomes, starting from the early 2000s.43 The MONICA and HAPIEE
studies provide an opportunity to investigate the impact of classical and non-
conventional risk factors on fatal CVD and to assess the predictive performance of the
original and extended SCORE models in CEE/FSU populations.
In summary, the high-risk SCORE scale is based on routinely measured classical risk
factors, and is easy to use in CEE/FSU. However, it has not been properly assessed
and/or recalibrated in these countries, and heterogeneous CVD mortality in the region
suggests that several variants of the high-risk SCORE might be necessary. In addition,
the prognostic potential of the classical risk factors included in SCORE is limited.
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Adding non-conventional risk factors to the model could improve the accuracy of total
CVD risk prediction, which is the focus of the next section.
2.3. Additional risk factors and cardiovascular risk prediction
As outlined in Section 2.2, however important the classical risk determinants are in
predicting total cardiovascular risk, they do not explain it completely. Therefore,
recently, there have been ongoing attempts to improve the performance of CVD scales
by including new, non-traditional risk factors, such as various biological, genetic, or
environmental characteristics (e.g.25-38). In CEE/FSU, socioeconomic disadvantage and
hazardous alcohol consumption appear to be the most likely candidates for inclusion in
the cardiovascular risk models, together with classical risk factors. The role of these two
additional factors in total CVD risk assessment will be discussed in more detail.
2.3.1. New risk factors as potential cardiovascular risk determinants
There is a general agreement that adding new variables could improve predictive ability
of multivariable risk functions by identifying more people with very high or very low
risk.15;32-34;86;177 However, numerous novel risk factors are not included in the two
principal CVD risk scales – the Framingham and SCORE instruments. These algorithms
do not take into account such factors as socioeconomic parameters, ethnicity, family
history of premature CVD, psychological stress, renal disease and microalbuminuria,
alcohol consumption, low physical activity, obesity, metabolic syndrome, insulin
resistance, triglycerides, fibrinogen, homocysteine, inflammation markers, and other
risk determinants.39;40;47;51 The limited number of risk factors included in the existing
risk assessment models, however artificial, reflects the essential feasibility issues.
Additional risk factors often improve predictive performance at the cost of extra
resources necessary for their measurement. Clinical acceptability, applicability, and
relevance for population screening programs are questionable for more extensive risk
scales. The large number of risk predictors in a model also complicates the creation of
visually displayable risk charts. Additionally, the models including new CVD risk
determinants often fail to demonstrate a substantial improvement in the traditional
measures of prognostic performance.8;40;86
In particular, there is limited potential for further improving the prognostic accuracy by
adding more predictors to the model. For example, out of 57 variables investigated in
the PROCAM study, eight were finally included in the eponymous risk scale.103
Nonetheless, when the PROCAM performance was assessed in the prospective PRIME
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study (Prospective Epidemiological Study of Myocardial Infarction), both the more
parsimonious Framingham model and the more extended PROCAM instrument
demonstrated substantial risk over-estimation in high and low-risk cohorts from
Northern Ireland and France, respectively.92 Recently, numerous studies on both
primary and secondary prevention have shown that adding new biomarkers (such as C-
reactive protein, N-terminal pro-brain natriuretic peptide, aldosterone, renin, insulin-like
growth factor-1, fibrinogen, D-dimer, plasminogen activator inhibitor-1, homocysteine,
lipoprotein-associated phospholipase A2, cystatin C, microalbuminuria, brachial flow-
mediated vasodilation, and ankle-brachial index) or genetic polymorphisms (for
example, for interleukin 18 or thrombomodulin), which are independent CVD
predictors, on the top of conventional risk factors does not markedly improve the model
performance (for instance27;30;31;33;34;37;38;40;75;178-186).
The problem of limited additional prognostic value is relevant for any new factors, since
most of them correlate with standard risk determinants, and are less prevalent in the
population than classical risk predictors.30;74;75;80;187 Age is the strongest predictor of
cardiovascular risk, which outweighs all the additional risk determinants in the
multivariable risk assessment.5;8;20;80;188 The nature of the most statistical models for
multivariable risk prediction implies that once a set of “core” variables (such as age) is
entered, AUROC or C-statistic, as measures of model discrimination, improve only
modestly when other statistically significant predictors are added (for definitions and
measures of model calibration and discrimination, see Section 2.1.1; for more detailed
description, see Methods, Section 4.5.3). Perfectly calibrated models of 10-year CVD
risk demonstrate the maximal AUROC/C-statistic of 0.75-0.90 when applied to
population-based cohorts.80 This measure is also limited by competing risks and
regression dilution bias, common to prospective studies.8 However, unchanged
discrimination could be matched with improved model calibration187, particularly in
those with intermediate risk, as demonstrated in the Women’s Health Study.81;115
Moreover, extended risk model could correctly reclassify substantial proportions of
individuals into different risk categories: for example, people with the traditionally
measured risk below the intervention threshold may be reclassified by the extended
scale into the higher-risk group and, hence, be administered a risk-reducing
intervention8;31;39;40;68;86;188 (for description of reclassification measures, see Sections
2.1.1 and 4.5.3). Therefore, a search for new cardiovascular risk determinants and the
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identification of the best-performing extended models can result in a more accurate risk
prediction and, ultimately, more effective risk reduction and CVD prevention.
The key steps for selecting new risk factors and incorporating them into risk models are
determined by the following principles. First, the evidence from prospective studies is
used for identifying independent predictors, associated with high relative risk of CVD in
multiple regression models. Second, the derived risk model is compared to the already
existing instruments, using traditional calibration and discrimination measures. Third,
the clinically relevant reclassification of risk categories by a new model is
assessed.8;39;59;189;190 Finally, even if new risk factors do not improve the model
performance, they could still benefit our knowledge on CVD pathophysiology (e.g.,
homocysteine191) and/or optimise cardiovascular prevention. For example, LDL-CH
may become a relatively weak risk predictor in future models, but lowering its levels
will nonetheless remain one of the key methods of cardiovascular risk reduction.8;177
Linking the theory and practice of this complex research area, several scientific
initiatives have been launched to identify new cardiovascular risk factors and optimise
the risk scales applicable to various European populations. One example is the
Emerging Risk Factors Collaboration (www.phpc.cam.ac.uk/ceu/research/erfc) – a
consortium of prospective studies linking fatal and non-fatal incident CVD events to
lipid and/or inflammatory markers.26 Currently, over 125 international cohorts are
involved, representing more than 1.1 million participants at baseline, over 11.7 million
person-years at risk, and approximately 69,000 major CVD outcomes. In future, this
project will be extended to metabolic, haemostatic, and other risk predictors; however,
there is no information available whether at some stage, socioeconomic parameters or
alcohol consumption might be considered as exposures of interest.
Another promising research initiative is the MORGAM Project (MONICA, Risk,
Genetics, Archiving, and Monograph; www.ktl.fi/morgam), prospectively studying
various phenotypical parameters, several hundred genetic factors, and the interaction of
genetic and environmental characteristics, based on MONICA and other relevant
cohorts.25;32 The risk component of this project aims to compare the risk coefficients for
classical and, later, new cardiovascular risk factors, including socioeconomic and
drinking characteristics, by age, gender and European country/region, using validated
coronary and cerebrovascular end-points. In future, these coefficients will be used to
derive more accurate European scores for CVD risk assessment.
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Of note, several studies have attempted to extend the original SCORE model by adding
extra risk determinants, in order to improve its predictive performance. Among 104,961
participants of the high and low-risk SCORE cohorts, who developed 2,463 fatal CVD
events over the follow-up of 991,058 person-years, adding HDL-CH to the SCORE
algorithm did not change the model calibration (P/O ratios 0.9-1.4), sensitivity (52-55%
for the 5% risk cut-off), or specificity (85%). The extended model demonstrated a
significant overall AUROC increase by 0.01 (p<0.01) and an NRI value of 2%
(p<0.01).192 The same research team explored the performance of the SCORE
instrument extended by resting heart rate among 30,858 FINRISK study participants.
Over the first 10 years of observation, 446 cardiovascular deaths were registered. For
the algorithm including resting heart rate, calibration was similar to that for the original
SCORE. The AUROC improvement did not exceed 0.01 in both genders and reached
borderline statistical significance in women only (p=0.05). The overall NRI value was
0.3% (non-significant).193
SCORE was also extended by the markers of subclinical organ damage, such as left
ventricular mass index, atherosclerotic carotid plaques, carotid/femoral pulse wave
velocity, and urine albumin/creatinine ratio, using the data on 1,968 middle-aged Danish
men and women who developed 81 CVD deaths over the 10-year follow-up.194 The
extended algorithm demonstrated slightly lower sensitivity (65% vs. 72% for the
original SCORE) and a significantly better specificity (81% vs. 75%; p<0.05) (no
calibration data were reported). The increase in C-statistic (0.02) was not significant,
and NRI reached only 9% (p=0.22). In two other, recently published studies, the
SCORE performance was slightly improved after extending the model by obesity and
parental history of MI195, or by ambulatory BP measurements and markers of
subclinical organ damage196; however, the end-points used (fatal and non-fatal CVD195
or fatal CVD, non-fatal MI, and non-fatal stroke196) were different from the SCORE
end-point (atherosclerotic fatal CVD).
Therefore, the improvement in the extended SCORE performance, even when
statistically significant, is still relatively modest in absolute terms, which questions its
clinical relevance. However, the range of the additional risk predictors used for the
SCORE extension has been limited (for example, to the best of my knowledge, there
have been no published studies extending the SCORE model by socioeconomic
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parameters or alcohol consumption characteristics), and it is possible that other factors
might increase the predictive potential of SCORE to a greater extent.
As mentioned in Section 2.2, accurate risk assessment is particularly important for
CEE/FSU populations, with their high CVD rates only partly explained by classical risk
factors (for example1;148;197). While healthcare quality, psychosocial factors, diet, birth
cohort effect, air pollution, and other non-conventional factors affect high CVD levels
across CEE/FSU, socioeconomic disadvantage and alcohol consumption appear to be
the major underlying risk determinants, which are widely spread and relatively easy to
measure.145;149;152;165;198-201 The complex associations between CVD mortality and
socioeconomic parameters or alcohol in CEE/FSU populations are described in the next
two sections.
2.3.2. Socioeconomic factors and cardiovascular risk
This section briefly summarises the international evidence on socioeconomic
inequalities in cardiovascular mortality and then presents in more detail the findings
from CEE/FSU, as the region of interest in this thesis. The potential role of traditional
risk factors in the socioeconomic gradient, as well as the independent impact of
socioeconomic circumstances on CVD risk, is also discussed. Finally, the prognostic
performance of the existing risk scales including or excluding socioeconomic
parameters is compared, and the issue of the best socioeconomic predictor(s) of
cardiovascular risk in the CEE/FSU settings is debated.
a) Socioeconomic inequalities in cardiovascular mortality
The results of numerous studies from the UK, USA, Canada, and other industrialised
countries, summarised in several key reviews (for example202-204), demonstrate that
starting from the second half of the 20th century, heart pathology had lost its “disease of
affluence” stigma, and an inverse social gradient in fatal CVD emerged and persisted. In
particular, socioeconomic disadvantage, operationalized via various measures of
education, occupation, and income/wealth, has been demonstrated to be independently
associated with increased CVD risk in Western populations.203;205-209
Although marital status is not among traditionally accessed socioeconomic parameters,
it reflects to some extent the individual’s socioeconomic circumstances and can
influence cardiovascular risk via multiple mechanisms discussed later in this section.
Thus, higher CVD and CHD mortality has been linked to non-married status among
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middle-aged Dutch men210, male Whitehall civil servants211, middle-aged British men
who participated in the BRHS Study212, American men and women taking part in the
National Longitudinal Mortality Study213, and middle-aged Scottish men and women.214
Importantly, the magnitude of absolute and relative socioeconomic discrepancies in
CVD varies substantially across populations.203;206;215 For example, in the 1990s, the
slope index of inequality, measuring absolute differences between CVD mortality rates
in the lowest and the highest socioeconomic groups, was twice as high in Czech, Polish,
and Lithuanian men as in men from England and Wales.206 For male coronary and
cerebrovascular mortality, the gap between CEE/FSU countries and Western Europe
was two and three-fold, respectively. In Czech, Polish, and Lithuanian women, the slope
indices of inequality for fatal CVD, CHD, and stroke were, on average, 1.5-4.5 times
higher than those in Western European women.
Therefore, the findings from the West cannot be mechanically extrapolated to CEE/FSU
settings, which are different in terms of both socioeconomic trajectories and
cardiovascular mortality trends. The CEE/FSU states have recently experienced much
more dramatic societal changes and greater fluctuations in population health than
Western Europe.144 In addition, after 1989, both all-cause and cardiovascular mortality
started decreasing in CEE, but not in FSU countries. The main underlying causes of this
divergence include the different economic baseline and speed of socioeconomic
transformations; varying baseline health status; differences in lifetime accumulation of
disadvantage and health risk; and different governmental and societal response to
transition.157;158;216 Such dissimilar socioeconomic scenarios could affect the variation in
cardiovascular mortality not only across, but also within countries.
In the CEE/FSU populations, the socioeconomic gradient in fatal CVD has received
relatively less attention than in the West, due to the understandable lack of complete,
updated epidemiological data from the transitional CEE/FSU states.146 Nevertheless, the
available data confirm substantial socioeconomic differentials in cardiovascular risk.
For example, among the workers of the Skoda factory, Pilsen, the Czech Republic, men
with lower than secondary education demonstrated higher CVD rates, compared to their
colleagues with secondary or university education. Based on the 11-year follow-up data
(1977-1988), the adjusted rate ratios were 1.42 for all (fatal and non-fatal) CHD, 1.69
for all MI, and 2.22 for all stroke.217 Cross-sectional analyses of the Czech MONICA
data from the later period (the mid-1980s to the early 1990s) were mostly focused on
66
socioeconomic patterns of cardiovascular risk factors (Section 2.3.2(b)), rather than
CVD mortality disparities across socioeconomic groups.
In a Polish cohort of over 3,000 adult Krakow residents, followed from 1968 for 13
years, CVD mortality was lower among men and women with elementary education
than in their peers with higher education (rate ratios 0.87 and 0.83, respectively). This
could be related to the earlier stages of Polish cardiovascular epidemic in the late 1960s
and 1970s, when CVD had not completely lost its “disease of affluence” status.218 Later,
in the Warsaw MONICA sample, 10-year CVD mortality (1983-1994) demonstrated a
clear inverse educational gradient: adjusted mortality rate ratio for people with low vs.
high education was 1.75. Additionally, higher levels of fatal CVD were observed in
non-married Polish men and women, compared to their married peers.146
The decline in Polish cardiovascular mortality, started from the early 1990s and linked
to the increased dietary intake of vegetable oils, vegetables, and fruit, was observed for
both genders and all age groups, irrespective of their socioeconomic
characteristics.162;219 However, relative educational differences in fatal CVD among 35-
64-year-old Poles increased from 1990 to 2000.155 In men, the CVD mortality rate
difference between the lowest and the highest educational group was at the same level
in 1990 and 2000, but the rate ratio increased from 1.88 to 2.86. This points to
increasing relative inequalities, despite stable or declining absolute differences, in
accordance with the “inverse equity hypothesis” proposed by Victora and co-authors.220
Similarly, in Polish women, CVD mortality rate difference declined by 19 per 100,000,
but the rate ratio increased from 2.42 to 3.34. For coronary and cerebrovascular
mortality in both genders, there was a tendency of slightly increasing rate differences,
but substantially growing rate ratios. As a result, in 2000, CHD and stroke death rates
among lower-educated Poles were approximately three times higher than in their
higher-educated peers.
In Lithuania, the analysis of the national routine statistics also demonstrated that
between 1989 and 2001, relative educational inequalities in cardiovascular mortality
significantly increased, due to both declining fatal CVD rates in higher-educated people
and increasing mortality in lower-educated Lithuanians. Of note, in 2001, the magnitude
of relative inequalities in fatal CVD was greater for Lithuanian women than for men.221
A later, more detailed analysis of these data155 showed that among Lithuanian men, the
CVD mortality rate difference between the lowest and the highest educational stratum
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increased from 187 to 422 per 100,000, while the rate ratio grew from 1.56 to 2.76. For
Lithuanian women, the respective rate difference increased from 96 to 202 per 100,000,
and the rate ratio rose from 2.02 to 4.67. In both genders, there was an increase in rate
differences and especially rate ratios for coronary and cerebrovascular mortality. In
2001, the levels of fatal CHD and stroke were 2.67 and 2.83 times higher in lower-
educated Lithuanian men than in their higher-educated peers. For women, the respective
figures were 5.14 and 3.32, denoting an even more pronounced educational gradient in
mortality. In addition, compared to Lithuanian married men and women, their never-
married, widowed, or divorced peers had a higher risk of fatal CVD in both 1989 and
2001.222 Over time, cardiovascular mortality rate differences increased for never-
married men (from 702.2 per 100,000 in 1989 to 839.8 per 100,000 in 2001) and
divorced men (from 274.6 to 515.0 per 100,000), as well as for divorced women (from
12.2 to 298.3 per 100,000). Mortality rate ratios increased in never-married men (1.77
vs. 1.88), divorced men (1.30 vs. 1.54), and divorced women (1.02 vs. 1.51).
In Russia, most studies focused on the increasing educational gradient in all-cause
mortality, due to deteriorating death rates in the least educated and declining mortality
in the best educated (e.g.223-226). Although there is relatively little evidence on
socioeconomic differences in fatal CVD, this issue has been better described for Russia
than for the Czech Republic, Poland, or Lithuania. In particular, the analysis of the
Russian national routine statistics demonstrated that in 1989, the ratios for CVD
mortality in the lowest vs. highest educational group were 1.41 and 1.56 for 20-69-year-
old Russian men and women, respectively.223 This ecological evidence is consistent
with the results of prospective individual-level studies. For example, in the collaborative
USA-USSR research project, the Lipid Research Clinics (LRC) Program, there was an
inverse association between education and coronary mortality in initially CHD-free
Moscow and St. Petersburg men, observed since 1975-1977 for 12 years. Among the
least educated males, the age and clinic-adjusted relative risk (RR) of coronary death
was 2.43, compared to their most educated peers.227
The Moscow and St. Petersburg male cohorts from the Russian LRC Study, followed
from 1975 to 1997, were also compared to similar cohorts from Oslo and Helsinki.
Educational inequalities in fatal CHD among Russian males were similar to those in
their Norwegian and Finnish counterparts: for example, standardised rate ratio was close
to 0.50 for high vs. low education. On the other hand, educational gap in stroke
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mortality was greater in Russia than in Norway and particularly in Finland: respective
rate ratios were 0.48, 0.52 and 0.60.228 A study by Plavinski and colleagues, which also
stemmed from the Russian LRC project, demonstrated that throughout the 1990s, CVD
and CHD mortality rates rapidly increased in Russian men with lower education, but
declined in those with higher education. Specifically, in two St. Petersburg cohorts,
initially examined in 1975-1977 and 1986-1988, the least educated 40-59-year-old men
from the later cohort had 10-year RR of 1.99 and 1.92 for cardiovascular and coronary
death, respectively, compared to the earlier cohort. In men with university education,
the respective RR were 0.64 and 0.57.224
An alternative, indirect technique for mortality analysis, based on widowhood, was used
in a Russian national sample, examined in 2000. Despite methodological differences
with the above-mentioned research, this study also showed an inverse educational
gradient in cardiovascular death rates. Male spouses of women with primary education
had 2.22 times higher CVD mortality than spouses of university-educated women.
Similar trends were observed in female spouses of men with varying educational
attainment.229
Among over 11,000 MONICA participants from Novosibirsk, who were examined in
1984, 1985-1986, 1988-1989, and 1994-1995 and had a mean follow-up duration of 10
years, the age-adjusted RR of fatal CVD and CHD for men with university vs. primary
education were 0.61 and 0.55, respectively; for women, the respective values were 0.55
and 0.11.230 In addition, divorced men, compared to their married peers, had
significantly higher age-adjusted RR of cardiovascular and coronary mortality (2.03 and
2.17, respectively). In women, however, marital status was inconsistently related to fatal
CVD and CHD.
Therefore, the available CEE/FSU data, although limited, confirm substantial
socioeconomic differentials in fatal CVD risk. The extent, to which conventional
cardiovascular risk factors account for this gradient, is discussed below.
b) Traditional risk factors and socioeconomic inequalities in CVD mortality
The inverse socioeconomic gradient in cardiovascular mortality could be, at least partly,
due to a higher prevalence of traditional risk factors in lower socioeconomic
groups.204;207;215 Over the last few decades, multiple Western studies have demonstrated
that a substantial part of socioeconomic inequalities in CVD is explained by the
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distribution of classical risk determinants. For instance, among Norwegian men and
women, CVD-free at baseline and followed for 26 years, lower education was a
significant predictor of fatal CHD (age-adjusted RR 1.33 and 1.72 for men and women,
respectively). After extra controlling for conventional risk determinants (smoking, SBP,
diastolic BP (DBP), TCH, BMI, physical activity) and marital status, this association
not only weakened, but also lost statistical significance (respective adjusted RR 1.03 for
men and 1.24 for women).231 In middle-aged men from France and Northern Ireland,
who were followed for incident CHD for five years in the PRIME study, higher
education was related to a significantly lower coronary risk after adjustment for age and
study centre (relative odds 0.72). Nonetheless, additional controlling for smoking, DBP,
TCH, DM, and fibrinogen resulted in the loss of statistical significance (relative odds
0.90).232 Similarly, a later analysis of the 10-year PRIME follow-up data demonstrated
that years of education were inversely and significantly linked to the risk of fatal and
non-fatal CVD events after adjustment for age and country (hazard ratio, HR, 0.92).
However, this link was no longer significant after additional adjustment for lifestyle
behaviours and conventional risk factors (HR 1.00).233 Among middle-aged participants
of the Melbourne Collaborative Cohort Study, the age, gender, and country of birth-
adjusted association between lower education and a higher nine-year risk of fatal CVD
(RR 1.66) was substantially weakened and lost its statistical significance after additional
controlling for behavioural and physiological cardiovascular risk factors (RR 1.17).234
The important role of conventional risk determinants was demonstrated for the CVD
gradient not only by education, but also by marital status, income, and occupation. For
example, in middle-aged male and female participants of the Framingham Offspring
Study, the reduction in the 10-year coronary risk for married vs. non-married status did
not reach statistical significance after controlling for age, SBP, TCH:HDL-CH,
smoking, BMI, and DM, as demonstrated by the adjusted RR of 0.92 for men and 0.85
for women.235 Among male participants of the Kuopio Ischemic Heart Disease Risk
Factor Study, the lowest vs. highest level of income was associated with significantly
higher age-adjusted relative hazards of fatal CVD.236 Accounting for 23 biological,
behavioural, psychological, and social risk factors reduced the hazards from 2.66 to
0.70, with a loss of statistical significance. In middle-aged British men – BRHS
participants, who were free of CHD in the beginning of the 20-year follow-up, manual
occupation was linked to a significantly higher coronary risk (age-adjusted HR 1.50).
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After controlling for adult coronary risk factors and height, the link between manual
occupation and CHD became non-significant (adjusted HR 1.20).237
Nonetheless, other studies have demonstrated that socioeconomic effects on
cardiovascular mortality are not fully due to the socioeconomic patterns of traditional
risk factors. In a national sample of middle-aged Americans who participated in the
NHANES I (National Health and Nutrition Examination Survey), RR of fatal CVD
doubled in those with the lowest vs. highest educational attainment.238 After controlling
for age, SBP, smoking, and BMI, RR were slightly reduced, but remained statistically
significant in men. In a later analysis of the NHANES I data, the adjusted risk of CHD
mortality associated with lower education (RR 1.5) was comparable to that for male
gender, current smoking, hypercholesterolemia, and high normal SBP (no unadjusted
RR values were reported).239 Among Finnish men and women, followed for over 11
years, primary education was linked to a higher risk of fatal CVD, after accounting for
age, study year, and pre-existing chronic disease (HR 1.46 for men and 2.16 for
women). While behavioural risk factors (smoking, alcohol, physical activity, diet, and
BMI) explained 54% and 22% of this difference in cardiovascular mortality, lower
education remained a statistically significant predictor of fatal CVD: adjusted HR were
1.21 for men and 1.90 for women.240 In the case-control INTERHEART study,
modifiable lifestyle factors, such as smoking, exercise, diet, alcohol, and abdominal
obesity, explained about 50% of the educational gradient for the first non-fatal acute
MI. However, after controlling for age, sex, region, lifestyle, psychosocial factors, and
other socioeconomic parameters (income, family possessions, and occupation), lower
education (8 years) was still significantly associated with higher MI odds (adjusted
odds ratio, OR, 1.31). Interestingly, the association between other socioeconomic
parameters and MI was weak, or even absent.241
In addition, non-married status has been linked to higher CVD mortality, even after
controlling for various cardiovascular risk factors and/or other socioeconomic
characteristics. For example, in middle-aged Dutch men, free of CVD at baseline, non-
married status was associated with a significantly higher 10-year risk of coronary
mortality (adjusted RR 2.2), after controlling for age, smoking, DBP, TCH, education,
and alcohol consumption.210 Among 40-64-year-old male Whitehall civil servants,
followed for 18 years, CVD and CHD mortality was significantly higher in widowed vs.
married individuals, even after accounting for age, smoking, SBP, TCH, DM, impaired
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glucose tolerance, BMI, height, lung function, disease at entry, and employment grade.
The mortality ratios were 1.33 and 1.46 for CVD and CHD, respectively.211 In 40-59-
year-old British men, who were followed for 11.5 years as participants of the BRHS,
single status was a significant predictor of CVD death (adjusted RR 1.5), independent of
age, smoking, SBP, TCH, BMI, physical activity, forced expiratory volume in 1 second,
disease/medication use at baseline, occupation, employment, and alcohol intake.212
Among middle-aged Scottish adults, free of CVD at baseline and followed for seven
years, behavioural risk factors, such as smoking, physical activity, and alcohol
consumption, as well as occupation, did not fully account for a significant increase in
CVD mortality risk among single men (adjusted RR 2.55), widowed men (RR 2.17),
single women (RR 2.06), and separated/divorced women (RR 2.22).214
A well-known example of the independent impact of employment grade on CVD risk is
the evidence from the Whitehall Study. In male British civil servants, an inverse
association between employment grade and CHD mortality was observed, with age-
adjusted 10-year risk in the lowest grade being 2.7 times higher than in the highest
one.242;243 After controlling for smoking, SBP, TCH, height, and blood glucose, the
association weakened (adjusted RR 2.1), but remained significant. A later analysis of
the Whitehall II data, with the follow-up length extended to 24 years, confirmed that
while health behaviours (smoking, alcohol, diet, and physical activity) explained to a
considerable extent the association between lower employment grade and CVD
mortality (29% or 45% when assessed at baseline only, or at baseline and throughout
the follow-up, respectively), the main association of interest still remained statistically
significant: the respective adjusted HR were 2.22 and 1.85.244
The extensive evidence on the inverse associations between various socioeconomic
characteristics, traditional risk factors, and CVD outcomes in Western populations has
been summarised in several reviews (for example202;203;208), demonstrating that both
conventional risk determinants and socioeconomic parameters are independently linked
to cardiovascular risk. In the CEE/FSU region, most of the data on socioeconomic
distribution of classical cardiovascular risk factors come from the MONICA
populations. As before, the evidence from the Czech Republic, Poland, Lithuania, and
Russia will be used in order to illustrate the associations between socioeconomic
measures and traditional cardiovascular risk determinants in CEE/FSU settings, as well
as to outline the role of these factors in CVD mortality inequalities. Although in the late
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1970s to the early 1980s, these populations demonstrated a direct link between
educational attainment and blood lipids245, later studies showed inverse associations
between the majority of conventional risk factors and socioeconomic parameters, which
may reflect the process of socioeconomic and epidemiological transition in the
CEE/FSU region.146
Among Czech MONICA participants, the dynamics of the main cardiovascular risk
factors from the mid-1980s to the early 1990s depended on educational attainment.246
Even though BP changes were small in all educational strata, TCH decline over 1988-
1992 was significantly greater in university-educated men than in males with primary
education (-0.47 vs. -0.23 mmol/l, respectively). In 1988, before the beginning of the
radical societal changes in the Czech Republic, no educational gradient in TCH
concentration was observed. Smoking prevalence increased only in women with
primary education (+5%), while in higher-educated women, it decreased by 1-2%. As a
result, in 1992, a clear inverse educational gradient in all cardiovascular risk factors was
observed in Czech men and women, with the most adverse risk profiles among the least
educated. In a later analysis of the cross-sectional 1992 data from the same MONICA
population, lower education, but not material deprivation, was associated with higher
levels of most risk factors.247 For instance, people with primary education had mean
TCH levels higher by 0.4-0.6 mmol/l than their university-educated peers. Primary
education was also associated with doubled and quadrupled odds of AH and smoking,
respectively. Among Czech adults participating in the Czech Health and Life Style
Study (2003), current smoking was significantly associated with lower education (for
instance, for university vs. primary education, adjusted OR was 0.33) and single or
divorced status (adjusted OR 1.30 and 1.67, respectively).248 Unfortunately, the cross-
sectional design of these studies did not allow the investigation of the impact of the risk
factor trends on CVD mortality across socioeconomic strata.
As a part of the CINDI Project (Countrywide Integrated Non-communicable Diseases
Intervention Program; 2001-2002), it was shown that in the adult population of an
industrial Polish town Lodz, higher education, but not higher income or married status,
was associated with a significantly lower prevalence of cumulative (3) cardiovascular
risk factors (AH, abdominal obesity, hypertriglyceridemia, low HDL-CH, and
hyperglycaemia). Compared to those with primary education, university-educated men
and women had OR of 0.51 and 0.14, respectively.249
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The 1997 survey of a Lithuanian representative sample, including 20-64-year-old men
and women, demonstrated that the age-adjusted odds of current smoking were
significantly lower in university vs. primary educated men (OR 0.61) and in men with
the highest vs. lowest income (OR 0.55). The inverse association between
socioeconomic characteristics and current smoking was also observed in Lithuanian
women, but it was not statistically significant. After additional adjustment for
nationality, residence type, and another socioeconomic parameter, the link between
smoking and either education or income failed to reach statistical significance for both
genders.250 Among Lithuanian MONICA participants, examined in 2001-2002, the
prevalence of some, but not all traditional risk factors was higher in manual workers
than in their peers with non-manual occupations.251 While regular smoking was more
prevalent in male manual workers (47.8% vs. 30.1%), the prevalence of AH, overweight
and obesity, leisure time physical inactivity, and low HDL-CH levels was similar
between these two occupational groups. In women, only obesity was significantly
associated with manual occupation (47.3% vs. 36.5%), while the prevalence of other
risk determinants did not differ substantially by occupation.
In Russia, smoking might be the best-examined cardiovascular risk factor in terms of its
socioeconomic distribution. Some inconsistencies between specific studies could be
explained not only by different study designs, but also by changing smoking trends
across socioeconomic groups and progressing tobacco epidemic in the region. For
instance, the results of the cross-sectional Russia Barometer Survey (1996)
demonstrated a statistically significant association between current smoking and
material deprivation: when comparing the most and the least deprived quartiles, the
adjusted OR were 1.69 in men and 2.00 in women. At the same time, smoking was
equally distributed across educational groups in both genders.252 By contrast, among
men and women from Taganrog, Southwest Russia (1998), lower education and
deprivation were both linked to doubled odds of smoking.253 In the 2001 LLH Study
(Living Conditions, Lifestyles and Health), which included Russia and seven other FSU
countries, education and economic position were inversely related to smoking in men,
but not in women.254 While the links between smoking and marital status were
inconsistent for men, in women, being divorced, separated, or widowed vs. being
married was associated with significantly higher odds of smoking (adjusted OR 1.54).
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Therefore, the available evidence is generally consistent with the existence of an inverse
socioeconomic gradient in conventional cardiovascular risk factors across CEE/FSU
populations. The research aimed at linking risk factor differentials to CVD mortality
gradients mostly comes from Russia and demonstrates rather contradictory results.
Some Russian studies failed to confirm an independent association between
socioeconomic characteristics and fatal circulatory disease after adjustment for
behavioural risk factors. For example, a case-control study (1998-1999) from the
Udmurt Republic, Central Russia, using verbal autopsy reports by proxies, showed an
elevated CVD death risk in lower-educated, non-married, and unemployed men of
working age. However, none of these associations, controlled for other socioeconomic
parameters and behavioural risk factors, such as smoking, reached statistical
significance: adjusted OR were 1.21 for lower education, 1.56 for never-married status,
and 1.58 for unemployment. A borderline significance was observed for the link
between cardiovascular mortality and smoking (adjusted OR 1.99).255
On the other hand, the findings from prospective studies support the hypothesis of an
independent socioeconomic effect on fatal CVD. For instance, using the 12-year follow-
up data from the above-mentioned Russian LRC Program, Dennis and colleagues
showed that coronary mortality in Moscow and St. Petersburg men, who were free of
CHD at baseline, was significantly higher in those least educated. Controlling for
classical risk factors and alcohol intake reduced the age and clinic-adjusted RR from
2.43 to 1.89, which left unexplained 78% of the excess mortality associated with lower
education. Relative risks for alcohol consumption or conventional risk determinants
(SBP, HDL-CH, LDL-CH, BMI, and number of cigarettes smoked daily), were not
reported.227
An example of the recent research on socioeconomic patterns of fatal CVD in Russia is
a cohort study, conducted as a part of the Novosibirsk MONICA Project.230 The
gradient in CVD, CHD, and stroke mortality was investigated by education and marital
status. Among over 11,000 men and women, who were examined in 1984, 1985-1986,
1988-1989, and 1994-1995 and followed for 10 years, higher education was associated
with lower CVD and CHD mortality. Specifically, the age-adjusted RR of
cardiovascular death for university vs. primary education was 0.61 in men and 0.36 in
women. For coronary mortality, the respective RR were 0.55 and 0.11. After controlling
for conventional risk factors, marital status, and drinking frequency, the RR changed
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only slightly: in men, to 0.81 for CVD mortality and 0.70 for CHD mortality, and in
women, to 0.31 for fatal CVD and 0.24 for fatal CHD. In both genders, 95% CI were
relatively wide and included 1.0, possibly due to limited outcome numbers (e.g., in
university-educated men, there were 48 and 26 cardiovascular and coronary deaths,
respectively; in women, the respective figures were 6 and 1); however, these findings
still support the inverse direction of the association between education and fatal
CVD/CHD. Moreover, divorced men, compared to their married peers, had significantly
higher age-adjusted RR of cardiovascular and coronary mortality (2.03 and 2.17,
respectively). This increased risk was not explained away by conventional risk factors
or lower education (respective adjusted RR 1.78 and 1.84). In women, marital status
was inconsistently related to fatal CVD and CHD. The magnitude of risk associated
with drinking frequency or with conventional risk determinants (smoking, TCH, SBP,
and BMI) was not presented. No clear association was observed between socioeconomic
characteristics and fatal stroke in both genders.
In men and women from Arkhangelsk, Northwest Russia, who were followed from
1999-2000 for 10 years, married status was linked to lower CVD mortality, even after
accounting for conventional and novel risk factors, education, and alcohol consumption.
Due to the limited outcome numbers (77 and 52 CVD deaths in men and women,
respectively), adjusted 95% CI were rather wide and included 1.0, but married status
was still associated with reduced cardiovascular risk (respective RR 0.75 and 0.57). The
link between education and fatal CVD was non-significant and inconsistent: adjusted
RR suggested a protective effect of higher education in men (0.78), but not in women
(1.34). For such classical risk factors as smoking and TCH, the direct association with
cardiovascular mortality failed to reach statistical significance, potentially because of
relatively low outcome numbers.256
The above-cited evidence is supported by the results of a recent review, which included
not only Czech, Polish, Lithuanian, and Russian data, but also the information from
other CEE/FSU states.257 This analysis demonstrated existing and growing inverse
socioeconomic gradient in CVD mortality across the region in the 1990s, mostly due to
deteriorating cardiovascular health in the lowest socioeconomic groups. However, the
observed inverse gradient in classical risk factors was less consistent than that for fatal
CVD.
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Therefore, the existing data from both Western and CEE/FSU populations demonstrate
that while traditional risk factors are differently distributed across socioeconomic
groups, they do not fully account for the socioeconomic gradient in CVD mortality. The
next section discusses the potential for incorporating socioeconomic predictors in
cardiovascular risk assessment scales.
c) Performance of cardiovascular risk instruments which include socioeconomic
parameters
As socioeconomic factors appear to have an independent impact on cardiovascular risk
levels, the majority of the currently used scales, which do not include socioeconomic
measures, may under-estimate the risk in those deprived or less affluent. For example,
among over 13,000 participants of the SHHEC study, observed 10-year coronary risk
was compared to that predicted by the Framingham scale, across the quintiles of the
Scottish Index of Multiple Deprivation, SIMD.104;205 The area-based SIMD reflects
current income, employment, housing, health, education, skills and training, and
geographic access to services and telecommunications. The Framingham scale over-
estimated the coronary risk overall and in each SIMD quintile. At the same time, the
socioeconomic gradient in CHD risk was substantially under-estimated. The observed
RR, from the least to most deprived quintile, were 1.00, 1.81, 1.98, 2.22, and 2.57, in
contrast to the predicted values of 1.00, 1.17, 1.19, 1.28, and 1.36, respectively.
Another prospective research project, the West of Scotland Study, examined the
Framingham score performance across different socioeconomic groups in the high-risk
Renfrew/Paisley cohort.258 The Framingham function under-estimated 10-year risk of
fatal CVD by 48% in manual workers and by 31% in non-manual participants; coronary
mortality was under-predicted by 44% and 22%, respectively. Under-estimation of fatal
CVD risk was also linked to the residence area deprivation, defined by the Carstairs-
Morris index. Moreover, among middle-aged British men, free from CVD at baseline
(1978-1980), the Framingham scale over-estimated the 10-year CHD risk to a greater
extent in non-manual vs. manual workers (respective P/O ratios 1.84 and 1.49). Better
Framingham sensitivity (56% vs. 52%) and specificity (79% vs. 73%) was observed
among participants in non-manual vs. manual occupations.259 In the same population,
the high-risk SCORE demonstrated a greater over-prediction of fatal CVD among non-
manual workers (P/O ratio 1.79 vs. 1.46 in manual workers), as well as better sensitivity
(61% vs. 57%) and specificity (77% vs. 69%, respectively).
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These examples demonstrate that the most affluent participants would be relatively
over-treated, and the most deprived would receive only a fraction of the actually needed
treatment, if the risk stratification process was based on the risk instrument not
containing socioeconomic parameters. Hence, to better identify people at increased risk
and to reduce existing socioeconomic inequalities in CVD, alternative approaches
should be used, encompassing not only traditional risk predictors, but also various
measures of deprivation and disadvantage.203;239;259;260
It was recently shown that adding socioeconomic disadvantage (operationalized as <12
years of education and/or low income) did not affect the Framingham scale
discrimination, but improved its calibration in the middle-aged participants of the ARIC
(Atherosclerosis Risk in Communities) cohort.261 Specifically, predicted coronary risk
changed from 3.7% to 3.1% in those from the higher socioeconomic group and from
3.9% to 5.2% in those from the lower socioeconomic group, compared to the respective
observed 10-year CHD levels of 3.2% and 5.6%. The results were also validated using
the NHANES III data, linked to the National Death Index. Moreover, in British middle-
aged men who participated in the BRHS, adding occupational social class to the
Framingham scale slightly improved risk reclassification, as demonstrated by NRI and
IDI values of 0.18% and 0.10%, respectively.259
At present, there are two cardiovascular risk scales including socioeconomic
characteristics – ASSIGN and QRISK/QRISK2 instruments, described in more detail in
Section 2.2.2. The Scottish ASSIGN score is based on traditional risk factors and social
deprivation, operationalized via the residence postcode-specific SIMD.104 Even though
the ASSIGN calibration ability was similar to that for the Framingham scale, with risk
over-estimation in both genders, the discrimination was better for the former instrument.
ASSIGN correctly identified 20% of the population accounting for 45% of
cardiovascular events over the next 10 years, and classified more deprived people at
high risk than the Framingham score. In a study comparing performance of ASSIGN,
QRISK, and Framingham scales in a UK cohort of general practice patients (THIN
database), ASSIGN demonstrated the steepest, and the closest to the observed,
deprivation gradient in cardiovascular risk.262 The recently developed QRISK/QRISK2
scale includes various traditional and clinical cardiovascular risk predictors, as well as
the Townsend deprivation score. Compared to the Framingham and ASSIGN
instruments, QRISK/QRISK2 demonstrated better discrimination and calibration. For
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instance, while the Framingham score and ASSIGN over-predicted CVD risk by at least
10%, the QRISK/QRISK2 estimations were very close to the observed risk levels, and
AUROC values were also the highest for QRISK/QRISK2.105-108
To summarise, adding socioeconomic parameters to the cardiovascular risk models is a
promising approach, as it may help to improve the accuracy of risk prediction in
disadvantaged individuals and populations, and, in perspective, to optimise
cardiovascular risk management and reduce both general CVD burden and CVD
inequalities. Given the marked socioeconomic disparities in CVD across the CEE/FSU
region, the risk scales incorporating socioeconomic characteristics may be of particular
importance there. However, neither ASSIGN, nor QRISK/QRISK2 was calibrated for
CEE/FSU, and the officially recommended SCORE scale does not contain any
socioeconomic measures. Additionally, SIMD and Townsend deprivation score are
hardly applicable to most CEE/FSU populations, as the local availability of area-level
socioeconomic measures is limited. It seems reasonable to investigate the predictive
potential of a new risk function, which would incorporate both traditional CVD risk
determinants and relevant socioeconomic indicators. The selection of optimal
socioeconomic parameters is the focus of the following section.
d) Optimal socioeconomic predictors of cardiovascular risk in CEE/FSU
Identifying the most appropriate measure(s) of socioeconomic influences on
cardiovascular risk in CEE/FSU populations is a challenging task. On the one hand, the
parameters should be context-specific and adequately reflect the local socioeconomic
features. On the other hand, they also need to be generalizable and comparable across
countries and over time, as well as be easily measured. An additional difficulty is the
different meaning of formally equivalent socioeconomic characteristics in different
socio-cultural environments, such as the developed countries of Western Europe and
North America vs. post-transitional CEE/FSU economies.
Various socioeconomic measures reflect different pathways connecting socioeconomic
circumstances and cardiovascular risk, and each indicator has its own strengths and
limitations.202;203;241;260;263-265 For instance, income/wealth is the best measure of current
material circumstances, representing the access to goods and services, including healthy
diet, safe housing, and adequate medical care. Occupation reflects current employment
status, prestige, workplace exposures (for example, psychosocial stress, drinking or
smoking “culture”) and certain lifestyle factors, such as physical activity. However,
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both income and occupation are relatively unstable and easily affected, among other
factors, by health status, including cardiovascular health, and by health behaviours such
as problem drinking. Income, as well as other wealth measures, is hard to
operationalize, and income-related questions are sensitive enough to compromise
response rates. Occupational categories might be too broad to adequately represent the
entire scope of work-related exposures and risk factors. By contrast, education as a
socioeconomic characteristic is easily measurable, relatively stable, and not affected by
later health status, behavioural factors, and other parameters. As the access to baseline
education becomes more universal, the birth cohort effects, potentially affecting the
education-CVD association, are declining over time. The mechanisms underlying both
short and long-term effects of education on cardiovascular risk include “influencing
life-style behaviours, problem-solving abilities, and values”, “acquisition of positive
social, psychological and economic skills and assets”, and “insulation from adverse
influences”.266
In CEE/FSU populations, the potential of various socioeconomic parameters as CVD
risk predictors could differ from that in the West.209 Specifically, official income and
occupation may capture the true material circumstances of individuals and households
less effectively, due to the substantial role that informal economy still plays in many
CEE/FSU states.144 Education has been the socioeconomic measure most widely used in
epidemiological studies in the region, and it also demonstrated the most consistent
health gradients.144;247 Early life health and health behaviours, such as excessive
drinking, could affect educational attainment, and this might be particularly relevant to
Russian settings.223 Nonetheless, the health impact on socioeconomic parameters is
weaker for education, compared to income/wealth or occupation, which minimises the
risk of reverse causality being the main explanation of the association between
socioeconomic circumstances and CVD. Importantly, in Russia and other CEE/FSU
countries, health effects of education are confounded by income and occupation
influences to a lesser extent than in the West. Higher education does not equal high
income, and, hence, education per se provides health-protective action, independently
from material circumstances.223;226;247
In addition, easily and routinely assessed, marital status has been recognized as a factor
which protects against CVD via such mechanisms as social connections, a sense of
social and familial role, socioeconomic support, and facilitation of health-promoting
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behaviours.214;267-271 These protective effects of marriage might be particularly
important in the CEE/FSU context.153 Importantly, across both Western and
Central/Eastern European populations, non-married status has been linked to higher
CVD mortality, especially in males, even after controlling for various cardiovascular
risk factors or other socioeconomic characteristics.210-214;230;256 Considering the
extensive evidence on independent cardioprotective effect of married status, this
measure appears highly relevant to the problem of CVD gradient in the region of
interest.
Therefore, the available evidence is consistent that a combination of classical risk
factors and other non-conventional risk determinants, such as socioeconomic
characteristics, should be included in the instruments for cardiovascular risk prediction
in CEE/FSU populations. Of note, there have been no published studies on the
CEE/FSU performance of cardiovascular risk scales, such as SCORE, after their
extension by socioeconomic parameters. Another additional risk factor could be
hazardous alcohol consumption, due to its wide prevalence in the region and the link to
CVD. The role of alcohol as a cardiovascular risk determinant in the CEE/FSU context
is debated in the next section.
2.3.3. Alcohol consumption and cardiovascular risk
First, the mechanisms linking alcohol and CVD are outlined, with the emphasis on this
association in CEE/FFU populations which are characterised by widespread hazardous
drinking. The complex relationship between alcohol and fatal CVD in CEE/FSU is then
addressed. Finally, some methodological aspects of including alcohol consumption
measures in the cardiovascular risk scales are discussed.
a) Alcohol and cardiovascular risk
The international evidence on the complex association between alcohol and
cardiovascular risk mostly comes from the studies performed in industrialised countries
of Western Europe and North America. In particular, alcohol drinking has been linked
primarily to CHD, but also to such CVD outcomes as cardiac arrhythmias, ischemic,
thromboembolic and hemorrhagic stroke, and sudden cardiac death.272-275 The amount,
frequency, and patterns of drinking could all affect cardiovascular risk. In systematic
reviews by Rehm and colleagues, higher average volume of alcohol consumption was
associated with an increased risk of hypertensive disease and hemorrhagic stroke, and
coronary risk was dependent on both drinking patterns and average volume of alcohol
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consumed.274;276 In contrast to drinking dose and patterns, alcohol beverage type seems
to be unrelated to CVD risk. The evidence on the greater cardioprotective potential of
wine277 is counterbalanced by the seemingly equal cardiovascular benefits of
moderately consumed wine, beer, or spirits.278-280
While moderate alcohol consumption protects against CVD, heavy, binge, and problem
drinking increases cardiovascular risk, which results in a U or J-shaped dose-response
curve (e.g.272-274;280-288). For instance, in a meta-analysis by Corrao and colleagues, the
alcohol-CHD relationship was J-shaped, with the lowest RR of 0.8 at the drinking level
of 20 g/day, a protective effect up to 72 g/day, and a significantly increased risk at 89
g/day.284 The same research team also demonstrated that cardioprotective effect of
alcohol is weaker in women, for fatal outcomes, and in the properly adjusted
prospective studies not including ex-drinkers in the non-drinker category.280
If actual cardioprotective effect of alcohol is relatively modest, then in individuals and
populations with hazardous drinking patterns, it would be outweighed by detrimental
impact on cardiovascular risk. Specifically, in a recent meta-analysis, binge and heavy
irregular drinking was shown to modify cardioprotective effect of alcohol.289 Compared
to abstainers, regular heavy drinkers and heavy irregular, binge drinkers had
significantly different RR of CHD: 0.75 vs. 1.10, respectively. The dose-response
relationship between alcohol consumption and CHD was also markedly different:
irregular drinkers (2 days a week) demonstrated a J-shaped curve, with nadir around
28 g of alcohol per week, and the last protective dose of 131 g per week. For those who
drank regularly, even high doses of alcohol had a protective effect, with an L-shaped
dose-response curve. Moreover, in a later meta-analysis by Roerecke and Rehm, which
specifically focused on irregular heavy drinking after controlling for consumption
volume, this drinking pattern was associated with a significantly increased coronary
risk, compared to regular moderate drinking (adjusted RR 1.45).290
The relationship between alcohol consumption and stroke is also complex, as
demonstrated in the recent meta-analysis by Patra and colleagues.291 Increasing alcohol
consumption was associated with a monotonous increase in fatal and non-fatal
hemorrhagic stroke risk. For example, compared to lifetime abstainers, men and women
consuming 96 g of pure alcohol per day had RR for hemorrhagic stroke mortality of
1.94 and 4.50, respectively. However, ischemic stroke had a curvilinear relationship,
similar to that for CHD: low to moderate consumption had protective effect against
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stroke mortality in both genders (nadir at 12 g/day, and last protective dose of 44 g/day),
but heavier drinking increased the risk. Of note, for both stroke types, risks for mortality
tended to be higher than for morbidity.
The dose-response relationship between alcohol and CVD is also supported by clinical
and physiological evidence. Thus, binge and irregular heavy drinking is associated with
adverse changes in HDL and LDL-CH profiles, hypercoagulation, BP elevation,
arrhythmia threshold reduction, and histological changes of the myocardial conducting
system. Importantly, these harmful effects are not confined to the drinking episode only,
but also extend to the alcohol withdrawal/cessation phase. On the other hand, moderate
alcohol intake demonstrates beneficial effects on blood lipids, platelet aggregation, and
fibrinolysis. Other cardioprotective mechanisms, such as reduced insulin resistance and
inflammation, vasodilatation, and pro-oestrogenic effect, have been reported but are
unlikely to play a key role.272-274;276;292;293
Therefore, the current evidence generally supports the concept of the dose-response
relationship between alcohol and CVD. However, extrapolating these, predominantly
Western, findings to CEE/FSU is problematic, as the substantial differences in drinking
patterns between populations could result in different magnitude and even direction of
alcohol effects on cardiovascular risk. The specifics of drinking patterns in CEE/FSU
populations are summarised below.
b) Alcohol consumption in CEE/FSU
While CEE and FSU countries demonstrate high per capita levels of alcohol
consumption, their drinking patterns are heterogeneous. For example, the Czech
Republic is characterised by wide-spread, regular beer drinking, high overall alcohol
consumption, and a relatively less hazardous drinking pattern. Poland, Lithuania, and
Russia share a culture of spirits consumption, with more detrimental drinking patterns,
such as bingeing.287;294;295 Moreover, unrecorded per capita consumption of alcohol in
Russia, Lithuania, and Poland, but not the Czech Republic, is substantially higher than
the world average level, and is mostly presented by homemade, highly concentrated
beverages with ethanol content 40%.296
These ecological findings have also been confirmed by the individual-level data
analyses. For example, as shown in the cross-sectional HAPIEE Study survey, in 1999-
2000 Russian men had a substantially lower mean annual alcohol intake and mean
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drinking frequency than their Czech peers.297 However, the mean alcohol dose per
session was almost twice as high in Russian males as in Czech and Polish men.
Bingeing, problem drinking, and negative consequences of drinking were twice as
common in Russians as in Czechs or Poles. The LLH Project also demonstrated that in
the early 2000s, Russia was characterised by relatively low frequency of alcohol
consumption, but large amounts per occasion and frequent heavy drinking situations.298
Abstention rates in Russian men and women were low (11% and 27%, respectively).
The reduced proportion of female abstainers, compared to 35-51% levels from the mid-
1990s surveys299-301, might be an alarming predictor of the future increase in alcohol-
related burden of disease among Russian women.
Not only the cross-sectional estimates, but also the trends in alcohol drinking across the
CEE/FSU region could be described as heterogeneous. Specifically, Czech and Polish
alcohol consumption levels have been relatively stable in the last few decades, while
Russia experienced dramatic fluctuations, with a rapid decline in the mid-to-late 1980s
followed by a marked increase.22 Between 1994 and 2006, the recorded alcohol
consumption rose by 30% in Russia, tripled in Lithuania, and hardly changed in the
Czech Republic and Poland. In 2006, recorded alcohol consumption levels in the Czech
Republic, Lithuania, and Russia exceeded the average European level (14.9, 12.9, and
11.1 vs. 10.7 litres per capita, respectively), while in Poland, they were only slightly
lower (10.4 litres).21
Importantly, widespread hazardous drinking is linked to the heavy burden of alcohol-
associated mortality and morbidity in the CEE/FSU region. In 2002, Russia and other
FSU countries demonstrated the world’s highest levels of alcohol-related burden of
death and disease.302 Alcohol accounted there for 18.6% and 5.4% of all deaths in men
and women, respectively, and this burden had not decreased since 2000.303 In Eastern
European populations, alcohol was the second most important risk factor for disease
burden after AH. A substantial proportion of the alcohol-related burden in men and
women was presented by CVD, which was responsible, respectively, for 129,000 and
40,000 alcohol-attributable deaths, 1,192,000 and 253,000 years of life lost, and
1,309,000 and 281,000 DALYs per year.302 In a country-specific analysis of the 2002
data, Russian and Lithuanian men had alcohol-attributed premature mortality almost
eight and six times higher, respectively, than British men.294 Even though for Russian
and Lithuanian women, the absolute rates were lower, the respective mortality ratios
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were high (3.6 and 3.2, compared to British women). In Czech and Polish males,
alcohol-attributable premature mortality was approximately 2.5 times higher than in the
UK, while Czech, Polish, and British women all had similar levels of alcohol-related
premature deaths. In regard to CVD mortality, Rehm and colleagues acknowledged that
their estimation of beneficial drinking effects could have resulted from inadequate
extrapolation of the data from countries with typical moderate regular alcohol
consumption to the countries with widespread binge drinking, such as Russia.
Therefore, the applicability of the Western data on the CVD-alcohol association to
CEE/FSU populations, which are different in terms of both volume and patterns of
alcohol consumption, is not straightforward. The following section presents the
principal findings from the relevant CEE/FSU studies, in order to specify and explore
the features of alcohol consumption as a cardiovascular risk factor in the region of
interest.
c) Alcohol and cardiovascular mortality in CEE/FSU
To date, the local evidence on the association between circulatory disease and drinking
in CEE/FSU settings mostly comes from Russia, due to the recent dramatic changes in
the Russian CVD rates and alcohol intake. In particular, substantial fluctuations in
Russian alcohol consumption due to the anti-alcohol campaign of 1985 and its collapse
coincided with the changing rates of deaths of various aetiology over the late 1980s to
the early 1990s.304 It has been suggested that these striking mortality fluctuations were
mostly explained by drinking and its effects not only on injuries and other alcohol-
related causes, but also on CVD (e.g.165;198;200;201;282;305-307). According to Nemtsov,
cardiovascular deaths were the second and the first causes contributing to the 1985-1986
decrease in alcohol-related mortality among Russian men and women, respectively.305
Leon and colleagues estimated that the 1985 campaign, resulting in a 25% drinking
reduction, was associated with the CVD mortality decrease of 9% in men and 6% in
women, while after 1987, a substantial increase was observed in both alcohol
consumption and fatal CVD.165
However, the proportion of heavy/problem drinkers in Russian women, even
considering potential under-reporting, did not seem high enough to explain away the
recent unprecedented fluctuations in female cardiovascular mortality (for
example299;300;304). Some earlier individual-level studies, such as the Russian LRC
Project, also did not support the hypothesis of alcohol as a major determinant of CVD
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mortality. Specifically, no clear association was observed between alcohol intake and
eight-year cardiovascular mortality in middle-aged Russians (the highest rates of fatal
CVD were registered in non-drinkers), while in their American peers, alcohol was
cardioprotective.308 This study, however, did not address the effects of drinking patterns
and bingeing on cardiovascular risk. Moreover, while HR for alcohol intake categories
were adjusted for classical risk factors, the impact of these factors on cardiovascular risk
was reported only for smoking. In particular, smoking was associated with at least
doubled adjusted hazards of CVD death (HR 1.95 for men and 2.82 for women). A later
analysis of the LRC data from St. Petersburg male cohorts showed that the input of high
alcohol consumption in the all-cause mortality increase among the lower-educated men
was relatively small (8-22%), and for CVD mortality it was expected to be even
smaller.224
Nonetheless, a statistically significant, independent of conventional risk factors,
association between hazardous drinking and CVD mortality was demonstrated in other
case-control and cohort CEE/FSU studies, in agreement with the Western
evidence.273;274;280-282;284;285;289-291 For example, in working-age men from Udmurt
Republic, Russia (1998-1999), the proxy-reported episodes of heavy beverage drinking
in the past year were associated with four-fold odds of fatal CVD after adjustment for
classical risk factors such as smoking, for education, marital status, and employment
(unadjusted OR 4.21 vs. adjusted OR 3.54).201;255 Regular alcohol consumption did not
demonstrate any substantial cardioprotective effect. The link between smoking and
CVD death had a borderline significance (adjusted OR 1.99). In a later case-control
study of Udmurt men (2003-2005), the proxy-reported non-beverage alcohol drinking
was linked to significantly increased odds of coronary and cerebrovascular mortality.
The OR value was approximately 3.0 after controlling for smoking, volume of beverage
alcohol, and education; however, no OR were reported for these covariates.309
Similarly, the findings of another case-control study performed in three Russian
industrial cities (Tomsk, Barnaul, and Biysk), demonstrated that in the 1990s, adjusted
risks of proxy-reported fatal acute non-MI CHD in male and female regular heavy
drinkers were three and nine times higher, respectively, than in occasional non-heavy
drinkers (OR 3.04 in men and 9.25 in women).310 Adjustment was performed for age,
city of residence, and smoking, but no respective OR were presented.
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Among middle-aged Novosibirsk men, who were examined between the mid-1980s and
the mid-1990s and had a mean follow-up of 9.5 years, frequent heavy drinking was
linked to almost double risks of CVD and CHD death after controlling for classical risk
factors and education.300 The respective adjusted RR were 2.05 and 1.81. Although the
latter 95% CI was relatively wide and included 1.0, due to the limited number of
coronary deaths (n=23) among frequent heavy drinkers, these findings still point to the
link between hazardous drinking and increased cardiovascular risk. The authors
reported that smoking was the most important confounder of the alcohol-mortality
associations; however, no RR values for any conventional risk determinants or
education were presented.300
In women from Arkhangelsk, examined in 1999-2000 and followed for 10 years, binge
drinking (consumption of 80 g of alcohol on one occasion at least once a month) was
significantly related to higher CVD mortality risk, after controlling for education and
marital status, as well as for conventional and novel cardiovascular risk factors
(adjusted RR 5.06). In their male peers, however, there was no clear link between binge
drinking and fatal CVD (adjusted RR 0.96). The relatively low number of outcomes (77
and 52 CVD deaths in men and women, respectively) could explain the fact that among
the covariates of interest, lower education or high DBP were inconsistently linked to
cardiovascular mortality, while for non-married status, smoking, and TCH, the link with
fatal CVD did not reach statistical significance.256
Therefore, the latest evidence from CEE/FSU is mostly consistent that alcohol effects
on CVD risk are not explained away by conventional risk factors. Including drinking
measures in the cardiovascular prognostic algorithms could improve the risk assessment
accuracy in CEE/FSU populations. On the other hand, it might also cause various
methodological problems, which is the focus of the next section.
d) Alcohol drinking measures and CVD risk assessment
Since both drinking dose and drinking patterns affect cardiovascular risk, theoretically,
they should both be included into risk scales. However, while the assessment of average
ethanol intake is methodologically developed, the drinking patterns are more
problematic to operationalize. Heavy episodic drinking is typically defined as
consumption of 4-5 drinks per occasion or per day311, but there are still no universal
definitions of “patterns of drinking” or “binge/hazardous drinking”.276 For example, in a
well-known review on alcohol and CVD282, the included cohort studies defined
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heavy/binge drinking as frequent hangovers or intoxication312;313, consumption of 6
bottles of beer per occasion314, registration as a heavy alcohol abuser315, and poor work
performance because of alcohol-related problems.316 However, none of these definitions
differentiated between episodic vs. frequent heavy drinking, and this distinction is
essential for adequate assessment of cardiovascular risk.
It is highly likely that in populations with different drinking patterns, different measures
of alcohol consumption predict CVD more efficiently.317 In addition, all self-reported
measures of alcohol consumption are prone to random and non-random
misclassification. Differential reporting of drinking may be affected by cardiovascular
risk factors and outcomes, as well as by numerous other variables, but the direction and
magnitude of this bias is hardly predictable.317 Investigating multiple drinking
characteristics could help to identify the most important context-specific predictors of
CVD and minimise the risk of misclassification. Although this approach is acceptable
for epidemiological or clinical research, in the real-world clinical practice – the key area
for cardiovascular risk assessment and control – only the strongest and the most
measurable predictors should be used. For example, in terms of feasibility, short
questionnaires on alcohol-related problems like CAGE318 could be more acceptable for
both clinicians and patients than an informative, but rather time-consuming graduated
frequency method.319-321 On the other hand, while simple questions on binge drinking
might provide the information which is the most relevant to cardiovascular risk
prediction, such a “straightforward” approach could alienate patients and, hence, be
avoided by clinicians. To my knowledge, no extensive comparison of drinking measures
in terms of their predictive value and clinical feasibility for cardiovascular risk
assessment has been performed in either Western populations or CEE/FSU countries.
To summarise Section 2.3.3, the existing evidence suggests that alcohol could be one of
the major determinants of high cardiovascular mortality in CEE/FSU, independently of
classical risk factors. Adding drinking measures to existing prognostic algorithms, such
as SCORE, could improve the accuracy of total cardiovascular risk assessment in
CEE/FSU populations, although thus far, no studies have addressed this issue. The last
section of the Background chapter summarises the current prospects on cardiovascular
risk assessment and outlines the gaps in the knowledge, which will be addressed in this
thesis.
88
2.4. Background summary
Cardiovascular disease remains the leading cause of mortality, morbidity, and disability
throughout the world. To tackle this major public health problem effectively, future
CVD cases should be prevented, by estimating and managing cardiovascular risk. Over
the last five decades, the concept and methodology of total cardiovascular risk
assessment have been developed, which use a combination of various conventional risk
factors for the early identification of asymptomatic individuals and groups at increased
risk of overt cardiovascular pathology. Among multiple existing risk assessment
instruments, the SCORE scale is one of the most widely used in both research and
clinical settings. It predicts the 10-year risk of fatal atherosclerotic CVD in middle-aged
people, based on age, gender, smoking, blood pressure, and blood lipids. SCORE is
officially recommended by the ESC for all European populations. Accounting for
Europe’s heterogeneity in terms of fatal CVD and classical risk factor levels, the high-
risk and low-risk SCORE charts were created.
At the same time, SCORE ability to accurately predict cardiovascular risk in external
settings is limited by the considerable variation in the baseline, or background, risk
across populations and over time. Moreover, conventional risk factors, captured by
SCORE, are important, but not exclusive determinants of cardiovascular risk. Numerous
novel risk markers have been shown to independently predict CVD and, to a varying
extent, to improve the prognostic performance of the risk models. These limitations
have been addressed, first, by SCORE recalibration (adjustment to the local settings by
introducing population-specific event rates and risk factor means) and, second, by
SCORE model extension (adding selected novel risk factors to the original algorithm).
While recalibrated SCORE versions typically demonstrate better prognostic
performance than the non-calibrated instrument, there is a need for the continuous
update and re-adjustment of local SCORE scales, particularly in populations with
rapidly changing levels of cardiovascular risk factors and fatal CVD. The improvement
in the prognostic performance of the extended SCORE models developed thus far was
relatively modest, which justifies the ongoing search for alternative extended SCORE
algorithms.
Importantly, the global burden of CVD is not evenly distributed, and some populations,
such as the countries of Central and Eastern Europe (CEE) and former Soviet Union
republics (FSU), face particularly high, but heterogeneous levels of cardiovascular
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mortality. CEE/FSU populations have a particular need for accurate cardiovascular risk
assessment and effective risk reduction. However, they also face additional gaps in the
knowledge on cardiovascular risk prediction. Specifically, using only one high-risk
version of the SCORE scale, currently recommended for all CEE/FSU countries, could
inadequately reflect the variation of the background cardiovascular risk and risk factor
patterns across the region. At present, the high-risk SCORE lacks both a prospective
assessment of its predictive performance and a proper country-specific recalibration in
CEE/FSU. In addition, conventional risk factors do not fully account for high CVD
rates in the region of interest. Socioeconomic characteristics, such as education or
marital status, and alcohol consumption, in particular hazardous drinking, have been
shown to predict fatal CVD independently of conventional risk determinants in both
Western and CEE/FSU contexts. Including socioeconomic characteristics or drinking
parameters in the cardiovascular risk function, together with classical risk factors, might
improve SCORE performance across CEE/FSU populations, but no attainable studies
have as yet investigated this hypothesis.
In order to address the current gaps in the knowledge on cardiovascular risk prediction
in CEE/FSU, the main aim and objectives of this thesis have been specified and will be
presented in Chapter 3. The methodological aspects of the study will then be discussed
in Chapter 4.
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Chapter 3. Aims and objectives
As summarised in the previous chapter, there are gaps in the knowledge on
cardiovascular risk prediction in CEE/FSU – a region with high rates of CVD mortality
and morbidity and, consequently, in particular need of accurate risk assessment and
effective risk management. Therefore, it is important to investigate the real-world
performance of CVD risk prediction instruments officially recommended for the local
settings, such as the SCORE scale.17;20
The overall aim of this thesis is to assess the predictive performance of the SCORE
scale in CEE/FSU populations, using individual-level data from two large international
population-based studies. Specifically, the SCORE algorithm is applied to Czech,
Polish, Lithuanian, and Russian MONICA samples42, as well as to Czech, Polish, and
Russian HAPIEE samples43, described in more detail in Chapter 4, in order to examine:
- how reliably SCORE predicts fatal cardiovascular events in CEE/FSU populations
with different levels of absolute risk (i.e. mortality levels);
- whether inclusion of socioeconomic parameters or alcohol consumption
characteristics improves the predictive performance of the SCORE instrument in
these populations.
The research hypotheses are as follows:
1) SCORE is a significant predictor of atherosclerotic CVD mortality in both genders,
across all MONICA and HAPIEE samples.
2) While SCORE discrimination is expected to be satisfactory in most samples, it
could be the case that for the CEE/FSU populations with the highest levels of fatal
CVD, such as Russia, the risk might be under-estimated by the original high-risk
SCORE instrument.
3) The prognostic performance of the SCORE model is expected to improve after
SCORE extension by socioeconomic parameters.
4) Adding alcohol consumption characteristics to the SCORE model could improve
its prognostic performance.
To achieve the study aims and to test the research hypotheses, the following specific
objectives are formulated:
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1) For each study-, population-, and gender-specific sample, to describe the
distribution of classical and additional cardiovascular risk factors and the levels of
fatal atherosclerotic CVD;
2) To explore the strength of the main association of interest, between SCORE and
atherosclerotic cardiovascular mortality, across MONICA and HAPIEE samples;
3) To evaluate SCORE calibration and discrimination in MONICA and HAPIEE
samples; in addition, to estimate the expected 10-year SCORE calibration in
HAPIEE;
4a) To examine the role of SCORE and socioeconomic parameters as predictors of
atherosclerotic CVD mortality;
4b) To investigate the calibration and discrimination of the SCORE model extended
by socioeconomic characteristics;
5a) To assess the role of SCORE and drinking parameters as predictors of fatal
atherosclerotic CVD;
5b) To estimate the calibration and discrimination of the SCORE model extended by
drinking characteristics;
6) To evaluate the strength of the overall associations between SCORE and fatal
atherosclerotic CVD before and after adjustment for extra risk determinants, using
the random effects meta-analysis approach.
The methodological aspects of achieving the research aims and objectives specified
above will be discussed in the next chapter.
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Chapter 4. Methods
In this chapter, the selection of the study population and samples is described, namely
Czech, Polish, Lithuanian, and Russian samples from the MONICA study, and Czech,
Polish, and Russian samples from the HAPIEE study. The measurement of the main
components of the SCORE model and the additional risk determinants (socioeconomic
parameters and alcohol consumption characteristics) is outlined. The final part of the
chapter presents the overall strategy of statistical analyses and their specific steps,
including the assessment of the performance of the original SCORE scale and the
evaluation of various measures of SCORE calibration and discrimination after adding
extra risk factors to the model.
4.1. Study population, samples, and subjects
This thesis examines the performance of the SCORE risk scale in CEE/FSU
populations, and, hence, it was advisable to obtain longitudinal local data on
cardiovascular mortality. Two of the largest international studies focusing on CVD in
CEE/FSU are MONICA and HAPIEE projects. Although the HAPIEE study provides
more recent estimates of fatal CVD rates (from the early 2000s onwards), its mean
follow-up is under seven years at the time of writing. Therefore, prospective data from
the CEE/FSU MONICA samples, typically followed from the mid-1980s for at least 10
years, are also used in the analyses.
4.1.1. MONICA population and samples
As described in Section 2.2.2 of the Background chapter, the international MONICA
project monitored the trends in CHD rates and conventional coronary risk factors across
age- and gender-stratified population samples from the mid-1980s to at least the mid-
1990s. The data on CVD (both CHD and non-CHD) mortality were also
collected.42;126;127;130;170;322 Typically, MONICA cohorts, aged 35-64 years at baseline,
consisted of several different samples, which were randomly selected from population
registers (electoral lists in Russia) and screened with a three to five-year interval; the
follow-up length was, therefore, maximal for the subjects from the first sample. In this
thesis, the 10-year follow-up data were used, as the SCORE scale predicts the 10-year
risk of fatal atherosclerotic CVD.20 Although the MONICA populations are not
completely representative of the respective countries as a whole, their characteristics are
still considered to be satisfactory approximations of the national CVD rates,
cardiovascular risk factors, and additional risk determinants.42
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Czech MONICA: The cohort included 9,458 people (4,692 men, 4,766 women), who
were urban and rural residents of the Praha-východ, Cheb, Chrudim, Jindřichův Hradec, 
Benešov, and Pardubice districts. The MONICA-1 sample (1,531 men, 1,544 women)
was examined in 1985, the MONICA-2 sample (1,534 men, 1,576 women) in 1988, and
the MONICA-3 sample in 1992 (1,627 men, 1,646 women). Only MONICA-3
participants are included in the present analyses, since the complete data on 10-year
mortality follow-up were not available for MONICA-1 and MONICA-2 samples. The
overall response rate for the MONICA-3 sample was 65%.160
Polish MONICA-Warsaw: The cohort from Warsaw (the capital city) consisted of
4,079 residents of two city districts (2,019 men, 2,060 women), who were followed for
10 years. Baseline screening took place in 1983-1984 for the MONICA-1 sample (1,309
men, 1,337 women), and in 1988-1989 for the MONICA-2 sample (710 men, 723
women). The response rates were 74% and 70% for MONICA-1 and MONICA-2,
respectively.323
Polish MONICA-Tarnobrzeg: The cohort from Tarnobrzeg (a south-eastern Polish
province consisting of small towns and rural communities) included 5,362 people
(2,502 men, 2,860 women). The MONICA-1 sample was examined in 1983-1984
(1,250 men, 1,472 women), the MONICA-2 sample in 1987-1988 (627 men, 684
women), and the MONICA-3 sample in 1992-1993 (625 men, 704 women). The follow-
up stopped in late December 1998, and no 10-year data were available for MONICA-3
participants; therefore, only MONICA-1 and MONICA-2 subjects are included in the
present analyses. The response rates were 82% and 73% for MONICA-1 and MONICA-
2, respectively.323
Lithuanian MONICA: The cohort consisted of four samples from Kaunas (the second
largest Lithuanian city and an economic, academic, and cultural centre); in total, 3,575
men and 3,816 women were screened. The MONICA-1 sample (1,339 men, 1,404
women) was examined in 1983-1985, the MONICA-2 sample (924 men, 934 women) in
1986-1987, the MONICA-3 sample (681 men, 686 women) in 1992-1993, and the
MONICA-4 sample (631 men, 792 women) in 2001-2002. For the MONICA-4
participants, no 10-year follow-up data were available; therefore, only subjects from the
MONICA-1, 2, and 3 samples are included in the present analyses. The respective
response rates were 70%, 70%, and 59%.324
94
Russian MONICA: The cohort included 9,835 residents (4,899 men, 4,936 women) of
the three districts of Novosibirsk (an industrial and scientific centre in Western Siberia).
The MONICA-1 sample (1,573 men, 1,602 women) was examined in 1985-1986, the
MONICA-2 sample (1,721 men, 1,666 women) in 1988-1989, and the MONICA-3
sample (1,605 men, 1,668 women) in 1994-1995. For each sample, the response rate
was approximately 72%.230
Since the SCORE instrument predicts cardiovascular risk in individuals without pre-
existing atherosclerotic CVD, people with a self-reported history or medical evidence of
MI, angina, or stroke are excluded from the present analyses. The subjects aged under
40 years at baseline are also excluded, as the SCORE scale predicts fatal CVD risk in
people over 40.20 For Tarnobrzeg samples, the deceased subjects with missing ICD
codes (n=16) are excluded, since it was not possible to reliably define their outcome
status (atherosclerotic CVD death vs. death from other causes). In total, 1,861, 2,437,
2,782, 3,806, and 5,669 MONICA participants from the Czech Republic, Poland
(Warsaw and Tarnobrzeg), Lithuania, and Russia, respectively, are included in the first
step of the analyses (Table 4.1.1, penultimate row).
Individuals with missing exposure values (classical risk factors included in SCORE and
socioeconomic measures) are not excluded from descriptive analyses, and an additional
“missing” category is created for these values. The survival analyses, for which the
complete case approach is used (for details, see Section 4.5.1), include 1,340, 2,404,
2,729, 3,301, and 5,253 MONICA participants from the Czech Republic, Poland
(Warsaw and Tarnobrzeg), Lithuania, and Russia, respectively (Table 4.1.1, last row).
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Table 4.1.1. MONICA sample selection
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men Women Men Women Men Women Men Women Men Women
Whole MONICA sample 1,627 1,646 2,019 2,060 1,877 2,156 2,944 3,024 4,899 4,936
Within the study age range
(40-64 years at baseline)
967 1,010 1,659 1,737 1,541 1,733 2,236 2,360 2,984 3,078
Without pre-existing CVD 898 963 1,264 1,173 1,301 1,481 1,897 1,909 2,751 2,918
Without missing ICD codes 898 963 1,264 1,173 1,279 1,466 1,897 1,909 2,751 2,918
Without missing SCORE
values
636 704 1,253 1,151 1,267 1,462 1,651 1,650 2,576 2,677
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4.1.2. HAPIEE population and samples
The HAPIEE (Health, Alcohol and Psychosocial factors In Eastern Europe) study
prospectively investigates the determinants of CVD and other chronic conditions in
CEE/FSU.43 It follows four cohorts from the Czech Republic (Havířov/Karviná, Hradec 
Králové, Jihlava, Kroměříž, Liberec, and Ústí nad Labem), Poland (Krakow), Russia 
(Novosibirsk), and Lithuania (Kaunas). Since the baseline (2002-2004), Czech, Polish,
and Russian cohorts have been followed for cause-specific mortality, including fatal
CVD, and for non-fatal CHD and strokes. As the Lithuanian cohort entered the study
later (2005), the current absolute number of circulatory deaths is insufficient to assess
CVD mortality. Therefore, only HAPIEE data from the first three countries are analysed
in this thesis.
The study participants – men and women aged 45-69 years – were randomly selected
from urban population registers (electoral lists in Russia). Although HAPIEE
populations are not entirely representative of the respective national populations, it can
still be assumed that their CVD mortality, cardiovascular risk profiles, and additional
risk determinants satisfactorily approximate those in the majority of Czech, Polish, and
Russian cities.43 The actual total HAPIEE sample size was 28,947, with an overall
response rate of 59% (55% in the Czech Republic, 61% in Poland, and 61% in
Russia).43
Due to delayed participation, some subjects took part in the baseline survey at the age of
70-73 years; in the present analyses, the upper limit for baseline age is extended to 70.9
years, while older individuals (n=86) are excluded. The thesis also does not include
people with a self-reported history of MI, angina, or stroke; therefore, in total, 23,265
subjects are included in the descriptive analyses: 7,633 from the Czech Republic, 8,316
from Poland, and 7,316 from Russia (Table 4.1.2, penultimate row). In the Czech
Republic and Poland, the study questionnaire was completed at home, prior to the
medical examination in a clinic, while in Russia, both parts of the study were performed
in a clinic. This explains the smaller proportion of Czech and Polish participants with
complete questionnaire and examination data (82% and 87%, respectively). However,
individuals with missing exposure values are not excluded from descriptive analyses,
and an additional “missing” category is created for these values. The survival analyses,
employing the complete case approach (see Section 4.5.1), included 6,018 participants
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from the Czech Republic, 7,209 from Poland, and 7,290 from Russia (Table 4.1.2, last
row).
Table 4.1.2. HAPIEE sample selection
Czech Republic Poland Russia
Men Women Men Women Men Women
Whole HAPIEE sample 4,124 4,732 5,230 5,498 4,269 5,094
Within the study age
range (45-70 years at
baseline)
4,077 4,704 5,230 5,498 4,264 5,088
Without pre-existing
CVD
3,405 4,228 3,986 4,330 3,254 4,062
Without missing
SCORE values
2,659 3,359 3,456 3,753 3,246 4,044
The population- and gender-specific distribution of classical and additional
cardiovascular risk factors and fatal atherosclerotic CVD levels in Czech, Polish,
Lithuanian, and Russian MONICA samples, as well as in Czech, Polish, and Russian
HAPIEE samples, will be presented in Chapter 5.
4.2. Ethical approval and informed consent
The MONICA study protocol was approved by the local ethics committees in each
participating country.42 The HAPIEE study protocol was approved by the University
College London/University College London Hospital ethics committee and by the local
ethics committees at each study centre.43 Before entering the project, all potential
participants received an explanatory invitation letter. All participants gave written
informed consent at baseline to take part in the questionnaire survey, medical
examination (including blood sample analyses), and the follow-up. This PhD project
uses already existing data and, therefore, did not require separate ethical approval.
4.3. Measurements
At baseline, MONICA participants were examined and interviewed in the clinic.
Among other procedures, an interview on demographic and socioeconomic parameters,
health behaviours and lifestyle, as well as BP measurement, anthropometry, and blood
sample collection, was performed.42
The baseline data collection in the HAPIEE Study included a questionnaire survey and a
clinical examination. The structured questionnaire focused on demographic and
socioeconomic characteristics, health status, health behaviours, lifestyle, and
psychosocial factors43. All questions were translated from English into each local
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language, back translated, and checked for accuracy. Anthropometry, measurement of
BP, lung function and cognitive function, plus a fasting venous blood sample collection,
were performed during the examination in the clinic. The description of BP and TCH
measurement is given in Section 4.3.2.
In the present analyses, only the variables relevant to the research aims and objectives
are used. These variables are described below in more detail.
4.3.1. Outcome
The study outcome was atherosclerotic cardiovascular death, either coronary or non-
coronary, in agreement with the SCORE end-points20 (see Table 4.3.1 for respective
ICD-9 and ICD-10 codes).
Table 4.3.1. Atherosclerotic coronary and non-coronary causes of death
ICD-9
code
ICD-10
code
Diagnosis
401-405 I10-I13 Hypertensive disease
410-414 I20-I25 Ischemic heart disease
426 I44-I45 Atrioventricular and left bundle-branch block; other conduction disorders
N/A I46.1 Sudden cardiac death, so described
427-429 I47-I51
Paroxysmal tachycardia, atrial fibrillation and flutter; other cardiac
arrhythmias; heart failure; complications and ill-defined descriptions of heart
disease
431 I61 Intracerebral haemorrhage
432-438 I63-I69
Cerebral infarction; stroke, not specified as haemorrhage or infarction;
occlusion and stenosis of precerebral arteries, not resulting in cerebral
infarction; occlusion and stenosis of cerebral arteries, not resulting in cerebral
infarction; other cerebrovascular diseases; cerebrovascular disorders in
diseases classified elsewhere; sequelae of cerebrovascular disease
440-443 I70-I73 Atherosclerosis; aortic aneurysm and dissection; other aneurysm; otherperipheral vascular diseases
798.1 R96.0 Instantaneous death
798.2 R96.1 Death occurring less than 24 hours from onset of symptoms, not otherwiseexplained
For MONICA cohorts, cause-specific mortality data came from the population-specific
routine systems of vital registration (national or local mortality registers) and were
classified according to ICD-9 or ICD-10 before and after January 1st 1997,
respectively.42;126 In the HAPIEE study, cardiovascular mortality data are obtained from
the same vital registration sources. Specifically, in the Czech Republic, the national
death register is being used. In Poland, the provincial death register covers the city of
Krakow and surrounding area. In Russia, the local mortality register covers selected
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Novosibirsk districts, from which HAPIEE participants were recruited.43 Typically, the
mortality data, coded according to ICD-10, become available in the end of the following
year.
4.3.2. SCORE risk determinants
As mentioned in Section 2.1.3 of the Background chapter, the SCORE scale predicts
10-year risk of fatal CVD in middle-aged men and women without pre-existing
atherosclerotic CVD.20 Based on 12 European cohorts, two separate SCORE charts
were created for low and high-risk countries, and the latter is officially recommended
for CEE/FSU populations.17 Since the recently introduced Czech and Polish SCORE
versions lack a proper description of their development and/or recalibration175;176, the
original high-risk SCORE scale is used as a core model for all countries of interest. For
comparison, the performance of the original low-risk scale is also investigated. The
SCORE predictions of 10-year risk of fatal CVD in populations at high and low risk are
presented in Tables A4.3.1-A4.3.2 (Appendix I). In addition, the performance of high
and low-risk non-dichotomised SCORE is assessed, by analysing individual levels of
SCORE-predicted absolute risk (percentages in the respective SCORE chart cells) as a
continuous variable, since it is well known that dichotomisation of continuous risk
predictors may result in a considerable loss of power and residual
confounding.59;76;78;82;325-327
For both SCORE versions, the risk determinants include age, gender, smoking status
(current smokers vs. never or ex-smokers), TCH (scales based on TCH vs. TCH:HDL-
CH ratio perform similarly), and SBP. In both MONICA and HAPIEE, the data on self-
reported smoking status were obtained from the baseline standard
questionnaire.42;43;126;130 Those currently and regularly smoking at least one cigarette per
day were regarded as current smokers; never and ex-smokers were considered non-
smokers, in accordance with the SCORE criteria.20
SBP measurement was performed after a five-minute rest, in a quiet room with
comfortable temperature, using a standard mercury sphygmomanometer (MONICA) or
a digital blood pressure monitor Omron M5-I (HAPIEE). SBP was measured in a sitting
position, on the right arm, with a two-minute interval between consecutive
measurements (two for MONICA, three for HAPIEE), and recorded as a continuous
variable, to the nearest two mm Hg.42;43
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TCH concentration was measured in a fasting venous blood sample, taken from the
antecubital vein, with the person in the sitting position and with minimal tourniquet use.
In MONICA, TCH levels were measured with an enzymatic method (CHOD-PAP kits,
Boehringer, Mannheim, Germany) in Czech and Lithuanian samples, while for Polish
and Russian samples, the direct Liebermann-Burchard method was used. In HAPIEE,
serum TCH levels for Czech, Polish, and Russian samples were measured using an
enzymatic method.43 All assay methods were calibrated, and all MONICA and HAPIEE
laboratories were subjected to internal quality control. In addition, external quality
control for MONICA was performed at the WHO Regional Lipid Reference Centre
(Institute for Clinical and Experimental Medicine, Prague, Czech Republic).42 In both
MONICA and HAPIEE, the TCH concentration was recorded as a continuous variable
(mmol/l).
4.3.3. Additional risk predictors
Based on the evidence summarised in Section 2.3.2 of the Background chapter,
selected socioeconomic parameters are considered as additional cardiovascular risk
factors in this thesis. Specifically, in MONICA and HAPIEE samples, education was
categorised as primary or less, vocational, secondary, or university level, and marital
status as married/cohabiting, single, separated/divorced, or widowed.42;43 For Polish
MONICA samples from Warsaw and Tarnobrzeg, no data on marital status were
available, while the information on education was obtained for all MONICA and
HAPIEE samples.
Since hazardous alcohol drinking may be an additional cardiovascular risk factor (see
Section 2.3.3), it is also included in the analyses. The associations between alcohol and
fatal CVD are investigated only for HAPIEE samples, because in MONICA, no
compatible data on alcohol consumption were available for all samples. In HAPIEE,
annual alcohol consumption and drinking patterns were estimated by the graduated
frequency (GF) method319-321, which assesses how often during the past 12 months more
than a specific amount of alcohol (approximately 0.5 drinks, 1-2, 3-4, 5-6, 7-9, or 10
drinks) was consumed; the frequency is measured on a 9-point scale, ranging from
“never” to “every day”. Based on the GF data, alcohol drinking frequency in the last
year (“never”, “less than once per month”, “1-3 times per month”, “at least once per
week”), and binge drinking (100 g of ethanol per drinking session at least once a
month) parameters were calculated. Additionally, the presence of alcohol-related
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problems in the last 12 months was assessed by the CAGE questionnaire318, which
asked whether the person had felt he/she should cut down on drinking; whether people
had annoyed the respondent by criticising his/her drinking; whether the person had felt
bad or guilty about his/her drinking; and whether he/she had a drink first thing in the
morning. Participants with two or more positive answers are considered as CAGE-
positive.
In the descriptive analyses, the original categories of socioeconomic parameters and
alcohol consumption characteristics are used. As the outcome numbers across the
original non-dichotomised categories are insufficient for performing analyses of
adequate power, these additional risk determinants are dichotomised, while estimating
the prognostic performance of the extended SCORE models (see Chapters 7-8).
Dichotomisation of alcohol consumption frequency was not appropriate, since this
variable demonstrated a J or U-shaped association with fatal CVD; therefore, only binge
drinking and CAGE were used in the analyses of the SCORE performance extended by
alcohol consumption measures (Chapter 8).
The present research focuses on the easily measurable socioeconomic characteristics
and alcohol consumption parameters, which will make the final extended models more
relevant and applicable to real-world clinical and epidemiological settings.189
4.4. Statistical power of the study
This thesis uses already existing MONICA and HAPIEE data, and, therefore, the size of
the samples could not be influenced. Considering the large sizes and relatively large
outcome numbers for the majority of MONICA and HAPIEE samples, the study power
is expected to be sufficient for an assessment of the association between baseline
SCORE, as the main exposure of interest, and atherosclerotic cardiovascular mortality.
Thus, in Czech MONICA samples, followed for 10 years, there were 75 atherosclerotic
CVD deaths (among all participants, regardless of the availability of the baseline
SCORE data). The total number of atherosclerotic cardiovascular deaths in the first 10
years was 110 and 82 for Polish MONICA samples from Warsaw and Tarnobrzeg,
respectively, and 95 for Lithuanian MONICA samples. Among Russian MONICA
participants, 295 atherosclerotic CVD deaths were registered within the first 10 years of
follow-up. During the period for which the complete data on cause-specific mortality
are available for HAPIEE subjects (until the end of 2009 for the Czech Republic, and
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until the end of 2008 for Poland and Russia), the observed number of atherosclerotic
cardiovascular deaths was 84, 71, and 147, respectively.
Since for several risk predictors, such as SBP and TCH in Czech and Polish HAPIEE
samples, the data were partially missing, the complete case analyses might have
decreased the number of observations and outcomes and, hence, reduced the study
power. As the main association of interest is between the conventional cardiovascular
risk predictors, captured by SCORE (exposure), and atherosclerotic CVD mortality
(outcome), only the cases with available data on both exposure and outcome are
included in the survival analyses and the analyses of SCORE prognostic performance.
Therefore, the calculation of the study power is also based on the complete case
approach.
In particular, assuming that the confidence level is 95% or 99%, and the lowest hazard
ratio (HR) for the comparison of atherosclerotic CVD mortality in the exposed (high-
risk SCORE 5%) vs. unexposed (SCORE <5%) participants is 1.25, the study power
was calculated for the smallest male and female MONICA and HAPIEE samples, in
order to obtain the most conservative estimates. For MONICA, the smallest samples
were from the Czech Republic (636 men, 704 women). For HAPIEE, the Czech samples
were also the smallest (2,659 men, 3,359 women; for details, see Section 4.1.2). As
shown in Table 4.4.1, for the 95% CI and the minimal HR of 1.25, statistical power was
at least 80% across these four samples. As all the other MONICA and HAPIEE samples
were larger, the respective study power was also higher and, hence, exceeded 80%.
Table 4.4.1. Study power calculation for Czech MONICA and HAPIEE samples
Hazard
ratio
Study power
95% CI 99% CI
Czech MONICA
Men Women Men Women
1.25 80.3% 84.1% 59.4% 64.97%
1.50 99.9% 99.9% 99.4% 99.8%
2.00 >99.9% >99.9% >99.9% >99.9%
Czech HAPIEE
Men Women Men Women
1.25 >99.9% >99.9% 99.9% >99.9%
1.50 >99.9% >99.9% >99.9% >99.9%
2.00 >99.9% >99.9% >99.9% >99.9%
Therefore, despite some expected loss of power in multiple regression analyses
(adjusting for socioeconomic parameters and alcohol consumption characteristics), the
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analyses of the link between the high-risk SCORE 5% and fatal CVD have sufficient
power to demonstrate efficiently even moderate associations (minimal HR 1.25)
between SCORE and atherosclerotic cardiovascular mortality. In addition, the power of
the random effects meta-analyses, which pool the sample-specific estimates of the
SCORE-fatal CVD association and assess the overall magnitude of this link (see
Section 4.5.4), is higher than the power of the analyses for individual samples.
4.5. Statistical analyses
This section outlines the strategy to deal with missing data and outliers and summarises
the reasons for performing complete case analyses. The statistical principles underlying
the SCORE prognostic model are introduced, followed by the description of the
measures that are used to assess the performance of original and extended SCORE
instruments. Finally, the specific steps of MONICA and HAPIEE data analyses are
described.
4.5.1. Missing data and outliers
For the MONICA samples, the percentage of missing data is generally low, with the
exception of TCH and SBP values in the Czech Republic and TCH values in Lithuania
(Chapter 5). Over 10% of SBP and TCH values are missing for Polish and Czech
HAPIEE samples, since these participants were clinically examined after the
questionnaire survey at home. The data range and consistency checks were also
performed, and any clinically improbable or inconsistent values (outliers) were set as
“missing”. In the descriptive analyses, a separate, additional category is created for the
missing values. For the risk prediction models, the observations with missing values are
excluded, and the complete case analyses are performed. The potential limitations of
this approach, as well as possible alternatives, will be addressed in the Discussion
chapter. However, it should be noted that the main aim of this thesis is to study the
individual-level relationship between the SCORE-predicted risk of fatal atherosclerotic
CVD and observed risk, which requires having information on both the former
(exposure) and the latter (outcome). Since individual SCORE values cannot be
calculated for the subjects with missing data on TCH and/or SBP, these participants are
excluded from the SCORE-based survival analyses and prognostic performance
analyses.
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The complete case approach has been extensively used in the area of cardiovascular risk
prediction (for example33;99;235;261;328-330). It was also demonstrated that non-response at
resurvey does not bias the associations between baseline cardiovascular risk factors and
later CVD mortality331, although more evidence is needed on the impact of non-
response to baseline surveys. The alternative to the complete case analysis would be
multiple imputation of missing data. The majority of the available multiple imputation
approaches are based on the assumption of data missing at random, or completely at
random.23;332-337 If the assumption of SCORE missing at random, or completely at
random, was true for MONICA and HAPIEE data, the mortality levels for subjects with
missing vs. non-missing SCORE values would be relatively similar, since the missing
SCORE group would represent a more or less equal mixture of individuals with risk
levels <5% and ≥5%. 
However, the observed levels of all-cause mortality and atherosclerotic CVD mortality
across MONICA and HAPIEE samples clearly demonstrate that the risk of death from
all causes, as well as the risk of cardiovascular death, was different in participants with
missing SCORE values, compared to their peers with non-missing SCORE (in Table
4.5.1, the 10-year observed mortality and the currently observed mortality data are
presented for MONICA and HAPIEE, respectively).
The degree of this discrepancy in the observed risk levels varied substantially across
samples, and also differed for all-cause vs. atherosclerotic cardiovascular mortality. In
particular, the ratio of all-cause mortality among subjects with missing vs. non-missing
SCORE ranged from 0.83 (Tarnobrzeg) to 1.83 (Warsaw and the Czech Republic) in
MONICA, and from 0.59 (Russia) to 1.99 (Poland) in HAPIEE. For fatal CVD, this
ratio varied from 0.86 (Lithuania) to 2.10 (Tarnobrzeg) in MONICA, and from 1.86 (the
Czech Republic) to 2.75 (Poland) in HAPIEE. As in the Russian HAPIEE sample, only
26 people had missing SCORE levels, no atherosclerotic CVD deaths were registered in
these individuals. For Czech and Polish HAPIEE samples, the levels of all-cause and/or
cardiovascular mortality among subjects with missing SCORE were even higher than in
people with SCORE 5%.
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Table 4.5.1. All-cause and atherosclerotic cardiovascular mortality by baseline SCORE
levels: MONICA and HAPIEE
Subsample
size, N
All deaths, N (%) Atherosclerotic
cardiovascular deaths,
N (%)
MONICA
Czech Republic
Non-missing SCORE 1,340 139 (10.37) 45 (3.36)
SCORE <5% 989 61 (6.17) 15 (1.52)
SCORE ≥5% 351 78 (22.22) 30 (8.55) 
Missing SCORE 521 99 (19.00) 30 (5.78)
Poland (Warsaw)
Non-missing SCORE 2,404 279 (11.61) 107 (4.45)
SCORE <5% 1,655 112 (6.77) 35 (2.11)
SCORE ≥5% 749 167 (22.30) 72 (9.61) 
Missing SCORE 33 7 (21.21) 3 (9.09)
Poland (Tarnobrzeg)
Non-missing SCORE 2,729 206 (7.55) 81 (2.97)
SCORE <5% 2,030 97 (4.78) 32 (1.58)
SCORE ≥5% 699 109 (15.59) 49 (7.01) 
Missing SCORE 16 1 (6.25) 1 (6.25)
Lithuania
Non-missing SCORE 3,301 271 (8.21) 84 (2.54)
SCORE <5% 2,476 121 (4.89) 34 (1.37)
SCORE ≥5% 825 150 (18.18) 50 (6.06) 
Missing SCORE 505 43 (8.52) 11 (2.18)
Russia
Non-missing SCORE 5,253 591 (11.25) 267 (5.08)
SCORE <5% 3,892 279 (7.17) 117 (3.01)
SCORE ≥5% 1,361 312 (22.92) 150 (11.02) 
Missing SCORE 416 62 (14.90) 28 (6.73)
HAPIEE
Czech Republic
Non-missing SCORE 6,018 248 (4.12) 56 (0.93)
SCORE <5% 3,764 91 (2.42) 13 (0.35)
SCORE ≥5% 2,254 157 (6.97) 43 (1.91) 
Missing SCORE 1,615 121 (7.49) 28 (1.73)
Poland
Non-missing SCORE 7,209 265 (3.68) 50 (0.69)
SCORE <5% 4,494 80 (1.78) 13 (0.29)
SCORE ≥5% 2,715 185 (6.81) 37 (1.36) 
Missing SCORE 1,107 81 (7.32) 21 (1.90)
Russia
Non-missing SCORE 7,290 475 (6.52) 147 (2.02)
SCORE <5% 4,082 122 (2.99) 18 (0.44)
SCORE ≥5% 3,208 353 (11.00) 129 (4.02) 
Missing SCORE 26 1 (3.85) 0 (0.00)
Therefore, as demonstrated in Table 4.5.1, the baseline SCORE values appear to be
missing not at random, and the missingness patterns vary across MONICA and HAPIEE
samples. The application of multiple imputation techniques, based on the assumption of
data missing at random, or completely at random, to MONICA and HAPIEE data can
produce biased results.338-341 Hence, the present research will primarily focus on the
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complete case analyses. To check the validity of this approach, the results of the Cox
regression (the analysis of the strength of the unadjusted association between the high-
risk dichotomous SCORE and fatal CVD) are compared for the complete and multiply
imputed data. This comparison is performed for the samples with the highest proportion
of missing SCORE values – Czech MONICA, Lithuanian MONICA, Czech HAPIEE,
and Polish HAPIEE. The imputation model, which is based on the chained equations
approach and generates 10 imputations, includes SCORE, additional risk factors
(education and marital status for both MONICA and HAPIEE, binge drinking and
CAGE for HAPIEE), atherosclerotic CVD death, and logarithm of survival time.
4.5.2. SCORE statistical analyses – general strategy
Before describing the steps of the SCORE performance assessment in MONICA and
HAPIEE samples, it is important to summarise the statistical principles underlying the
original SCORE algorithm. The SCORE scale predicts 10-year risk of atherosclerotic
cardiovascular mortality in middle-aged individuals. The risk model has two
components: one defines the shape of the baseline survival function, separately for men
and women, and the other calculates relative risks for each risk factor – smoking, TCH,
and SBP.20 Risk factor coefficients were derived from the whole SCORE dataset, since
their effects are assumed to be similar in both genders, across countries, and over time.
The original SCORE risk functions were calculated using a Weibull proportional
hazards model, stratified by cohort and sex. Age was defined as a measure of risk
exposure time, rather than a risk factor in a traditional log-linear approach. However,
the semiparametric Cox regression models, used for cross-checking the risk predictions,
performed similarly.9;20
For both the Weibull and Cox-based risk estimates to be informative, it is essential to
know how close the predicted and observed risks are, and how well the low and high-
risk groups are differentiated. The next section, therefore, introduces various measures
which denote the performance of prognostic models, such as SCORE.
4.5.3. Measures of predictive model performance
As outlined in Section 2.1.1, the main measures of model performance are calibration
and discrimination. Calibration ability of a risk score reflects how close the predicted
and observed risks are, with a predicted to observed risk ratio of 1.0 indicating perfect
calibration.9;10;39;55;58;59;68;108;188 Predicted and observed risks could be compared not
only for the whole samples, but also across age groups108, or for individuals above and
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below the established risk cut-off.68 In a formal test of model calibration, the Hosmer-
Lemeshow test, predicted risk values (typically, gender-specific) are compared to
observed values within the deciles of estimated risk.56 Lower values of Hosmer-
Lemeshow χ2 and higher p values indicate a smaller difference between predicted vs.
observed risk, and therefore, better calibration.56;58;73 The Gronnesby-Borgan test is an
equivalent of the Hosmer-Lemeshow test for survival data analysis, based on martingale
residuals.342 However, due to the limited outcome numbers in the country- and gender-
specific MONICA and HAPIEE subgroups, the Gronnesby-Borgan model would
collapse on only two risk quantiles, and so the traditional Hosmer-Lemeshow test is
used instead. It should be noted that the results of this test might be affected when at
least two individuals have the same predicted risk levels, or when these levels are
relatively low.56;57 The test results are also sensitive to small deviations in fit when the
sample size increases, and the null hypothesis of perfect fit is almost always rejected in
larger samples.343
Calibration performance of the SCORE model in a specific external population could be
improved by adjusting the baseline hazard function to the local background levels of
CVD mortality and risk factors, via the recalibration procedure (not to be confused with
calibration as a model performance parameter).10;140;344-348 Thus, while model
calibration appears a more flexible measure of prognostic performance, which
potentially can be “fitted” to a specific population, it does not provide information on
such a key, intrinsic quality of the risk-predicting algorithm as the accuracy of
discrimination between subjects who will or will not develop the outcome of interest.
Discrimination is considered more important than calibration by some authors, since the
former cannot be improved by adjustment or recalibration of the model.55;69;349-351
Specifically, discrimination is the ability of a model to separate the participants who
will experience events (such as fatal CVD) during the follow-up from the individuals
who will remain event-free.55;58;59;68;352 Threshold measures of discrimination include
sensitivity (probability of high-risk score for people with subsequent events), specificity
(probability of low-risk score for people without subsequent events), the ratio of true vs.
false positives (likelihood ratio positive, LR+, or sensitivity/1 – specificity), and the
ratio of false to true negatives (likelihood ratio negative, LR-, or (1-
sensitivity)/specificity), for a particular risk cut-off (5% for the SCORE model).
Additionally, the risk threshold could be characterised in terms of positive and negative
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predictive values (PPV and NPV), which reflect the outcome probability in the high-risk
group (PPV), and the probability of no outcome in the low-risk group (NPV).68;70;71 The
summary measures of discrimination are presented by the area under the receiver
operating characteristic curve (AUROC) and the Harrell’s C-statistic (AUROC
equivalent for the survival models).69 AUROC plots the sensitivity (true positive rate)
against “1 - specificity” (false positive rate) across all consecutive cut-offs for the
outcome probability. The AUROC or C-statistic values of 0.5 and 1.0 indicate minimal
vs. ideal discrimination, respectively.10;69-71;76;82;83;353
Royston’s R2 index is a recently introduced discrimination measure for survival analysis
models. R2 statistic represents the amount of the outcome variation accounted for by
risk predictors in the proportional hazards model.59;72 In the present analyses, R2 statistic
was adjusted by the model dimension (the number of covariates), in order to facilitate
the subsequent assessment of the extended SCORE performance. The bootstrap CI were
calculated, using the minimal recommended replication number of 1,000.72
The additional prognostic information, provided by extra risk predictors, could be
assessed by LR tests, where lower p values denote more pronounced differences
between the nested baseline and extended models and, hence, better predictive
performance of the latter instrument. The nested approach means that the extended
model contains all of the markers from the baseline model.39;73 The discrimination
improvement of the extended model could also be quantified via risk reclassification
parameters, such as net reclassification index (NRI) and integrated discrimination
improvement (IDI). NRI represents the net proportion of people who move from one
clinically relevant risk group to another, as a result of adding a new risk
predictor.9;39;71;79 In this thesis, the additional risk factors (socioeconomic parameters
and alcohol consumption characteristics) are dichotomised, due to limited outcome
numbers across the original categories, and, hence, are specific to MONICA and
HAPIEE samples. Therefore, IDI, which is relatively independent of risk thresholds and
categories, is used instead of NRI. IDI quantifies the separation between the individuals
who will experience an outcome and those who will not, in terms of the average
predicted risks for these two groups, across all possible cut-offs. In other words, this
summary reclassification measure reflects the extended model’s ability to improve
average sensitivity without compromising average specificity.39;71;79;82-85 Small IDI
values, even if statistically significant, mean that the average individual change in the
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risk predicted by the new, extended model is modest and, hence, the impact on the
clinical decision making is minimal.84;86;188;354
After introducing the prognostic performance measures employed in the present
research, the next section will describe how these measures are used when applying the
original and extended SCORE scales to MONICA and HAPIEE samples.
4.5.4. Step-by-step analyses of MONICA and HAPIEE data
As summarised in Section 2.1.3, the prognostic performance of the original, non-
calibrated SCORE in external Western European populations was typically worse than
in the cohorts used for deriving this instrument, but could be substantially improved by
the adjustment/recalibration procedure.9;10;20;64;140;141 However, to my knowledge, no
published studies have investigated the performance of the original or recalibrated
SCORE instruments in CEE/FSU, and no systematic attempt has been made for these
populations to evaluate the prognostic value of such new cardiovascular risk factors as
socioeconomic parameters and alcohol drinking when added to the SCORE risk
predictors. Therefore, the present analyses include the following steps for each
MONICA and HAPIEE sample, separately for men and women:
Step 1. Describing the distribution of classical CVD risk factors (age, smoking, TCH,
and SBP) and additional cardiovascular risk determinants (socioeconomic parameters
and alcohol consumption measures), as well as the levels of atherosclerotic CVD
mortality (see Chapter 5).
Step 2. Investigating the role of high and low-risk SCORE as predictors of
atherosclerotic cardiovascular mortality, using the standard Cox, competing-risks, and
Weibull regression models (Chapter 6, Section 6.1).
Step 3. Assessing calibration of the original high and low-risk SCORE scales (predicted
to observed risk ratio in whole samples, across age groups, and above/below the 5% risk
threshold; Hosmer-Lemeshow test) (Section 6.2).
Step 4. Estimating the 10-year HAPIEE levels of atherosclerotic CVD mortality, based
on the country-specific MONICA data or the exponential model projections; comparing
the HAPIEE mortality levels predicted by high and low-risk SCORE to these estimates,
in order to approximate the 10-year SCORE calibration across HAPIEE samples
(Section 6.3).
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Step 5. Assessing discrimination of the original high and low-risk SCORE (sensitivity,
specificity, LR+, LR-, PPV, NPV, AUROC, Harrell’s C-statistic, and Royston’s R2
index) (Section 6.4).
Step 6. Exploring the potential of socioeconomic variables for the SCORE model
extension by evaluating the role of SCORE, education, and marital status as predictors
of atherosclerotic CVD mortality, and by investigating the calibration and
discrimination (measures listed for Step 3, plus LRT p values and IDI) of SCORE
extended by socioeconomic characteristics (Chapter 7).
Step 7. Assessing the potential of alcohol consumption measures for the SCORE model
extension by investigating the role of SCORE and drinking parameters as predictors of
fatal atherosclerotic CVD, and by estimating the calibration and discrimination
(measures listed for Step 4) of SCORE extended by drinking characteristics (Chapter
8).
Step 8. Combining the sample-specific effect estimates in the random effects meta-
analyses, to assess the overall strength of the association between SCORE and
atherosclerotic cardiovascular mortality before and after adjustment for socioeconomic
parameters or alcohol consumption characteristics (Chapter 9).
For Steps 2-8, the use of proportional hazards regression models, primarily Cox
regression, is justified by the high p values in Schoenfeld’s test across all MONICA and
HAPIEE samples. For each SCORE version (dichotomous and continuous high and
low-risk instrument), p values were 0.10 and 0.36 for MONICA and HAPIEE
samples, respectively. The strength of the main association of interest, between SCORE
and atherosclerotic CVD mortality, is investigated in the classical Cox regression
models, the parametric Weibull models which were originally used for the SCORE
development20, and the competing-risks models, which take into account the risk of
death from causes other than atherosclerotic CVD. Specifically, the “naïve” Cox
analysis could over-estimate the risk, since it assumes that in the future, the outcome of
interest (such as fatal atherosclerotic CVD) could be registered even in the subjects who
will actually never develop it, due to the already occurred competing outcome (such as
non-CVD death). This limitation can be addressed by using the competing-risks
regression approach.355-358
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For Steps 2-8, the data from all MONICA waves have been pooled within samples,
because for the association between the risk predicted by any SCORE version and
observed atherosclerotic CVD mortality, there was no evidence of confounding by or
statistical interaction with the MONICA study wave. Specifically, there were no
substantial changes in the SCORE hazard ratios after adding the study wave to the
model, and the LR tests comparing the models with and without the interaction
produced high p values.
For Step 4, the estimation of 10-year CVD mortality for HAPIEE samples is based on
the mortality patterns in the MONICA samples from respective countries. Specifically,
for the MONICA-based estimates, it was assumed that the ratio between the death
numbers registered at a pre-specified cut-off point (the mean follow-up time in complete
years: six, five, and four years for the Czech, Polish, and Russian HAPIEE samples,
respectively) and the death numbers observed during the 10-year follow-up period
would be similar for MONICA and HAPIEE subjects from the same country. These
ratios are calculated for Czech, Polish, and Russian MONICA samples, separately for
men and women. The mortality patterns in the urban MONICA population of Warsaw
are expected to be a better approximation of the respective patterns among urban Polish
HAPIEE subjects (the residents of Krakow). Projecting these country- and gender-
specific ratios onto the currently observed numbers of cardiovascular deaths in HAPIEE
samples provides the estimates of the 10-year atherosclerotic CVD mortality among
HAPIEE men and women. These estimates are used for the analyses of the expected 10-
year SCORE calibration across HAPIEE samples. An alternative approach for
estimating the 10-year HAPIEE mortality and calibration, based on the exponential
survival model, is also presented.
For Steps 6-7, all the extended risk models would include significant, according to LRT
p values, interactions between the main exposure of interest (SCORE, as a dichotomous
or continuous high and low-risk scale) and additional risk predictors (socioeconomic
measures or drinking characteristics). Extending the SCORE model by more than one
additional risk predictor (for example, adding both education and marital status to
SCORE) would be possible if the collinearity of these extra risk factors is ruled out, as
denoted by low values of phi correlation coefficient (a measure of association between
two binary variables). Using OR for the assessment of this association was problematic,
due to the distribution of additional risk factors in the samples. Thus, the majority of
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participants reported no bingeing and had CAGE score <2, while the number of so-
called discordant observations (binge drinking only, or positive CAGE only) was low,
particularly in women. Therefore, phi coefficients were considered a more appropriate
measure to evaluate the strength of the association between education and marital status,
or binge drinking and CAGE, across MONICA and HAPIEE samples. Of note, the
SCORE model could not be simultaneously extended by socioeconomic parameters and
alcohol consumption characteristics, as that would restrict the analyses to HAPIEE
samples only (compatible data on alcohol consumption were not available for all
MONICA samples), and also result in very low outcome numbers across the subgroups
defined by both socioeconomic characteristics and drinking measures.
For Step 8, assessing the pooled impact of SCORE on atherosclerotic CVD mortality,
both before and after controlling for additional cardiovascular risk predictors, the
random effects, rather than fixed effects, meta-analysis technique has been chosen a
priori, in order to obtain more conservative estimates.359-361
All statistical analyses are performed using Stata/IC 11.0 (StataCorp LP, Texas, USA).
To summarise, Chapter 4 has described the selection of the study samples (MONICA
and HAPIEE) and the measurement of the prognostic model components, including
atherosclerotic CVD mortality as the outcome, SCORE as the main exposure, and
socioeconomic parameters and alcohol consumption characteristics as the additional
exposures of interest. The principles of the prognostic performance assessment were
summarised and followed by the description of the specific analytical steps used to
study SCORE performance in MONICA and HAPIEE samples, before and after
extending the SCORE model by additional risk predictors. The results of the respective
analyses will be presented in the next five chapters.
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Chapter 5. Description of the study samples
Before investigating the prognostic performance of the original and extended SCORE
instruments in MONICA and HAPIEE participants (Chapters 6-9), the study samples
will be described in terms of their baseline demographic characteristics and the
distribution of both classical, SCORE-comprising risk factors and additional risk
determinants, such as socioeconomic parameters and alcohol consumption
characteristics. The levels of 10-year (MONICA) and currently observed (HAPIEE)
atherosclerotic CVD mortality will also be presented.
5.1. MONICA: SCORE risk factors, additional risk determinants, and
fatal atherosclerotic CVD
The study population included only people aged 40 years or older at baseline, since the
SCORE scale predicts cardiovascular risk in subjects aged 40-65 years. The mean age
of MONICA participants was close to 50 years, varying from 50.77.3 years in Czech
men to 52.56.8 years in Polish men from Tarnobrzeg. The five-year age group sizes
were similar, with slightly lower proportion of people aged 60-64 years: from 14.5% to
17.1% in men from the Czech Republic and Tarnobrzeg, respectively (Table 5.1.1), and
from 15.0% to 18.0% in Lithuanian and Russian women, respectively (Table 5.1.2).
The prevalence of traditional risk factors included in the SCORE instrument was
relatively high. Smoking prevalence was over 30% in men from all samples, and
exceeded 20% in Czech women and Polish women from Warsaw. By contrast, the
proportion of smokers in women from Tarnobrzeg, Kaunas and Novosibirsk was under
10%. Mean levels of TCH tended to be slightly higher in women than in men, and were
close to 6 mmol/l across all samples. The highest TCH concentrations were observed
among Czech men (6.21.3 mmol/l) and Czech women (6.31.3 mmol/l). Mean SBP
levels were close to 140 mm Hg in both genders, with maximal values registered in
Polish men and women from Warsaw (142.323.9 mm Hg and 142.625.0 mm Hg,
respectively).
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Table 5.1.1. Baseline characteristics of MONICA samples (men)
Categories Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
N % N % N % N % N %
Age groups
40-44 258 28.73 273 21.60 223 17.44 443 23.35 480 17.40
45-49 207 23.05 262 20.73 265 20.72 373 19.66 616 22.40
50-54 161 17.93 253 20.02 276 21.58 374 19.72 569 20.70
55-59 142 15.81 285 22.55 296 23.14 417 21.98 634 23.00
60-64 130 14.48 191 15.11 219 17.12 290 15.29 452 16.40
Current smoking
Yes 329 36.64 666 52.69 717 56.06 668 35.21 1474 53.60
No 528 58.80 598 47.31 562 43.94 1,228 64.73 1271 46.20
Missing 41 4.57 0 0.00 0 0.00 1 0.05 6 0.20
TCH
Mean (SD) 6.22 (1.32) 5.61 (0.95) 5.47 (0.99) 5.97 (1.20) 5.58 (1.16)
Missing 257 28.62 11 0.87 12 0.94 246 12.97 174 6.30
SBP
Mean (SD) 140.68 (19.52) 142.25 (23.92) 136.63 (21.15) 137.51 (19.96) 136.19 (20.13)
Missing 255 28.40 0 0.00 0 0.00 1 0.05 1 0.05
Education
University 77 8.57 254 20.09 60 4.69 521 27.46 529 19.20
Secondary/vocational 211 23.50 423 33.47 309 24.16 642 33.84 1,026 37.30
Lower 500 55.68 587 46.44 910 71.15 731 38.53 1,179 42.90
Missing 110 12.25 0 0.00 0 0.00 3 0.16 17 0.60
Marital status
Single 59 6.57 N/A N/A 50 2.64 57 2.10
Married 651 72.49 1,752 92.36 2,516 91.50
Divorced 57 6.35 71 3.74 115 4.20
Widowed 20 2.23 16 0.84 54 2.00
Missing 111 12.36 8 0.42 9 0.30
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Table 5.1.2. Baseline characteristics of MONICA samples (women)
Categories Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
N % N % N % N % N %
Age groups
40-44 229 23.78 254 21.65 268 18.28 443 23.21 548 18.80
45-49 237 24.61 253 21.57 318 21.69 394 20.64 629 21.60
50-54 165 17.13 237 20.20 313 21.35 395 20.69 602 20.60
55-59 170 17.65 245 20.89 309 21.08 391 20.48 613 21.00
60-64 162 16.82 184 15.69 258 17.60 286 14.98 526 18.00
Current smoking
Yes 196 20.35 364 31.03 109 7.44 77 4.03 97 3.30
No 717 74.45 809 68.97 1,357 92.56 1,832 95.97 2,813 96.40
Missing 50 5.19 0 0.00 0 0.00 0 0.00 8 0.30
TCH
Mean (SD) 6.34 (1.25) 5.74 (1.03) 5.69 (1.07) 6.29 (1.23) 5.89 (1.32)
Missing 259 26.90 22 1.88 4 0.27 257 13.46 239 8.20
SBP
Mean (SD) 139.58 (19.05) 142.61 (25.02) 141.64 (24.27) 137.56 (22.44) 138.69 (22.81)
Missing 249 25.86 0 0.00 0 0.00 2 0.11 2 0.01
Education
University 39 4.05 153 13.04 32 2.18 417 21.84 435 14.90
Secondary/vocational 264 27.41 533 45.44 264 18.01 729 38.19 1,398 47.90
Lower 559 58.05 487 41.52 1,170 79.81 754 39.50 1,065 36.50
Missing 101 10.49 0 0.00 0 0.00 9 0.47 20 0.70
Marital status
Single 14 1.45 N/A N/A 91 4.77 104 3.60
Married 665 69.06 1,568 82.14 2,123 72.80
Divorced 89 9.24 126 6.60 313 10.70
Widowed 94 9.76 123 6.44 367 12.60
Missing 101 10.49 1 0.05 11 0.40
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Socioeconomic profile of MONICA samples was characterised by a relatively high
prevalence of lower education (Tables 5.1.1-5.1.2). The proportion of lower-educated
people was the highest in Tarnobrzeg (71.2% and 79.8% for men and women,
respectively), while the percentage of men and women with university education was
the highest in Lithuania (27.5% and 21.8%, respectively). The majority of the
participants (70%) were married; however, the proportion of those divorced or
widowed was higher in women than in men (for Polish samples, data on marital status
were unavailable). For widowed women vs. men from the Czech Republic, Lithuania,
and Russia, this difference was 4.4, 7.7, and 6.3-fold, respectively.
The proportion of participants with missing data on SCORE components (mostly TCH
and SBP) varied across MONICA samples. For example, TCH values were missing in
one-fourth of the Czech men and women, but available for almost all Polish participants
(Tables 5.1.1-5.1.2). Since individual SCORE values cannot be calculated for the
subjects with missing data on major risk factors, a complete case analysis was
performed (Methods, Section 4.5.1). The primary goal was to investigate the individual-
level relationship between SCORE-predicted and observed risk of atherosclerotic CVD
death, which requires having information on both exposure and outcome. After
excluding the participants with missing SCORE values, the final MONICA samples
consisted of 1,340 people from the Czech Republic, 2,404 from Warsaw, 2,729 from
Tarnobrzeg, 3,301 from Lithuania, and 5,253 from Russia (Table 5.1.3; for detailed
description of the MONICA sample selection, see Methods, Section 4.1.1).
In the samples including the data from two (Warsaw and Tarnobrzeg) or three
MONICA waves (Kaunas and Novosibirsk), the observed mortality risk typically
declined over time, particularly in men. However, for the main association of interest
(between the SCORE-predicted and observed risk), there was no evidence of statistical
interaction or confounding by the MONICA study wave (Methods, Section 4.5.4).
Therefore, the sample-specific data from all MONICA waves were pooled, which also
maximised the outcome numbers in the analyses.
As expected, the absolute numbers of atherosclerotic CVD deaths, registered within the
first 10 years of the follow-up, were higher in larger samples. Specifically, these
numbers were the highest in Russian men and women (181 and 86, respectively), and
the lowest in Czech men and women (32 and 13, respectively) (Table 5.1.3).
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Table 5.1.3. Observed 10-year atherosclerotic CVD mortality in MONICA men and
women
Czech
Republic
Poland
(Warsaw)
Poland
(Tarnobrzeg)
Lithuania Russia
M W M W M W M W M W
Sample size, N 636 704 1,253 1,151 1,267 1,462 1,651 1,650 2,576 2,677
Observed
CVD deaths,
N (%)
32
(5.03)
13
(1.85)
86
(6.68)
21
(1.82)
62
(4.89)
19
(1.30)
58
(3.51)
26
(1.58)
181
(7.03)
86
(3.21)
Among MONICA men, the percentage of atherosclerotic CVD deaths registered during
10 years was the highest in Novosibirsk (7.0%), lower in Warsaw (6.7%), the Czech
Republic (5.0%) and Tarnobrzeg (4.9%), and the lowest in Kaunas (3.5%). The
observed risk of fatal CVD in men was, on average, twice as high as in women from the
respective samples (see Kaplan-Meier survival estimates in Figures 5.1.1-5.1.5).
Among MONICA women, the highest and the lowest atherosclerotic CVD mortality
levels were registered, respectively, in Novosibirsk (3.2%) and Tarnobrzeg (1.3%).
Figure 5.1.1. Observed 10-year atherosclerotic CVD mortality by gender in the
Czech MONICA sample: Kaplan-Meier survival estimates
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Figure 5.1.2. Observed 10-year atherosclerotic CVD mortality by gender in the
Polish (Warsaw) MONICA sample: Kaplan-Meier survival estimates
.8
5
.9
.9
5
1
0 2 4 6 8 10
Follow-up, years
95% CI 95% CI
men women
Figure 5.1.3. Observed 10-year atherosclerotic CVD mortality by gender in the
Polish (Tarnobrzeg) MONICA sample: Kaplan-Meier survival estimates
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Figure 5.1.4. Observed 10-year atherosclerotic CVD mortality by gender in the
Lithuanian MONICA sample: Kaplan-Meier survival estimates
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Figure 5.1.5. Observed 10-year atherosclerotic CVD mortality by gender in the Russian
MONICA sample: Kaplan-Meier survival estimates
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Therefore, these descriptive results demonstrated relatively high, although
heterogeneous, levels of cardiovascular risk factors and atherosclerotic CVD mortality
in MONICA samples. Cardiovascular mortality was particularly high in Russian men
and women.
5.2. HAPIEE: SCORE risk factors, additional risk determinants, and
fatal atherosclerotic CVD
Following the description of male and female MONICA samples, the data on
demographic characteristics, risk factor distribution, and atherosclerotic cardiovascular
mortality will be presented for contemporary HAPIEE samples. The mean baseline age
of HAPIEE participants was 57.27.0 years, ranging from 56.66.9 years in Polish
women to 57.77.1 years in Czech men. The slightly higher mean age in HAPIEE vs.
MONICA subjects was due to the difference in the original lower age limits for these
two studies (35 and 45 years, respectively; see Methods, Section 4.1). As shown in
Table 5.2.1, male and female HAPIEE participants were equally distributed across the
five age groups.
The prevalence of classical risk factors included in the SCORE scale was high across all
HAPIEE samples. Except for Russian women, both genders demonstrated high
prevalence of current smoking (over 20%), which was the highest in Russian men
(51.1%). TCH levels tended to be slightly higher in women than in men, and among
Russian females, TCH concentration reached 6.5 mmol/l. In men, on the other hand,
mean SBP levels were generally higher than in women, and slightly exceeded 140 mm
Hg.
Socioeconomic characteristics of the HAPIEE samples had both common and specific
features. The percentage of participants with primary education was low across all
samples (<12%), with the exception of Czech women (17%). The proportion of
university-educated people was higher in Poland and Russia than in the Czech Republic
(for men, 32.0% and 31.0% vs. 18.7%; for women, 30.0% and 27.7% vs. 11.0%,
respectively). Similar to MONICA participants, the majority of HAPIEE subjects
(>60%) were married, while the percentage of those divorced or widowed for women
was higher than for men. There was a 4.3, 4.7, and 5.8-fold difference in the proportion
of widowed women vs. men from the Czech Republic, Poland, and Russia, respectively
(Table 5.2.1).
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Table 5.2.1. Baseline characteristics of HAPIEE samples (men and women)
Categories Czech Republic Poland Russia
Men Women Men Women Men Women
N % N % N % N % N % N %
Age groups
45-49 617 18.12 822 19.44 831 20.85 982 22.68 614 18.87 838 20.63
50-54 706 20.73 916 21.67 866 21.73 1,014 23.42 694 21.33 845 20.80
55-59 692 20.32 790 18.68 850 21.32 889 20.53 702 21.57 888 21.86
60-64 702 20.62 972 22.99 723 18.14 759 17.53 594 18.25 696 17.13
65+ 688 20.21 728 17.22 716 17.96 686 15.84 650 19.98 795 19.57
Current smoking
Yes 928 27.25 936 22.14 1,389 34.85 1,158 26.74 1,662 51.08 412 10.14
No 2,433 71.45 3,235 76.51 2,584 64.83 3,159 72.96 1,592 48.92 3,650 89.86
Missing 44 1.29 57 1.35 13 0.33 13 0.30 0 0.00 0 0.00
TCH
Mean (SD) 5.66 (1.04) 5.86 (1.04) 5.78 (1.10) 5.93 (1.09) 5.99 (1.18) 6.49 (1.31)
Missing 740 21.73 865 20.46 518 13.00 560 12.93 6 0.18 16 0.39
SBP
Mean (SD) 143.87 (18.36) 134.23 (19.36) 141.62 (20.19) 133.15 (20.83) 141.57 (22.67) 141.59 (25.68)
Missing 642 18.85 691 16.34 528 13.25 569 13.14 3 0.09 2 0.05
Education
University 637 18.71 446 10.55 1,277 32.04 1,284 29.65 1,008 30.98 1,127 27.74
Secondary 1,076 31.60 1,761 41.65 1,301 32.64 1,900 43.88 1,220 37.49 1,344 33.09
Vocational 1,477 43.38 1,288 30.46 1,060 26.59 635 14.67 683 20.99 1,230 30.28
Primary 196 5.76 717 16.96 345 8.66 505 11.66 343 10.54 361 8.89
Missing 19 0.56 16 0.38 3 0.08 6 0.14 0 0.00 0 0.00
Marital status
Married 2,854 83.82 2,906 68.73 3,466 86.95 2,894 66.84 2,859 87.86 2,461 60.59
Single 99 2.91 103 2.44 166 4.16 333 7.69 94 2.89 210 5.17
Divorced 332 9.75 647 15.30 212 5.32 405 9.35 191 5.87 595 14.65
Widowed 105 3.08 556 13.15 135 3.39 689 15.91 110 3.38 796 19.60
Missing 15 0.44 16 0.38 7 0.18 9 0.21 0 0.00 0 0.00
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(continued)
Categories
Czech Republic Poland Russia
Men Women Men Women Men Women
N % N % N % N % N % N %
Drinking frequency
Never 187 5.49 689 16.30 776 19.47 1,867 43.12 402 12.35 598 14.72
<1/month 545 16.01 1,337 31.62 731 18.34 1,199 27.69 523 16.07 2,270 55.88
1-3/month 563 16.53 996 23.56 953 23.91 773 17.85 785 24.12 847 20.85
≥ 1/week 2,016 59.21 1,034 24.46 1,499 37.61 467 10.79 1,544 47.45 347 8.54 
Missing 94 2.76 172 4.07 27 0.68 24 0.55 0 0.00 0 0.00
Binge drinking
No 2,689 78.97 3,925 92.83 3,556 89.21 4,275 98.73 2,184 67.12 4,006 98.62
Yes 622 18.27 131 3.10 43 10.11 31 0.72 1,070 32.88 56 1.38
Missing 94 2.76 172 4.07 27 0.68 24 0.55 0 0.00 0 0.00
CAGE score ≥ 2
No 2,998 88.05 3,956 93.57 3,525 88.43 4,208 97.18 2,574 79.10 4,000 98.47
Yes 310 9.10 80 1.89 383 9.61 44 1.02 680 20.90 62 1.53
Missing 97 2.85 192 4.54 78 1.96 78 1.80 0 0.00 0 0.00
123
For HAPIEE samples, the data on alcohol consumption parameters, as additional
predictors of cardiovascular risk, were also available. As presented in Table 5.2.1, the
percentage of self-reported non-drinkers was the highest in Polish men and women
(19.5% and 43.1%, respectively). The prevalence of alcohol consumption at least once a
week was maximal in Czech men (59.2%) and women (24.5%). However, Russian men
demonstrated the most hazardous drinking patterns, with the highest prevalence of binge
drinking (32.9%) and CAGE score 2 (20.9%), which was approximately twice as high
as in their Czech and Polish peers. Among Czech, Russian, and Polish women,
hazardous drinking was reported by less than 4%.
The proportions of HAPIEE subjects with missing data for SCORE components, such
as TCH and SBP, were higher in the Czech Republic and Poland (approximately 20%
and 13%, respectively), and lower in Russia (<1%) (Table 5.2.1). Since this thesis is
aimed at studying the individual-level relationship between SCORE-predicted risk of
fatal atherosclerotic CVD (exposure) and observed risk (outcome), only the
observations with complete data on both exposure and outcome were included in the
survival analyses and analyses of SCORE prognostic performance (Methods, Section
4.5.1). After excluding participants with missing SCORE values, the final HAPIEE
samples consisted of 6,018 people from the Czech Republic, 7,209 from Poland, and
7,290 from Russia (Table 5.2.2; for detailed description of the HAPIEE sample
selection, see Methods, Section 4.1.2).
The absolute numbers of atherosclerotic CVD deaths were the highest in Russian
HAPIEE men and women (105 and 42, respectively), despite the shortest mean follow-
up period (approximately 4.5 years vs. 6.2 and 5.2 years for the Czech and Polish
samples, respectively) (Table 5.2.2).
Table 5.2.2. Observed atherosclerotic CVD mortality in HAPIEE men and women
Czech Republic Poland Russia
Men Women Men Women Men Women
Sample size, N 2,659 3,359 3,456 3,753 3,246 4,044
Mean follow-up,
years (SD)
6.14 (0.99) 6.25 (0.78) 5.15 (0.77) 5.22 (0.59) 4.35 (1.02) 4.62 (0.78)
Observed CVD
deaths, N (%)
37
(1.39)
19
(0.57)
34
(0.98)
16
(0.43)
105
(3.23)
42
(1.04)
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Among Russian men, the percentage of atherosclerotic CVD deaths registered during
the follow-up was two-three times higher than among their Czech and Polish peers
(3.2% vs. 1.4% and 1.0%, respectively). The currently observed levels of fatal CVD in
women were lower than in men from the respective countries (see Kaplan-Meier
survival estimates in Figures 5.2.1-5.2.3), but still reflected the same ranking across the
samples, being higher in Russia (1.0%) than in the Czech Republic (0.6%) or Poland
(0.4%).
Figure 5.2.1. Observed atherosclerotic CVD mortality by gender in the Czech HAPIEE
sample: Kaplan-Meier survival estimates
.9
.9
5
1
0 2 4 6
Follow-up, years
95% CI 95% CI
men women
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Figure 5.2.2. Observed atherosclerotic CVD mortality by gender in the Polish HAPIEE
sample: Kaplan-Meier survival estimates
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Figure 5.2.3. Observed atherosclerotic CVD mortality by gender in the Russian
HAPIEE sample: Kaplan-Meier survival estimates
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To summarise, the findings presented in Chapter 5 have addressed the first research
objective – the description of cardiovascular risk factor patterns and CVD mortality
across MONICA and HAPIEE samples. Both studies demonstrated relatively high,
although not uniform, levels of classical and additional cardiovascular risk factors, as
well as higher levels of fatal CVD in Russian participants vs. subjects from the other
CEE/FSU countries of interest. The next chapter will investigate how this heterogeneity
is reflected in the prognostic performance of SCORE across study samples.
127
Chapter 6. Performance of the original SCORE scale
In this chapter, the strength of the main association of interest, between baseline levels
of conventional cardiovascular risk factors, captured by the original, non-extended
SCORE, and fatal atherosclerotic CVD, is explored across all MONICA and HAPIEE
samples (Section 6.1). SCORE calibration (Sections 6.2-6.3) and discrimination
(Section 6.4) in MONCA and HAPIEE are also evaluated.
6.1. SCORE as a predictor of atherosclerotic CVD mortality
The predictive performance of SCORE in MONICA and HAPIEE samples could be
assessed, first of all, by the strength of the association between the exposure of interest
(SCORE-predicted risk at baseline) and the outcome (atherosclerotic CVD death) in the
survival models. The main focus of the present analyses is the performance of the high-
risk dichotomous SCORE (5% vs. <5%), as the officially recommended and, hence,
the most clinically relevant version of SCORE for CEE/FSU populations. In addition,
the performance of the high-risk continuous SCORE, as well as the dichotomous and
continuous low-risk SCORE, is examined. The results of survival analyses obtained
with the standard Cox models, competing-risks regression models, and Weibull models
were almost identical for all study samples. Therefore, the findings from the standard
Cox analyses are presented in Section 6.1, while the outputs from the other two models
can be found in Appendix II.
6.1.1. SCORE as a predictor of atherosclerotic CVD mortality in MONICA
Across all male MONICA samples, high-risk SCORE 5% at baseline was significantly
associated with higher 10-year atherosclerotic CVD mortality, as shown in Table 6.1.1.
The hazard ratios (HR) varied from 2.7 in Russia to 5.3 in the Czech Republic (although
for Czech men, the absolute number of outcomes was the lowest, and 95% CI for HR
the widest). In addition, one-point increase in SCORE was associated with a significant
elevation in CVD risk, with HR for continuous SCORE close to 1.10 and 95% CI
excluding 1.0 across all male samples. In most female samples, baseline high-risk
SCORE 5% was also linked to a significant increase in fatal CVD risk (Table 6.1.1).
The magnitude of this increase was the largest among Russian women (HR 6.3) and the
smallest among Polish women from Warsaw (1.7). For both dichotomous and
continuous SCORE, HR values were typically higher in women than in men from
respective samples, although it should be noted that 95% CI were also wider in women,
due to lower outcome numbers.
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Table 6.1.1. Dichotomous and continuous high-risk SCORE and 10-year atherosclerotic CVD mortality in MONICA men and women:
hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
5.32 (2.30-12.30) 4.50 (2.68-7.56) 3.06 (1.77-5.29) 3.99 (2.24-7.10) 2.66 (1.96-3.62)
Continuous SCORE
(per 1% increase)
1.09 (1.06-1.12) 1.10 (1.07-1.12) 1.11 (1.08-1.14) 1.08 (1.05-1.12) 1.11 (1.09-1.13)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
5.02 (1.64-15.36) 1.70 (0.57-5.06) 4.15 (1.49-11.52) 5.07 (2.20-11.66) 6.32 (4.08-9.79)
Continuous SCORE
(per 1% increase)
1.23 (1.06-1.43) 1.21 (1.10-1.33) 1.33 (1.16-1.53) 1.27 (1.16-1.39) 1.34 (1.27-1.41)
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The complete case-based and the multiple imputation-based approaches produced very
similar results for Czech and Lithuanian participants, despite the fact that these
MONICA samples had higher levels of SCORE missingness (for description of the
imputation model, see Section 4.5.1). For example, in Czech MONICA men, HR values
for the complete case and multiple imputation-based analyses were 5.32 and 5.20,
respectively (detailed results for all samples available on request). Therefore, it was
unlikely that the complete case approach (Table 6.1.1) has substantially biased the
estimates of the association between the high-risk dichotomous SCORE and fatal CVD
across MONICA samples.
Similar patterns, confirming the association between baseline SCORE and
atherosclerotic CVD mortality, were observed for the low-risk dichotomous and
continuous SCORE in most samples (see Appendix II, Table A6.1.1). Across
MONICA samples, the results of the standard Cox, competing-risks, and Weibull
regression analyses were similar (see Tables A6.1.2-A6.1.3 for dichotomous and
continuous high and low-risk SCORE). Since the 10-year risk of death from other
causes (not atherosclerotic CVD) was relatively low across samples, taking it into
account in the competing-risks analyses only slightly reduced the strength of the main
association of interest. The exact values of SCORE HR and 95% CI were very close for
all three types of survival analysis, demonstrating a clear link between the levels of
predicted and observed 10-year CVD mortality.
6.1.2. SCORE as a predictor of atherosclerotic CVD mortality in HAPIEE
As mentioned earlier, the current follow-up duration for all HAPIEE samples is under
10 years. Therefore, in HAPIEE participants, the strength of the association between
baseline high-risk SCORE values 5% and the risk of atherosclerotic CVD death over
the next 4.5-6 years was analysed. Due to the shorter follow-up and lower outcome
numbers, 95% CI for SCORE HR were quite wide in both genders. Nonetheless, higher
risk at baseline appeared to be a significant predictor of CVD mortality in men (HR
10.5, 2.6, and 7.6 in the Czech Republic, Poland, and Russia) and women (HR 3.6, 8.8,
and 7.4, respectively) (Table 6.1.2). One-point increase in baseline SCORE was also
significantly associated with elevated cardiovascular risk: HR for continuous SCORE
reached 1.1 in men and 1.2-1.3 in women.
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Table 6.1.2. Dichotomous and continuous high-risk SCORE and atherosclerotic CVD
mortality in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
10.51 (2.53-43.71) 2.56 (1.11-5.87) 7.63 (3.35-17.40)
Continuous SCORE
(per 1% increase)
1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
3.59 (1.44-8.91) 8.79 (3.19-24.18) 7.36 (3.77-14.38)
Continuous SCORE
(per 1% increase)
1.20 (1.06-1.35) 1.32 (1.22-1.43) 1.32 (1.24-1.41)
Despite a higher proportion of missing SCORE values in Czech and Polish men and
women, the HR values for the dichotomous high-risk SCORE were very similar for the
complete case-based and the multiple imputation-based approaches (the imputation
model is described in Section 4.5.1). Thus, for Polish HAPIEE men, the respective
values were 2.56 and 2.66 (detailed results for all samples available on request). These
findings suggest that the use of the observations with non-missing SCORE values
(Table 6.1.2) was unlikely to substantially bias the HAPIEE findings on the link
between SCORE and cardiovascular mortality.
In both genders, the dichotomous and continuous low-risk SCORE demonstrated similar
patterns, confirming the significant link between the predicted and currently observed
cardiovascular mortality (see Appendix II, Table A6.1.4). The currently observed risk
of death from other causes (not atherosclerotic CVD) was relatively low across HAPIEE
samples, and the strength of the main association of interest was reduced only
marginally in the competing-risks models. Overall, standard Cox, competing-risks, and
Weibull regression analyses all provided similar results for the high-risk SCORE, as
well as for its low-risk version, and showed that the higher SCORE-predicted risk was a
significant determinant of fatal atherosclerotic CVD (Tables A6.1.5-A6.1.6).
While in most MONICA and HAPIEE samples, the association between baseline
SCORE and observed cardiovascular mortality was statistically significant, the strength
of this association varied across samples and did not clearly reflect the “FSU vs. CEE”
gradient in fatal CVD rates, which was described in Chapter 5. This lack of consistency
could be due to a combination of several factors. The relative risks associated with each
of the SCORE-comprising risk factors are considered to be universal across populations
and over time (Methods, Section 4.5.2), regardless of the baseline risk variation which
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is reflected in the observed cross-sample mortality gradient. Therefore, SCORE HR
values are expected to be relatively similar for different samples and at different points
in time. However, these values were influenced by the marked variation in sample sizes
and outcome numbers for both MONICA and HAPIEE.
In addition, the magnitude of the SCORE-fatal CVD link could be affected by multiple
non-classical risk determinants. The impact of such measured and non-measured factors
may vary across populations and over time, and, hence, could lead to heterogeneity of
the sample-specific SCORE effect estimates. To assess the potential impact of some
additional risk determinants, such as socioeconomic parameters and alcohol
consumption characteristics, on the link between SCORE and atherosclerotic
cardiovascular mortality, the association of interest was adjusted for education and/or
marital status (Chapter 7), as well as for binge drinking and/or CAGE score (Chapter
8). Moreover, to provide a combined estimate of the magnitude of this association, the
unadjusted and adjusted findings from individual samples were pooled in the random
effects meta-analyses, as described in Chapter 9.
To conclude Section 6.1, SCORE was a significant predictor of fatal atherosclerotic
CVD in MONICA and HAPIEE men and women, as shown by the results of standard
Cox regression, competing-risks Cox analysis and Weibull analysis, for high and low-
risk versions of dichotomous and continuous SCORE. These findings have addressed
the second research objective (the assessment of the main association of interest,
between SCORE-predicted and observed cardiovascular mortality) and demonstrated a
statistically significant link between baseline SCORE and subsequent fatal CVD, which
supports the first research hypothesis. This is an important step in exploring SCORE
performance in the populations of interest. However, the strength of this association
does not provide sufficient information on the closeness between SCORE predictions
and observed mortality, or on the accuracy of separating the subjects who would
develop the outcome (atherosclerotic CVD death) from those who would remain
outcome-free. Therefore, the next three sections are focused on SCORE calibration and
discrimination in MONICA and HAPIEE.
6.2. SCORE calibration
As described in Methods (Section 4.5.3), calibration is one of the performance
characteristics of a prognostic model, which reflects the agreement between the
predicted (P) and observed (O) risk. Calibration could be assessed with the P/O ratio,
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where values of 1.0, <1.0, and >1.0 denote perfect calibration, risk under-prediction,
and risk over-prediction, respectively.
6.2.1. SCORE calibration in MONICA
In all male MONICA samples, cardiovascular risk levels predicted by the high-risk
SCORE version (which is officially recommended for CEE/FSU populations) were
relatively high and varied from 5.0% in Kaunas to 5.8% in Warsaw (Table 6.2.1).
Among MONICA women, predicted risk was considerably lower and approached 2%,
ranging from 1.6% in Lithuania to 2.0% in Poland (Warsaw) (Table 6.2.2). Since age is
the major determinant of cardiovascular risk, the levels of predicted risk increased, as
expected, from younger to older age groups in both genders.
The closeness of predicted and observed atherosclerotic CVD mortality was satisfactory
in most samples, as demonstrated by P/O ratio values close to 1.0. The risk was slightly
over-predicted in Czech men, Polish men from Tarnobrzeg, and Lithuanian men
(respective P/O ratios 1.05, 1.11, and 1.43), and under-predicted in men from Warsaw
and Novosibirsk (0.87 and 0.76, respectively) (Table 6.2.1). Among women, the high-
risk SCORE version slightly over-estimated mortality risk in Warsaw and Tarnobrzeg
(respective P/O values 1.08 and 1.27), relatively accurately reflected it in the Czech
Republic and Kaunas (0.96 and 1.01, respectively), and under-predicted the risk in
Novosibirsk (0.52) (Table 6.2.2). Therefore, the extent of risk under-estimation was
maximal in the Russian sample, for both men and women. Across age groups, as well as
in subjects with SCORE levels <5% vs. 5%, most P/O ratios were close to the
respective sample-specific values; occasional deviations could be due to low outcome
numbers, or absence of outcomes, in some groups (Tables 6.2.1-6.2.2). For women
aged 40-45 years, the number of predicted deaths was zero, as both high and low-risk
SCORE versions assign these women to the category of “zero risk” (Appendix I,
Tables A4.3.1-A4.3.2).
The calibration assessment was also performed for the low-risk SCORE version, even
though it is not officially recommended for CEE/FSU populations. Low-risk SCORE
under-estimated 10-year atherosclerotic cardiovascular mortality in all male and female
MONICA samples (Appendix II, Tables A6.2.1-A6.2.2). The magnitude of this under-
prediction was maximal in Russian men and women (P/O ratios 0.40 and 0.29,
respectively), in agreement with the findings for the high-risk SCORE.
133
Table 6.2.1. Predicted (P) by high-risk SCORE and observed (O) 10-year atherosclerotic CVD mortality by age groups
and SCORE level in MONICA men
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
P O P/O P O P/O P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole
sample
5.26
(5.55)
N=33.5
5.03
N=32
1.05 5.78
(5.51)
N=72.4
6.68
N=86
0.87 5.43
(4.80)
N=69.0
4.89
N=62
1.11 5.03
(4.89)
N=83.1
3.51
N=58
1.43 5.36
(4.89)
N=138.1
7.03
N=181
0.76
Age groups, years
40-44.9 1.04
(0.57)
N=1.8
1.16
N=2
0.90 1.06
(0.52)
N=2.9
3.32
N=9
0.32 1.02
(0.52)
N=2.3
2.71
N=6
0.38 0.96
(0.52)
N=3.8
1.02%
N=4
0.94 0.96
(0.53)
N=4.4
3.96
N=18
0.24
45-49.9 3.93
(2.33)
N=5.6
4.20
N=6
0.94 3.78
(2.07)
N=9.8
3.85
N=10
0.98 3.53
(1.84)
N=9.3
2.28
N=6
1.55 3.24
(2.02)
N=10.3
1.57
N=5
2.06 3.33
(1.91)
N=19.4
4.12
N=24
0.81
50-54.9 5.37
(3.41)
N=7.2
5.22
N=7
1.03 5.04
(3.31)
N=12.7
5.98
N=15
0.84 4.75
(3.06)
N=13.0
5.47
N=15
0.87 4.22
(2.68)
N=12.6
2.68
N=8
1.58 4.52
(2.73)
N=24.2
6.92
N=37
0.65
55-59.9 8.00
(4.89)
N=8.1
4.95
N=5
1.62 8.34
(4.69)
N=23.5
9.57
N=27
0.87 7.27
(4.34)
N=21.4
5.78
N=17
1.26 7.38
(4.63)
N=27.9
6.08
N=23
1.21 7.46
(4.46)
N=44.5
7.55
N=45
0.99
60-64.9 12.49
(8.54)
N=10.7
13.95
N=12
0.90 12.46
(7.46)
N=23.6
13.23
N=25
0.94 10.63
(6.11)
N=22.9
8.37
N=18
1.27 10.82
(5.98)
N=28.4
6.87
N=18
1.58 11.22
(6.16)
N=45.67
14.00
N=57
0.80
SCORE level
<5% 1.98
(1.16)
N=7.2
1.92
N=7
1.03 2.08
(1.15)
N=13.5
2.77
N=18
0.75 2.30
(1.20)
N=15.9
2.60
N=18
0.89 1.98
(1.13)
N=19.1
1.66
N=16
1.19 2.25
(1.20)
N=32.9
4.31
N=63
0.52
≥5% 9.67 
(6.04)
N=26.2
9.23
N=25
1.05 9.76
(5.57)
N=59.0
11.26
N=68
0.87 9.18
(4.82)
N=52.9
7.64
N=44
1.20 9.31
(4.94)
N=63.9
6.13
N=42
1.52 9.44
(4.92)
N=105.2
10.59
N=118
0.89
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Table 6.2.2. Predicted (P) by high-risk SCORE and observed (O) 10-year atherosclerotic CVD mortality by age groups
and SCORE level in MONICA women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
P O P/O P O P/O P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole
sample
1.78
(2.11)
N=12.5
1.85
N=13
0.96 1.96
(2.45)
N=22.6
1.82
N=21
1.08 1.68
(1.93)
N=24.6
1.30
N=19
1.29 1.60
(1.94)
N=26.4
1.58
N=26
1.01 1.67
(2.00)
N=44.7
3.21
N=86
0.52
Age groups, years
40-44.9 0.00
(0.00)
N=0.0
0.59
N=1
N/A 0.00
(0.00)
N=0.0
0.00
(0)
N/A 0.00
(0.00)
N=0.0
0.37
N=1
N/A 0.00
(0.00)
N=0.0
0.25
N=1
N/A 0.00
(0.00)
N=0.0
0.38
N=2
N/A
45-49.9 1.02
(0.50)
N=1.8
0.00
N=0
N/A 0.91
(0.52)
N=2.3
2.01
N=5
0.45 0.79
(0.53)
N=2.5
0.32
N=1
2.47 0.90
(0.39)
N=3.1
0.29
N=1
3.10 0.72
(0.50)
N=4.2
2.04
N=12
0.35
50-54.9 1.46
(0.81)
N=1.8
2.42
N=3
0.60 1.53
(1.17)
N=3.6
0.00
N=0
N/A 1.17
(0.64)
N=3.7
0.32
N=1
3.66 1.22
(0.68)
N=4.0
0.62
N=2
1.97 1.15
(0.66)
N=6.4
1.61
N=9
0.71
55-59.9 2.68
(1.58)
N=3.4
3.13
N=4
0.86 3.03
(1.97)
N=7.3
3.33
N=8
0.91 2.37
(1.49)
N=7.3
3.25
N=10
0.73 2.44
(1.51)
N=7.8
2.82
N=9
0.87 2.35
(1.39)
N=12.9
4.74
N=26
0.50
60-64.9 5.12
(2.64)
N=5.5
4.63
N=5
1.11 5.34
(3.41)
N=9.4
4.55
N=8
1.17 4.32
(2.42)
N=11.1
2.33%
N=6
1.85 4.54
(2.52)
N=11.6
5.10
N=13
0.89 4.54
(2.59)
N=21.0
8.01
N=37
0.57
SCORE level
<5% 1.17
(1.08)
N=7.3
1.28
N=8
0.91 1.20
(1.10)
N=12.1
1.69
N=17
0.71 1.21
(1.09)
N=16.2
1.05
N=14
1.15 1.14
(1.08)
N=17.2
1.19
N=18
0.96 1.16
(1.09)
N=28.2
2.22
N=54
0.52
≥5% 6.58 
(2.08)
N=5.3
6.25
N=5
1.05 7.24
(2.72)
N=10.5
2.76
N=4
2.62 6.76
(1.71)
N=8.3
4.07
N=5
1.66 6.67
(2.05)
N=9.3
5.76
N=8
1.16 6.66
(2.04)
N=16.5
12.96
N=32
0.51
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In addition, calibration of continuous high and low-risk SCORE was assessed with the
Hosmer-Lemeshow goodness-of-fit test. This test quantifies the agreement between
predicted and observed events across risk deciles (Methods, Section 4.5.3). Since the
outcome numbers in country and gender-specific subgroups were relatively low,
especially in women, the results of the Gronnesby-Borgan test (equivalent of the
Hosmer-Lemeshow test, recommended for survival data analysis and based on
martingale residuals; Section 4.5.3) were not informative, as the model collapsed on
only two risk quantiles.
In most male MONICA samples, the Hosmer-Lemeshow χ2 values were under 20 for
both high and low-risk SCORE predictions, which denoted good calibration (Table
6.2.3). Only in Lithuanian men, the high-risk SCORE demonstrated slightly worse fit of
the model (χ2 20.9). In each sample, Hosmer-Lemeshow-assessed calibration was
slightly better, as demonstrated by lower χ2 values, for low vs. high-risk SCORE
version. A similar pattern was observed among MONICA females, with slightly better
calibration for low vs. high-risk SCORE in each sample, and higher χ2 values in
Lithuanian women (Table 6.2.3).
Table 6.2.3. Calibration of high and low-risk continuous SCORE estimated by Hosmer-
Lemeshow test in MONICA men and women
Czech
Republic
Poland
(Warsaw)
Poland
(Tarnobrzeg)
Lithuania Russia
Men
High-risk
SCORE, χ2 (p)
15.41
(0.0311)
13.89
(0.0533)
4.62
(0.7059)
20.98
(0.0018)
4.56
(0.7132)
Low-risk
SCORE, χ2 (p)
9.41
(0.0938)
9.26
(0.0991)
4.33
(0.5025)
14.99
(0.0104)
4.53
(0.4753)
Women
High-risk
SCORE, χ2 (p)
7.89
(0.0958)
8.42
(0.0722)
11.19
(0.0245)
20.89
(0.0003)
13.92
(0.0076)
Low-risk
SCORE, χ2 (p)
6.18
(0.1032)
8.25
(0.0411)
6.61
(0.0367)
20.52
(<0.0001)
11.62
(0.0088)
It should be noted, however, that the Hosmer-Lemeshow test results are affected when
two or more individuals have the same predicted risk (especially when the estimated
risk levels are relatively low) (Methods, Section 4.5.3). This could explain lower χ2
values for low vs. high-risk SCORE predictions. Therefore, evaluating the calibration
using P/O ratios (Tables 6.2.1-6.2.2) might be a more informative method to assess the
agreement between predicted and observed CVD mortality in MONICA samples.
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6.2.2. SCORE calibration in HAPIEE
In each male HAPIEE sample, mean levels of 10-year fatal CVD, predicted by high-risk
SCORE, exceeded the cut-off value of 5% (7.5% in the Czech Republic, 7.4% in
Poland, and 9.1% in Russia). Among women from the respective countries, the
predicted risk was approximately three times lower, reaching 2.5%, 2.5%, and 3.1%
(Tables 6.2.4-6.2.5). The progressive increase in predicted risk from younger to older
age groups was expected, based on the key role of age as a major CVD risk determinant.
Therefore, the fact that predicted levels of CVD mortality in HAPIEE samples were
approximately 1.5 times higher than in respective MONICA samples could be
predominantly explained by the higher mean age of HAPIEE participants.
Given the current limited duration of the follow-up (the 10-year mortality data are not
yet available), the high-risk SCORE calibration cannot be adequately assessed in
HAPIEE. Calibration results, based on the comparison between predicted and estimated
10-year risk of atherosclerotic cardiovascular mortality across HAPIEE samples will be
presented in Section 6.3. For the currently available HAPIEE data on fatal CVD, all P/O
ratios exceeded 1.0, as expected (Tables 6.2.4-6.2.5), but their ranking was not
explained by the mean follow-up length. In Russian samples, which had the shortest
follow-up duration, the magnitude of risk over-estimation was substantially smaller
(P/O ratios 2.81 and 2.96 in men and women, respectively) than in Czech (5.40 and
4.44) or Polish (7.52 and 5.70) samples. All P/O ratios for the subgroups defined by
age, or SCORE level <5% vs. 5%, exceeded 1.0 and were close to the respective
values for the whole samples. As expected, risk over-estimation was more pronounced
in the younger age groups and people with SCORE values <5% (Tables 6.2.4-6.2.5).
The low-risk SCORE also over-estimated the 10-year risk of fatal atherosclerotic CVD
in all HAPIEE samples, even though P/O ratios were understandably lower than for
high-risk predictions (Appendix II, Tables A6.2.3-A6.2.4). For Russian men and
women, P/O ratios were approaching 1.0 already (1.50 and 1.70, respectively), despite
the shortest mean follow-up time of 4.5 years.
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Table 6.2.4. Predicted (P) by high-risk SCORE and observed (O) atherosclerotic CVD mortality by age groups
and SCORE level in HAPIEE men
Czech Republic Poland Russia
P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole sample 7.51 (5.99)
N=199.7
1.39
N=37
5.40 7.37 (5.89)
N=254.7
0.98
N=34
7.52 9.07 (7.27)
N=294.4
3.23
N=105
2.81
Age groups, years
<50 3.11 (1.89)
N=14.3
0.22
N=1
14.14 3.24 (2.05)
N=22.8
0.28
N=2
11.57 3.63 (2.00)
N=22.2
0.65
N=4
5.59
50-54.9 4.19 (2.63)
N=21.9
0.38
N=2
11.03 4.28 (2.84)
N=32.1
0.93
N=7
4.60 4.98 (3.17)
N=34.5
1.59
N=11
3.13
55-59.9 6.47 (4.04)
N=35.7
1.63
N=9
3.97 7.04 (4.12)
N=52.1
0.81
N=6
8.69 8.32 (5.18)
N=58.3
3.14
N=22
2.65
60-64.9 10.23 (6.36)
N=58.7
2.09
N=12
4.90 10.46 (5.98)
N=66.3
0.79
N=5
13.24 13.68 (7.76)
N=80.9
4.06
N=24
3.37
65 12.50 (6.69)
N=69.1
2.35
N=13
5.32 12.98 (6.96)
N=81.5
2.23
N=14
5.82 15.18 (7.94)
N=98.7
6.77
N=44
2.24
SCORE level
<5% 2.64 (1.05)
N=25.9
0.20
N=2
13.20 2.70 (0.95)
N=36.5
0.52
N=7
5.19 2.88 (0.90)
N=29.7
0.58
N=6
4.97
≥5% 10.35 (5.85) 
N=173.8
2.08
N=35
4.98 10.38 (5.76)
N=218.3
1.28
N=27
8.11 11.95 (7.14)
N=264.8
4.47
N=99
2.67
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Table 6.2.5. Predicted (P) by high-risk SCORE and observed (O) atherosclerotic CVD mortality by age groups
and SCORE level in HAPIEE women
Czech Republic Poland Russia
P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole sample 2.53 (2.39)
N=85.0
0.57
N=19
4.44 2.45 (2.41)
N=92.0
0.43
N=16
5.70 3.08 (2.90)
N=124.6
1.04
N=42
2.96
Age groups, years
<50 0.72 (0.55)
N=4.7
0.00
N=0
N/A 0.76 (0.53)
N=6.5
(0.23%)
N=2
3.30 0.85 (0.49)
N=7.1
0.12
N=1
7.08
50-54.9 1.08 (0.72)
N=7.7
0.28
N=2
3.86 1.16 (0.72)
N=10.2
0.11
N=1
10.55 1.25 (0.76)
N=10.5
0.36
N=3
3.47
55-59.9 2.05 (1.41)
N=12.5
0.33
N=2
6.21 2.13 (1.44)
N=16.5
0.26
N=2
8.19 2.34 (1.52)
N=20.6
0.23
N=2
10.17
60-64.9 3.80 (2.38)
N=30.3
0.75
N=6
5.07 4.10 (2.37)
N=27.3
0.30
N=2
13.67 5.22 (2.86)
N=36.3
1.44
N=10
3.63
65 5.12 (2.62)
N=29.8
1.55
N=9
3.30 5.42 (2.89)
N=31.5
1.55
N=9
3.50 6.30 (2.91)
N=50.0
3.27
N=26
1.93
SCORE level
<5% 1.64 (1.11)
N=45.7
0.40
N=11
4.10 1.57 (1.07)
N=49.3
0.19
N=6
8.26 1.66 (1.07)
N=50.7
0.39
N=12
4.26
≥5% 6.85 (2.23) 
N=39.4
1.39
N=8
4.93 6.94 (2.36)
N=42.5
1.63
N=10
4.26 7.45 (2.32)
N=73.9
3.02
N=30
2.47
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The calibration of high and low-risk continuous SCORE in HAPIEE samples was also
assessed with the Hosmer-Lemeshow test, where χ2 values <20 denote good calibration.
Table 6.2.6 presents the results of the Hosmer-Lemeshow analyses, based on predicted
risk deciles. In Czech and Polish men, χ2 values were substantially lower than 20, for
both high and low-risk SCORE. In Russian men, however, the model fit was worse (χ2
29.8 and 36.5 for high and low-risk SCORE, respectively). On the other hand, in all
female samples, both versions of SCORE demonstrated good calibration, with χ2 values
ranging from 2.0 in Poland to 7.3 in the Czech Republic.
Table 6.2.6. Calibration of high and low-risk SCORE estimated by Hosmer-Lemeshow
test in HAPIEE men and women
Czech Republic Poland Russia
Men
High-risk SCORE, χ2 (p) 9.38
(0.3116)
9.06
(0.2483)
29.83
(0.002)
Low-risk SCORE, χ2 (p) 6.87
(0.3332)
7.20
(0.3028)
36.52
(<0.0001)
Women
High-risk SCORE, χ2 (p) 7.30
(0.1990)
2.03
(0.7305)
5.36
(0.3738)
Low-risk SCORE, χ2 (p) 3.74
(0.2907)
2.56
(0.4653)
3.00
(0.5586)
Suboptimal SCORE calibration in Russian men could be partly explained by the fact
that in larger samples, Hosmer-Lemeshow test results are more sensitive to small
deviations in fit (Methods, Section 4.5.3). In addition, a substantial number of
participants had the same, relatively low levels of predicted mortality, due to the chart-
based nature of SCORE instrument, which could also affect the Hosmer-Lemeshow test
results. Thus, it may be more informative to assess SCORE calibration in HAPIEE by
evaluating the ratios of predicted to observed levels of CVD mortality.
In summary, the high-risk SCORE demonstrated good calibration in most MONICA
samples, while under-predicting the risk of fatal atherosclerotic CVD in Russian men
and women. In all HAPIEE samples, the 10-year risk predictions exceeded the currently
observed mortality, since the current HAPIEE follow-up is less than 10 years. The
magnitude of this over-prediction was minimal in Russian samples, which suggests that
at the 10-year point, high-risk SCORE can under-predict the risk of fatal CVD among
Russian men and women. These findings agree with the second research hypothesis,
which suggested satisfactory prognostic performance of SCORE across the majority of
the samples, but risk under-prediction in the samples with higher levels of
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cardiovascular mortality, such as those from Russia. Due to the present difference in the
follow-up length between MONICA and HAPIEE, the direct comparison of SCORE
calibration ability in these two studies is not possible. However, SCORE calibration,
based on estimated 10-year CVD mortality in HAPIEE samples, will be compared to
MONICA findings in the next section.
6.3. Estimated 10-year SCORE calibration in HAPIEE
As summarised in Section 2.1.3, the SCORE instrument predicts the 10-year risk of
fatal atherosclerotic CVD. Thus, the adequate assessment of SCORE performance
requires that the populations of interest are followed up for at least 10 years. While the
relevant prospective data are available for MONICA samples, the follow-up of the
HAPIEE subjects is currently less than 10 years. Therefore, it has been decided to
estimate the 10-year atherosclerotic mortality in HAPIEE, based on the country-specific
patterns of fatal CVD distribution by the follow-up year in MONICA. An alternative
approach is to use the “MONICA-independent” estimations by the exponential survival
model. The estimated levels of fatal atherosclerotic CVD are then compared to
predicted mortality, in order to evaluate the expected 10-year SCORE calibration.
6.3.1. MONICA-based estimates of 10-year SCORE calibration
For each male and female MONICA sample, the distribution of atherosclerotic CVD
deaths across all 10 years of the follow-up is presented in Table 6.3.1. As expected, the
absolute numbers of deaths tended to increase with longer follow-up, denoting the
sample ageing. This tendency was more pronounced in men vs. women, and in larger
vs. smaller samples (for example, Russian vs. Czech ones, which respectively included
three vs. one study wave(s); Methods, Section 4.1.1).
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Table 6.3.1. Observed numbers of atherosclerotic CVD deaths by follow-up year:
MONICA men and women
Follow-up
year
Czech
Republic
Poland
(Warsaw)
Poland
(Tarnobrzeg)
Lithuania Russia All
samples
Men
1st 3 1 3 5 12 24
2nd 0 8 3 5 23 39
3rd 2 7 3 0 17 29
4th 3 8 5 4 16 36
5th 5 7 7 5 17 41
6th 3 12 10 9 17 51
7th 5 7 11 6 18 47
8th 4 14 2 9 23 52
9th 4 8 9 8 23 52
10th 3 14 9 7 15 48
TOTAL 32 86 62 58 181 419
Women
1st 0 1 0 2 4 7
2nd 1 1 1 1 7 11
3rd 1 1 1 1 8 12
4th 2 2 1 0 7 12
5th 2 4 0 1 5 12
6th 0 3 1 1 8 13
7th 4 0 2 6 13 25
8th 0 4 6 4 14 28
9th 3 3 5 4 8 23
10th 0 2 2 6 12 22
TOTAL 13 21 19 26 86 165
Similarly, absolute numbers of deaths in HAPIEE participants tended to increase with
longer follow-up and sample ageing (Table 6.3.2), although for the last years of the
follow-up, these numbers were slightly lower. This was due to the delayed participation
in the baseline survey (fewer people had six or seven complete years of follow-up) and
also to the one-two-year lag between the fatal event and the register data on cause-
specific mortality becoming available (Methods, Section 4.3.1). Since this lag differed
across three populations of interest, being minimal in the Czech Republic and maximal
in Russia, the mean follow-up time, in complete years, varied from six among Czech
participants to five in their Polish peers and four in Russian subjects (Table 6.3.3).
Despite the shortest follow-up period, Russian men developed three times as many
outcomes than their peers from the Czech Republic and Poland, while this difference
was two-fold in Russian women vs. Czech or Polish females.
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Table 6.3.2. Observed numbers of atherosclerotic CVD deaths by follow-up year:
HAPIEE men and women
Follow-up
year
Czech Republic Poland Russia
Men Women Men Women Men Women
1st 2 2 5 2 20 6
2nd 2 4 6 5 20 6
3rd 7 1 6 2 23 3
4th 9 3 8 2 26 12
5th 8 4 6 4 8 11
6th 5 2 3 1 8 4
7th 4 3 - - - -
TOTAL 37 19 34 16 105 42
Assuming that the ratio between the death numbers registered at a pre-specified cut-off
point (six, five, and four years for Czech, Polish, and Russian samples, respectively) and
the death numbers observed during the complete, 10-year follow-up period would be
similar for MONICA and HAPIEE subjects from the same country, these ratios were
first calculated for each MONICA sample, separately for men and women. It should be
noted that only Polish participants from Warsaw were included in this analysis, since
mortality patterns in this urban population were expected to be a better approximation
of the respective patterns among urban Polish HAPIEE subjects (residents of Krakow
City). The proportion of the atherosclerotic CVD deaths registered within the country-
specific period of interest, out of the total number of deaths over 10 years, was similar
in MONICA men and women from the same country (Table 6.3.3). Projecting these
country and gender-specific ratios on the currently observed numbers of cardiovascular
deaths in HAPIEE samples provided the estimates of the 10-year atherosclerotic CVD
mortality among HAPIEE men and women.
Understandably, these estimates, presented in Table 6.3.3, cannot substitute the actually
observed HAPIEE data on 10-year cardiovascular mortality, which are yet to be
obtained. However, it can be noticed that the 10-year estimates for Czech and Polish
HAPIEE men (2.8% and 2.7%, respectively) were substantially lower than the 10-year
mortality levels observed in MONICA men from the same countries (5.0% and 6.7%;
see Section 5.1). Among Czech and Polish HAPIEE women, the estimated mortality
(1.2% and 1.0%) was also lower than the respective MONICA levels of fatal CVD
(1.9% and 1.8%). By contrast, the 10-year estimates of cardiovascular mortality for
Russian HAPIEE men and women (8.6% and 3.4%, respectively) were slightly higher
than the fatal CVD levels in their MONICA peers (7.0% and 3.2%). This difference
might reflect the underlying heterogeneous trends in fatal CVD across CEE/FSU
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populations over the last few decades (Section 2.2.1). In agreement with the current
discrepancies between Russian vs. Czech or Polish national mortality rates21, the 10-
year estimates of fatal CVD were at least three times higher in Russian HAPIEE men
and women (8.6% and 3.4%, respectively) than among their peers from the Czech
Republic (2.8% and 1.2%) or Poland (2.7% and 1.0%, respectively).
Table 6.3.3. Estimation of 10-year atherosclerotic CVD mortality in HAPIEE men and
women, based on observed MONICA mortality
Czech Republic Poland Russia
Men Women Men Women Men Women
Observed HAPIEE
deaths, N (%)
37
(1.39)
19
(0.57)
34
(0.98)
16
(0.43)
105
(3.23)
42
(1.04)
Current mean HAPIEE
follow-up, complete
years
6 5 4
Observed MONICA
deaths in 10 years, N
(%)
32
(5.03)
13
(1.85)
86
(6.68)
21
(1.82)
181
(7.03)
86
(3.21)
Observed MONICA
deaths in relevant
follow-up period and
10 years, N/N (%)
16/32
(50.00)
6/13
(46.15)
31/86
(36.05)
9/21
(42.86)
68/181
(37.57)
26/86
30.23)
Estimated HAPIEE
deaths in 10 years,
N (%)
74.0
(2.78)
41.2
(1.23)
94.2
(2.73)
37.3
(0.99)
279.3
(8.60)
139.0
(3.44)
In order to assess the expected 10-year calibration of the high-risk SCORE, these
MONICA-based estimates were compared to predicted mortality levels, and the ratios
of predicted to estimated (P/E) mortality were calculated for each HAPIEE sample
(Table 6.3.4). For Czech and Polish men, the high-risk SCORE demonstrated a 2.7-fold
over-prediction of the estimated 10-year cardiovascular mortality, while in their female
peers, the gap between predicted and estimated risk of fatal CVD was only slightly
smaller (P/E ratios 2.06 and 2.48 in Czech and Polish women, respectively). Therefore,
despite the evidence of good calibration of the high-risk SCORE in Czech and Polish
MONICA samples (Section 6.2.1), this scale appeared to over-estimate the risk in
contemporary populations from respective countries. The agreement between the 10-
year estimated atherosclerotic CVD mortality and the high-risk SCORE predictions
was, however, good for HAPIEE men from Russia, as denoted by the P/E ratio of 1.06.
Among Russian HAPIEE women, the level of predicted risk was lower than the
estimated mortality (P/E ratio 0.90), although to a lesser extent than in their MONICA
peers.
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Table 6.3.4. Predicted (P) by high-risk SCORE and estimated (E) atherosclerotic CVD
mortality in HAPIEE men and women
Czech Republic Poland Russia
P E P/E P E P/E P E P/E
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Men 7.51
(5.99)
N=199.7
2.78
N=74.0
2.70 7.37
(5.89)
N=254.7
2.73
N=94.2
2.70 9.07
(7.27)
N=294.4
8.60
N=279.3
1.06
Women 2.53
(2.39)
N=85.0
1.23
N=41.2
2.06 2.45
(2.41)
N=92.0
0.99
N=37.3
2.48 3.08
(2.90)
N=124.6
3.44
N=139.0
0.90
These results suggest that the use of different SCORE versions in Czech and Polish vs.
Russian samples might improve the agreement between predicted and estimated risk of
fatal atherosclerotic CVD. To check this possibility, the calibration of the low-risk
SCORE scale was investigated across HAPIEE samples, although this SCORE version
is presently not recommended for CEE/FSU populations. As seen in Table 6.3.5, the
low-risk SCORE continued to over-predict the 10-year estimated levels of fatal CVD
among Czech and Polish participants (P/E ratios from 1.19 in Czech women to 1.40 in
Polish females and 1.44 in both Czech and Polish men), but to a lesser extent than the
high-risk version of this instrument (respective P/E ratios 2.06-2.70). However, the low-
risk SCORE was able to predict only a half of the estimated 10-year cardiovascular
mortality among men and women from Novosibirsk (P/E ratios 0.56 and 0.52,
respectively).
Table 6.3.5. Predicted (P) by low-risk SCORE and estimated (E) atherosclerotic CVD
mortality in HAPIEE men and women
Czech Republic Poland Russia
P E P/E P E P/E P E P/E
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Men 4.00
(3.32)
N=106.4
2.78
N=74.0
1.44 3.92
(3.26)
N=135.5
2.73
N=94.2
1.44 4.84
(4.07)
N=157.1
8.60
N=279.3
0.56
Women 1.46
(1.54)
N=49.0
1.23
N=41.2
1.19 1.39
(1.56)
N=52.2
0.99
N=37.3
1.40 1.77
(1.83)
N=71.6
3.44
N=139.0
0.52
This is consistent with the findings for the high-risk SCORE and implies that the
SCORE calibration might be improved, once the low-risk scale is used for the
contemporary Czech and Polish populations, and the high-risk version is applied to
Russian populations. These results, together with the data on risk under-estimation in
Russian MONICA samples (Section 6.2.1), support the second research hypothesis of
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differential SCORE calibration across CEE/FSU populations with varying levels of
background risk.
6.3.2. Exponential model-based estimates of 10-year SCORE calibration
An alternative method for obtaining the 10-year estimates of HAPIEE calibration is
based on the exponential model. This approach assumes a relatively constant mortality
rate362, and, hence, does not account for potential fluctuations, which are more likely in
the samples with lower levels of fatal CVD, such as Czech and Polish women.
However, this method provides the estimates which are not derived from the 10-15-
year-old MONICA data. The estimated 10-year mortality (M10) in HAPIEE samples
was calculated as: M10 = 1 – [1 – Mx ]10/x, where Mx is mortality at x years of the follow-
up.
The exponential estimates of the 10-year cardiovascular mortality in HAPIEE men and
women (Appendix II, Table A6.3.1) were slightly lower than the respective MONICA-
based estimates. In addition, the exponential estimates for Czech and Polish HAPIEE
men (2.3% and 2.0%, respectively) were lower than the fatal CVD levels observed in
MONICA men from respective countries (5.0% and 6.7%; Section 6.3.1). Similarly,
among Czech and Polish HAPIEE women, exponentially estimated CVD mortality
(1.0% and 0.9%) was lower than the respective MONICA levels (1.9% and 1.8%).
While for Russian HAPIEE women, exponentially estimated mortality (2.6%) was
somewhat lower than the mortality observed in their MONICA peers (3.2%), the
estimates for Russian HAPIEE men (7.9%) slightly exceeded the levels of fatal CVD
observed in male MONICA participants from this country (7.0%). Consistent with the
presently observed discrepancies between national Russian vs. Czech or Polish
cardiovascular mortality rates21, the exponential estimates of 10-year fatal CVD levels
in HAPIEE were at least three times higher in Russian men and women (7.9% and
2.6%, respectively) than in their peers from the Czech Republic (2.3% and 1.0%) or
Poland (2.0% and 0.9%, respectively).
For each HAPIEE sample, mortality predicted by the high-risk SCORE, exponentially
estimated 10-year mortality, and the P/E ratio, as a measure of 10-year SCORE
calibration, are presented in Table A6.3.2 (Appendix II). In the Czech Republic and
Poland, the high-risk SCORE demonstrated at least a 2.7-fold over-prediction of the
estimated 10-year cardiovascular mortality (P/E ratios 3.25 and 2.66 in Czech men and
women; 3.78 and 2.85 in their Polish peers). Among Russian men and women, the
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agreement between the estimated CVD mortality and the high-risk SCORE predictions
was good (respective P/E ratios 1.15 and 1.19). These results generally agree with the
findings for the MONICA-based estimates of the 10-year SCORE calibration in
HAPIEE and suggest that the high-risk SCORE might adequately predict cardiovascular
risk in contemporary Russian populations.
With P/E ratios being at least twice as high in the Czech Republic and Poland as in
Russia, the use of different SCORE versions in Czech and Polish vs. Russian samples
might be advisable. Accordingly, the calibration of the low-risk SCORE was assessed in
each HAPIEE sample. In Czech and Polish samples, the low-risk SCORE continued to
over-predict the 10-year estimated levels of fatal CVD (P/E ratios from 1.54 in Czech
women to 2.01 in Polish men), but to a lesser extent than the high-risk SCORE (P/E
ratios 2.66-3.78). In Russian men and women, however, the low-risk scale predicted
<70% of the estimated mortality (respective P/E ratios 0.61 and 0.69) (Table A6.3.3).
Therefore, both exponential model-based and MONICA-based projections were
consistent with the second research hypothesis and suggested that the low-risk SCORE
is more appropriate for contemporary Czech and Polish settings, while the high-risk
SCORE version continues to be more suitable for Russia.
Both the MONICA-derived and exponential model-derived estimates of 10-year CVD
mortality in HAPIEE samples represent the aggregate projections, which cannot be
extrapolated on the individual level. Thus, it was not possible to use these estimates for
assessing the associations between fatal CVD and exposures of interest, or for
evaluating the discrimination potential of the original SCORE scale and extended
SCORE-based instruments. Nonetheless, the estimation procedure demonstrated that
better calibration was achieved by the high-risk SCORE in Russian samples, and by the
low-risk SCORE in Czech and Polish samples. Although no conclusion can be made
before the actual 10-year data on observed HAPIEE mortality are available, it is
possible that CEE/FSU populations require a further differentiation in the SCORE
versions which are officially recommended to them.
6.4. SCORE discrimination
The next step of the analysis was to assess discrimination, another important aspect of
SCORE performance, in both MONICA and HAPIEE. Discrimination, which reflects
how accurately the risk assessment instrument separates subjects who will experience
the outcome from those who will not, was assessed by sensitivity, specificity, the ratio
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of true to false positives (likelihood ratio positive, LR+), the ratio of false to true
negatives (likelihood ratio negative, LR-), positive and negative predictive values (PPV
and NPV), area under the receiver operating characteristic curve (AUROC) and
Harrell’s C-statistic (AUROC equivalent for survival models), as well as by the recently
introduced Royston’s R2 index (for parameter description, see Methods, Section 4.5.3).
6.4.1. SCORE discrimination in MONICA
As shown in Table 6.4.1, sensitivity of the high-risk SCORE was relatively high in all
male MONICA samples, varying from 0.65 in Russia to 0.79 in Warsaw. Specificity
was somewhat lower, ranging from 0.54 in Warsaw to 0.60 in Lithuania. Therefore, the
high-risk SCORE correctly identified up to 80% of MONICA men who experienced an
atherosclerotic CVD death within the next 10 years, and up to 60% of the men who did
not develop a fatal CVD. The proportion of true positives (high-risk people with an
outcome) was 1.5-1.9 times higher than the proportion of false positives (high-risk
people without the outcome). Across all samples, LR- was below 1.0, as the proportion
of the low-risk subjects who developed the outcome (false negatives) was small. Due to
the relatively low outcome frequency, the PPV values were low in all male samples
(approximately 0.10). By contrast, NPV values exceeded 0.96. In other words, while
only a small proportion of high-risk men developed a CVD death within the 10-year
follow-up period, almost all low-risk males remained outcome-free.
The AUROC values were over 0.50 (the value corresponding to overall discrimination
no better than chance) across all male samples, being the highest for Czech men (0.69)
and the lowest for Russian men (0.62). As expected, the values of Harrell’s C-statistic
were very close to the AUROC ones. In the subsequent analyses of extended SCORE
performance, Harrell’s C will be used instead of AUROC, since the former parameter
allows assessing summary discrimination of multivariate models, enriched by additional
risk predictors.
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Table 6.4.1. Discrimination characteristics of the 5% cut-off for high-risk SCORE predicting 10-year atherosclerotic CVD mortality
in MONICA men and women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Sensitivity 25/32=0.7813 68/86=0.7907 44/62=0.7098 42/58=0.7241 118/181=0.6519
Specificity 358/604=0.5927 631/1167=0.5407 673/1205=0.5585 949/1593=0.5957 1399/2395=0.5841
LR+
(sensitivity/
1-specificity)
78.13/40.73=1.92 70.07/45.93=1.53 70.98/44.15=1.61 72.41/40.43=1.79 65.19/41.59=1.57
LR-
((1-sensitivity)/
specificity)
21.87/59.27=0.37 20.93/54.07=0.39 29.02/55.85=0.52 27.59/59.57=0.46 34.81/58.41=0.60
PPV 25/271=0.0923 68/604=0.1126 44/576=0.0764 42/686=0.0612 118/1114=0.1059
NPV 358/365=0.9808 631/649=0.9723 673/691=0.9740 949/965=0.9834 1399/1462=0.9569
AUROC (95% CI) 0.69 (0.61-0.76) 0.67 (0.62-0.71) 0.63 (0.58-0.69) 0.66 (0.60-0.72) 0.62 (0.58-0.65)
Harrell’s C 0.6900 0.6665 0.6319 0.6645 0.6188
Women
Sensitivity 5/13=0.3846 4/21=0.1905 5/19=0.2632 8/26=0.3077 32/86=0.3721
Specificity 616/691=0.8915 989/1130=0.8752 1325/1443=0.9182 1493/1624=0.9193 2376/2591=0.9170
LR+
(sensitivity/
1-specificity)
38.46/10.85=3.55 19.05/12.48=1.53 26.32/8.18=3.20 30.77/8.07=3.81 37.21/8.30=4.48
LR-
((1-sensitivity)/
specificity)
61.54/89.15=0.69 80.95/87.52=0.93 73.68/91.82=0.80 69.23/91.93=0.75 62.79/91.70=0.69
PPV 5/80=0.0625 4/145=0.0276 5/123=0.0407 8/139=0.0576 32/247=0.1296
NPV 616/624=0.9872 989/1006=0.9831 1325/1339=0.9895 1493/1511=0.9881 2376/2430=0.9778
AUROC (95% CI) 0.64 (0.50-0.78) 0.53 (0.45-0.62) 0.59 (0.49-0.69) 0.61 (0.52-0.70) 0.65 (0.59-0.70)
Harrell’s C 0.6374 0.5354 0.5922 0.6134 0.6428
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Among MONICA women, sensitivity of the high-risk SCORE was much lower than in
men (from 0.19 in Warsaw to 0.39 in the Czech Republic), while its specificity was
higher, approaching 0.90 in all female samples (Table 6.4.1). Therefore, SCORE
correctly selected the majority of low-risk women who remained outcome-free, but
identified only 20-40% of the women who would die from CVD in the next 10 years.
Due to the low percentages of false positives in all female samples, the LR+ values
were relatively high, varying from 1.5 in Warsaw to 4.5 in Novosibirsk. Women had a
higher proportion of false negatives than men and, as a result, higher LR- values.
Similar to men, low PPV values (≤0.13) and high NPV values (≥0.98) were observed in 
all female samples. AUROC and Harrell’s C values were lower in women than in men,
being the closest to 0.50 (inadequate discrimination) in Warsaw (0.54) and the highest
in Novosibirsk (0.64).
The low-risk SCORE demonstrated lower sensitivity and higher specificity across all
MONICA samples, compared to the high-risk SCORE version (Appendix II, Table
A6.4.1). The values of AUROC and C-statistic for the low vs. high-risk SCORE were
either similar or slightly lower.
An additional discrimination measure is the amount of the outcome variation accounted
for by risk predictors. Royston’s R2 index is an indicator of explained variation
specifically created for survival analysis (Methods, Section 4.5.3). In the present study,
R2 statistic was adjusted by the model dimension (to facilitate the subsequent
assessment of the extended SCORE performance), and bootstrap CI were calculated,
using the minimal recommended replication number of 1,000. In male MONICA
samples, the proportion of variation explained by dichotomous high-risk SCORE was
the highest in the Czech Republic (R2=0.32) and the lowest in Novosibirsk (0.13). In
women, due to fewer outcomes, the proportion of explained variation was typically
smaller than in men (Table 6.4.2). In most samples, R2 values were higher for
continuous high-risk SCORE than for its widely used dichotomous version, and reached
0.35 for Czech men and 0.47 for women from Novosibirsk.
A similar tendency, characterized by a higher proportion of explained variation in men
vs. women (due to larger outcome numbers in the former), and for continuous vs.
dichotomous SCORE (possibly, due to dichotomisation-caused information loss), was
observed for the low-risk version of SCORE (Appendix II, Table A6.4.2).
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Table 6.4.2. Discrimination of high-risk SCORE estimated by Royston’s R2 in MONICA men and women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous
SCORE
0.3169
(0.1042, 0.5817)
0.2605
(0.1354, 0.4015)
0.1593
(0.0442, 0.3247)
0.2421
(0.0905, 0.4230)
0.1336
(0.0646, 0.2261)
Continuous
SCORE
0.3488
(0.1290, 0.6326)
0.2877
(0.1527, 0.4416)
0.2802
(0.1247, 0.4748)
0.1427
(0.0359, 0.2922)
0.2691
(0.1688, 0.3860)
Women
Dichotomous
SCORE
0.2452
(0.0000, 0.7025)*
0.0052
(0.0000, 0.2196)*
0.1475
(0.0000, 0.5473)*
0.2264
(0.0000, 0.5633)*
0.3376
(0.1491, 0.5235)
Continuous
SCORE
0.1845
(0.0000, 0.5338)*
0.2526
(0.0000, 0.6374)*
0.3248
(0.0869, 0.5731)
0.3259
(0.1513, 0.5247)
0.4706
(0.3046, 0.6312)
* Lower confidence limits calculated as negative were regarded as 0.
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In summary, the traditional risk factors comprising SCORE accounted for <50% of the
outcome variation across MONICA samples, despite a significant association between
SCORE and atherosclerotic CVD mortality, previously shown in Section 6.1.1.
6.4.2. SCORE discrimination in HAPIEE
For HAPIEE samples, sensitivity, specificity, and other parameters of the high-risk
SCORE discrimination were calculated based on the available mortality data. Since the
current follow-up length for HAPIEE is less than 10 years, the results obtained should
be interpreted cautiously. In male samples, the high-risk SCORE sensitivity reached
0.95, 0.80, and 0.94 in Czech, Polish, and Russian men, respectively, while its
specificity was lower (0.37, 0.39, and 0.33, respectively) (Table 6.4.3). This means that
the high-risk SCORE correctly identified at least 80% of the men who died from
atherosclerotic CVD during the follow-up, but under 40% of the men who did not
develop this outcome. The LR+ was 1.3-1.5, due to a relatively high percentage of
outcome-free people at high risk. The LR- did not exceed 1.0 and was the lowest in
Czech men (0.15). While PPV values were very low (0.01-0.05), NPV values exceeded
0.99 across all male samples. In other words, even though only a small percentage of
high-risk men developed an outcome during the current follow-up period, almost all
low-risk men remained event-free. The summary discrimination of high-risk SCORE
was satisfactory, as denoted by relatively high values of AUROC and Harrell’s C-
statistic (from 0.60 in Poland to 0.66 in the Czech Republic).
In women, sensitivity of the high-risk SCORE was lower than in men, varying from
0.42 in the Czech Republic to 0.71 in Russia (Table 6.4.3). However, SCORE
specificity was substantially higher in women, reaching 0.76-0.84. As a result, LR+
values were also higher in women. The values of LR- were relatively high, due to a
considerable proportion of low-risk women who would develop the outcome. Compared
to their male peers, Czech women had slightly lower AUROC and Harrell’s C values. In
Polish and Russian women, these parameters were higher than in men from respective
samples and reached 0.73-0.74, which denoted a good summary discrimination of the
high-risk SCORE.
Across all HAPIEE samples, the low-risk SCORE, compared to its high-risk version,
showed lower sensitivity and higher specificity, as well as generally comparable
AUROC and Harrell’s C values (Appendix II, Table A6.4.3).
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Table 6.4.3. Discrimination characteristics of the 5% cut-off for high-risk SCORE predicting atherosclerotic CVD mortality
in HAPIEE men and women
Czech Republic Poland Russia
Men
Sensitivity 35/37=0.9460 27/34=0.7941 99/105=0.9429
Specificity 978/2622=0.3730 1346/3422=0.3933 1024/3141=0.3260
LR+ (sensitivity/1-specificity) 94.60/62.70=1.51 79.41/60.67=1.31 94.29/67.40=1.40
LR- ((1-sensitivity)/specificity) 5.40/37.30=0.15 20.59/39.33=0.52 5.71/32.60=0.18
PPV 35/1679=0.0209 27/2103=0.0128 99/2216=0.0447
NPV 978/980=0.9980 1346/1353=0.9948 1024/1030=0.9942
AUROC (95% CI) 0.66 (0.62-0.70) 0.59 (0.52-0.66) 0.63 (0.61-0.66)
Harrell’s C 0.6595 0.5964 0.6290
Women
Sensitivity 8/19=0.4211 10/16=0.6250 30/42=0.7143
Specificity 2773/3340=0.8302 3135/3737=0.8389 3040/4002=0.7596
LR+ (sensitivity/1-specificity) 42.11/16.98=2.48 62.50/16.11=3.88 71.43/24.04=2.97
LR- ((1-sensitivity)/specificity) 57.89/83.02=0.70 37.50/83.89=0.45 28.57/75.96=0.38
PPV 8/575=0.0139 10/612=0.0163 30/992=0.0302
NPV 2773/2784=0.9961 3135/3141=0.9981 3040/3052=0.9961
AUROC (95% CI) 0.63 (0.51-0.74) 0.73 (0.61-0.86) 0.74 (0.67-0.81)
Harrell’s C 0.6267 0.7413 0.7356
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In male HAPIEE samples, the proportion of the outcome variation explained by the
dichotomous high-risk SCORE was maximal in the Czech Republic (R2=0.31) and
minimal in Poland (0.08) (Table 6.4.4). Compared to respective male samples, the
proportion of explained variation was smaller in Czech women (0.18), but higher in
Polish and Russian women (0.53 and 0.47, respectively). Since the dichotomisation of
SCORE might have resulted in the loss of predictive information, R2 values for
continuous SCORE were typically higher than those for the traditional, dichotomous
instrument, and reached 0.42 in Czech men and 0.69 in Polish women.
Table 6.4.4. Discrimination of high-risk SCORE estimated by Royston’s R2 in HAPIEE
men and women
Czech Republic Poland Russia
Men
Dichotomous SCORE 0.3075
(0.1593, 0.4873)
0.0838
(0.0000, 0.2957)*
0.2304
(0.1376, 0.3370)
Continuous SCORE 0.4216
(0.1977, 0.6531)
0.3501
(0.1004, 0.6291)
0.3154
(0.1950, 0.4561)
Women
Dichotomous SCORE 0.1747
(0.0000, 0.5294)*
0.5263
(0.0729, 0.8626)
0.4729
(0.2419, 0.7022)
Continuous SCORE 0.1708
(0.0000, 0.4592)*
0.6910
(0.2503, 0.9375)
0.6003
(0.3603, 0.7928)
* Lower confidence limits calculated as negative were regarded as 0.
Similar results were obtained for low-risk SCORE, with a larger proportion of explained
variation typically observed for continuous vs. dichotomous scale, and maximal R2
values registered in Czech men and Polish women (0.42 and 0.72, respectively, for the
continuous instrument) (Appendix II, Table A6.4.4).
A direct comparison of the SCORE discrimination in MONICA vs. HAPIEE samples
was not possible, due to the current difference in the follow-up length between these
two studies. However, SCORE sensitivity appeared to be higher, and specificity lower
in most HAPIEE samples, compared to the MONICA samples. The proportion of
explained variation was more or less similar in respective MONICA and HAPIEE
samples. Overall, the MONICA and HAPIEE data have demonstrated satisfactory
SCORE discrimination, as assessed by traditional discrimination measures. Together
with the findings presented in Sections 6.2-6.3, these results have addressed the third
research objective (the examination of SCORE performance in MONICA and HAPIEE)
and supported the second research hypothesis of satisfactory SCORE discrimination but
varying calibration, with risk under-estimation in Russian samples.
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Chapter 7. Education, marital status, and SCORE
performance
Although the discrimination of the dichotomised high-risk SCORE, as assessed by
traditional parameters, was more or less satisfactory in MONICA and HAPIEE, this
SCORE version typically did not explain more than 50% of the outcome variation.
These findings suggest that SCORE performance may benefit from adding other
cardiovascular risk predictors to the model. Therefore, it has been explored whether
extending the predictive model by socioeconomic parameters or alcohol consumption
measures improves its calibration and discrimination, in accordance with the third and
fourth research hypotheses.
For MONICA, additional risk factors included education (all samples) and marital status
(Czech, Lithuanian, and Russian samples; no data on marital status were available for
Poland). For HAPIEE, these parameters included education, marital status, alcohol
consumption frequency, binge drinking, and CAGE score. In order to obtain stable
effect estimates, most additional risk predictors were dichotomised. In particular,
education was defined as “higher” (university, secondary, or vocational) or “lower”
(primary or less), while marital status categories included “married”
(married/cohabiting) and “non-married” (single, divorced/separated, or widowed).
Before including additional risk factors into the SCORE-based predictive model,
calibration and discrimination of the original SCORE instrument were evaluated in the
stratified data (for example, in higher vs. lower-educated people, and married vs. non-
married participants, separately for men and women), to investigate whether the risk
might be over-predicted in more advantaged subjects and under-predicted in their less
advantaged peers. The analyses of SCORE performance by education and marital status
in MONICA and HAPIEE failed to demonstrate any substantial difference in calibration
or discrimination for participants with higher vs. lower education, or for married vs.
non-married subjects (results available on request). The original SCORE performance
was similar across socioeconomic strata, which suggested that there is no interaction
between SCORE and education or marital status. However, this did not yet mean that
socioeconomic characteristics would be irrelevant for extension of the SCORE model.
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7.1. SCORE, education, and marital status as predictors of
atherosclerotic CVD mortality
The next step of the analysis was to combine SCORE and education or marital status in
prognostic models and to assess their role as predictors of atherosclerotic CVD
mortality in MONICA and HAPIEE men and women. The baseline Model 1, which
only included SCORE, was compared to Model 2 (SCORE and education), Model 3
(SCORE and marital status), and Model 4 (SCORE, education, and marital status). The
mutual adjustment of SCORE and socioeconomic effects was possible, since no
statistical interaction has been found between SCORE (both dichotomous and
continuous high and low-risk versions) and either education or marital status in LR tests
(all p values for interaction terms >0.1). In addition, as there was no marked collinearity
between education and marital status across MONICA and HAPIEE samples (all phi
correlation coefficient values <0.1, as shown in Tables 7.1.1-7.1.2), it was possible to
simultaneously include these two parameters in the extended SCORE model (Model 4).
Table 7.1.1. Phi correlation coefficients for education and marital status in MONICA
men and women
Czech
Republic
Poland
(Warsaw)*
Poland
(Tarnobrzeg)*
Lithuania Russia
Men 0.0463 N/A N/A 0.0038 -0.0031
Women 0.0065 N/A N/A 0.0324 0.0764
* For Polish samples, data on marital status were unavailable.
Table 7.1.2. Phi correlation coefficients for education and marital status in HAPIEE
men and women
Czech Republic Poland Russia
Men 0.0841 0.0402 0.0487
Women 0.0199 0.0280 0.0722
7.1.1. SCORE, education, and marital status as predictors of atherosclerotic CVD
mortality in MONICA
In most MONICA samples, high-risk SCORE 5% remained a significant predictor of
10-year CVD mortality after controlling for education, marital status, or both (Table
7.1.3). This adjustment slightly changed HR values for SCORE (reduced or increased,
depending on the sample), but overall, it did not substantially affect the strength of the
association between SCORE and fatal CVD. The only exceptions were Lithuanian and
Russian female samples, where adjustment for education resulted in a slightly more
pronounced reduction in SCORE HR (from 5.1 to 3.8 in Lithuania and from 6.3 to 5.4
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in Russia). It suggests that the association of interest could be partly explained by
educational differences in these samples; however, due to fewer outcomes and wider
95% CI in women vs. men, these findings should be interpreted with caution.
Across all samples, with the exception of Polish women from Tarnobrzeg, lower
education was linked to a higher risk of 10-year CVD mortality. After adjustment for
SCORE, this association reached statistical significance in men from Warsaw and
Novosibirsk (HR 1.6 and 1.7, respectively), as well as in women from Warsaw, Kaunas,
and Novosibirsk (HR 4.5, 4.4, and 1.7, respectively). In Warsaw and Kaunas, the
detrimental effect of lower education seemed to be more pronounced in women than in
men, while in Novosibirsk, no gender difference was observed for the association
between lower education and fatal CVD risk.
Not being married was linked to a higher 10-year risk of atherosclerotic CVD in all
male and female MONICA samples (data on marital status were unavailable for Polish
subjects). After controlling for SCORE, this association was statistically significant in
Czech and Russian men (HR 5.1 and 1.7, respectively), but not in women, suggesting
that the protective effect of marriage may be more important for men. On the other
hand, the absence of statistical significance for the marital status-fatal CVD association
in women could be due to lower outcome numbers.
Overall, these findings seem to support the use of education (Warsaw men and women,
Lithuanian women, Russian women), marital status (Czech men), or both education and
marital status (Russian men) as additional independent predictors of atherosclerotic
CVD mortality. Similar results were obtained for continuous high-risk SCORE
(Appendix III, Table A7.1.1), as well as for dichotomous and continuous low-risk
SCORE (Tables A7.1.2-A7.1.3), confirming the existence of positive, albeit
heterogeneous, links between socioeconomic disadvantage and fatal CVD in MONICA
samples.
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Table 7.1.3. Dichotomous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality
in MONICA men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 5.32 (2.30-12.30) 4.50 (2.68-7.56) 3.06 (1.77-5.29) 3.99 (2.24-7.10) 2.66 (1.96-3.62)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 5.35 (2.31-12.38) 4.32 (2.56-7.27) 2.90 (1.67-5.05) 3.75 (2.08-6.76) 2.43 (1.78-3.33)
Lower education
(vs. higher)
1.20 (0.58-2.49) 1.56 (1.02-2.41) 1.44 (0.76-2.73) 1.30 (0.77-2.20) 1.70 (1.25-2.30)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 5.73 (2.46-13.33) N/A N/A 4.05 (2.28-7.21) 2.70 (1.99-3.68)
Non-married (vs. married) 5.13 (2.51-10.50) 1.93 (0.88-4.26) 1.73 (1.12-2.68)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 5.77 (2.47-13.43) N/A N/A 3.82 (2.12-6.88) 2.48 (1.81-3.40)
Lower education
(vs. higher)
1.16 (0.56-2.42) 1.29 (0.76-2.18) 1.66 (1.23-2.25)
Non-married (vs. married) 5.14 (2.51-10.52) 1.92 (0.87-4.23) 1.76 (1.13-2.72)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 5.02 (1.64-15.36) 1.70 (0.57-5.06) 4.15 (1.49-11.52) 5.07 (2.20-11.66) 6.32 (4.08-9.79)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 4.72 (1.53-14.58) 1.62 (0.54-4.80) 4.26 (1.52-11.96) 3.78 (1.60-8.90) 5.44 (3.44-8.60)
Lower education
(vs. higher)
1.55 (0.42-5.69) 4.48 (1.64-12.23) 0.82 (0.27-2.49) 4.35 (1.70-11.09) 1.70 (1.09-2.66)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 4.96 (1.62-15.17) N/A N/A 4.98 (2.16-11.49) 6.22 (3.98-9.71)
Non-married (vs. married) 2.15 (0.70-6.58) 1.26 (0.50-3.15) 1.22 (0.77-1.91)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 4.67 (1.51-14.43) N/A N/A 3.77 (1.60-8.91) 5.44 (3.42-8.66)
Lower education
(vs. higher)
1.54 (0.42-5.67) 4.35 (1.70-11.09) 1.64 (1.05-2.58)
Non-married (vs. married) 2.16 (0.71-6.60) 1.03 (0.39-2.75) 1.22 (0.77-1.91)
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7.1.2. SCORE, education, and marital status as predictors of atherosclerotic CVD
mortality in HAPIEE
After accounting for education and marital status, the association between high-risk
SCORE 5% and atherosclerotic CVD mortality remained significant in all HAPIEE
samples (Table 7.1.4). This adjustment slightly changed SCORE HR values, to a
greater extent for education than for marital status, in both men (unadjusted vs.
education-adjusted HR 10.5 vs. 9.6 in the Czech Republic, 2.6 vs. 2.4 in Poland, and 7.6
vs. 7.1 in Russia) and women (3.6 vs. 3.4, 8.8 vs. 7.7, and 7.4 vs. 6.7, respectively).
These findings, suggesting a more important role of education vs. marital status as a
partial explanation of the SCORE-fatal CVD link, should be interpreted carefully, due
to a relatively short follow-up of HAPIEE subjects, hence fewer outcomes and wider
95% CI.
Across all samples, the fatal CVD risk was higher among lower-educated subjects than
in their higher-educated peers. After controlling for SCORE, lower education was a
significant predictor of cardiovascular mortality in all male samples (HR 3.3, 2.6, and
1.8 for Czech, Polish, and Russian men, respectively). In all female samples, lower
education was linked to a two-fold increase in fatal CVD risk; however, this association
did not reach statistical significance, probably due to lower outcome numbers among
women. Higher risk of atherosclerotic CVD death among non-married participants was
observed across all samples, with HR ranging from 1.3 in Polish women to 2.6 in Polish
men. After adjustment for SCORE, this association was statistically significant in Polish
men (HR 2.6), Russian men (2.3), and Russian women (2.6).
These results are consistent with the possible addition of education (Czech men),
marital status (Russian women), or both (Polish and Russian men), as independent
predictors of CVD mortality, to the SCORE model. Similar findings, showing positive,
although heterogeneous across samples, associations between SCORE, education,
marital status, and fatal CVD in HAPIEE were obtained for continuous high-risk
SCORE (Appendix III, Table A7.1.4) and dichotomous and continuous low-risk
SCORE (Tables A7.1.5-A7.1.6).
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Table 7.1.4. Dichotomous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality
in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 10.51 (2.53-43.71) 2.56 (1.11-5.87) 7.63 (3.35-17.40)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 9.61 (2.30-40.06) 2.39 (1.04-5.51) 7.06 (3.08-16.14)
Lower education (vs. higher) 3.25 (1.35-7.83) 2.61 (1.13-6.02) 1.84 (1.15-2.95)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 10.70 (2.57-44.50) 2.49 (1.09-5.73) 7.65 (3.35-17.44)
Non-married (vs. married) 1.70 (0.78-3.72) 2.57 (1.20-5.50) 2.32 (1.47-3.66)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 9.74 (2.34-40.66) 2.35 (1.02-5.42) 7.12 (3.11-16.29)
Lower education (vs. higher) 3.04 (1.24-7.41) 2.50 (1.08-5.77) 1.77 (1.10-2.84)
Non-married (vs. married) 1.57 (0.71-3.48) 2.48 (1.16-5.32) 2.26 (1.43-3.56)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 3.59 (1.44-8.91) 8.79 (3.19-24.18) 7.36 (3.77-14.38)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 3.36 (1.34-8.43) 7.71 (2.75-21.68) 6.68 (3.37-13.24)
Lower education (vs. higher) 1.97 (0.74-5.24) 2.27 (0.77-6.68) 1.87 (0.90-3.85)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 3.47 (1.40-8.65) 8.48 (3.06-23.53) 6.74 (3.44-13.19)
Non-married (vs. married) 1.91 (0.78-4.71) 1.32 (0.49-3.56) 2.55 (1.34-4.86)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 3.25 (1.29-8.17) 7.48 (2.64-21.21) 6.20 (3.13-12.30)
Lower education (vs. higher) 1.91 (0.72-5.09) 2.23 (0.76-6.59) 1.74 (0.84-3.59)
Non-married (vs. married) 1.88 (0.76-4.64) 1.27 (0.47-3.46) 2.49 (1.31-4.74)
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To summarise Section 7.1, significant associations between SCORE and cardiovascular
mortality were observed in both MONICA and HAPIEE even after adjustment for
socioeconomic parameters, which addressed Research Objective 4a. The link between
SCORE and fatal atherosclerotic CVD appeared to be influenced, to a varying extent,
by education and marital status, as demonstrated by the changes in SCORE HR values
after controlling for these additional risk determinants. This concurs with the suggestion
of differential impact of extra risk factors on the magnitude of the SCORE-fatal CVD
association across populations and over time. However, this impact was relatively
modest for all MONICA and HAPIEE samples, and did not result in the loss of
statistical significance for the main association of interest, which supports the first
research hypothesis of SCORE as a significant predictor of cardiovascular risk.
Most MONICA and HAPIEE samples demonstrated positive associations between
socioeconomic parameters and cardiovascular mortality, after accounting for the effects
of SCORE. These associations were statistically significant in some, but not all samples,
which could be due to limited outcome numbers and reduced power of multiply
adjusted analyses. Statistical significance of the SCORE-adjusted associations between
additional risk determinants and fatal CVD supports the rationale for extending SCORE
by these factors, but does not automatically mean that the extended models will have
better calibration and discrimination. Therefore, prior to recommending specific
socioeconomic parameters (if any) to be added to SCORE, as the third research
hypothesis suggests, the predictive performance of such extended models needs to be
investigated, which is the focus of the next section.
7.2. Calibration and discrimination of the SCORE model extended by
education and marital status
To investigate whether enriching SCORE with additional risk determinants, such as
education and marital status, improves its prognostic performance in MONICA and
HAPIEE samples, various measures of calibration and discrimination were compared
for the baseline Model 1 (SCORE only) vs. Model 2 (SCORE and education), Model 3
(SCORE and marital status), and Model 4 (SCORE, education, and marital status).
Specifically, the values of Hosmer-Lemeshow χ2, Harrell’s C-statistic, and Royston’s R2
index were compared across these models. Additional prognostic information, provided
by extra risk predictors, was also assessed by LR test p values and by integrated
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discrimination improvement (IDI). To enable these cross-model comparisons, the
present analyses included only subjects with known education and marital status.
7.2.1. Calibration and discrimination of the SCORE model extended by education
and marital status in MONICA
Since the comparison of the predicted to observed CVD deaths by both education and
marital status would not be informative, due to very low outcome numbers across
individual strata, SCORE calibration of extended models in MONICA and HAPIEE
was assessed with the Hosmer-Lemeshow goodness-of-fit test. This test quantifies the
agreement between predicted and observed events across risk deciles (Methods, Section
4.5.3), and was, therefore, applied to the continuous high and low-risk versions of
SCORE.
The results of the Hosmer-Lemeshow analyses for MONICA samples are presented in
Table 7.2.1. In most male samples, χ2 values were under 20 for high-risk SCORE
predictions across all four models, which denoted satisfactory calibration. However, in
Lithuanian men, most χ2 values exceeded 20, which points to imperfect fit of both
original and extended SCORE models. Adding education to the SCORE model reduced
Hosmer-Lemeshow χ2 values (and, therefore, improved calibration) in Czech men (from
17.2 to 9.4), Polish men from Warsaw (from 13.9 to 10.7), and, to a lesser extent, in
Lithuanian men (from 20.6 to 18.0). By contrast, in men from Tarnobrzeg and
Novosibirsk, the original SCORE model fitted somewhat better than the education-
extended one (χ2 values 4.6 vs. 9.2, and 4.4 vs. 4.5, respectively). Analysing the
calibration of the SCORE model extended by marital status produced mixed results:
compared to the original instrument, this model was better calibrated in Czech men
(respective χ2 values 17.2 vs. 13.8), but not in their peers from Lithuania (20.6 vs. 28.4)
or Russia (4.4 vs. 5.7, respectively). For Polish samples, data on marital status were
unavailable (Methods, Section 4.3.3), hence, the calibration analyses could only be
performed for Models 1 and 2.
In women, almost all Hosmer-Lemeshow χ2 values were under 20, and extending the
baseline SCORE model by education and/or marital status would generally result in
improved calibration (Table 7.2.1). Thus, adding education to the original SCORE scale
decreased χ2 values in women from the Czech Republic (from 7.9 to 5.8), Warsaw
(from 8.4 to 7.1), Lithuania (from 19.2 to 9.1), and Russia (from 14.9 to 11.2), but not
in their peers from Tarnobrzeg, who showed a slight increase in χ2 (from 11.2 to 13.9).
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Compared to the baseline model, marital status-extended instrument demonstrated
worse calibration in Czech women (χ2 values 7.9 vs. 12.1, respectively) and Novosibirsk
females (14.9 vs. 21.3), but not in women from Kaunas (19.2 vs. 12.1, respectively).
Table 7.2.1. Continuous high-risk SCORE, education, marital status, and 10-year
atherosclerotic CVD mortality in MONICA men and women: Hosmer-Lemeshow (HL)
test results
Czech
Republic
Poland
(Warsaw)
Poland
(Tarnobrzeg)
Lithuania Russia
HL χ2 (p)
Men
Model 1
(SCORE
only)
17.15
(0.0164)
13.89
(0.0533)
4.62
(0.7059)
20.55
(0.0022)
4.41
(0.7313)
Model 2
(SCORE and
education)
9.38
(0.2264)
10.69
(0.2201)
9.16
(0.3291)
18.01
(0.0212)
4.52
(0.8079)
Model 3
(SCORE and
marital status)
13.84
(0.0542)
N/A N/A 28.40
(0.0002)
5.74
(0.5709)
Model 4
(SCORE,
education, and
marital status)
17.86
(0.0126)
N/A N/A 20.62
(0.0082)
6.47
(0.5944)
Women
Model 1
(SCORE
only)
7.89
(0.0959)
8.42
(0.0772)
11.19
(0.0245)
19.17
(0.0007)
14.92
(0.0049)
Model 2
(SCORE and
education)
5.80
(0.4454)
7.09
(0.3123)
13.93
(0.0304)
9.10
(0.1051)
11.75
(0.0383)
Model 3
(SCORE and
marital status)
12.07
(0.0338)
N/A N/A 12.12
(0.0165)
21.25
(0.0007)
Model 4
(SCORE,
education, and
marital status)
7.74
(0.2575)
N/A N/A 9.21
(0.2380)
11.54
(0.1169)
Therefore, among the four models of interest, the best calibration for men from
Tarnobrzeg and Novosibirsk and for women from Tarnobrzeg was shown by Model 1;
for Czech, Polish (Warsaw), and Lithuanian men and women by Model 2; and for
Russian women by Model 4.
In the analysis of the low-risk SCORE calibration in MONICA, the Hosmer-Lemeshow
test typically produced lower χ2 values than the high-risk SCORE calibration
assessment (Appendix III, Table A7.2.1). However, the patterns of calibration change
after extending the original SCORE model by education and/or marital status were
heterogeneous and generally similar to those patterns for the high-risk version of
SCORE. Thus, the results of the calibration assessment in MONICA samples were
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inconclusive and could not identify a single best-performing instrument among the four
analysed models. Since discrimination is considered an intrinsically more important
characteristic of prognostic performance than calibration (for details, see Methods,
Section 4.5.3), the next step of the analysis was to explore various discrimination
measures for Models 1-4.
Among MONICA men, the values of Harrell’s C-statistic slightly increased when
education and/or marital status were added to the original high-risk SCORE instrument
(Table 7.2.2). Such a modest discrimination improvement could be due to the low
sensitivity of C-statistic to the model extension, even when additional risk determinants
are highly significant independent risk predictors (for details, see Background, Section
2.1.1). The best discrimination, as denoted by the highest C-statistic, among Polish men
from Warsaw and Tarnobrzeg was observed for Model 2 (SCORE and education;
respective C values 0.69 and 0.65); among Czech men for Model 3 (SCORE and marital
status; 0.76); and among Lithuanian and Russian men for Model 4 (SCORE, education,
and marital status; 0.70 and 0.66, respectively). In women, adding education and/or
marital status to the original high-risk SCORE also resulted in increased values of
Harrell’s C-statistic (Table 7.2.3). Among Polish women from Warsaw and Tarnobrzeg,
these values were the highest for Model 2 (0.69 and 0.60, respectively), and among
Czech, Lithuanian, and Russian women for Model 4 (0.75, 0.74, and 0.71).
In addition, discrimination of Models 1-4 was assessed with Royston’s R2 index. This
parameter was adjusted by model dimension, and 95% CI were calculated, using the
minimal recommended bootstrap replication number of 1,000. Among MONICA men,
extending the dichotomous high-risk SCORE by socioeconomic parameters would
typically result in some R2 increase, even though the 95% CI for all extended
instruments were overlapping with the 95% CI for the baseline model (Table 7.2.2).
The best discrimination, as denoted by the highest R2, in Polish men from Warsaw and
Tarnobrzeg was observed for Model 2 (respective R2 values 0.28 and 0.16); in Czech
and Lithuanian men for Model 3 (0.53 and 0.25, respectively); and in Russian men for
Model 4 (0.19). In women, the results were generally similar, even though most R2
values were lower than in men from respective samples (Table 7.2.3). The proportion of
explained variation among women from Tarnobrzeg was the highest for Model 1
(R2=0.15); among women from Warsaw, Kaunas, and Novosibirsk for Model 2 (0.25,
0.45, and 0.37, respectively); and among Czech women for Model 3 (0.27).
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The difference in discrimination ability of original vs. extended SCORE models was
also assessed by likelihood ratio tests (LRT), where lower p values indicate a larger
difference in predictive performance between two nested models (Methods, Section
4.5.3). According to the LRT results for male samples (Table 7.2.2), the extended
instruments which performed better than the original SCORE were Model 2 (SCORE
and education) in Warsaw and Novosibirsk men (p=0.04 and <0.01, respectively);
Model 3 (SCORE and marital status) in Czech and Russian men (p<0.01 and 0.02); and
Model 4 (SCORE, education, and marital status) in Czech and Russian men (p<0.01 for
both samples). Across female samples (Table 7.2.3), the only extended scales
performing better than the baseline instrument were Model 2 in women from Warsaw,
Kaunas, and Novosibirsk (p<0.01, <0.01, and 0.03, respectively), and Model 4 for
women from Kaunas (p<0.01).
Finally, the improvement in the SCORE-based model discrimination was quantified via
a recently introduced integrated discrimination improvement (IDI), which measures the
separation between the subjects who develop an outcome and those who do not, in
terms of the average predicted risks for these two groups (Methods, Section 4.5.3). In
men, adding education and/or marital status to the original SCORE improved model
discrimination very slightly (Table 7.2.2). For Model 2, the highest IDI value reached
0.36% in Novosibirsk men, while for Models 3 and 4, the highest IDI values were
observed in Czech men (4.11% and 4.07%). In women, the discrimination improvement
for extended SCORE models was even more modest (Table 7.2.3). The highest IDI
values for Model 2 were observed in Warsaw women (0.91%); for Model 3, in Czech
women (0.13%); and for Model 4, in Lithuanian women (0.70%).
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Table 7.2.2. Dichotomous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA men:
Harrell’s C, Royston’s R2, LRT p value, and integrated discrimination improvement (IDI)
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.6867 0.6665 0.6319 0.6644 0.6220
R2 0.3057
(0.0764, 0.5502)
0.2605
(0.1405, 0.4076)
0.1593
(0.0398, 0.3211)
0.2419
(0.0941, 0.4343)
0.1408
(0.0676, 0.2322)
Model 2 (SCORE and education)
Harrell’s C 0.7011 0.6931 0.6457 0.6854 0.6525
R2 0.2914
(0.0945, 0.5731)
0.2799
(0.1532, 0.4389)
0.1625
(0.0500, 0.3481)
0.2414
(0.1037, 0.4318)
0.1719
(0.1024, 0.2701)
LRT p value 0.7154 0.0405 0.2437 0.3304 0.0010
IDI (p value) -0.00014
(0.77817)
0.00326
(0.12816)
0.00129
(0.16621)
<0.00001
(0.99941)
0.00363
(0.01292)
Model 3 (SCORE and marital status)
Harrell’s C 0.7587 N/A N/A 0.6767 0.6356
R2 0.5332
(0.2588, 0.7796)
0.2537
(0.0989, 0.4548)
0.1550
(0.0851, 0.2538)
LRT p value <0.0001 0.1302 0.0193
IDI (p value) 0.04106
(0.00711)
0.00192
(0.26219)
0.00196
(0.12433)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7402 N/A N/A 0.6991 0.6630
R2 0.5228
(0.2551, 0.8036)
0.2525
(0.1222, 0.4630)
0.1860
(0.1141, 0.2824)
LRT p value 0.0002 0.2060 0.0003
IDI (p value) 0.04068
(0.00693)
0.00168
(0.31093)
0.00547
(0.00564)
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Table 7.2.3. Dichotomous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.6372 0.5354 0.5922 0.6200 0.6471
R2 0.2443
(0.0000, 0.7478)*
0.0052
(0.0000, 0.2194)*
0.1475
(0.0000, 0.5697)*
0.2505
(0.0000, 0.6090)*
0.3518
(0.1810, 0.5236)
Model 2 (SCORE and education)
Harrell’s C 0.7000 0.6885 0.5946 0.7408 0.6962
R2 0.2220
(0.0000, 0.7182)*
0.2495
(0.0160, 0.6008)
0.1212
(0.0000, 0.5580)*
0.4466
(0.2001, 0.7260)
0.3735
(0.2084, 0.5513)
LRT p value 0.4971 0.0013 0.7249 0.0008 0.0285
IDI (p value) -0.00079
(0.72702)
0.00911
(0.00048)
0.00022
(0.60651)
0.00695
(0.03391)
0.00169
(0.35834)
Model 3 (SCORE and marital status)
Harrell’s C 0.7138 N/A N/A 0.6388 0.6738
R2 0.2721
(0.0000, 0.7617)*
0.2296
(0.0000, 0.5757)*
0.3507
(0.1991, 0.5520)
LRT p value 0.1939 0.8921 0.3687
IDI (p value) 0.00129
(0.75402)
-0.00006
(0.47351)
-0.00009
(0.91470)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7532 N/A N/A 0.7427 0.7061
R2 0.2500
(0.0000, 0.7944)*
0.4291
(0.1702, 0.7671)
0.3717
(0.2158, 0.5752)
LRT p value 0.3428 0.0038 0.0641
IDI (p value) 0.00112
(0.83336)
0.00695
(0.03370)
0.00185
(0.38298)
* Lower confidence limits calculated as negative were regarded as 0.
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In most MONICA samples, discrimination analysis of the models based on continuous
high-risk SCORE demonstrated slightly higher values of Harrell’s C-statistic and R2,
compared to the dichotomous SCORE-based models, which could be explained by the
dichotomisation-related loss of prognostic power (Appendix III, Tables A7.2.2-
A7.2.3). Nonetheless, LRT p values and IDI values were more or less similar for
dichotomous and continuous high-risk SCORE, as original and extended models.
Similarly, LRT p values and IDI values were relatively close for high and low-risk
dichotomous SCORE-based instruments, although the latter SCORE version typically
demonstrated slightly lower values of Harrell’s C-statistic and Royston’s R2 (Tables
A7.2.4-A7.2.5). Analysing discrimination of Models 1-4 based on low-risk
dichotomous vs. continuous SCORE, or high vs. low-risk continuous SCORE (Tables
A7.2.6-A7.2.7), provided similar results, showing slightly better discrimination
parameters of extended SCORE scales.
To summarise, in MONICA samples, the inclusion of education and/or marital status in
the original SCORE model resulted in some discrimination improvement. However, the
magnitude of this improvement, as quantified by IDI, varied across samples and,
overall, was relatively modest.
7.2.2. Calibration and discrimination of the SCORE model extended by education
and marital status in HAPIEE
To check whether the MONICA results could be replicated in more recent data,
calibration and discrimination of the four models of interest were assessed in HAPIEE
participants. Calibration of the high-risk SCORE, both as the original instrument and its
education and/or marital status-extended variants, was satisfactory in male samples
from the Czech Republic and Poland, as denoted by Hosmer-Lemeshow χ2 values under
20 (Table 7.2.4). Russian men, however, demonstrated a worse model fit, with χ2 values
ranging from 18.9 to 29.8. The latter could be explained by the Hosmer-Lemeshow test
sensitivity to small deviations in fit for larger samples, as well as for samples where at
least two subjects have the same levels of predicted risk, especially when these levels
are relatively low (Methods, Section 4.5.3). Adding education and/or marital status to
the original SCORE model reduced χ2 values, denoting better model fit, across all male
HAPIEE samples. The best calibration was observed in Russian men for Model 2
(SCORE and education; χ2 18.9) and in Czech or Polish men, for Model 3 (SCORE and
marital status; χ2 6.7 and 13.1, respectively).
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In women, all Hosmer-Lemeshow χ2 values were under 20, but adding education and/or
marital status to the original SCORE model did not result in better calibration (Table
7.2.4). The best calibration was observed in Polish and Russian women for Model 1
(SCORE only; respective χ2 2.0 and 5.4), and in Czech women for Model 2 (SCORE
and education; 5.7). This lack of calibration improvement for extended models could be
partly explained by the already low χ2 values for the original SCORE, as well as by the
same, relatively low levels of predicted risk in a substantial proportion of HAPIEE
women.
Table 7.2.4. Continuous high-risk SCORE, education, marital status, and
atherosclerotic CVD mortality in HAPIEE men and women: Hosmer-Lemeshow (HL)
test results
Czech Republic Poland Russia
HL χ2 (p)
Men
Model 1
(SCORE only)
10.72
(0.2178)
16.28
(0.0386)
29.83
(0.0002)
Model 2 (SCORE and
education)
8.87
(0.3532)
14.12
(0.0786)
18.88
(0.0155)
Model 3 (SCORE and
marital status)
6.70
(0.5698)
13.06
(0.1096)
26.90
(0.0003)
Model 4 (SCORE,
education, and
marital status)
9.64
(0.2916)
13.68
(0.0905)
23.23
(0.0031)
Women
Model 1
(SCORE only)
7.28
(0.2009)
2.03
(0.7306)
5.36
(0.3738)
Model 2 (SCORE and
education)
5.69
(0.3375)
3.29
(0.5106)
7.96
(0.1586)
Model 3 (SCORE and
marital status)
10.06
(0.1221)
2.20
(0.8206)
7.41
(0.2848)
Model 4 (SCORE,
education, and
marital status)
18.27
(0.0108)
3.70
(0.7166)
7.23
(0.2997)
The results of the calibration assessment for the low-risk SCORE in HAPIEE men and
women were more or less similar to those for the high-risk SCORE version (Appendix
III, Table A7.2.8), with no single model demonstrating the best fit across all samples.
The next step was to study various discrimination parameters for Models 1-4 in
HAPIEE samples. In men, a slight increase in Harrell’s C-statistic was observed for the
education and/or marital status-extended SCORE models, compared to the original,
dichotomous high-risk SCORE instrument (Table 7.2.5). The highest C values (0.68-
0.71) were observed for Model 4 (SCORE, education, and marital status) in men from
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all three countries of interest. In women from the Czech Republic, Harrell’s C values for
Models 1-4 were lower than in Czech men, while for Polish and Russian women, they
were higher than in men from the respective samples (Table 7.2.6). Nonetheless, the
same pattern of higher Harrell’s C for extended SCORE scales was observed across all
female samples, with Model 4 demonstrating the best discrimination (C-statistic 0.68-
0.78).
The analysis based on the R2 measure of explained variation confirmed that, in general,
the model discrimination in HAPIEE men and women was better for extended SCORE
instruments, compared to the original risk scale (Tables 7.2.5-7.2.6). However, across
all samples, 95% CI for extended models were overlapping with those for the baseline
model and were relatively wide. The highest proportion of explained variation was
observed for Model 4 in men from the Czech Republic (0.37), Poland (0.20), and Russia
(0.30), as well as in Czech and Russian women (0.22 and 0.56, respectively). Although
in Polish women, the absolute value of R2 statistic was marginally higher for Model 2
(0.55) than for Model 4 (0.53), these results should be interpreted with caution, due to
relatively few outcomes in this sample.
The comparison of the baseline vs. extended SCORE models in LR tests suggested that
in men, most extended instruments performed better than the original SCORE (Table
7.2.5). The lowest LRT p values in Czech men were observed for Model 2 (SCORE and
education; p=0.02), while in Polish and Russian men, the lowest p values were obtained
for Model 4 (SCORE, education, and marital status; p=0.01 and <0.01, respectively). In
women, however, most extended models failed to demonstrate a better performance,
according to the LRT results, which could be explained by fewer outcomes among
female HAPIEE subjects (Table 7.2.6). The only exception was the female Russian
sample, which had the highest outcome number, despite the shortest follow-up time.
Specifically, in Russian women, Models 3 and 4 seemed to perform better than the
baseline Model 1 (LRT p values <0.01 for both comparisons).
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Table 7.2.5. Dichotomous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.6589 0.5962 0.6290
R2 0.3042
(0.1351, 0.4863)
0.0835
(0.0000, 0.2934)*
0.2304
(0.1464, 0.3385)
Model 2 (SCORE and education)
Harrell’s C 0.6889 0.6361 0.6535
R2 0.3643
(0.1626, 0.6048)
0.1372
(0.0000, 0.4121)*
0.2542
(0.1610, 0.3825)
LRT p value 0.0202 0.0415 0.0171
IDI (p value) 0.00412
(0.08328)
0.00181
(0.11383)
0.00243
(0.04203)
Model 3 (SCORE and marital status)
Harrell’s C 0.6839 0.6349 0.6638
R2 0.3158
(0.1628, 0.5137)
0.1508
(0.0054, 0.4463)
0.2812
(0.1815, 0.4056)
LRT p value 0.1767 0.0258 0.0009
IDI (p value) 0.00075
(0.36530)
0.00209
(0.06535)
0.00468
(0.01082)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7068 0.6771 0.6824
R2 0.3659
(0.1848, 0.6199)
0.1974
(0.0223, 0.4971)
0.3007
(0.1978, 0.4370)
LRT p value 0.0385 0.0123 0.0003
IDI (p value) 0.00453
(0.07561)
0.00346
(0.02612)
0.00681
(0.00233)
* Lower confidence limits calculated as negative were regarded as 0.
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Table 7.2.6. Dichotomous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.6277 0.7412 0.7356
R2 0.1788
(0.0000, 0.5546)*
0.5255
(0.1329, 0.8382)
0.4729
(0.2458, 0.6985)
Model 2 (SCORE and education)
Harrell’s C 0.6445 0.7464 0.7497
R2 0.1985
(0.0000, 0.6424)*
0.5486
(0.0997, 0.9059)
0.4882
(0.2560, 0.7117)
LRT p value 0.1954 0.1601 0.1096
IDI (p value) 0.00079
(0.34764)
0.00187
(0.25032)
0.00186
(0.16387)
Model 3 (SCORE and marital status)
Harrell’s C 0.6688 0.7552 0.7675
R2 0.2065
(0.0000, 0.6299)*
0.5081
(0.0839, 0.8586)
0.5458
(0.2931, 0.7684)
LRT p value 0.1619 0.5909 0.0031
IDI (p value) 0.00089
(0.26968)
0.00021
(0.63073)
0.00510
(0.00168)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.6745 0.7641 0.7754
R2 0.2222
(0.0000, 0.6993)*
0.5302
(0.1209, 0.8904)
0.5548
(0.3333, 0.7760)
LRT p value 0.1735 0.3338 0.0046
IDI (p value) 0.00179
(0.20254)
0.00180
(0.22343)
0.00690
(0.00296)
* Lower confidence limits calculated as negative were regarded as 0.
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In addition, the changes in discrimination for the extended vs. original SCORE models
in HAPIEE samples were quantified using the IDI parameter. In men, the inclusion of
education and/or marital status in the SCORE risk scale resulted in a very modest
discrimination improvement (Table 7.2.5). For Model 2, the highest IDI value reached
0.41% in Czech men, while for Models 3 and 4, the respective maximal values were
0.47% and 0.68% in Russian men. The findings for women confirmed that the
discrimination improvement for extended vs. baseline SCORE models was not
substantial (Table 7.2.6). The highest IDI values for Models 2, 3, and 4 reached only
0.19% (Polish women), 0.51% (Russian women), and 0.69% (Russian women),
respectively.
For most HAPIEE samples, the discrimination analysis of continuous high-risk
SCORE-based Models 1-4 produced slightly higher values of Harrell’s C-statistic and
Royston’s R2, compared to their dichotomous high-risk SCORE equivalents, since
dichotomisation is likely to result in the loss of prognostic power of the model
(Appendix III, Tables A7.2.9-A7.2.10). Nonetheless, the LRT p values and IDI values
were relatively close for dichotomous and continuous high-risk SCORE, as original and
extended instruments. These values were also similar for high and low-risk dichotomous
SCORE-based models, even though for the latter, Harrell’s C and Royston’s R2
parameters were slightly higher in men and slightly lower in women (Tables A7.2.11-
A7.2.12). Comparing various discrimination measures for the models based on low-risk
dichotomous vs. continuous SCORE, or on high vs. low-risk continuous SCORE,
provided similar results, which confirmed a modest, sample-specific improvement in
discrimination for the prognostic instruments extended by education and/or marital
status (Tables A7.2.13-A7.2.14). The degree of this improvement did not exceed 1% in
both HAPIEE men and women, regardless of the SCORE version used as a baseline
model (high vs. low-risk, or dichotomous vs. continuous).
To conclude Section 7.2, the investigation of the education and/or marital status-
extended SCORE performance in MONICA and HAPIEE (Research Objective 4b)
failed to identify the best performing instrument out of the four models examined. The
extension of the original SCORE scale by adding socioeconomic parameters was
accompanied by an improvement in some, but not all, calibration and discrimination
indices. Trying to consider the dynamics of all studied performance measures, since to
my knowledge, no hierarchy currently exists for calibration and discrimination
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characteristics39;76;326;358, the following “better-performing” models were identified for
male MONICA samples: Model 2 (SCORE and education) in Poland (both Warsaw and
Tarnobrzeg); Model 3 (SCORE and marital status) in the Czech Republic and Lithuania;
and Model 4 (SCORE, education, and marital status) in Russia. For female MONICA
samples, the “better-performing” SCORE versions were Model 2 in Warsaw,
Tarnobrzeg, and Kaunas; Model 3 in the Czech Republic; and Model 4 in Novosibirsk.
Among HAPIEE men, the “better-performing” risk assessment instrument was Model 4
for the Czech Republic, Poland, and Russia, while in HAPIEE women, it was Model 2
for Poland, and Model 4 for the Czech Republic and Russia. It should be noted, though,
that the results for HAPIEE samples could change when the 10-year follow-up data
become available.
Importantly, better statistical characteristics of the extended models do not always mean
better clinical performance. Integrated discrimination improvement (IDI) appears to be
the most clinically relevant performance measure, since it quantifies the change in the
ability of the extended risk model to distinguish between individuals with and without
the future outcome, compared to the baseline model. Across all MONICA and HAPIEE
samples, IDI values were under 5% in men and under 1% in women, which suggests a
very modest improvement in SCORE performance after adding education and/or marital
status to the model. Therefore, the available data for MONICA and HAPIEE disagree
with the third research hypothesis and justify the use of the original SCORE in
CEE/FSU populations, as its prognostic performance appeared to be only marginally
worse, compared to education and/or marital status-extended SCORE modifications.
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Chapter 8. Alcohol consumption and SCORE
performance in HAPIEE
As reviewed in Section 2.3.3 (Background), various alcohol consumption
characteristics could significantly predict fatal CVD, independently of traditional
cardiovascular risk factors. Since in CEE/FSU populations, high levels of CVD
mortality are combined with a relatively high prevalence of hazardous drinking, it was
important to investigate whether adding alcohol consumption parameters to
cardiovascular risk prediction models, such as SCORE, might improve their predictive
performance. As a preliminary step of this investigation, SCORE calibration and
discrimination were assessed across alcohol consumption strata (for example, in binge
drinkers vs. non-bingers, and in those with CAGE score <2 vs. 2), separately for
HAPIEE men and women (for MONICA samples, compatible alcohol consumption data
were unavailable). Currently, the follow-up of HAPIEE subjects is under 10 years, and
the observed levels of fatal CVD are lower than the high-risk SCORE predictions across
all samples. It might be the case that the extent of this risk over-estimation is lower, and
the discrimination between the subjects who develop or do not develop an outcome is
less accurate in hazardous drinkers, compared to their peers who did not report
hazardous alcohol consumption at baseline.
The stratified analyses of the HAPIEE data (results available on request) demonstrated
that the categorical variable of alcohol consumption frequency could not be
dichotomised, as its association with fatal CVD seemed to be J or U-shaped. Observed
mortality tended to be higher, and predicted to observed mortality ratio appeared lower
in self-reported “never-drinkers” and/or people consuming alcohol at least once a week,
compared to those who reported drinking 3 times a month. To some extent, higher
CVD rates in “never-drinkers” could be explained by the “sick quitter” effect
(e.g.280;285;363). The specifics of HAPIEE data collection did not allow the differentiation
between true never-drinkers and ex-drinkers across all samples. Excluding all “never-
drinkers” from the analyses would dramatically reduce the sample size, especially for
HAPIEE women. Therefore, the analyses were focused on binge drinking and CAGE
score, as the main alcohol consumption parameters of interest. Across HAPIEE
samples, SCORE showed similar prognostic performance among binge drinkers vs.
non-bingers, or in people with CAGE score <2 vs. 2. Calibration and discrimination of
the original SCORE did not substantially differ between the hazardous drinking strata,
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but these results did not yet reject the possibility that adding bingeing and/or CAGE to
the SCORE model could improve its performance.
8.1. SCORE and alcohol consumption parameters as predictors of
atherosclerotic CVD mortality
In order to assess the role of hazardous drinking parameters as potential independent
predictors of fatal atherosclerotic CVD, the next step of the analysis was to combine
SCORE, binge drinking, and CAGE in prognostic models. The baseline Model 1
(SCORE only) was compared to Model 2 (SCORE and binge drinking), Model 3
(SCORE and CAGE), and Model 4 (SCORE, binge drinking, and CAGE). Since LR
tests demonstrated no statistical interaction between various SCORE versions
(dichotomous and continuous high and low-risk scale) and either binge drinking or
CAGE (all p values for interaction terms >0.3), the mutual adjustment of SCORE and
drinking parameters was appropriate.
While phi correlation coefficient values did not demonstrate marked collinearity
between the two measures of hazardous alcohol consumption (all values <0.4; see
Table 8.1.1), OR for the association between binge drinking and CAGE were relatively
high, particularly in women (results available on request). However, considering the
distribution of hazardous drinking parameters in the samples, when the majority of
subjects reported no bingeing and were CAGE-negative, and the number of so-called
discordant observations (binge drinking without positive CAGE, or positive CAGE in
the absence of bingeing) was low, assessing the strength of the bingeing-CAGE
association via OR might be problematic. Moreover, as the aim of this research is to
investigate the prognostic performance of extended SCORE models, rather than
compare the impact of different alcohol consumption measures as cardiovascular risk
predictors, it was decided to include both binge drinking and CAGE in the extended
SCORE (Model 4).
Table 8.1.1 Phi correlation coefficients for binge drinking and CAGE score in HAPIEE
men and women
Czech Republic Poland Russia
Men 0.2269 0.3396 0.3745
Women 0.2079 0.1995 0.2655
In all HAPIEE samples, high-risk SCORE 5% significantly predicted the currently
observed CVD mortality, both before and after adjustment for binge drinking and/or
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CAGE (Table 8.1.2). This adjustment resulted in modest, sample-specific changes of
SCORE HR values. Czech men demonstrated some SCORE HR reduction after
controlling for binge drinking or CAGE (unadjusted HR 10.5 vs. respective adjusted
HR 10.3 and 10.0). At the same time, accounting for either hazardous drinking
parameter barely changed the SCORE HR for Polish and Russian men. Among Czech
and Russian women, adjustment for hazardous drinking slightly increased the SCORE
HR values, and to a greater extent for CAGE than for binge drinking (respective
unadjusted HR 3.6 and 7.4, vs. CAGE-adjusted HR 4.2 and 7.7). In Polish women,
however, controlling for binge drinking did not affect the SCORE HR, while accounting
for CAGE resulted in a minimal HR reduction (unadjusted HR 8.8 vs. CAGE-adjusted
HR 8.7).
Thus, the impact of hazardous drinking measures on the SCORE-fatal CVD association
was modest, without substantial changes in the strength of this link, or loss of statistical
significance. After controlling for the effects of both binge drinking and positive CAGE
(Model 4), SCORE 5% was linked to a marked increase in cardiovascular death risk
(HR 9.7, 2.6, and 7.6 in Czech, Polish, and Russian men and 4.2, 8.7, and 7.8 in women
from the respective countries). Nonetheless, due to the current HAPIEE follow-up being
under 10 years, the outcome numbers were relatively low, and 95% CI were quite wide,
especially for women, which warrants a cautious interpretation of these high HR values.
For all male samples, there was no evidence that binge drinking was a significant
predictor of atherosclerotic CVD death after controlling for the dichotomous high-risk
SCORE, since all adjusted HR values approached 1.0 (from 0.9 for Poland to 1.2 for
Russia) (Table 8.1.2). Among Czech and Russian women, binge drinking was linked to
an increased risk of cardiovascular mortality, but this association was significant only in
the latter sample, with respective SCORE-adjusted HR of 2.0 and 5.8. In Polish women,
the numbers of observations and outcomes were too low to calculate HR for binge
drinking. In most HAPIEE samples, additional adjustment for CAGE (Model 4) only
slightly affected HR for binge drinking, but in Russian women, it resulted in the loss of
statistical significance (HR 3.3).
CAGE score 2 was linked to a higher risk of fatal CVD in men from the Czech
Republic, Poland, and Russia when adjusted for SCORE only (Model 3: HR 1.2, 1.7,
and 1.1, respectively), or for SCORE and binge drinking (Model 4: respective HR 1.3,
1.9, and 1.1). Nonetheless, CAGE could not be regarded as an independent, significant
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predictor of cardiovascular risk, since all 95% CI in Models 3 and 4 included 1.0 (Table
8.1.2). While in Polish women, HR values for CAGE, adjusted for SCORE (Model 3) or
for SCORE and binge drinking (Model 4), could not be calculated due to the low
numbers of observations and outcomes, Czech and Russian women demonstrated a link
between CAGE 2 and elevated risk of CVD mortality. Among Czech females, 95% CI
of CAGE HR included 1.0 for Model 3 and Model 4. In Russian women, this
association lost statistical significance after additional controlling for binge drinking
(HR 5.6 for Model 3 vs. 3.2 for Model 4).
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Table 8.1.2. Dichotomous high-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality
in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 10.51 (2.53-43.71) 2.56 (1.11-5.87) 7.63 (3.35-17.40)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 10.26 (2.46-42.71) 2.56 (1.12-5.89) 7.62 (3.34-17.38)
Binge drinking (vs. no binge drinking) 0.96 (0.40-2.30) 0.87 (0.27-2.84) 1.18 (0.79-1.75)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 10.00 (2.40-41.66) 2.58 (1.12-5.93) 7.63 (3.35-17.40)
CAGE 2 (vs. <2) 1.19 (0.42-3.37) 1.67 (0.65-4.31) 1.13 (0.72-1.78)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 9.67 (2.32-40.36) 2.60 (1.13-5.96) 7.63 (3.35-17.39)
Binge drinking (vs. no binge drinking) 0.78 (0.29-2.10) 0.69 (0.20-2.45) 1.16 (0.76-1.77)
CAGE 2 (vs. <2) 1.32 (0.44-3.94) 1.89 (0.69-5.20) 1.06 (0.65-1.73)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 3.59 (1.44-8.91) 8.79 (3.19-24.18) 7.36 (3.77-14.38)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 4.08 (1.61-10.35) 8.78 (3.19-24.16) 7.72 (3.93-15.15)
Binge drinking (vs. no binge drinking) 2.01 (0.27-15.17) too few observations 5.75 (1.38-24.02)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 4.19 (1.64-10.67) 8.69 (3.16-23.92) 7.74 (3.94-15.20)
CAGE 2 (vs. <2) 3.85 (0.51-29.23) too few observations 5.64 (1.35-23.59)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 4.21 (1.65-10.70) 8.65 (3.14-23.79) 7.78 (3.97-15.24)
Binge drinking (vs. no binge drinking) 1.49 (0.17-13.25) too few observations 3.29 (0.54-20.03)
CAGE 2 (vs. <2) 3.36 (0.38-30.11) too few observations 3.19 (0.52-19.42)
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Similarly, the analysis of binge drinking, CAGE, and continuous high-risk SCORE
(Appendix IV, Table A8.1.1), or dichotomous and continuous low-risk SCORE (Tables
A8.1.2-A8.1.3) demonstrated that in HAPIEE men, there was no clear link between
binge drinking and CVD mortality, while CAGE 2 was related to a higher risk of
cardiovascular death, but not significantly. In women, these links were not statistically
significant after adjustment for SCORE, or for SCORE and another parameter of
hazardous drinking.
To summarise Section 8.1, the assessment of the associations between SCORE,
drinking measures, and fatal CVD across HAPIEE samples (Research Objective 5a) has
demonstrated that positive SCORE (≥5%) was a statistically significant predictor of the 
currently observed cardiovascular mortality in men and women, after accounting for the
effects of hazardous alcohol consumption. The strength of the link between SCORE and
fatal CVD seemed to be affected, to a varying extent, by binge drinking (Czech men)
and CAGE (Czech men; Czech, Polish, and Russian women), as shown by
heterogeneous changes in the SCORE HR values after adjustment for these extra risk
determinants. This suggests differential influence of additional risk factors on the
magnitude of the SCORE-fatal CVD association across populations. However, the
impact of hazardous drinking was modest for all samples, and did not result in the loss
of statistical significance for the link between SCORE and currently observed
cardiovascular mortality. These findings agree with the first research hypothesis of
SCORE as a significant determinant of fatal CVD.
By contrast, the HAPIEE data did not provide strong support for the fourth research
hypothesis which suggests inclusion of binge drinking and/or CAGE in the SCORE-
based prognostic algorithm. One of the possible explanations could be the present
follow-up length, which limited outcome numbers and reduced the analysis power,
especially in women. The next section investigates whether the absence of statistically
significant associations between hazardous drinking and CVD mortality manifested in
the lack of SCORE performance improvement after adding binge drinking and/or
CAGE to the model.
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8.2. Calibration and discrimination of the SCORE model extended by
alcohol consumption parameters
To assess the SCORE performance improvement, if any, after adding binge drinking
and CAGE to the original SCORE scale, various measures of calibration and
discrimination were compared for the baseline Model 1 (SCORE only) vs. Model 2
(SCORE and binge drinking), Model 3 (SCORE and CAGE), and Model 4 (SCORE,
binge drinking, and CAGE). In particular, the values of Hosmer-Lemeshow χ2, Harrell’s
C-statistic, and Royston’s R2 were compared across these four models, separately for
HAPIEE men and women. The additional prognostic information provided by
hazardous drinking parameters was assessed via LR test p values and integrated
discrimination improvement (IDI). These analyses included only participants with
available data on binge drinking and CAGE, in order to enable the cross-model
comparisons.
The comparison of the predicted to observed CVD death ratios by both binge drinking
and CAGE would not be informative, due to relatively few outcomes in each individual
stratum, especially in women. Therefore, the calibration of extended SCORE models
was assessed with the Hosmer-Lemeshow test, applied to continuous high and low-risk
SCORE versions. In Czech and Polish men, χ2 values were under 20 for high-risk
SCORE predictions across all four models of interest, denoting satisfactory calibration
(Table 8.2.1). Among Russian men, however, all χ2 values exceeded 20, which signifies
an imperfect fit of both original and alcohol-extended SCORE models and could be
partly explained by the Hosmer-Lemeshow test sensitivity to small deviations in fit for
larger samples, and for samples where at least two subjects have identical levels of
predicted risk, or these levels are relatively low (Methods, Section 4.5.3). Including
binge drinking in the SCORE model resulted in slightly increased Hosmer-Lemeshow
χ2 values (and, therefore, deteriorated calibration) among Czech men (from 7.2 to 8.1)
and Polish men (from 9.17 to 11.2). Russian men demonstrated a somewhat better fit for
the model extended by binge drinking than for the original SCORE (respective χ2 values
27.0 vs. 29.8).
Compared to the original instrument (Model 1), the calibration of the CAGE-extended
SCORE (Model 3) appeared to be slightly better in Czech men (respective χ2 values 7.2
vs. 6.6) and Russian men (29.8 vs. 28.6), but not among their Polish peers (9.1 vs. 12.9).
The instrument with the best calibration was Model 3 (SCORE and CAGE) for Czech
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men and Model 4 (SCORE, binge drinking, and CAGE) for Russian men, even though
the calibration improvement in both cases was minimal. Among Polish men, adding
hazardous drinking parameters to SCORE did not result in better calibration.
In women, Hosmer-Lemeshow χ2 values were under 20 for all four models, but
extending SCORE by binge drinking and/or CAGE typically did not result in improved
calibration (Table 8.2.1). Adding binge drinking to the original SCORE scale increased
χ2 values in Czech women (from 8.8 to 9.3) and Russian women (from 5.4 to 8.6), while
not affecting SCORE calibration in Polish females (2.0). Compared to the baseline
Model 1, the fit of the CAGE-extended instrument (Model 3) appeared to be slightly
better among Czech women (respective χ2 values 8.8 vs. 8.1), the same among Polish
women (2.0), and somewhat worse in Russian women (5.4 vs. 8.9). Out of the four
models explored, the best calibration among HAPIEE women was observed for Models
1 and 3 in the Czech Republic and for Model 1 in Poland and Russia (in the Polish
sample, χ2 values were identical across all models, but Model 1 was the most
parsimonious). The absence of the marked calibration improvement for the extended
models could be due to the already low χ2 values for the original SCORE instrument,
and also due to a large proportion of women with the same, relatively low predicted risk
levels (Methods, Section 4.5.3).
Table 8.2.1. Continuous high-risk SCORE, binge drinking, CAGE, and atherosclerotic
CVD mortality in HAPIEE men and women: Hosmer-Lemeshow (HL) test results
Czech Republic Poland Russia
HL χ2 (p)
Men
Model 1
(SCORE only)
7.24
(0.5113)
9.07
(0.2477)
29.83
(0.0002)
Model 2 (SCORE and
binge drinking)
8.11
(0.4226)
11.16
(0.1926)
26.99
(0.0007)
Model 3 (SCORE and
CAGE)
6.58
(0.5828)
12.88
(0.1161)
28.62
(0.0004)
Model 4 (SCORE,
binge drinking, and
CAGE)
7.01
(0.5359)
14.50
(0.0696)
26.18
(0.0010)
Women
Model 1
(SCORE only)
8.76
(0.1190)
2.04
(0.7282)
5.36
(0.3738)
Model 2 (SCORE and
binge drinking)
9.26
(0.0548)
2.04
(0.7277)
8.63
(0.1246)
Model 3 (SCORE and
CAGE)
8.08
(0.0885)
2.04
(0.7282)
8.91
(0.1126)
Model 4 (SCORE,
binge drinking, and
CAGE)
13.00
(0.0113)
2.04
(0.7281)
11.19
(0.0478)
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The calibration assessment of the original and extended low-risk SCORE typically
produced lower χ2 values than the high-risk SCORE calibration analysis (Appendix IV,
Table A8.2.1). It could be explained by the fact that in most samples, the currently
observed CVD mortality is closer to the low-risk SCORE predictions, due to the follow-
up length presently being under 10 years. Nonetheless, the pattern of calibration
changes, after extending the low-risk SCORE by binge drinking and/or CAGE, was
similar to that observed for the high-risk SCORE. The low-risk SCORE-based
instruments with the best fit were Model 2 for Czech men (χ2 6.9) and Polish men (5.2)
and Model 4 for Russian men (35.1). In women, the best-calibrated scales were Model 3
for the Czech Republic (χ2 value 4.3); Models 1 and 2 for Poland (2.6 for both models);
and Models 1 and 3 for Russia (3.0 and 2.9, respectively).
Overall, the results of the calibration assessment in HAPIEE were inconclusive and did
not identify a single model which would demonstrate the best performance across all
samples. Moreover, the extent of calibration improvement, observed for the hazardous
drinking-extended SCORE models, was rather modest. The next step of the analysis was
to explore various measures of discrimination, another important characteristic of
prognostic performance, for Models 1-4 in HAPIEE men and women.
Across all male samples, the values of Harrell’s C slightly increased when binge
drinking and/or positive CAGE were added to the dichotomous high-risk SCORE
(Table 8.2.2). Such a minimal improvement is consistent with relatively low sensitivity
of C-statistic to the model extension, and also with the absence of statistically
significant, SCORE-independent associations between the measures of hazardous
drinking and current CVD mortality (Section 8.1). The highest Harrell’s C values,
denoting the best discrimination, were observed in Russian men for Model 2 (SCORE
and binge drinking; 0.64); in Czech men for Model 3 (SCORE and CAGE; 0.66); and in
Polish men for Model 4 (SCORE, binge drinking, and CAGE; 0.63). In women, the
inclusion of binge drinking and/or positive CAGE in the original SCORE also resulted
in a minimal increase in Harrell’s C (Table 8.2.3). The highest values were registered in
Czech females for Model 2 (0.66), and in their Polish and Russian peers for Model 4
(0.74 and 0.77, respectively).
The values of Royston’s R2, a measure of explained variation for survival models, did
not change substantially in HAPIEE men after the addition of binge drinking and/or
positive CAGE to the dichotomous high-risk SCORE (Table 8.2.2). The highest R2
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values were observed in Czech and Russian men for Model 1 (SCORE only; 0.30 and
0.22, respectively), and in Polish men for Model 3 (SCORE and CAGE; 0.09). In the
Czech Republic, the proportion of the explained outcome variation tended to be slightly
lower for women than for men, while in Poland and Russia, it appeared to be higher in
females than in males. However, due to lower outcome numbers in women, 95% CI for
Royston’s R2 were typically wider (Table 8.2.3). Therefore, high R2 values in female
samples should be interpreted cautiously. Regardless of gender differences in R2 values,
HAPIEE women also demonstrated the lack of marked discrimination improvement
after adding hazardous drinking parameters to the dichotomous high-risk SCORE. In
Polish women, the highest R2 index (0.53) was observed for the baseline Model 1.
Among Czech and Russian women, R2 values were the highest for Models 3 and 4,
respectively, but they did not substantially differ from the Model 1 values (0.22 for
Czech females and 0.47-0.50 for their Russian peers).
The difference in the discrimination ability of original vs. alcohol-extended SCORE
models was also assessed in likelihood ratio tests (LRT). In each male sample, no
extended instrument performed better than the original SCORE, with all p values
exceeding 0.3 (Table 8.2.2). A similar result was observed for Czech women (all LRT p
values >0.2), while in Polish women, the low numbers of observations and outcomes
prevented the acquisition of meaningful LRT findings (Table 8.2.3). In Russian women
(a female sample with the highest outcome number, despite the shortest follow-up), both
Model 2 (SCORE and binge drinking) and Model 3 (SCORE and positive CAGE) were
performing marginally better than Model 1 (both p values 0.06). The magnitude of this
improvement decreased after the SCORE adjustment for both binge drinking and
CAGE, as denoted by p value of 0.09 for Model 4.
In addition, the potential change in SCORE discrimination, after extending the original
model by hazardous drinking parameters, was assessed using integrated discrimination
improvement (IDI). In men, including binge drinking and/or positive CAGE in the
original SCORE scale resulted in a very modest discrimination improvement (Table
8.2.2). The highest IDI values, registered for Model 4 (SCORE, binge drinking, and
CAGE) across all male samples, did not exceed 0.05%. In women, the improvement in
the discrimination of alcohol-extended models was also minimal, with the highest IDI
values reaching only 0.18% in the Czech Republic (Model 3), 0.002% in Poland (Model
3), and 0.05% in Russia (Model 4) (Table 8.2.3).
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Table 8.2.2. Dichotomous high-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.6582 0.5971 0.6290
R2 0.2986
(0.1181, 0.4881)
0.0851
(0.0000, 0.2858)*
0.2304
(0.1432, 0.3403)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.6605 0.6001 0.6443
R2 0.2859
(0.1317, 0.4994)
0.0686
(0.0000, 0.3088)*
0.2286
(0.1427, 0.3450)
LRT p value 0.6960 0.8335 0.4193
IDI (p value) 0.00005
(0.82256)
0.00002
(0.70365)
0.00034
(0.37348)
Model 3 (SCORE and CAGE)
Harrell’s C 0.6638 0.6148 0.6317
R2 0.2854
(0.1380, 0.4912)
0.0855
(0.0000, 0.3506)*
0.2266
(0.1461, 0.3424)
LRT p value 0.7248 0.3118 0.6050
IDI (p value) -0.00001
(0.97562)
0.00043
(0.37518)
0.00007
(0.72787)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.6613 0.6286 0.6432
R2 0.2743
(0.1513, 0.5064)
0.0743
(0.0000, 0.3455)*
0.2238
(0.1444, 0.3373)
LRT p value 0.8233 0.5032 0.7001
IDI (p value) 0.00008
(0.84499)
0.00050
(0.29915)
0.00034
(0.38090)
* Lower confidence limits calculated as negative were regarded as 0.
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Table 8.2.3. Dichotomous high-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.6415 0.7411 0.7356
R2 0.2153
(0.0000, 0.6199)*
0.5254
(0.1021, 0.8701)
0.4729
(0.2484, 0.6918)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.6585 0.7425 0.7555
R2 0.1970
(0.0000, 0.6023)*
0.5042
(0.0835, 0.8277)
0.4984
(0.2941, 0.6948)
LRT p value 0.5285 too few observations 0.0576
IDI (p value) <0.00001
(0.99603)
0.00001
(0.00022)
0.00023
(0.70817)
Model 3 (SCORE and CAGE)
Harrell’s C 0.6415 0.7431 0.7507
R2 0.2207
(0.0000, 0.6967)*
0.5060
(0.0814, 0.8404)
0.4977
(0.2935, 0.7083)
LRT p value 0.2777 too few observations 0.0600
IDI (p value) 0.00181
(0.38049)
0.00002
(0.00022)
0.00021
(0.72203)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.6576 0.7441 0.7653
R2 0.1939
(0.0000, 0.7103)*
0.4826
(0.0625, 0.8380)
0.5016
(0.2813, 0.7260)
LRT p value 0.5235 too few observations 0.0845
IDI (p value) 0.00145
(0.39110)
0.00001
(0.00022)
0.00050
(0.60983)
* Lower confidence limits calculated as negative were regarded as 0.
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In most HAPIEE samples, the continuous vs. dichotomous high-risk SCORE, using
both the original and extended models, demonstrated slightly higher values of such
discrimination parameters as Harrell’s C and Royston’s R2, which could be due to the
dichotomisation-related loss of prognostic power (Appendix IV, Tables A8.2.2-A8.2.3).
At the same time, LRT p values and IDI values were more or less similar for the
instruments based on dichotomous and continuous high-risk SCORE. In addition, LRT
p values and IDI values were relatively close for high and low-risk dichotomous
SCORE-derived models, despite the fact that the values of Harrell’s C and Royston’s R2
for the latter vs. former SCORE version were slightly higher in men and slightly lower
in women (Tables A8.2.4-A8.2.5). Comparing discrimination parameters of the
instruments based on low-risk dichotomous vs. continuous SCORE, or high vs. low-risk
continuous SCORE (Tables A8.2.6-A8.2.7), provided similar results. Most importantly,
the findings for continuous high-risk, dichotomous low-risk, and continuous low-risk
SCORE versions were consistent with the evidence obtained for the officially
recommended SCORE algorithm (dichotomous high-risk scale): the inclusion of binge
drinking and/or positive CAGE in the original SCORE either did not affect or only
marginally improved the model discrimination.
In summary, the investigation of the hazardous drinking-extended SCORE performance
in HAPIEE samples (Research Objective 5b) has shown that adding binge drinking and
positive CAGE to the original instrument did not result in a marked improvement of
calibration and/or discrimination of the prognostic model. Alcohol-extended models,
based on the dichotomous high-risk SCORE, explained only 7-29% and 19-51% of the
outcome variation in HAPIEE men and women, respectively. The degree of
discrimination improvement for these extended models, quantified by IDI, was under
1% in all samples. The failure of binge drinking and CAGE to add prognostic value to
the SCORE instrument could be, at least partly, explained by the relatively short follow-
up time and limited outcome numbers in the samples. In women, the prevalence of self-
reported hazardous drinking was low, which also restricted the analysis power.
It is possible that the 10-year follow-up data will demonstrate the additional value of
hazardous drinking characteristics in predicting the risk of CVD mortality among
HAPIEE participants. However, the current evidence disagrees with the fourth research
hypothesis and is instead consistent that SCORE performance in HAPIEE does not
improve, or improves only marginally, after the inclusion of binge drinking and/or
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positive CAGE in the original instrument. Together with the data which demonstrated a
modest improvement in calibration and discrimination for the education and/or marital
status-extended models (Section 7.2), these findings support the use of the original
SCORE in CEE/FSU populations. To investigate whether this conclusion is still
relevant when the effect estimates from different MONICA and HAPIEE samples are
pooled, the overall strength of the association between SCORE and fatal CVD was
assessed before and after the adjustment for socioeconomic and alcohol consumption
parameters, using the random effects meta-analysis technique. The results of these
combined analyses are presented in Chapter 9.
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Chapter 9. SCORE as a predictor of atherosclerotic
CVD mortality in pooled analyses
As demonstrated in Chapters 6-8, SCORE was a significant predictor of fatal
atherosclerotic CVD in most MONICA and HAPIEE samples, both before and after
adjustment for various measures of socioeconomic position or hazardous drinking.
However, this association was less consistent for lower education and/or non-married
status, which were linked to CVD mortality in some, but not all, MONICA and
HAPIEE samples. There was no evidence of independent associations between binge
drinking or CAGE score and the current risk of cardiovascular death in HAPIEE
samples. Moreover, the magnitude of the impact of socioeconomic parameters and
hazardous drinking characteristics on the main association of interest varied
considerably across individual samples.
One of the possible explanations for this inconsistency could be the limited sample sizes
and outcome numbers in the study-, country-, and gender-specific analyses. The pooling
of the individual-level observations into one dataset was not possible, due to the
inability to gain direct access to the Russian MONICA data, as well as due to marked
cross-sample differences in the strength of the associations between CVD mortality,
SCORE, socioeconomic parameters, and alcohol consumption characteristics.
Producing combined estimates of calibration and discrimination for the original and
extended SCORE models did not appear feasible without pooling the individual-level
data. However, it was possible to pool the SCORE effect estimates (HR and 95% CI)
from MONICA and HAPIEE samples, using the random effects meta-analysis
technique which provides more conservative results than the fixed effects approach
(Methods, Section 4.5.4).
9.1. SCORE as a predictor of atherosclerotic CVD mortality in pooled
unadjusted analyses
The first step of the combined analyses was to assess the role of positive SCORE (5%)
as a predictor of fatal atherosclerotic CVD in all MONICA and all HAPIEE samples,
separately for men and women (Research Objective 6). Pooled analyses were focused
on the dichotomous high-risk SCORE, which is the instrument officially recommended
for use in CEE/FSU populations.
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9.1.1. SCORE in pooled unadjusted analyses: combining effect estimates from
individual MONICA samples
In most MONICA samples, the high-risk SCORE 5% was significantly associated with
fatal atherosclerotic CVD (Section 6.1.1). The data on sample-specific effect estimates,
as well as the combined HR and 95% CI, are presented in Figures 9.1.1-9.1.2. While
among men, sample-specific HR values varied from 2.7 in Russia to 5.3 in the Czech
Republic, none of the 95% CI included 1.0 (Figure 9.1.1). In accordance with these
findings, the combined analysis demonstrated that positive SCORE was significantly
associated with an increased 10-year risk of cardiovascular mortality, with a pooled HR
of 3.4 and a relatively narrow 95% CI.
Figure 9.1.1. Dichotomous high-risk SCORE and 10-year atherosclerotic CVD
mortality in MONICA men: sample-specific and combined hazard ratios and 95%
confidence intervals
All samples
PL-T
RU
Sample
LT
PL-W
CZ
3.06 (1.77, 5.29)
2.66 (1.96, 3.62)
4.50 (2.68, 7.56)
5.32 (2.30, 12.30)
HR (95% CI)
3.40 (2.64, 4.37)
3.99 (2.24, 7.10)
1.5 2 4 8 16
Hazard ratio
In all female MONICA samples, the high-risk SCORE 5% was linked to a higher risk
of atherosclerotic CVD death. However, due to lower outcome numbers in women than
in men, 95% CI were relatively wide and, for Warsaw females, even included 1.0
(Figure 9.1.2). The pooling of the sample-specific effect estimates produced a narrower
95% CI and a combined HR of 4.8.
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Figure 9.1.2. Dichotomous high-risk SCORE and 10-year atherosclerotic CVD
mortality in MONICA women: sample-specific and combined hazard ratios and 95%
confidence intervals
All samples
PL-W
RU
Sample
PL-T
CZ
LT
6.32 (4.08, 9.79)
4.15 (1.49, 11.52)
5.02 (1.64, 15.36)
HR (95% CI)
4.78 (3.20, 7.14)
1.70 (0.57, 5.06)
5.07 (2.20, 11.66)
1.5 2 4 8 16
Hazard ratio
It might appear that positive SCORE was associated with a higher CVD risk in
MONICA women, compared to MONICA men (respective HR 4.8 vs. 3.4).
Nevertheless, this difference should be interpreted with caution, since the respective
95% CI overlapped. The next section investigates the magnitude and statistical
significance of the pooled unadjusted association between SCORE and fatal CVD in
contemporary HAPIEE samples.
9.1.2. SCORE in pooled unadjusted analyses: combining effect estimates from
individual HAPIEE samples
Among HAPIEE men, positive SCORE was a significant predictor of fatal
atherosclerotic CVD, but the sample-specific HR varied considerably, from 2.6 in
Poland to 10.5 in the Czech Republic (Figure 9.1.3). The combined 95% CI was still
relatively wide, due to the current HAPIEE follow-up being under 10 years, and, hence,
the limited number of outcomes. The overall HR was 5.4, somewhat higher than the
combined effect estimate for MONICA men (3.4).
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Figure 9.1.3. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE men: sample-specific and combined hazard ratios and 95% confidence
intervals
All samples
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7.63 (3.35, 17.40)
10.51 (2.53, 43.71)
HR (95% CI)
5.39 (2.29, 12.69)
2.56 (1.11, 5.87)
1.5 2 4 8 16 32 64
Hazard ratio
One of the possible explanations could be the follow-up difference for HAPIEE vs.
MONICA. When the 10-year data are available for HAPIEE samples, the combined HR
could become closer to the MONICA value. This scenario is supported by the current
overlap of the respective 95% CI. Additional explanation of the difference between
MONICA vs. HAPIEE SCORE HR could be potential residual confounding by multiple
extra risk determinants not included in SCORE. The effects of these measured
(socioeconomic parameters or hazardous drinking characteristics) and non-measured
factors could vary across populations and over time and, therefore, affect the magnitude
of the SCORE-fatal CVD association to a different extent.
Among HAPIEE women, relatively low outcome numbers resulted in wide sample-
specific 95% CI, as well as in the substantially varying HR values (Figure 9.1.4). The
combined HR (6.3) was somewhat higher than the respective values for HAPIEE men
(5.4) or MONICA women (4.8), probably due to chance. All pooled 95% CI for these
three HR considerably overlapped, and it is possible that after 10 years of HAPIEE
follow-up, the respective combined effect estimates will be relatively close to one
another. The currently observed SCORE HR discrepancies could also be due to the
differential effect of multiple potential confounders on the association of interest.
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Figure 9.1.4. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE women: sample-specific and combined hazard ratios and 95% confidence
intervals
All samples
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HR (95% CI)
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1.5 2 4 8 16 32
Hazard ratio
Thus, the combination of the sample-specific results by study and gender in the random
effects meta-analyses confirmed the significant association between the high-risk
SCORE 5% and cardiovascular mortality in MONICA and HAPIEE men and women,
which supports the first research hypothesis. The overall increase in the risk of fatal
CVD was at least three-fold in MONICA and at least five-fold in HAPIEE. The
difference between gender-specific pooled estimates for MONICA vs. HAPIEE could
be partly explained by a shorter follow-up, fewer outcomes, and limited analysis power
for HAPIEE samples. Moreover, while the SCORE model is based on the proportional
hazards assumption (satisfied by both MONICA and HAPIEE data; Methods, Section
4.5.4) and, hence, suggests relative stability of SCORE HR values, there is still room for
potential residual confounding by manifold non-classical risk factors. In this thesis,
additional risk determinants included socioeconomic parameters and hazardous drinking
characteristics. Sections 9.2-9.3 evaluate the changes in strength and statistical
significance of the pooled association between positive SCORE and atherosclerotic
CVD mortality after adjustment for these risk factors.
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9.2. SCORE as a predictor of atherosclerotic CVD mortality in pooled
analyses adjusted for education and marital status
Across individual MONICA and HAPIEE samples, positive SCORE was shown to
predict cardiovascular risk even after adjustment for education and marital status
(Section 7.1), and the combined unadjusted effect of SCORE on fatal CVD risk was
significant in the random effects meta-analyses (Section 9.1). To check whether this
pooled effect changed after controlling for socioeconomic measures of interest, the
respective adjusted sample-specific HR were combined, separately for men and women.
Since for MONICA participants from Warsaw and Tarnobrzeg, the association between
SCORE and fatal CVD could not be controlled for marital status (these data were
unavailable for Polish MONICA samples), the present analysis of MONICA data
included only samples from the Czech Republic, Lithuania, and Russia.
9.2.1. SCORE in pooled analyses adjusted for socioeconomic parameters:
combining effect estimates from individual MONICA samples
In MONICA men, the adjustment for education marginally weakened the overall
association between SCORE and 10-year atherosclerotic CVD mortality (unadjusted vs.
adjusted HR 3.4 vs. 3.2) and did not result in the loss of statistical significance (Figure
9.2.1, top and upper middle panels). Controlling for marital status slightly increased the
combined HR to 3.5 (Figure 9.2.1, lower middle panel). The SCORE-CVD association
did not change its magnitude substantially when the effects of both socioeconomic
parameters were taken into account, as demonstrated by the education and marital
status-adjusted HR of 3.4 (Figure 9.2.1, bottom panel). These findings suggest only a
modest impact of education and/or marital status on the association of interest and also
confirm the existence of the significant, education and marital status-independent link
between the high-risk SCORE 5% and the 10-year atherosclerotic CVD mortality
among MONICA men.
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Figure 9.2.1. Dichotomous high-risk SCORE and 10-year atherosclerotic CVD
mortality in MONICA men: sample-specific and combined hazard ratios and 95%
confidence intervals before adjustment (top panel) and after adjustment for education
(upper middle panel), marital status (lower middle panel), and education and marital
status (bottom panel)
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5.32 (2.30, 12.30)
3.99 (2.24, 7.10)
2.66 (1.96, 3.62)
3.37 (2.28, 4.98)
5.35 (2.31, 12.38)
3.75 (2.08, 6.76)
2.43 (1.78, 3.33)
3.24 (2.08, 5.06)
5.73 (2.46, 13.33)
4.05 (2.28, 7.21)
2.70 (1.99, 3.68)
3.50 (2.31, 5.30)
5.77 (2.47, 13.43)
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HR (95% CI)
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Hazard ratio
Similar to men, controlling for education slightly reduced HR for the overall SCORE-
fatal CVD association among MONICA women from the Czech Republic, Lithuania,
and Russia (unadjusted vs. adjusted combined HR 5.9 vs. 5.0), without affecting its
statistical significance (Figure 9.2.2, top and upper middle panels). However, in
contrast to their male peers, MONICA women demonstrated a modest HR reduction
(HR 5.8) after accounting for marital status (Figure 9.2.2, lower middle panel). As a
result, taking into consideration the impact of both socioeconomic characteristics
weakened the association of interest to some extent, as demonstrated by the difference
between the unadjusted HR of 5.9 and the education and marital status-adjusted HR of
5.0 (Figure 9.2.2, bottom panel).
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Figure 9.2.2. Dichotomous high-risk SCORE and 10-year atherosclerotic CVD
mortality in MONICA women: sample-specific and combined hazard ratios and 95%
confidence intervals before adjustment (top panel) and after adjustment for education
(upper middle panel), marital status (lower middle panel), and education and marital
status (bottom panel)
No adjustment
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5.02 (1.64, 15.36)
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3.78 (1.60, 8.90)
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HR (95% CI)
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Hazard ratio
While the changes in HR were more pronounced for women than for men, these
findings might be partly explained by lower outcome numbers in female participants. In
addition, although marital status and, to a greater extent, education appeared to affect
the association between SCORE and cardiovascular atherosclerotic mortality in women,
the magnitude of this impact was relatively modest. The closeness of the non-adjusted
and the education and marital status-adjusted HR and 95% CI supports the role of
positive SCORE as a statistically significant, independent predictor of fatal CVD among
Czech, Lithuanian, and Russian females.
Therefore, according to the results of the random effects meta-analyses, the high-risk
SCORE 5% significantly predicted 10-year atherosclerotic CVD mortality among
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MONICA men and women, even after controlling for the socioeconomic parameters of
interest. To compare these findings with the results obtained in contemporary CEE/FSU
settings, the next step was to perform similar meta-analyses for male and female
HAPIEE samples.
9.2.2. SCORE in pooled analyses adjusted for socioeconomic parameters:
combining effect estimates from individual HAPIEE samples
Among HAPIEE men, the strength of the pooled association between positive SCORE
and fatal CVD somewhat decreased after controlling for education (unadjusted vs.
adjusted HR 5.4 vs. 5.0) (Figure 9.2.3, top and upper middle panels). Once accounted
for marital status, the combined effect estimate barely changed (HR 5.4), which
suggests that the association of interest could be affected more by education than by
marital status (Figure 9.2.3, lower middle panel). Finally, when the combined
association between positive SCORE and the currently observed atherosclerotic CVD
mortality was adjusted for both education and marital status, its strength slightly
reduced, as denoted by the HR of 5.0 (Figure 9.2.3, bottom panel). However, the high-
risk SCORE 5% remained a statistically significant predictor of cardiovascular death
in HAPIEE men, even after accounting for both socioeconomic parameters of interest.
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Figure 9.2.3. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE men: sample-specific and combined hazard ratios and 95% confidence
intervals before adjustment (top panel) and after adjustment for education (upper middle
panel), marital status (lower middle panel), and education and marital status (bottom
panel)
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The combined analysis of the significant SCORE-fatal CVD association in HAPIEE
women demonstrated some reduction in HR values (from 6.3 to 5.7) after adjustment
for education (Figure 9.2.4, top and upper middle panel). Accounting for the effect of
marital status also reduced the strength of this association, but the impact of marital
status appeared to be slightly smaller than that for education, as suggested by adjusted
HR of 5.9 (Figure 9.2.4, lower middle panel). The education and marital status-adjusted
link between SCORE 5% and atherosclerotic CVD death was slightly weaker than the
unadjusted association (pooled adjusted HR 5.4), but still statistically significant
(Figure 9.2.4, bottom panel). Therefore, although the effect of SCORE as a
cardiovascular risk predictor in women could be, to some extent, explained by the
impact of education and marital status, the overall magnitude of the risk increase among
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females with SCORE 5% was at least five-fold, even after adjustment for these
socioeconomic characteristics.
Figure 9.2.4. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE women: sample-specific and combined hazard ratios and 95% confidence
intervals before adjustment (top panel) and after adjustment for education (upper middle
panel), marital status (lower middle panel), and education and marital status (bottom
panel)
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5.90 (3.66, 9.52)
3.25 (1.29, 8.17)
7.48 (2.64, 21.21)
6.20 (3.13, 12.30)
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To summarise Section 9.2, the results of the random effects meta-analyses demonstrated
that in MONICA and HAPIEE men and women, the high-risk SCORE 5% predicted
the risk of atherosclerotic CVD mortality, independently of the impact of education and
marital status. This is consistent with the first research hypothesis of SCORE as a
significant determinant of cardiovascular risk. Moreover, these findings, together with
the absence of marked improvement in the SCORE model performance after adding
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education and/or marital status (Section 7.2), support the use of the original SCORE
instrument in CEE/FSU populations.
Overall adjusted effects of positive SCORE on the fatal CVD risk were comparable for
MONICA and HAPIEE women (pooled HR 5.0 and 5.4, respectively), but somewhat
lower for MONICA men than for their HAPIEE peers (respective HR 3.4 vs. 5.0),
which could partly be due to the current HAPIEE follow-up being under 10 years and,
therefore, restricted outcome numbers and larger random errors. When the 10-year
HAPIEE data become available, they may demonstrate that the strength of the SCORE-
fatal CVD association is similar to that in MONICA men. This possibility is indirectly
supported by the currently observed overlap between the pooled adjusted 95% CI for
MONICA and HAPIEE men, as well as by the closeness of the SCORE effect estimates
for MONICA and HAPIEE women. In addition, the impact of measured and non-
measured non-classical risk factors on the association between SCORE and
cardiovascular mortality could vary across populations and over time, and, hence, might
affect the magnitude of this association both in individual samples and in combined
analyses.
In this thesis, additional risk predictors included not only socioeconomic parameters,
but also measures of hazardous alcohol consumption. The overall strength of the
hazardous drinking-adjusted associations between SCORE and fatal CVD will be
addressed in the following section.
9.3. SCORE as a predictor of atherosclerotic CVD mortality in pooled
analyses adjusted for binge drinking and CAGE
Positive SCORE appeared to be a hazardous drinking-independent determinant of fatal
CVD risk across individual HAPIEE samples (see Section 8.1). Moreover, the
combined unadjusted effect of SCORE on cardiovascular risk was significant for both
HAPIEE men and women (Section 9.1.2). Therefore, the next step was to check
whether this pooled effect remained statistically significant after controlling for
hazardous alcohol consumption, by combining the respective adjusted effect estimates
in the gender-specific meta-analytic models.
Adjustment for binge drinking barely affected the strength of the link between SCORE
and the risk of atherosclerotic CVD mortality in HAPIEE men, as demonstrated by
unadjusted vs. adjusted HR of 5.4 vs. 5.3 (Figure 9.3.1, top and upper middle panels).
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Similarly, controlling for another measure of hazardous drinking – CAGE score 2 –
did not substantially weaken the significant link (adjusted HR 5.3) between positive
SCORE and cardiovascular risk (Figure 9.3.1, lower middle panel). When the SCORE-
fatal CVD association was adjusted for both bingeing and CAGE, the reduction in its
magnitude was minimal (adjusted HR 5.3) (Figure 9.3.1, bottom panel). These findings
support the independent role of SCORE 5% as a predictor of cardiovascular mortality
in HAPIEE men.
Figure 9.3.1. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE men: sample-specific and combined hazard ratios and 95% confidence
intervals before adjustment (top panel) and after adjustment for binge drinking (upper
middle panel), CAGE (lower middle panel), and binge drinking and CAGE (bottom
panel)
No adjustment
CZ
PL
RU
All samples
Adjustment for binge drinking
CZ
PL
RU
All samples
Adjustment for CAGE
CZ
PL
RU
All samples
Adjustment for binge drinking & CAGE
CZ
PL
RU
All samples
Sample
10.51 (2.53, 43.71)
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2.56 (1.12, 5.89)
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HR (95% CI)
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Hazard ratio
In contrast to men, HAPIEE women showed some increase in the combined effect
estimate after controlling for binge drinking, from 6.3 to 6.7, respectively (Figure 9.3.2,
top and upper middle panels). The significant association between the high-risk SCORE
201
5% and the currently observed CVD mortality also became somewhat stronger, once
the impact of CAGE was taken into account (pooled adjusted HR 6.8) (Figure 9.3.2,
lower middle panel). Similarly, controlling for the detrimental effects of both hazardous
drinking measures slightly increased the pooled HR to 6.8 (Figure 9.3.2, bottom panel).
Figure 9.3.2. Dichotomous high-risk SCORE and atherosclerotic CVD mortality in
HAPIEE women: sample-specific and combined hazard ratios and 95% confidence
intervals before adjustment (top panel) and after adjustment for binge drinking (upper
middle panel), CAGE (lower middle panel), and binge drinking and CAGE (bottom
panel)
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3.59 (1.44, 8.91)
8.79 (3.19, 24.18)
7.36 (3.77, 14.38)
6.28 (3.85, 10.24)
4.08 (1.61, 10.35)
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HR (95% CI)
1.5 2 4 8 16 32
Hazard ratio
The magnitude of the association between positive SCORE and fatal CVD appeared to
be larger in HAPIEE females, compared to their male peers, as demonstrated by the
respective binge drinking and CAGE-adjusted HR of 6.8 vs. 5.3. However, these results
require a cautious interpretation. First, both 95% CI were not only wide, possibly due to
the current follow-up being under 10 years, but also overlapped considerably. Second,
202
for HAPIEE women, the self-reported prevalence of binge drinking and/or CAGE 2
was low, especially in Poland, which resulted in limited outcome numbers among
female bingers or CAGE-positives. Third, since in CEE/FSU populations, drinking
remains less culturally acceptable for women than for men298;301;364, the gender-specific
misreporting of hazardous alcohol consumption could partly affect the magnitude of the
adjusted SCORE-fatal CVD association. Overall, a very modest change in the strength
of the main association of interest after adjustment for hazardous drinking, together with
the absence of prognostic performance improvement for the SCORE model extended by
binge drinking and/or CAGE (see Section 8.2), supports the use of the original SCORE
in CEE/FSU.
The meta-analysis findings were consistent with the sample-specific results and, in
agreement with the first research hypothesis, confirmed that among HAPIEE men and
women, the high-risk SCORE 5% was a statistically significant and hazardous
drinking-independent determinant of atherosclerotic cardiovascular death. Among men,
the overall strength of the association of interest was comparable after adjustment for
binge drinking and CAGE (HR 5.3) and after controlling for education and marital
status (HR 5.0). However, in women, accounting for both hazardous drinking
parameters increased the combined HR to 6.8, while adjustment for both socioeconomic
measures reduced it to 5.4. This discrepancy should be interpreted with caution, due to
the very low outcome numbers across the small-sized subgroups of female bingers
and/or CAGE-positives. Only when the 10-year follow-up data become available, will it
be seen whether the strength of the link between SCORE and fatal CVD in HAPIEE
women increases after controlling for hazardous drinking, or whether it does not change
substantially, similar to the results for HAPIEE men.
To conclude Chapter 9, positive SCORE has been shown to predict CVD mortality
significantly and independently of either socioeconomic characteristics or hazardous
drinking parameters, not only across individual MONICA and HAPIEE male and
female samples, but also in the random effects meta-analyses, which additionally
supports the first research hypothesis.
Therefore, in Chapters 5-9, various aspects of SCORE performance in MONICA and
HAPIEE samples were studied, comparing predicted, observed, and estimated levels of
atherosclerotic CVD mortality, and investigating not only the two versions of the
original SCORE scale, but also the models extended by socioeconomic parameters or by
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measures of hazardous alcohol consumption. The main findings of the thesis will be
summarised in the first section of the next chapter.
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Chapter 10. Discussion
This chapter summarises the results of the thesis and then discusses its methodological
limitations and strengths. A critical analysis of the findings, placed in a broader context
of the evidence available from the existing literature, is also presented. The future
directions of CVD risk assessment and reduction are debated. The chapter closes with
research and policy implications and overall conclusions of the thesis.
10.1. Summary of the findings
The main findings of the thesis can be summarised as follows. First, the positive
SCORE (5% as assessed by the high-risk version of this scale, recommended by the
European Society of Cardiology) was a significant predictor of atherosclerotic CVD
mortality across MONICA and HAPIEE samples and in both genders, which confirmed
the first research hypothesis.
Second, the calibration of the non-extended high-risk SCORE was good in most
MONICA samples, with the exception of Russia where the observed risk was
substantially higher than the SCORE predictions. Comparing the estimated 10-year
CVD mortality in HAPIEE samples with the predictions by high and low-risk SCORE
versions showed that better calibration could be achieved by the high-risk SCORE in
Russian samples and by the low-risk SCORE in Czech and Polish samples. Most
discrimination parameters of the high-risk SCORE were satisfactory in the majority of
MONICA and HAPIEE samples. These findings were consistent with the second
hypothesis of varying SCORE calibration, despite its satisfactory discrimination, across
the CEE/FSU populations of interest.
Third, education and marital status were significantly and independently from SCORE
associated with atherosclerotic CVD mortality in some, but not all, MONICA and
HAPIEE samples. However, the inclusion of these additional risk determinants in the
prognostic model did not substantially improve its calibration and discrimination
parameters, which does not support third research hypothesis and justifies the use of the
original SCORE scale.
Fourth, the inclusion of binge drinking or positive CAGE in the SCORE model either
did not change or only marginally improved its calibration and discrimination
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parameters. These findings fail to support the fourth research hypothesis and to warrant
the extension of SCORE by hazardous drinking characteristics.
Finally, the question of the strength and independence of the associations between
SCORE and fatal CVD was revisited in the meta-analyses of sample-specific effect
estimates. The pooled associations between the high-risk SCORE 5% and
atherosclerotic cardiovascular death remained statistically significant and independent
of socioeconomic measures, or hazardous drinking characteristics.
10.2. Methodological limitations and strengths of the present study
Before discussing the results of the present study in the context of the external evidence,
it is important to highlight some methodological aspects of this thesis. In particular, the
use of data from two separate studies, MONICA and HAPIEE, is discussed in this
section, as well as representativeness of the samples, response rates, and data
comparability. The issues of random error, study power, data missingness, and
systematic error are also debated, followed by the analysis of the limitations and
strengths of the SCORE model and additional risk factors. The last part of the section
outlines other methodological issues, such as the evolving nature of the presently
available measures of prognostic performance.
10.2.1. Use of the data from two separate studies
The major feature of the thesis was the employment of several datasets from two
separate studies, MONICA and HAPIEE. These studies were conducted during two
different historical periods: the MONICA follow-up typically lasted from the mid-1980s
to the mid-1990s, while HAPIEE started in 2002-2004 and is ongoing. These two
studies included different samples, rather than the same re-examined and followed-up
subjects. For the region of interest, MONICA and HAPIEE data are the best available
approximations of the national levels of cardiovascular risk factors and fatal CVD,
respectively, for the 1980-1990s (the period characterized by the divergence of CVD
rates in CEE/FSU) and the 2000s (the period of continuing decline in fatal CVD across
CEE vs. fluctuating, but still high CVD levels in FSU).
While at present, MONICA data might appear to possess mostly historical interest, their
strength is the availability of the 10-year follow-up information, which is required to
adequately assess SCORE calibration and discrimination. As the HAPIEE study started
in the early 2000s, the 10-year follow-up results will be unavailable for the next few
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years. Nonetheless, the HAPIEE data better reflect the current levels of CVD and its
determinants in the region of interest, and also provide additional information on novel
risk factors (for example, alcohol consumption). Moreover, the 10-year levels of
atherosclerotic cardiovascular mortality in HAPIEE samples, as well as the 10-year
SCORE calibration, could be estimated, based on the MONICA mortality patterns or the
exponential survival model.
10.2.2. Sample representativeness
In both MONICA and HAPIEE studies, the subjects were randomly selected from the
population registers in the Czech Republic, Poland, and Lithuania, and electoral lists in
Russia. The characteristics of six districts in the Czech Republic, two Warsaw districts
and the towns and rural communities of the Tarnobrzeg province in Poland, Kaunas in
Lithuania, and three Novosibirsk districts in Russia are generally considered as
satisfactory approximations of the national levels of CVD, cardiovascular risk factors,
and additional risk determinants.42;159;160;323 Although predominantly urban HAPIEE
samples are not entirely representative of the populations of whole countries, it can be
assumed that overall, cardiovascular risk profiles, socioeconomic characteristics,
drinking patterns, and CVD mortality in Czech towns, Krakow, and Novosibirsk
satisfactorily approximate those in urban populations of the Czech Republic, Poland,
and Russia, respectively.297;300;301;365
10.2.3. Response rates
Another factor, restricting generalizability of the MONICA and HAPIEE results, was
non-response to the baseline survey. Although within specific countries, MONICA
response rates somewhat declined over time (Methods, Section 4.1.1), the lowest rates
were 60% or higher. Similarly, the percentage of HAPIEE responders (approximately
60%) reflects the general trend of declining response rates in population studies.43
Although these figures are similar to the response rates observed in other contemporary
studies in CEE/FSU or elsewhere (e.g.366-368), it is likely that MONICA and HAPIEE
participants were healthier and more affluent, compared to the non-responders. For
example, the HAPIEE non-responders from Poland had substantially higher all-cause
mortality than their peers who participated in the study (Professor A. Pajak, personal
communication).
As baseline SCORE levels could not be measured in MONICA and HAPIEE non-
responders, the strength of the SCORE-fatal CVD link also could not be assessed in
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these individuals. The extent of the “healthy volunteer” effect, when the study non-
responders tend to be less healthy than responders (e.g.369-371), could vary across
populations and especially over time, which might affect the between-sample
comparisons of the main association of interest. Although the “healthy volunteer”
phenomenon could weaken the strength of this association, the real sample-specific
effects were unlikely to be lower than the ones observed.
An additional problem was non-response to clinical examination, which is particularly
relevant to the Czech and Lithuanian MONICA samples and Czech and Polish HAPIEE
samples (for example, approximately 20% of Czech HAPIEE participants did not attend
the clinic). The resulting missingness of the baseline SCORE data appeared to be non-
random, as suggested by the typically higher levels of total and CVD mortality across
study and country-specific subgroups with missing vs. available SCORE (for details,
see Methods, Section 4.5.1). The potential implications and solutions for the problem of
SCORE data missingness are discussed in more detail in Section 10.2.6.
Therefore, the MONICA and HAPIEE samples were not entirely representative of the
respective national populations, and their estimates of cardiovascular mortality and risk
factors were, to some extent, affected by non-response. However, no better individual-
level datasets are presently available for the assessment of cardiovascular risk factors
and CVD mortality in CEE/FSU populations. The present investigation of SCORE
prognostic performance could be regarded as a useful step in the complex process of
SCORE recalibration for CEE/FSU (see Section 10.4.1).
10.2.4. Data comparability
Although this thesis used data from four countries for MONICA and three countries for
HAPIEE, the comparability of the international baseline and prospective data could be
regarded as high. Within each study, the same methods were used for all centres, and
the protocols of the cardiovascular part of both MONICA and HAPIEE were very close.
In MONICA and HAPIEE, the baseline survey and physical examination were
performed by trained study personnel, according to standardized methods, with internal
and external quality control. The individual-level data on cause-specific mortality were
also obtained similarly for both studies, via the same national or local mortality
registers.
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10.2.5. Random error and study power
In order to assess the role of chance as a possible explanation of MONICA and HAPIEE
findings and to represent the most likely effect estimates in the study populations, 95%
CI were calculated for all HR. As the number of statistical tests was relatively large,
some “statistically significant” results might be due to chance. However, the main
association of interest (SCORE-fatal CVD) was consistently positive and significant at
the different analysis steps, for both genders, across countries, and over time, which
makes chance an unlikely explanation. All research hypotheses were formulated a
priori, before performing statistical analyses. The results of this thesis appear to be
plausible and consistent with the extensive external evidence base, confirming that
SCORE is a reliable predictor of cardiovascular mortality.
As described in Methods (Section 4.4), the study power, based on the confidence level
of 95% and the minimal increase of 25% in the risk of fatal CVD among the participants
with SCORE 5% vs. <5%, was at least 80% across all MONICA and HAPIEE
samples. Multiple regression analyses, adjusting the association of interest for
socioeconomic characteristics and alcohol consumption parameters, would inevitably
reduce the study power. This was, to some extent, addressed by assessing the magnitude
of the pooled association in the random effects meta-analyses (Chapter 9).
The statistical power of a risk assessment study depends not only on the sample size and
prognostic ability of the predictors, but also on the number of events or, more
specifically, the number of “events per variable” (EPV) which is calculated as the
outcome number divided by the number of predictors in the model.69;327;372;373
According to the current consensus, advised EPV values are 10, in order to provide
stable coefficient estimates for individual predictors69;327;372;373, although recently, a
more relaxed approach has been introduced, with EPV of 5-9 considered acceptable.374
Since MONICA and HAPIEE studies were not designed specifically for the assessment
of prognostic performance of extended risk models, EPV values were reasonably high
for some, but not all, country- and gender-specific samples (Table 10.2.1). For the
original, non-extended SCORE model (one predictor), EPV exceeded 10 for all
samples. For the models extended by one additional risk factor (either education, or
marital status, or binge drinking, or CAGE, in addition to SCORE; two predictors in
total), EPV values were maximal in Russian MONICA men (90.5) and minimal in
Czech MONICA women (6.5). Finally, for the SCORE instrument extended either by
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two socioeconomic parameters, or by two hazardous drinking characteristics (three
predictors in total), EPV were expectedly lower and ranged from 60.3 in Russian
MONICA men to 4.3 in Czech MONICA women.
Table 10.2.1. Number of events per variable (EPV) for original and extended SCORE
models: MONICA and HAPIEE samples
EPV
Men Women
MONICA
Czech Republic
SCORE 32 13
SCORE + one extra predictor 16 6.5
SCORE + two extra predictors 10.7 4.3
Poland (Warsaw)
SCORE 86 21
SCORE + one extra predictor 43 10.5
SCORE + two extra predictors 28.7 7
Poland (Tarnobrzeg)
SCORE 62 19
SCORE + one extra predictor 31 9.5
SCORE + two extra predictors 20.7 6.3
Lithuania
SCORE 58 26
SCORE + one extra predictor 29 13
SCORE + two extra predictors 19.3 8.7
Russia
SCORE 181 86
SCORE + one extra predictor 90.5 43
SCORE + two extra predictors 60.3 28.7
HAPIEE
Czech Republic
SCORE 37 19
SCORE + one extra predictor 18.5 9.5
SCORE + two extra predictors 12.3 6.3
Poland
SCORE 34 16
SCORE + one extra predictor 17 8
SCORE + two extra predictors 11.3 5.3
Russia
SCORE 105 42
SCORE + one extra predictor 52.5 21
SCORE + two extra predictors 35 14
Thus, the thesis findings require cautious interpretation for the samples with lower EPV,
such as Czech MONICA men and women, or Polish HAPIEE women. The results for
these samples should be regarded as lacking clear evidence of prognostic performance
improvement for the extended SCORE, rather than definitely proving the absence of
such an improvement.
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10.2.6. Missing data
Another important factor limiting the study power was the missingness of baseline
SCORE values, due to non-attendance or incompleteness of the clinical examination in
some MONICA (the Czech Republic and Lithuania) and HAPIEE samples (the Czech
Republic and Poland) (see Chapter 5). Participants with missing baseline values of
TCH and/or SBP were excluded from survival analyses and analyses of SCORE
prognostic performance. This analytical strategy is in agreement with the so-called
complete case approach, which has been extensively used in the area of cardiovascular
risk assessment (e.g.33;99;235;261;328-330).
However, the complete case approach reduces the sample size and outcome numbers
and decreases the study precision and power.335;339;375;376 An alternative would be
multiple imputation, which allows for missing data uncertainty, by creating numerous
different imputed datasets and combining their results, and produces valid interferences,
due to averaging the missing data distribution based on observed data (e.g.334;336;338-
340;375;377). The available multiple imputation methods are typically based on the
assumption of data missing at random, or completely at random.23;332-337 Baseline
SCORE values in MONICA and HAPIEE appeared to be missing not at random, and
the missingness patterns varied across samples (Methods, Section 4.5.1). Since using
the imputation techniques which are based on the random missingness assumption for
the analysis of MONICA and HAPIEE data could produce biased results338-341, the
present study employed the compete case approach.
As excluding the observations with non-randomly missing values cannot be entirely
bias-free (for example334;337-339), the complete case approach could have, to some extent,
affected the strength of the SCORE-fatal CVD association in MONICA and HAPIEE
samples. Nonetheless, it has previously been demonstrated that among the second-stage
non-responders (people who participated in the initial health interview survey, but failed
to take part in the following health examination), the predicted levels of major CVD risk
factors, such as TCH or SBP, were within 95% CI of the respective values in the
participants who attended the examination.378 Moreover, the relationships between
selected interview variables and several health outcomes (e.g., poor self-rated health and
longstanding illness) were not affected substantially when the analyses were confined
only to the health examination participants.378 As the second-stage non-response rate in
the above-cited study (49%) was higher than in Czech and Lithuanian MONICA
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samples (<30%) or Czech and Polish HAPIEE samples (<22%), these findings support
the validity of MONICA and HAPIEE estimates. In another study, the associations
between baseline cardiovascular risk factors and subsequent CVD mortality were shown
to be unaffected by the resurvey non-response.331
The absence of a marked non-responder bias, as reported by Boshuizen and
colleagues378, could be explained by the fact that second-stage non-responders comprise
a mixture of groups with different reasons for not participating, different connections
between these reasons and health outcomes, and, hence, potential partial cancellation of
the non-response influences. This explanation is consistent with the findings of the
present research (results available on request) which suggested that in HAPIEE, some
examination non-responders were “too ill”, as denoted, for example, by worse self-rated
health, while others were “too healthy”, reporting no previous CVD diagnosis,
hospitalisation, or treatment (in MONICA, similar analyses of second-stage non-
response were not feasible, due to limited availability of covariate data). Therefore, it is
not possible to predict the magnitude, or even the direction, of the difference in the
SCORE-fatal CVD association between participants with complete examination data vs.
those with missing TCH and/or SBP values.
Finally, the strength of the association between the high-risk dichotomous SCORE and
atherosclerotic fatal CVD was assessed in the Cox regression analyses using not only
complete, but also multiply imputed data for the samples with the highest proportion of
missing baseline SCORE values – Czech and Lithuanian MONICA and Czech and
Polish HAPIEE (for the description of the imputation model, see Section 4.5.1). Across
these samples, the HR values were very close for both approaches (Sections 6.1.1-
6.1.2), which suggested that the results of the complete case MONICA and HAPIEE
analyses were unlikely to be markedly biased.
10.2.7. Misclassification
As some of the variables assessed in this thesis were self-reported (such as prevalent
CVD at baseline, smoking, education, marital status, binge drinking, and CAGE), both
non-differential and differential misclassification might have taken place. Non-
differential misclassification would reduce the strength of the associations between
exposure variables and the outcome of interest, while differential misclassification
could lead to both under- and over-estimation of these associations.
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While the probability of exposure misclassification during the baseline interviews and
examinations in MONICA and HAPIEE could not be excluded completely, it was
minimized via the use of standard questionnaires, protocols, and procedures by well-
qualified local research personnel. Due to the prospective nature of the study, the
assessment of baseline exposures and covariates took place before the outcome data
were available. Participants whose higher cardiovascular risk levels were known to their
relatives, general practitioners, and other health professionals might have been more
likely to be assigned an atherosclerotic CVD cause of death, compared to their peers
without known elevation of cardiovascular risk. However, the ascertainment of the
outcome was performed by the local mortality register personnel, who were not aware
of the clinical characteristics of the MONICA or HAPIEE subjects.
The present study excluded people with self-reported pre-existing CVD, such as earlier
diagnosed CHD or stroke (Methods, Section 4.1). These prevalent CVD cases were not
verified against medical records in MONICA or HAPIEE samples.42;43 There is a
possibility that some subjects without valid CHD or stroke diagnosis could be wrongly
excluded from the present analyses. Since non-fatal CVD tends to be over-reported
across populations, mostly due to poor discrimination between different types of
cardiovascular events379-381, this scenario was more likely than the opposite situation,
when participants with earlier diagnosed CVD did not report it at baseline and, hence,
were erroneously included in the analyses. Excluding participants who wrongly reported
prevalent CVD could potentially reduce the outcome numbers, affect the study power,
and dilute the main association of interest, between baseline SCORE levels in CVD-free
people and subsequent cardiovascular mortality.
The estimates of self-reported smoking status in epidemiological surveys have been
shown to be reasonably accurate and only slightly different from the data obtained by
the so-called gold standard methods, such as carbon monoxide or cotinine
measurements.382-384 Due to lower cultural acceptability of female smoking in
Russia385;386, some under-reporting was possible among women from Novosibirsk.
Similarly, smoking could be under-reported by Lithuanian women, although there are
no published studies confirming this possibility. The risk of misclassification of
baseline SBP and TCH levels was likely to be similar in participants who subsequently
did or did not develop fatal atherosclerotic CVD. In HAPIEE, TCH measurements were
performed by local laboratories, and, hence, systematic between-country differences
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could not be excluded. However, it is not possible to speculate on the direction and
magnitude of the potential impact of these differences on the SCORE performance
across countries. Moreover, the findings of country-specific analyses were unlikely to
be affected. The potential problem of SBP and TCH regression to the mean is discussed
in Section 10.2.8(b).
The possibility that education and marital status categories were misreported was low.
Even if there was some misclassification across their full scales, it should not have
substantially affected the results, as both socioeconomic parameters were dichotomised
(lower vs. higher education, and married vs. non-married status; for further discussion
on dichotomisation of additional risk factors, see Section 10.2.9(b)).
All data of alcohol consumption were self-reported by HAPIEE participants. This could
result in over- or, more likely, under-estimation of drinking patterns. However, first, it is
known that the GF method, employed in HAPIEE, under-estimates alcohol
consumption to a lesser extent than other techniques.311;320 Second, the degree of
drinking under-reporting is expected to have a lower magnitude than in Western
populations, since alcohol does not seem to be associated with social stigma in male
CEE/FSU populations.297;300;301;387-389 Third, it was demonstrated earlier that self-
reported drinking correlated with serum gamma-glutamiltransferase (GGT)
concentrations in a subsample of Russian MONICA men.297;300 In other words, self-
reported drinking measures, despite under-estimating the actual consumption, still
satisfactorily reflect the ranking of participants in terms of their drinking behaviour.
Accordingly, in the HAPIEE participants who would later develop or not develop fatal
atherosclerotic CVD, the degree of hazardous drinking under-reporting was likely to be
similar. Such a non-differential misclassification would weaken the association between
alcohol and CVD mortality and, hence, undermine the prognostic value of hazardous
drinking measures as cardiovascular risk determinants. This should also be the case for
the Polish HAPIEE sample, where a wrongly imposed filter question in the health
questionnaire resulted in additional, albeit non-differential, under-reporting of alcohol
consumption frequency.
A possibility for differential misclassification of drinking measures would, however,
arise if HAPIEE subjects with more hazardous drinking patterns and at a higher CVD
risk under-reported their alcohol consumption to a greater extent than non-hazardous
drinkers. This is particularly relevant to HAPIEE women, since traditionally, female
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drinking is socially stigmatized in the CEE/FSU populations.298;301;364;390 In addition,
non-conventional measures of hazardous drinking, such as surrogate/non-beverage
alcohol consumption, zapoi, or frequent hangovers391;392, which can be more strongly
related to cardiovascular risk, were not measured in HAPIEE samples at baseline. This
could lead to under-estimation of the link between alcohol and fatal CVD, due to both
selection bias (subjects with positive non-conventional measures of hazardous drinking
less likely to participate) and information bias (incomplete drinking information
obtained from the participants). The above-mentioned factors might, to some extent,
explain the lack of an independent association between hazardous drinking and CVD
mortality observed across HAPIEE samples (Section 10.3.4).
Differential misclassification of the outcome could happen if the registration of fatal
atherosclerotic CVD was less likely in disadvantaged people (those with lower
education and/or non-married status) or hazardous drinkers (bingers and CAGE-
positives). However, for all MONICA and HAPIEE samples, mortality registers
covered the whole population of the respective district, city, region, or country, and
combined various sources of mortality data. The outcomes of interest could still be
missed, if the participant moved out of the coverage area, but the likelihood of moving
out was expected to be lower for people experiencing socioeconomic disadvantage or
hazardous drinking.
Another possibility for differential outcome misclassification would occur if fatalities of
other aetiology among those with additional risk exposures (namely, adverse
socioeconomic circumstances or hazardous alcohol consumption) were coded as
atherosclerotic CVD deaths. It has been suggested that a substantial proportion of
“coronary deaths” in Russians is presented by alcohol-related deaths, such as alcohol
poisoning or alcoholic cardiomyopathy.169;200;201;310;393 If that was true for HAPIEE
participants, fatal CVD would be over-diagnosed in hazardous drinkers, compared to
their peers who did not report hazardous drinking at baseline. This would result in a
stronger and more consistent association between alcohol and cardiovascular mortality
than was observed. Neither bingeing nor CAGE were significant predictors of CVD
death in any of the HAPIEE samples (Section 8.1), and therefore, it is unlikely that
baseline hazardous drinking was linked to a higher chance of misclassifying the cause
of death as atherosclerotic fatal CVD.
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10.2.8. Limitations and strengths of SCORE as a prognostic model
The primary methodological tool of this thesis was the SCORE model of cardiovascular
risk. The intrinsic limitations and strengths of SCORE have been reflected in the
analyses of MONICA and HAPIEE data, as discussed in this section.
a) Probability approach
The key limitation that SCORE shares with most other risk prediction instruments is
related to the considerable non-reducible variability of the binary outcome data. While a
model can successfully predict the proportion of people with/without an outcome at a
pre-specified time point, it is still uncertain for individual participants whether they
survive or not, and what is their individual survival time with a relatively narrow
confidence interval.40;394 This limitation is the major explanation of the fact that
discrimination parameters did not reach “ideal” values (such as AUROC/C-statistic of
1.0) in MONICA and HAPIEE data analyses, as well as in many other studies.
Despite the innate uncertainty of the assessment of fatal CVD risk over the next 10
years, SCORE provides point estimates of the predicted risk without any CI. Ignoring
this uncertainty, which arises from variability of regression coefficients in the statistical
model, the population-level distribution of risk predictors, and “behaviour” of individual
atherosclerotic plaques58;73;395, can create a false sense of precision in both clinicians
and patients, when SCORE is used for the prediction of individual cardiovascular risk
levels. At the same time, all evidence-based practice currently employs the application
of average population effects to individuals. A single-estimate approach also makes
SCORE more user-friendly, more interpretable, and more applicable to the time-
constrained clinical practice settings.9;10
b) Broad categorisation and cross-sectional assessment of SCORE components
Although some SCORE components, such as SPB and TCH, are essentially continuous
variables, the SCORE chart presents them as rather arbitrary categories. While
considering smoking status as a dichotomous parameter (presence vs. absence of current
smoking) appears straightforward, it ignores such important characteristics of smoking-
related behaviour as, for example, the number of cigarettes smoked daily, the specific
quit date in ex-smokers, or passive smoking exposure. Categorization of continuous risk
predictors leads to a loss of statistical power and residual confounding59;76;78;82;325-327
(see Methods, Section 4.3.2). This SCORE limitation could not be completely resolved
in the thesis; however, it was partly addressed by investigating the performance of
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continuous vs. dichotomous SCORE instruments in MONICA and HAPIEE samples
(Section 10.2.8(c)).
Due to potential regression to the mean, the levels of such risk factors as SBP and TCH
could undergo systematic change over time, which may dilute the strength of their
associations with cardiovascular outcomes.132;177;244;396-399 It is also known that CVD
treatment decreases the true effect of risk factors on the outcomes by up to 50%.58;134 As
the SCORE model does not account for these effects, it might over-predict the risk in
people who start treatment after the initial examination. Since repeated measurements of
major cardiovascular risk factors were not performed for most MONICA and HAPIEE
samples, and the data on CVD treatment uptake were unavailable for both MONICA
and HAPIEE, the present study focused on baseline levels of risk determinants.
Ultimately, this approach agrees with the general concept of the SCORE instrument –
assessment of the 10-year risk based on current levels of risk factors.
c) Dichotomised risk threshold
SCORE not only categorises continuous risk factors, but also dichotomises the well-
known phenomenon of cardiovascular risk continuum into lower vs. higher-risk, and
establishes this threshold as a basis for withholding vs. starting therapeutic
interventions. This has several implications. First, it has been shown that for most CVD
risk assessment instruments, the risk cut-offs, or intervention thresholds, lack balance
between sensitivity and specificity, which reflects the stochastic nature of any risk scale
and, hence, the implicit limitations of any threshold.100 Second, apart from the above-
mentioned dangers of categorisation, dichotomisation of the continuous explanatory
variables, as an “extreme form of rounding”, could affect the overall predictive ability
of the model.325 In order to address this limitation, the performance of dichotomous vs.
continuous SCORE instrument was evaluated across MONICA and HAPIEE samples;
as expected, the continuous SCORE version demonstrated slightly better calibration and
discrimination (Sections 6.2 and 6.4). Third, as age is the major determinant of risk
level in any cardiovascular scale, including SCORE, the predicted mortality levels were
relatively high in MONICA and HAPIEE participants, who were at least 40 years old at
baseline. Subsequently, a considerable proportion of people at increased risk remained
outcome-free, as demonstrated by low PPV values. Such an approach could potentially
lead to unnecessary medicalization of otherwise healthy middle-aged and older
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individuals135;136, and needs to be counterbalanced by taking into account other
traditional and novel factors influencing total cardiovascular risk.
Indeed, the current ESC guidelines on cardiovascular prevention explain that clinicians
should consider numerous additional factors before deciding on the necessity of
intervention17, rather than be confined to the “black-and-white” thinking that risk 4%
automatically means no intervention, and risk 6% means intervention. In the present
analysis of MONICA and HAPIEE data, socioeconomic characteristics and hazardous
drinking parameters were selected as extra predictors of interest which could affect the
risk of atherosclerotic cardiovascular mortality in addition to, and independently from,
SCORE-comprising factors. The strengths and limitations of these selected
characteristics will be discussed in Section 10.2.9.
d) Fatal atherosclerotic CVD as an outcome
SCORE estimates the 10-year risk of fatal atherosclerotic cardiac events and, hence,
does not take into account the burden of CVD morbidity, which remains high, both in
Europe as a whole and in CEE/FSU countries. On the other hand, the HAPIEE data on
incident non-fatal CHD and stroke (results not presented) clearly demonstrate that
CEE/FSU countries vary considerably in terms of the availability of information needed
to validate and harmonise non-fatal CVD diagnoses. The cause-specific mortality data
are much more comparable, both across the countries and over time. Although some
context-specific systematic misclassification of outcomes within the broad category of
atherosclerotic CVD deaths might occur, it was unlikely to affect the main association
of interest, between SCORE and atherosclerotic cardiovascular mortality, in CEE/FSU
populations.
e) Applicability of the high-risk SCORE version to CEE/FSU context
SCORE is the only cardiovascular risk scale which exists in two versions (high and
low-risk) and, therefore, reflects Europe’s heterogeneity in terms of the background
risk. However, the high-risk version of SCORE, currently recommended for the
CEE/FSU region, was, in fact, developed without using local data. As reported in
Section 2.2.3, the estimates based on the 30-year-old findings from Scandinavian
cohorts could over-predict CVD mortality in some CEE/FSU countries and under-
predict it elsewhere. Accordingly, across the contemporary HAPIEE samples, high-risk
SCORE could substantially over-estimate the 10-year risk of fatal CVD in the Czech
Republic and Poland, but not in Russia (see Section 6.3 for the estimates of 10-year
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SCORE calibration in HAPIEE). Adjusting, or recalibrating, the original SCORE
instrument for specific CEE/FSU countries should improve the prognostic performance
of this scale in the region of interest, as discussed in more detail in Section 10.4.1.
10.2.9. Limitations and strengths of additional risk factors
When assessing such a multifaceted concept as cardiovascular risk as a whole, or even
investigating only two of its determinants, namely socioeconomic disadvantage and
hazardous drinking, residual confounding is hardly avoidable. Even a wide array of
measures may not capture all the relevant aspects of socioeconomic milieu and alcohol
consumption profile which may directly or indirectly influence the risk of
cardiovascular pathology. In addition, a broader categorisation, such as dichotomisation,
of additional risk parameters increases the risk of residual confounding. The limitations
and strengths of the socioeconomic characteristics and drinking parameters employed in
this thesis are discussed below.
a) Selection of socioeconomic parameters and alcohol consumption measures of
interest
As outlined in Section 2.3.2 (Background), no single “ideal” socioeconomic
characteristic has been identified thus far for the CEE/FSU context (or elsewhere).
When assessing socioeconomic CVD gradient in this region, it is advisable to consider
several parameters reflecting different mechanisms of socioeconomic influences on
CVD. Education and marital status refer to different pathways between
socioeconomic/sociodemographic circumstances and cardiovascular health and disease
(such as the acquisition of beneficial skills and assets for the former and familial and
social connections for the latter; for details, see Section 2.3.2(d)), and they both have
been shown to independently predict CVD across Western and CEE/FSU populations.
These routinely measured parameters were available for both MONICA and HAPIEE
samples (with the exception of marital status data unavailability for Polish MONICA
participants). They also did not demonstrate any marked statistical collinearity, which
allowed their inclusion in the extended SCORE model not only separately, but also in
combination (Section 6.1). In addition, the potential differences in the contextual
meaning of lower education or non-married status across countries and over time,
specifically in terms of their influence on cardiovascular risk, should not substantially
affect the magnitude of the associations between socioeconomic parameters, SCORE,
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and fatal CVD, as the performed analyses were study- (MONICA vs. HAPIEE) and
country-specific.
In HAPIEE, additional socioeconomic parameters were measured, which included
various characteristics of absolute and relative deprivation. However, the
generalizability and clinical applicability of these results would be limited, since
respective data are not routinely collected in epidemiological studies on CVD risk
(hence, they were not available for MONICA samples) and are problematic to obtain in
clinical practice settings. These extra socioeconomic measures also did not provide
sufficient outcome numbers across original categories, and lacked pre-existing, accepted
cut-off points for potential dichotomisation. Arbitrary dichotomisation of these
measures would undermine the comparability of HAPIEE findings with external
evidence. Therefore, although focusing on only two parameters, such as education and
marital status, does not capture the complex phenomenon of socioeconomic and
sociodemographic position of individuals263;265, this restriction ensured data
comparability not only across MONICA and HAPIEE samples, but also with other
existing and future studies.
Currently, no single standardized, universally accepted measure of drinking patterns or
hazardous drinking exists.274;276 However, in this thesis, there were several reasons for
concentrating on binge drinking and CAGE score as the selected characteristics of
alcohol consumption, a multicomponent health behaviour. First, these parameters are
relatively easy to measure and comparable across HAPIEE samples and with findings
from other studies. Their validity and reliability in the HAPIEE population were
previously demonstrated.365 Second, there is a lack of universally accepted cut-off
points for drinking amount measures as cardiovascular risk predictors.276;288 In HAPIEE
samples, alcohol consumption frequency could not be dichotomised, due to the J or U-
shaped association with fatal CVD (Section 8.1). This non-linear association could be
partly due to the well-known “sick quitter” effect.273;274;276;280;285;363;400 The available
data did not permit the differentiation between never-drinkers and ex-drinkers. Since
excluding all self-reported “never-drinkers” from the analyses would result in a
substantial sample size reduction, especially for HAPIEE women, it was decided to
consider bingeing and CAGE as the main alcohol consumption parameters of interest.
Although binge drinking and positive CAGE were more correlated than education and
marital status (Section 8.1), the aim of this thesis was to explore the prognostic
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performance of extended SCORE, rather than quantify the relative impact of hazardous
drinking parameters as CVD risk predictors. Therefore, it was decided to
simultaneously include bingeing and CAGE in the extended SCORE model.
Education, marital status, binge drinking, and CAGE are only few parameters out of the
wide range of socioeconomic characteristics and alcohol consumption measures which
potentially influence cardiovascular risk. Other components of these two important
groups of CVD risk determinants will be further discussed in Section 10.4.3.
b) Dichotomisation and cross-sectional assessment of additional risk factors
The limitations of categorising or dichotomising risk predictors, mentioned in Section
10.2.8(b), also apply to the socioeconomic parameters and hazardous drinking measures
employed in this thesis. While the original categories of extra risk predictors were used
in descriptive analyses, the estimation of prognostic performance of the extended
SCORE models required dichotomisation, as the outcome numbers across original non-
dichotomised categories were insufficient for performing analyses of adequate power
(Methods, Section 4.3.3). Broader categories of educational attainment or marital status
were also more comparable across MONICA and HAPIEE samples. Moreover,
bingeing and CAGE were originally constructed as dichotomous measures of hazardous
drinking.
This thesis analysed only the baseline measures of socioeconomic circumstances and
alcohol consumption. While educational attainment was expected to be relatively stable
in the selected age groups, the other three parameters of interest (marital status, binge
drinking, and CAGE) could change over the study time and possibly modify the level of
CVD risk predicted at baseline. In addition, across HAPIEE samples, it was not feasible
to differentiate not only between never- and ex-drinkers, but also between the subjects
who could never be considered as binge drinkers and/or CAGE-positives from the
people with previous history of hazardous drinking and, hence, higher “residual”
cardiovascular risk.311;398;401 These limitations might have affected the strength of the
association between current hazardous alcohol consumption and fatal CVD in HAPIEE
participants. At the same time, the evidence from the subsample of Russian MONICA
men suggested that their drinking patterns were sufficiently stable over a six-year
period.300 Finally, focusing on the current levels of risk factors, whether classical or
novel, such as socioeconomic disadvantage or hazardous drinking, in order to estimate
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the future risk of cardiovascular outcomes, agrees with the general concept of total risk
prediction (Section 10.2.8(b)).
c) Residual confounding
Socioeconomic disadvantage and hazardous drinking are only two groups of variables
out of the wide array of additional, non-conventional risk determinants which might
influence cardiovascular risk. Given the assumption of relatively stable and, hence,
generalizable risk coefficients for SCORE20, one of the possible explanations of slightly
different SCORE HR across MONICA and HAPIEE samples could be the so-called
“case-mix” phenomenon, which denotes dissimilarity in the distribution of predictors
(both included and not included in the model) and outcomes between the participants in
different centres or populations.98;346;350;394;402
Specifically, MONICA and HAPIEE samples could differ by the distribution of
potential residual confounders – so-called “omitted predictors”, which may still affect,
to a varying extent, the strength of the main association of interest, as well as the
performance of prognostic models. However, increasing the number of non-omitted
predictors would reduce the power and precision of the analyses, via decreasing EPV
values (Section 10.2.5). The justification, benefits, and limitations of extending
cardiovascular risk models, such as SCORE, with new risk predictors will be discussed
in Section 10.4.4.
10.2.10. Other methodological issues
The results of MONICA and HAPIEE data analyses, presented in this thesis, could be
partly explained by the employed statistical measures of model calibration and
discrimination. Currently, no single parameter of prognostic performance can capture all
the different aspects of risk prediction, and therefore, the use of multiple measures is
recommended.76 There is no “hierarchy” for different indices of prognostic
performance, although discrimination is typically considered as a core, intrinsic
property of the model, which, unlike calibration, cannot be adjusted in external
populations. The discrimination measures which reflect the risk reclassification in the
extended model are regarded as more sensitive to the positive changes in the model’s
performance, and also as more clinically relevant, with the potential to influence clinical
decisions and outcomes (for details, see Methods, Section 4.5.3). Therefore, while
several measures of calibration and discrimination of the original and extended SCORE
models were assessed for MONICA and HAPIEE samples, the main focus was on the
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practically relevant indices of reclassification, such as IDI. Relatively low IDI values,
obtained for SCORE models after adding socioeconomic parameters or hazardous
drinking characteristics, are in agreement with current external evidence: in attainable
studies, the majority of extended risk models have demonstrated a very modest
reclassification improvement.
In particular, in some studies, a model based on traditional cardiovascular risk factors
was extended by a single additional risk predictor, for example, HDL-CH71, glycated
haemoglobin35, fibrinogen37, carotid-femoral pulse wave velocity403, ankle-brachial
index184, or coronary artery calcification score.36 In other studies, the model was
expanded by different combinations of novel biomarkers, such as troponin I, N-terminal
pro-brain natriuretic peptide, midregional proadrenomedullin, midregional proatrial
natriuretic peptide, cystatin C, high-sensitivity C-reactive protein (hsCRP), fibrinogen,
interleukin (IL) 6, IL-8, tumour necrosis factor (TNF) alpha, lipoprotein-associated
phospholipase 2, glycated haemoglobin, or insulin-like growth factor-1 (e.g.32-34;38;186).
A statistically significant improvement in AUROC/Harrell’s C-statistic and/or
significant NRI or IDI values for extended risk models have been demonstrated in some
of these studies32;33;36;38;71;186;403, but not in others.34;35;37;184 Even when the
discrimination improvement for the extended model was statistically significant, it was
still modest in absolute terms: the maximal increase in AUROC/C-statistic was 0.1033,
while the highest IDI value was 12%.38 Similarly, the extension of SCORE scale with
HDL-CH192, resting heart rate193, or biochemical and instrumental markers of
subclinical organ damage194 increased AUROC/C-statistic values by 0.01-0.02, and NRI
did not exceed 9%.
While the limited improvement in prognostic performance, observed across MONICA
and HAPIEE samples, might be primarily related to the nature of extended models per
se (Section 10.2.9), it could also be affected by the choice of statistical parameters. The
recently introduced measures of prognostic performance, such as reclassification
indices, are considered “work in progress”, as, for example, the exact interpretation of
IDI magnitude remains a challenge.79;85;354;404 However, MONICA and HAPIEE results
were generally consistent across all performance indices, which supported their validity.
To summarise Section 10.2, this thesis has several limitations, such as the use of data
from two separate studies, relatively low outcome numbers in some subgroup analyses,
and limited follow-up length in HAPIEE. On the other hand, it also has some important
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strengths, for instance, comparison of generally compatible prospective data across
several CEE/FSU populations and over time; examination of several versions of the
original SCORE instrument, as well as of the SCORE models extended by a range of
additional risk factors; evaluation of sample-specific and combined effect estimates; and
the assessment of numerous statistical measures of calibration and discrimination. These
strengths support the validity of the results and enable the comparison of MONICA and
HAPIEE findings with the results of other studies.
10.3. Consistency of the results with the evidence from other studies
In this section, the thesis findings are compared and contrasted with the data from other
studies, performed both inside and outside the region of interest. The following issues
are addressed: the prevalence of classical and additional cardiovascular risk factors and
the levels of atherosclerotic CVD mortality (Section 10.3.1); performance of the
original SCORE scale (Section 10.3.2); socioeconomic parameters and SCORE
(Section 10.3.3); and alcohol consumption characteristics and SCORE (Section 10.3.4).
10.3.1. Distribution of cardiovascular risk factors and fatal CVD levels
The performance of cardiovascular risk scales, including SCORE, depends on the levels
of the major risk factors, such as smoking, SBP, and TCH, and the levels of the baseline
risk, i.e. population levels of CVD mortality. Therefore, it is important to compare these
parameters in MONICA and HAPIEE samples not only between these two studies, but
also to respective national levels, despite the limited representativeness of the former in
regard to entire populations of the Czech Republic, Poland, Lithuania, and Russia.
Similar comparison also needs to be performed for the additional cardiovascular risk
determinants of interest, such as socioeconomic characteristics (namely, education and
marital status) and alcohol consumption measures (binge drinking and CAGE). The
rationale for these comparisons is to confirm that MONICA and HAPIEE levels of risk
factors and CVD mortality adequately reflect the respective national cross-sectional
estimates and trends and, hence, could be used for the investigation of SCORE
performance in CEE/FSU settings.
Smoking: As outlined in Chapter 5, both MONICA and HAPIEE samples
demonstrated a relatively high, although not uniform, baseline prevalence of classical
cardiovascular risk factors. In particular, smoking prevalence was over 30% in men
from all MONICA samples, and exceeded 20% in Czech women and Polish women
from Warsaw. By contrast, the proportion of smokers in Polish women from Tarnobrzeg
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and their Lithuanian and Russian peers was under 10%. These findings generally agree
with the relevant national data, collected independently from MONICA surveys and
collated in the WHO Global InfoBase.173 Thus, in the Czech Republic, the smoking
prevalence in 35-64-year-old men and women, who participated in the 1993 Survey of
the Health Status of the Czech Population, was 36.7% and 24.7%, respectively. In the
urban Polish population, 53.9% of men and 48.2% of women aged over 16 years were
current smokers (1986), while for the rural population, the respective figures were
35.5% and 14.7% (1985). In Lithuania, the national prevalence of current smoking in
1994 was 39.7% in 35-64-year-old men and 5.0% in women of the same age. According
to the national data for 1996, as the year closest to the period of interest, smoking
prevalence was 61.3% in Russian men aged 35-64 years, and 10.3% in their female
peers.
In HAPIEE samples, compared to MONICA samples from the respective countries,
smoking prevalence was lower among Czech and Polish men, relatively stable in Czech
and Polish women or Russian men, and higher among Russian women. These patterns
agree with the dynamics demonstrated by the data from the WHO Global InfoBase and
other sources, obtained in the early to mid-2000s. Thus, among 45-74-year-old Czech
men and women – participants of the 2002 Survey of the Health Status of the Czech
Population, the proportion of current smokers was 25.8% and 17.4%, respectively.173
The analysis of Czech MONICA and post-MONICA data by Cifkova and colleagues
demonstrated that smoking prevalence in 25-64-year-old Czech men declined from
39.7% in 1992 to 35.4% in 2000-2001, while in Czech women, the respective figures
were quite stable (approximately 23%).160 In Polish general population aged over 40
years, smoking prevalence was 37.0% and 24.7% among men and women, respectively,
in 2007, as the database year closest to the period of interest.173 These estimates were
similar to the 2005 smoking prevalence reported for 25-74-old Polish men and women
(40.1% and 25.1%, respectively).158 Among Russian LLH study participants, aged 40
years or older in 2001, the respective figures were 56.9% and 9.5%.173 In Russian men
and women from Arkhangelsk, examined in 1999-2000 at the age of ≥18 years, 
smoking prevalence was 56.7% and 21.3%, respectively, which was slightly higher than
in male and female Russian HAPIEE samples and could be due to the younger mean
age of the Arkhangelsk cohort.256 The difference in the age distribution might also
explain higher smoking prevalence in 25-64-year-old Russian men (66%) and women
(15-21%) from Pitkäranta and Aunus districts of Karelia, examined in 2002-2003.405
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Therefore, the higher mean age of HAPIEE vs. MONICA participants could, to some
extent, explain certain dynamics (such as lower smoking prevalence in HAPIEE men
from the Czech Republic and Poland), but not all the changes in smoking levels (such as
higher rates in HAPIEE women from Russia). In addition, population-level data confirm
the existing trends of decreasing smoking prevalence in Czech and Polish men and
increasing smoking rates in Russian women, which reflects the transition of the
respective populations via different stages of tobacco epidemic.254
Total cholesterol: In all MONICA samples, mean TCH levels were close to 6 mmol/l,
which agrees with the WHO data for the respective period.173 However, it should be
noted that, for the countries of interest, the respective WHO estimates of TCH levels
were sourced from MONICA samples. In Czech male and female MONICA-3
participants, mean TCH levels reported in the WHO Global InfoBase were 6.0 and 5.9
mmol/l, respectively. Among Polish men and women from MONICA-Warsaw, mean
levels of TCH were 5.6 and 5.7 mmol/l, respectively, while in MONICA-Tarnobrzeg,
they were 5.4 and 5.6 mmol/l. In men and women from MONICA-Kaunas, mean TCH
levels were 6.0 and 6.2 mmol/l. Among MONICA-Novosibirsk participants, these
levels were 5.6 mmol/l in men and 5.8 mmol/l in women.173 Therefore, due to limited
data availability, an adequate comparison between MONICA findings from the present
study and independent national estimates is not feasible.
In HAPIEE samples, mean levels of TCH were slightly lower in Czech males and
females, compared to their MONICA peers, while in Russian men and women, these
levels were somewhat higher than in MONICA. The latter, but not the former could be
partly explained by the higher mean age of HAPIEE subjects. In Polish men and
women, mean TCH levels did not differ substantially for HAPIEE vs. MONICA. These
findings generally concur with the dynamics demonstrated by the national/subnational
data from WHO or other sources. However, the systematic WHO analysis of worldwide
TCH trends among adults aged 25 years or older406 mostly, although not exclusively,
employed CEE/FSU data from MONICA surveys and, hence, has limited potential for
external comparison of the thesis findings. According to the WHO analysis, mean levels
of TCH in both Czech men and women decreased from 5.8 mmol/l to 5.1 mmol/l in
2008.406 Similarly, among Czech adults from MONICA and post-MONICA samples,
mean TCH levels decreased from 6.0 mmol/l (1992) to 5.3 mmol/l (2007-2008).160 A
minimal TCH decline was observed for Polish women (5.3 mmol/l in 1990 and 5.2
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mmol/l in 2008), while TCH concentrations remained stable (5.3 mmol/l) in their male
peers.406
The WHO analysis also demonstrated some TCH decline for Russia, from 5.3 mmol/l
(1990) to 4.9 mmol/l (2008) for men, and from 5.6 to 5.1 mmol/l, respectively, for
women. By contrast, the comparison of the Russian MONICA and HAPIEE data did not
show any reduction in TCH levels, which could be due to the difference in sample
selection and sample characteristics between this thesis and the analysis by Farzadfar
and colleagues.406 Moreover, mean TCH levels among adult men and women from
Arkhangelsk examined in 1999-2000 (5.0 and 5.2 mmol/l, respectively)256, as well as in
Karelian men and women examined in 2002-2003 (5.3 and 5.1-5.5 mmol/l,
respectively)405, were somewhat lower than in male and female HAPIEE participants
from Novosibirsk. This is most likely explained by the younger mean age of the
subjects in these two studies from Northwest Russia.
Systolic blood pressure: In MONICA samples, mean SBP levels were relatively high
and close to 140 mm Hg in both genders. The consistency of these results with the
WHO Global InfoBase estimates173 is not surprising, as the respective Global InfoBase
data were MONICA-derived, which prohibited an adequate external comparison of the
findings from the present study. In particular, mean SBP levels reported by WHO for
Czech MONICA-3 men and women were 134.4 and 129.9 mm Hg, respectively.173
Among Polish men and women participating in MONICA-Warsaw, mean SBP levels
reached 142.3 and 135.1 mm Hg, respectively. In MONICA-Tarnobrzeg participants,
the respective levels were 135.1 and 137.7 mm Hg. In male and female Lithuanian
MONICA subjects, they were 136.7 and 135.2 mm Hg, respectively. Among Russian
MONICA participants from Novosibirsk, mean SBP was 133.6 mm Hg in men and
134.1 mm Hg in women.173 As expected, these figures are very close to the results
obtained from descriptive analyses of MONICA samples in this thesis.
Mean SBP levels generally followed the same pattern as TCH concentrations, being
similar or lower in male and female HAPIEE subjects from the Czech Republic and
Poland, compared to their MONICA peers. By contrast, men and women from Russian
HAPIEE samples had slightly higher SBP levels than Russian MONICA participants.
These patterns largely agree with the WHO findings and the data from other sources.
According to the WHO systematic analysis, which included CEE/FSU data not only
from MONICA, but also from other, independent studies, mean levels of SBP in Czech
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men aged 25 years or older decreased from 136.1 mm Hg in 1990 to 133.7 mm Hg in
2008; in Czech women, respective figures were 132.5 and 125.7 mm Hg.407 A slightly
less pronounced reduction was observed in the Czech MONICA and post-MONICA
population, aged 25-64 years: mean SBP levels changed from 134.2 mm Hg (1993) to
132.5 mm Hg (2007-2008) for men, and from 130.2 to 126.7 mm Hg for women.159;160
In Polish men, SBP levels remained relatively stable (135.9 mm Hg in 1990 and 135.0
mm Hg in 2008), while their female peers demonstrated some SBP reduction (from
133.0 to 129.7 mm Hg, respectively).407
In Russia, the overall decline in SBP was relatively modest: from 133.7 mm Hg (1990)
to 132.3 mm Hg (2008) for men and from 132.3 to 128.5 mm Hg for women.407 For
Russian HAPIEE vs. MONICA data analysed in this thesis, no SBP reduction was
detected, which might be explained by the difference in selection and characteristics of
the samples in the present study vs. the WHO analysis. Of note, mean SBP levels
among Karelian men and women (140-146 and 136-140 mm Hg, respectively; 2002-
2003)405 were similar to those in male and female HAPIEE samples from Novosibirsk,
despite the younger mean age of the subjects in the former study.
Education: In MONICA samples, the prevalence of lower education was relatively
high, approximately 40% or higher. The percentage of men and women with university
education was the highest in Lithuania (over 20%), followed by Russia, Warsaw, the
Czech Republic, and Tarnobrzeg. These data mostly agree with the national statistics
from the WHO Health for All database.21 Specifically, in the Czech Republic, the
overall percentage of people aged over 25 years with higher than secondary education
was 8.5% (1991); in Poland, 7.9% (1988); in Lithuania, 12.6% (1989); and in Russia,
14.1% (1989) (no gender-specific levels were reported).
In all HAPIEE samples, the proportion of lower-educated participants was substantially
smaller than in the respective MONICA samples, which might reflect improved access
to further education in people born later in the 20th century, whose educational
attainment potential was less affected by World War II and its aftermath.146;227 In the
CEE/FSU region, the progressive decline in the proportion of lower-educated people
over time has been confirmed, for example, in the adult Polish population, where the
prevalence of lower educational attainment (primary or lower secondary education)
decreased from 66.4% in 1990-1991 to 52.9% in 2002.155 Across the waves of the
Novosibirsk MONICA study, from 1985-1986 to 1994-1995, the percentage of people
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with primary education decreased from 31% to 26% in men and from 26% to 19% in
women.387 Similarly, this proportion declined from 42% in the late 1970s to 27% in the
late 1980s among St. Petersburg men.224 A comparable decline, from 38% in 1980 to
17% in 2000, was reported by Murphy and colleagues for a Russian national sample.225
Marital status: As expected for the age groups involved in MONICA and HAPIEE
studies, the majority of the participants (>65% and >60%, respectively) were
married/cohabiting (data on marital status were unavailable for Polish MONICA).
According to the United Nations statistics from the late 1980s or the early 1990s (for the
age group 40-64 years, to compare the results with MONICA) and from the early 2000s
(for 45-69-year-olds, to enable the comparison with HAPIEE), the proportion of
married/cohabiting Czech men and women was 82.7% and 74.2% in 1991 and 78.2%
and 68.2% in 2001, respectively. In 1988, 87.7% and 75.4% of Polish men and women
were married; in 2001, the respective figures were 82.9% and 69.5%. Among
Lithuanian men and women, 85.8% and 69.9% were married in 1989, while in 2001,
this proportion was 78.9% and 60.5%, respectively. In Russia, the percentage of married
men and women was 86.2% and 67.0%, respectively, in 1989, compared to 80.9% and
59.6% in 2002.408 Therefore, it can be concluded that marriage rates in MONICA and
HAPIEE participants were generally close to those in respective national populations
for the relevant time periods.
Alcohol consumption: The patterns of alcohol consumption were assessed only in
HAPIEE samples (Methods, Section 4.3.3), and the prevalence of self-reported alcohol
abstinence in the last year (ranging among men from 5.5% in the Czech Republic to
19.5% in Poland, and among women, from 14.7% in Russia to 43.1% in Poland) was
the only parameter that could be compared with the national data from respective
countries. Typically, the national estimates were considerably higher. For example, in
45-74-year-old participants of the 2002 Survey of the Health Status of the Czech
Population, the proportion of non-drinkers was 30.8% in men and 68.1% in women.173
According to the recent WHO report, the percentage of non-drinkers was 10.7% and
23.0% in Czech men and women aged over 15 years (2003); 16.4% and 34.3% in Polish
men and women (2007); and 29.0% and 50.6% in Russian men and women (2003).287
The most likely explanation of this discrepancy is a more thorough data collection and a
lesser degree of under-reporting in HAPIEE samples, especially in Russia. On the other
hand, in the secondary analysis of the 2002 WHO data, the proportion of non-drinkers
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or “very light drinkers” (0-24 g/day) was 9.0%, 16.4%, and 13.8% among Czech,
Polish, and Russian men, and 19.9%, 34.3%, and 27.5% in women from the respective
countries296, which is somewhat closer to the HAPIEE findings.
The rates of non-drinking in individual-level CEE/FSU studies were also close to the
HAPIEE estimates. Among male and female Russian participants of the LLH study
(2001), the prevalence of non-drinking was 11% and 27%, respectively.298 In a
relatively young cohort from Arkhangelsk, examined in 1999-2000, it was 12.2% and
27.1% in men and women, respectively.256 As expected, the proportion of non-drinkers
across male HAPIEE samples from the Czech Republic, Poland, and Russia (5.5%,
19.5%, and 12.4%, respectively) was close to that among Czech, Polish, and Russian
men from the pilot HAPIEE study (6%, 14%, and 11% in 1999-2000).297 The
percentages of female non-drinkers from the respective countries were also relatively
similar for the main HAPIEE study (16.3%, 43.1%, and 14.7%) and the pilot HAPIEE
project (17%, 24%, and 16%). In addition, the percentage of Russian male non-drinkers
in HAPIEE was very close to the average estimate (13.7%) among MONICA-
Novosibirsk men examined in 1984-1985, 1988-1989, and 1994-1995.300 Although in
1994-1995, the proportion of non-drinkers in MONICA-Novosibirsk samples
(approximately 8% for both men and women)301 was somewhat lower than the HAPIEE
estimates, it could be partly explained by the slightly lower mean age of the participants
in the former study.
The prevalence of binge drinking in Czech, Polish, and Russian HAPIEE men (18.3%,
10.1%, and 32.9%, respectively) was similar to that in the male participants of the pilot
HAPIEE study (16%, 7%, and 26%, respectively)409, confirming the most hazardous
drinking pattern in Russian men. Binge drinking prevalence in female participants of the
pilot HAPIEE was low (percentages not reported), which also agreed with the findings
from the main study (1-3%). Moreover, the Russian estimates from the main HAPIEE
study were somewhat lower than those obtained for the latest survey (1994-1995) of
binge drinking prevalence in MONICA-Novosibirsk men and women (51% and 5%,
respectively).301 This could be due to not only the lower mean age of the participants,
but also the lower cut-off for bingeing in the latter vs. former study (80 g vs. 100 g of
pure alcohol at least once a month, respectively). For a higher threshold (120 g at least
once a month), respective MONICA figures were 36% in men and 2% in women, which
is very similar to HAPIEE values, as well as to the estimates from a national Russian
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sample examined in 1996 (31% of men and 3% of women reported consuming 78.5 g
of ethanol on one occasion at least once a month).299
Despite some difference in the definitions of binge drinking for HAPIEE vs. LLH (for
the latter study, 80 g of alcohol from beer, 90 g from wine, or 86 g from spirits on
one occasion at least once every two-three weeks), the prevalence of bingeing was
relatively similar in Russian HAPIEE men and women (32.9% and 1.4%) and male and
female LLH participants (30% and 4%, respectively).410 However, HAPIEE estimates
of binge drinking were somewhat lower than the 2003 findings from the recent WHO
report: 34.4% and 6.0% in Czech men and women, respectively; 22.1% and 5.8% in
Russian men and women; no compatible data were available for Poland.287 This could
be explained by a different definition of “heavy episodic drinking” by WHO
(consumption of 60 g of pure alcohol on at least one occasion weekly).
The prevalence of positive CAGE score in male Czech, Polish, and Russian HAPIEE
samples (9.1%, 9.6%, and 20.9%, respectively) was relatively close to that in their peers
from the pilot HAPIEE (18.5%, 13.7%, and 34.8%). In women, positive CAGE was
substantially less prevalent than in men, both in the main study (1.9%, 1.0%, and 1.5%)
and across pilot HAPIEE samples (3.5%, 0.7%, and 2.6%, respectively).297 No external
data on the positive CAGE prevalence across the populations of interest were attainable.
However, HAPIEE estimates of hazardous drinking in Novosibirsk men were more or
less comparable to the prevalence of problematic beverage drinking and non-beverage
alcohol consumption (13.3%) among working-age Izhevsk men.392
Cardiovascular mortality: Among MONICA men, the percentage of participants who
died from atherosclerotic CVD over a 10-year period was the highest in Novosibirsk
(7.0%), lower in Warsaw (6.7%), the Czech Republic (5.0%) and Tarnobrzeg (4.9%),
and the lowest in Kaunas (3.5%). Among MONICA women, the highest cardiovascular
mortality levels were registered in Novosibirsk (3.2%), followed by the Czech Republic
(1.9%), Warsaw (1.8%), Kaunas (1.6%), and Tarnobrzeg (1.3%). Similar ranking of
cardiovascular mortality was shown by the national data from the WHO Health for All
database, which were reported for both genders, all ages, and 2005 as the latest follow-
up year for MONICA samples included in the thesis. Specifically, the national fatal
CVD rates (per 100,000) were substantially higher for Russia (837.3) than for the Czech
Republic (419.0), Poland (384.2), or Lithuania (562.8).21
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In HAPIEE, the percentage of atherosclerotic CVD deaths registered during the current
follow-up period was also higher among Russian men than in their Czech and Polish
peers (3.2% vs. 1.4% and 1.0%, respectively). The same ranking was observed for
female HAPIEE samples, with Russian levels of cardiovascular mortality (1.0%) being
higher than Czech (0.6%) or Polish ones (0.4%). This gap between Russia vs. the Czech
Republic or Poland was confirmed by the WHO data for 2008 (the latest follow-up year
for HAPIEE samples from Poland and Russia): Russian levels of fatal CVD were 724.2
per 100,000, while Czech and Polish levels were, respectively, 355.6 and 356.9 per
100,000.21
Therefore, the levels of cardiovascular risk factors and CVD mortality reported in this
thesis were consistent with the respective national/subnational levels, despite the limited
representativeness of MONICA and HAPIEE samples. This supports the validity of
MONICA and HAPIEE findings on SCORE performance, which are discussed below.
10.3.2. Performance of the original SCORE
The investigation of the SCORE prognostic performance in MONICA and HAPIEE
samples involved evaluating the strength of the SCORE-fatal CVD association and
measuring calibration and discrimination of the original SCORE instrument. The results
of each of these analysis steps are summarised below and discussed in the context of
attainable external evidence.
a) Strength of the SCORE-fatal CVD association
The main association of interest, between baseline SCORE and fatal atherosclerotic
CVD, was statistically significant across individual MONICA and HAPIEE samples
and in the combined analyses (Sections 6.1 and 9.1). Thus, in MONICA men, sample-
specific HR values varied from 2.7 in Russia to 5.3 in the Czech Republic, while the
random effects meta-analysis produced a pooled HR of 3.4. Among MONICA women,
HR for the SCORE-fatal CVD association ranged from 1.7 in Warsaw to 6.3 in
Novosibirsk, and the combined HR (4.8) was slightly higher than in men. However, this
gender difference should be interpreted cautiously, due to the 95% CI overlap. In
HAPIEE men, sample-specific HR varied considerably, from 2.6 in Poland to 10.5 in
the Czech Republic; the pooled HR reached 5.4, with a relatively wide 95% CI due to
the current follow-up being under 10 years. Among HAPIEE women, sample-specific
HR ranged from 3.6 in the Czech Republic to 8.8 in Poland. Although the pooled HR
(6.3) was somewhat higher than the respective values in HAPIEE men or MONICA
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women, the respective combined 95% CI overlapped. Some gender- and study-specific
difference in the SCORE HR values could be partly explained by the limited follow-up
length in HAPIEE, as well as by the “case-mix” phenomenon (varying influence of
measured and unmeasured covariates on the association of interest; see Section
10.2.9(c)). The analysis of the currently available data is not adequately powered to
distinguish between the presence of genuine HR differences vs. chance.
To my knowledge, only two other studies have previously reported the magnitude of the
SCORE-CVD association. Among middle-aged Austrian men and women, the strength
of a significant link between baseline SCORE (as a continuous variable, assessed with
the non-calibrated low-risk scale) and 10-year CVD mortality was reported only after
adjustment for several physiological and socioeconomic parameters, such as obesity,
hyperglycaemia, triglycerides, GGT, and job status.123 Since no unadjusted HR were
presented, and the set of covariates differed from that used in the present study, these
results were not directly comparable. However, the HR values presented by Ulmer and
colleagues (1.1 for men and 1.2 for women)123 were still very close to the findings for
the high-risk continuous SCORE in MONICA men and women (1.1 and 1.2-1.3,
respectively), or in HAPIEE men and women (1.1 and 1.2-1.3, respectively).
Among adult participants of the Greek ATTICA study, HellenicSCORE levels, derived
from age, gender, smoking, TCH, and SBP, were significantly associated with the five-
year risk of incident CVD, as demonstrated by the OR of 1.2 per 1% increase in
HellenicSCORE.411 Despite the difference in the analysed SCORE versions and
outcomes (any incident CVD event in ATTICA vs. atherosclerotic fatal CVD in
MONICA and HAPIEE) or employed statistical analysis methods (logistic regression
vs. Cox regression, respectively), the strength of the SCORE-CVD association observed
in the study by Vlismas and colleagues411 and across MONICA and HAPIEE samples
was very similar. Therefore, the present study and the evidence from Austrian and
Greek samples confirm the important role of SCORE as a cardiovascular risk predictor,
which agrees with the first research hypothesis.
In the thesis, estimates of the association between baseline SCORE (both dichotomous
and continuous versions of the high and low-risk instrument) and fatal CVD were very
close for the standard Cox, competing-risk, and Weibull regression analyses (Section
6.1). This agrees with the results obtained earlier for the SCORE Project dataset20 and
the Framingham Study data412, and also demonstrates that the impact of competing risk
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(mortality from causes other than atherosclerotic CVD) on the main association of
interest was minimal. The latter could be due to the relatively high levels of mortality
from CVD, compared to mortality from other causes, in MONICA and HAPIEE
samples of middle-aged CEE/FSU populations.
b) SCORE calibration
The high-risk SCORE demonstrated good calibration in most MONICA samples, as
confirmed by the relative closeness of P/O ratio to 1.0 and the low Hosmer-Lemeshow
χ2 values. This SCORE version, however, under-predicted risk in Russian men and
women. Across HAPIEE samples, followed for less than 10 years, the actual P/O ratios
were understandably over 1.0 (see Section 6.2). The MONICA-based and the
exponential model-based 10-year projections of CVD mortality in HAPIEE (Section
6.3) suggested that high-risk SCORE is likely to over-estimate the risk of fatal CVD in
contemporary Czech and Polish samples, while in Russia, the risk might be either not
over-estimated or even under-estimated. The use of the low-risk SCORE improved the
estimated calibration in Czech and Polish participants, but at a price of markedly under-
predicting the fatal CVD risk in Russia. In agreement with the second research
hypothesis, these findings suggest that the low-risk SCORE might be better suited for
the use in contemporary Czech and Polish populations, while the high-risk instrument
may be preferred for Russia.
It is difficult to compare the SCORE calibration estimates from this thesis to other data
from CEE/FSU populations, due to the lack of studies on SCORE prognostic
performance in this region. For example, among 40-70-year-old male participants of the
Polish WOBASZ study (2003-2005), the prevalence of high-risk SCORE levels 5%
was somewhat lower than in Polish HAPIEE subjects (46% vs. 61%), possibly due to
the lower mean age of WOBASZ participants. For women, these figures were similar in
WOBASZ and HAPIEE (21% and 16%, respectively).413 However, in WOBASZ, mean
SCORE levels were not reported; moreover, predicted risk was not linked to observed
CVD mortality, which made the assessment of SCORE performance impossible.
The findings from Western studies suggest that the high-risk SCORE tends to over-
predict cardiovascular risk in populations with declining rates of CVD mortality, which
agrees with the estimates of the expected 10-year SCORE calibration in Czech and
Polish HAPIEE samples (P/E ratios of 2.1-3.8). For example, although the high-risk
SCORE is officially recommended for Iceland and Norway, these populations
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demonstrated worse calibration for high vs. low-risk instrument. Among middle-aged
Icelanders, P/O ratios for high and low-risk SCORE were 1.6 and 0.8 in men, and 2.1
and 1.2 in women.63 In middle-aged Norwegians, the high-risk SCORE substantially
over-predicted the risk of fatal CVD: P/O ratios ranged from 1.9 to 2.2 for men and
from 1.7 to 2.7 for women. However, for the low-risk SCORE, respective P/O ratios
were closer to 1.0 (1.1-1.3 and 1.1-1.8).125 Although Austria is also considered a “high-
risk SCORE” country, even the low-risk SCORE version was shown to over-predict the
10-year CVD risk in middle-aged Austrian men (P/O ratio 1.2) and, to a greater extent,
women (P/O ratio 1.9).123
These examples suggest that the SCORE calibration may be improved by the
adjustment of the risk scale to local settings (so-called recalibration). Indeed, local
SCORE versions typically show better calibration than the original, non-calibrated
SCORE. For instance, in middle-aged Belgian men and women, the calibration of the
locally adapted SCORE was excellent, as demonstrated by the overall P/O ratio of 1.0
and the Hosmer-Lemeshow χ2 value of 8.3.66 Among middle-aged Australians, the local
SCORE model demonstrated lower Hosmer-Lemeshow χ2 values (and, hence, better
calibration) than the non-calibrated high and low-risk scales: 2.3 vs. 32.8 and 4.4 for
men, and 7.4 vs. 27.3 and 12.9 for women, respectively.67 However, even recalibrated
SCORE might become poorly calibrated. Among middle-aged people from North
Sweden, the local SCORE over-estimated the risk of fatal CVD, as shown by P/O ratios
of 1.6 for both men and women.143 In Dutch adults, the local SCORE version
demonstrated poor calibration, with the Hosmer-Lemeshow χ2 value of 35141. In
another, partly overlapping Dutch population sample, the local SCORE and the original
high-risk instrument over-estimated the fatal CVD risk, while the low-risk SCORE
showed relatively good calibration: respective P/O values were 1.3, 1.9, and 0.9 in men,
and 1.8, 1.8, and 1.1 in women.142
As demonstrated by the above-cited studies and MONICA and HAPIEE results for the
Czech Republic and Poland, even if original or recalibrated SCORE versions previously
showed good calibration, it does not exclude the possibility that calibration ability will
decline over time. On the other hand, if SCORE calibration was initially not ideal, it
might improve later, as suggested by the comparison of Russian MONICA and HAPIEE
data. These findings emphasize the need for the ongoing update and adjustment of all
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CVD risk scales, including the original and recalibrated SCORE instruments, to
contemporary settings (for details, see Section 10.4.1).
c) SCORE discrimination
The high-risk SCORE generally demonstrated satisfactory discrimination in both
MONICA and HAPIEE samples, as shown in Section 6.4. In HAPIEE, the assessment
of SCORE discrimination was based on the available mortality data for the current
follow-up covering less than 10 years, hence, the results obtained should be interpreted
cautiously. Due to the previously mentioned lack of the attainable CEE/FSU studies on
SCORE prognostic performance, MONICA and HAPIEE findings need to be compared
with the evidence from the Western populations. In the latter, SCORE has typically
shown good discrimination ability, regardless of the specific version assessed (the
original high or low-risk instrument or the local, recalibrated scale). However, the fact
that published Western studies have mostly focused on only one or two measures of
SCORE discrimination further complicates any comparison with the MONICA and
HAPIEE estimates.
Sensitivity of the high-risk SCORE was higher than its specificity both in MONICA
men (0.7-0.8 vs. 0.5-0.6) and HAPIEE men (0.8-0.9 vs. 0.3-0.4, respectively). However,
the opposite was true for MONICA women (specificity 0.9 vs. sensitivity 0.2-0.4) and
HAPIEE women (0.8 vs. 0.4-0.7, respectively). This gender difference may be partly
explained by the considerably higher number of outcomes in male participants of both
studies, compared to females. Similar to the findings for MONICA and HAPIEE men,
SCORE sensitivity was higher than its specificity in some Western studies. The original
SCORE publication reported that across high-risk cohorts, the high-risk instrument
showed sensitivity of 0.6-0.8 and specificity of 0.5-0.7 (no gender-specific estimates
were presented).20 The recalibrated SCORE showed high sensitivity (0.8) and slightly
lower specificity (0.7) in middle-aged Belgians.66
Other Western studies demonstrated limited sensitivity and better specificity of SCORE
across various middle-aged populations, which is consistent with the results obtained for
MONICA and HAPIEE women. The specificity of the low-risk scale across low-risk
SCORE Project cohorts (0.9) was higher than its sensitivity (0.2-0.4).20 In the FINRISK
study participants, the sensitivity of the non-calibrated high-risk SCORE reached 0.6 in
men and 0.2 in women; for specificity, respective values were 0.7 and 0.9.328 Among
Icelandic adults, sensitivity and specificity were 0.7 and 0.8 for the high-risk SCORE
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version, and 0.4 and 0.9 for the low-risk instrument.63 In a Spanish population,
specificity of the low-risk SCORE (0.9) was considerably higher than its sensitivity
(0.3).122 Among Austrian men and women, the low-risk SCORE sensitivity was
relatively low (0.6 and 0.1, respectively), while SCORE specificity was high for both
genders (0.9).123 Therefore, these findings suggest that in the populations where the
levels of atherosclerotic CVD mortality are declining (most Western populations), or are
relatively low (MONICA and HAPIEE women), SCORE is less effective for identifying
the people who will die from CVD during the follow-up than for selecting the
individuals who will not develop the outcome of interest.
The positive predictive values (PPV) were low in all MONICA and HAPIEE samples
(approximately 0.1), in contrast to high negative predictive values (NPV), which
exceeded 0.9. To the best of my knowledge, SCORE PPV were assessed in only two
studies, neither of which also reported NPV. Specifically, in the middle-aged Spanish
population, the non-calibrated low-risk SCORE demonstrated PPV of 0.1.122 Among
middle-aged Austrians, PPV was only 0.1 in men and <0.1 in women for the low-risk
SCORE.123 These results agree with the MONICA and HAPIEE findings and suggest
that only a small proportion of individuals with positive (≥5%) SCORE will die from 
atherosclerotic CVD within the next decade. However, since PPV is always low for
relatively rare outcomes, in this case it cannot be regarded as the most appropriate
discrimination measure.
The AUROC and Harrell’s C-statistic values exceeded 0.5 (the value denoting overall
discrimination no better than chance) across all male MONICA samples (0.6-0.7), being
somewhat lower (0.5-0.6) in MONICA women. Among HAPIEE men and women,
these values reached 0.6-0.7. The values of summary discrimination measures in
MONICA and HAPIEE were only slightly lower than the estimates from the studies of
middle-aged Western populations. For example, the original SCORE publication
reported AUROC values of 0.7 and 0.7-0.8 for high and low-risk cohorts, respectively.20
In a Norwegian population sample, AUROC reached 0.7 for the non-calibrated high-
risk SCORE125, while in Icelandic men and women, AUROC for both high and low-risk
SCORE was 0.8.63 Among Austrian men and women, AUROC values for the non-
calibrated low-risk SCORE approached 0.8.123 The recalibrated SCORE produced
similar or higher values of AUROC/C-statistic, compared to non-calibrated versions.
Thus, in Australian men and women, discrimination of the locally adjusted SCORE, as
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well as the original high and low-risk versions, was good, as demonstrated by C-statistic
values of 0.8 for men and 0.7 for women.67 Among Dutch and Belgian adults, the local
SCORE versions produced AUROC/C-statistic values over 0.8.66;141
The maximal proportion of outcome variation explained by dichotomous high-risk
SCORE reached 32% and 34% in MONICA men and women, respectively. SCORE
also explained a relatively modest proportion of the outcome variation in male and
female HAPIEE samples (up to 31% and 53%, respectively). These results are
consistent with the findings of the ecological analysis of cross-sectional MONICA data,
which demonstrated that smoking, high BP, and high TCH explained up to 21% of
CVD mortality in men and 35% in women.126 Similarly, a later analysis of the
MONICA data from the early 1990s showed that contemporary levels of traditional
cardiovascular risk factors accounted for 30% and 45% of coronary mortality variation
in men and women, respectively.149 It might not be appropriate to compare the
individual-level R2 estimates obtained in this thesis to the results of the ecological
analyses. However, to the best of my knowledge, no attainable prospective CEE/FSU or
Western studies have assessed the magnitude of the outcome variation explained
specifically by SCORE, using individual-level data.
To summarise Section 10.3.2, while SCORE was a significant predictor of
atherosclerotic fatal CVD across MONICA and HAPIEE samples, it failed to explain
more than 50% of the variation in cardiovascular mortality risk. One possibility to
improve SCORE discriminatory potential might be extending the risk model by extra
predictors, such as socioeconomic characteristics and alcohol consumption parameters,
which is discussed in the next two sections.
10.3.3. Education, marital status, and SCORE performance
This section debates the role of SCORE, education, and marital status as cardiovascular
mortality predictors. It also discusses SCORE calibration and discrimination after the
model has been extended by socioeconomic parameters.
a) Strength of the SCORE-fatal CVD association, adjusted for education and marital
status
Across individual MONICA and HAPIEE samples, the association between SCORE
risk levels and 10-year atherosclerotic CVD mortality remained statistically significant
and did not change its strength substantially after controlling for education and/or
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marital status (Section 7.1). In the random effects meta-analyses (Section 9.2), the
adjustment for socioeconomic parameters only slightly reduced the strength of the main
association of interest, which was relatively similar in MONICA and HAPIEE women
(respective pooled HR 5.0 and 5.4), and slightly lower in MONICA vs. HAPIEE men
(HR 3.4 vs. 5.0, respectively). The difference in MONICA vs. HAPIEE HR for men
should be regarded with care, since the respective pooled 95% CI overlapped. The
possible explanations of this difference could include limited outcome numbers over the
current HAPIEE follow-up and the varying extent of residual confounding influences on
the magnitude of the SCORE-CVD mortality association (so-called “case-mix”; see
Section 10.2.9(c)). Moreover, this HR discrepancy is less important than the fact that in
both MONICA and HAPIEE, positive SCORE was a significant predictor of
cardiovascular death, independent of such risk factors as lower education and/or non-
married status.
To compare these findings with the external evidence is not possible, as, to the best of
my knowledge, no published studies thus far have investigated the changes in the
strength of the link between SCORE and fatal CVD before and after adjustment for
socioeconomic parameters. However, an Austrian study reported HR for the continuous
low-risk SCORE after controlling for multiple covariates, including job status.123 These
HR values (1.1 in men and 1.2 in women) were similar to those for the continuous high-
risk SCORE in MONICA and HAPIEE men (1.1) and women (1.2-1.3), after
adjustment for both education and marital status. Similar effect estimates were obtained
in an adult Greek population for a continuous HellenicSCORE (OR 1.1) after
adjustment for numerous extra risk determinants, including the socioeconomic index
based on education and family income.411 These findings support the first research
hypothesis of SCORE as a significant cardiovascular risk predictor, independent of
socioeconomic characteristics.
Although the links between additional risk factors, such as socioeconomic parameters or
hazardous drinking measures, and cardiovascular mortality were not the primary focus
of the thesis, it is still important to compare the observed magnitude of these
associations with the relevant external evidence. First, if the direction and strength of
the links between additional risk determinants and fatal CVD are consistent between
this and other studies, it will indirectly justify the validity of MONICA and HAPIEE
data on the association between SCORE and cardiovascular mortality, after adjustment
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for extra risk factors. Second, if both the MONICA and HAPIEE data and the results
from other studies demonstrate that education and marital status independently predict
fatal CVD, it will support the extension of the SCORE model by these socioeconomic
parameters.
In almost all MONICA and HAPIEE samples, lower education and non-married status
were linked to a significant or non-significant increase in CVD risk, even after
controlling for SCORE (Section 7.1). Only in MONICA women from Tarnobrzeg, did
lower-educated participants appear to be at a lower risk (HR 0.8), although this
association did not reach statistical significance. It might be explained by the fact that
Tarnobrzeg sample was predominantly rural, and slightly “behind” the rest of the
samples in the process of socioeconomic and epidemiological transition, characterised
by the well-described phenomenon of inverse social gradient in cardiovascular risk
factors and CVD mortality (e.g.146;202-204). Specifically, for Poland, it was shown that
fatal CVD rates were higher in higher-educated Krakow residents in the late 1960s and
1970s218, while in the 1980-1990s, higher cardiovascular mortality was observed in
lower-educated Warsaw adults.146
Once the effects of SCORE and both socioeconomic parameters on cardiovascular
mortality risk were simultaneously taken into account (not possible for Polish
MONICA, due to the unavailability of marital status data), selected study samples
demonstrated a statistically significant positive association between fatal CVD and
lower education (Lithuanian MONICA women, Russian MONICA men and women,
and Czech, Polish, and Russian HAPIEE men) or non-married status (Czech and
Russian MONICA men, Polish HAPIEE men, and Russian HAPIEE men and women).
While no external attainable studies, to my knowledge, have adjusted the impact of
lower education or non-married status by the baseline SCORE level, such an adjustment
was performed by a varying set of classical risk determinants (for details, see
Background, Section 2.3.2). In some CEE/FSU studies, socioeconomic characteristics
were significant, independent predictors of CVD mortality. For example, among male
participants of the Russian LRC Study227, adjusted RR for lower vs. higher education
(1.9) agreed with the findings for Russian men from MONICA (SCORE-adjusted HR
1.7) and HAPIEE (1.8), despite some differences in end-points, covariates, and
education categories between the LRC Study and this thesis. It was also demonstrated
earlier for male MONICA-Novosibirsk participants230 that divorced status is related to a
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significantly increased risk of CVD death (adjusted RR 1.8). This effect size is very
close to that obtained in the thesis for non-married MONICA men from Novosibirsk
(adjusted HR 1.8).
Many Western studies have also shown an independent, statistically significant link
between lower educational attainment and higher CVD risk, similar to the findings for
Russian MONICA men and women (adjusted HR 1.7 and 1.6, respectively), Lithuanian
MONICA women (4.4), and Czech, Polish, and Russian HAPIEE men (3.0, 2.5, and
1.8, respectively). Lower education was a significant predictor of fatal CVD among
American participants of the NHANES I study (adjusted RR ranged from 1.5 to
2.3)238;239 and Finnish men and women (adjusted HR 1.2 and 1.9, respectively).240
Moreover, increased risk of cardiovascular death, which was not explained by classical
risk factors, has been observed not only for non-married men from Czech MONICA
(adjusted HR 5.1), Russian MONICA (1.8), Polish HAPIEE (2.5), and Russian HAPIEE
(2.3), but also for non-married middle-aged Dutch men (adjusted RR 2.2)210, widowed
male Whitehall civil servants (adjusted mortality rate 1.3)211, single male BRHS
participants (adjusted RR 1.5)212, and single, widowed, or separated/divorced middle-
aged Scottish men and women (adjusted RR varied from 2.1 to 2.6).214
By contrast, in other study samples (Czech MONICA men and women, Lithuanian
MONICA men, and Czech, Polish, and Russian HAPIEE women), an association
between lower education and higher risk of fatal CVD failed to achieve statistical
significance after accounting for conventional risk factors. This is in agreement with
several CEE/FSU studies, performed in Udmurt men of working age255, Novosibirsk
men and women230, and Arkhangelsk men256, as well as with some Western studies of
Norwegian men and women231, middle-aged men from France and Northern Ireland
who participated in the PRIME study232;233, and middle-aged participants of the
Melbourne Collaborative Cohort Study.234 After taking classical risk determinants into
account, the increase in cardiovascular mortality risk associated with non-married status
was non-significant not only in Lithuanian MONICA men and women, Czech
MONICA women, Russian MONICA women, and Czech HAPIEE men and women,
but also among men and women from Novosibirsk230 or Arkhangelsk256, male and
female Framingham Offspring Study participants235, and French and Northern Irish men
who took part in the PRIME study.233
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The lack of statistically significant, independent associations between socioeconomic
parameters and fatal CVD in most MONICA and HAPIEE samples, or in some of the
above-cited CEE/FSU and Western research projects, might be partly explained by
limited outcome numbers in some studies, but could also be due to the fact that multiple
mechanisms of adverse effects of lower education and non-married status on
cardiovascular health involve classical risk factors, such as smoking. Controlling for
these conventional risk determinants, captured by SCORE, might result in over-
adjustment and attenuate a positive link between socioeconomic factors and CVD
mortality.211;255;414
Therefore, both the results of this thesis and the evidence from other studies generally
support the role of not only SCORE, but also socioeconomic disadvantage as important
predictors of cardiovascular risk. This was the rationale behind extending the original
SCORE model by socioeconomic characteristics, such as education and marital status.
Such an extension was expected to improve SCORE calibration and discrimination, in
agreement with the third research hypothesis. In the next section, the prognostic
performance of extended SCORE in MONICA and HAPIEE samples is compared with
the findings available in the literature.
b) Calibration and discrimination of the SCORE model extended by education and/or
marital status
In most MONICA and HAPIEE samples, the extension of the SCORE instrument by
education and/or marital status failed to substantially improve the model calibration,
probably because Hosmer-Lemeshow χ2 values were relatively low even before the
model extension (Section 7.1). The changes in discrimination were more promising for
extended SCORE models, as demonstrated by increased values of Harrell’s C-statistic
and Royston’s R2 index, as well as by low p values in LR tests. However, it was not
possible to identify a single extended model which would produce universally better
discrimination measures across all study-, country-, and gender-specific samples. The
overall change in the discrimination of extended models, operationalized via integrated
discrimination improvement (IDI), was modest, <5% for MONICA men and <1% for
MONICA women, HAPIEE men, or HAPIEE women. Therefore, the MONICA and
HAPIEE results support the use of the original SCORE for cardiovascular risk
prediction in CEE/FSU populations, as its performance was very similar to that for the
education and marital status-extended models.
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To my knowledge, no studies have assessed the changes in calibration or discrimination
of SCORE (or other cardiovascular risk scales) extended by socioeconomic parameters
in CEE/FSU populations. However, several Western studies investigated the changes in
selected calibration and/or discrimination indices for the extended Framingham risk
scale, with mixed results. Adding either current or lifetime social class, or the area
deprivation (operationalized via the Carstairs-Morris index) to the Framingham model
did not improve its discrimination in middle-aged Scottish men.415 Among middle-aged
participants of ARIC and NHANES III studies, adding lower socioeconomic position
(<12 years of education or low income) improved the Framingham scale calibration
without substantially affecting its discrimination.261 One study259 assessed the overall
discrimination improvement for the Framingham scale extended by socioeconomic
parameters. In particular, adding occupational social class to the Framingham model
slightly improved risk reclassification in middle-aged BRHS participants, as reflected
by low NRI and IDI values (0.2% and 0.1%, respectively). Indirectly, these findings are
consistent with the results for MONICA and HAPIEE samples, where the addition of
education and/or marital status marginally improved the overall SCORE discrimination.
The absence of a marked performance improvement for the models extended by
socioeconomic parameters might appear contradictory to the evidence of better
performance of the cardiovascular risk scales which incorporate socioeconomic
characteristics, such as ASSIGN and QRISK/QRISK2, compared to traditional
instruments, such as Framingham scale (Background, Section 2.3.2). ASSIGN, which
includes the area-based SIMD (Scottish Index of Multiple Deprivation), demonstrated
better discrimination104 and a steeper, closer to the observed, deprivation gradient in
CVD risk262 than the Framingham score. QRISK/QRISK2, which included a different
area-based deprivation index (Townsend deprivation score), showed better calibration
and discrimination than the Framingham instrument.105-108 However, these studies
compared different risk scales, rather than nested models, and, hence, they did not
address directly the issue of incremental prognostic value of socioeconomic parameters
when added to classical risk factors.
Therefore, MONICA and HAPIEE findings, as well as the current evidence from other
studies, support the use of the original SCORE instrument. It remains to be seen
whether future research identifies suitable ways of extending cardiovascular risk models
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by socioeconomic characteristics, in order to improve the prognostic performance in
specific populations (Section 10.4.3).
10.3.4 Alcohol consumption and SCORE performance
Another important predictor of CVD risk in CEE/FSU is alcohol consumption. This
section, structured in a similar way to Section 10.3.3, puts the HAPIEE findings on
SCORE and alcohol in the context of external evidence.
a) Strength of the SCORE-fatal CVD association, adjusted for alcohol consumption
parameters
Across all HAPIEE samples, baseline high-risk SCORE 5% remained a significant
predictor of atherosclerotic cardiovascular death after accounting for binge drinking
and/or CAGE. This adjustment barely affected the strength of the main association of
interest (Section 8.1). Similarly, in the random effects meta-analyses (Section 9.3), the
overall association did not change substantially after taking both measures of hazardous
drinking into account. While the alcohol-adjusted overall association between SCORE
and fatal CVD appeared to be stronger in HAPIEE women (adjusted HR 6.8) than in
their male peers (HR 5.3), these findings should be interpreted with care. Not only did
95% CI for these values overlap, but also the outcome numbers across small subgroups
of female bingers or CAGE-positives were relatively low, possibly due to limited
cultural acceptability and, hence, under-reporting of hazardous drinking in CEE/FSU
women.298;301;364
To my knowledge, no published CEE/FSU or Western studies have compared the
potential of SCORE, or any other risk scale, as a cardiovascular mortality predictor
before and after adjustment for alcohol consumption parameters. At the same time,
smoking, one of the classical risk factors, appeared a significant, or close to significant,
predictor of fatal CVD, even after controlling for alcohol and other risk determinants,
among male and female LRC Study participants308, or in working-age Udmurt men.255
While SCORE remained a significant determinant of atherosclerotic cardiovascular
mortality in all HAPIEE samples after accounting for hazardous drinking, the SCORE-
adjusted associations between fatal CVD and either bingeing or positive CAGE were
substantially weaker (Section 8.1). After controlling for SCORE and CAGE, the link
between bingeing and CVD mortality failed to reach statistical significance in all
samples, and was even negative in Czech and Polish men. Positive CAGE did not
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significantly predict fatal CVD in HAPIEE men and women, once the effects of SCORE
and binge drinking were taken into account.
The absence of significant associations between hazardous drinking and fatal CVD
across HAPIEE samples could be, to some extent, explained by the current follow-up
being less than 10 years and the limited outcome numbers, particularly in women. When
the 10-year data are available for HAPIEE, it might be that bingeing and/or CAGE will
become more reliable predictors of cardiovascular death, independent of SCORE and
each other. This would agree with the evidence of the important role of various drinking
measures as significant predictors of fatal CVD risk, even after controlling for
conventional and novel risk determinants, which has been obtained in numerous
Western studies273;274;280-282;284;285;289-291 and several CEE/FSU studies performed in
working-age Udmurt men201;255;309, men and women from Tomsk, Barnaul, and
Biysk310, middle-aged Novosibirsk men300, and Arkhangelsk women256 (for details, see
Background, Section 2.3.3).
However, currently, the findings from most HAPIEE samples demonstrate a positive,
albeit not significant after adjustment, association between atherosclerotic CVD
mortality and binge drinking (Russian men, Czech and Russian women; adjusted HR
1.2-3.3) or positive CAGE (men from all three countries, Czech and Russian women;
adjusted HR 1.2-3.4). Similarly, in Novosibirsk men, followed for 9.5 years, binge
drinking was linked to a non-significant adjusted increase in CHD mortality (RR 1.3).300
Despite the difference in binge drinking definitions between the study by Malyutina and
colleagues (160 g of alcohol on a typical occasion at least once a month)300 and this
thesis, as well as some difference in study outcomes and covariates, these earlier
obtained results are relatively close to the findings for HAPIEE men from Novosibirsk
(adjusted HR 1.2).
The absence of a clear association between binge drinking and CVD risk among Czech
and Polish HAPIEE men (adjusted HR 0.8 and 0.7, respectively, with both 95% CI
including 1.0) was consistent with the results of some CEE/FSU studies which also
failed to establish a link between hazardous drinking and cardiovascular mortality. For
example, in two St. Petersburg cohorts, followed throughout the 1980s and 1990s, the
10-year fatal CVD rates were similar in men with low and high alcohol consumption.224
The 13-year follow-up of the LRC Study participants also did not show any marked
difference in adjusted cardiovascular mortality hazards between male and female
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drinkers vs. non-drinkers.308 Bingeing did not appear to be associated with fatal CVD
risk among middle-aged Novosibirsk men (adjusted RR 0.9)300 or men from
Arkhangelsk (RR 0.9).256
The lack of a consistent, independent association between hazardous drinking and fatal
CVD across HAPIEE samples and in some of the above-cited external studies could be
due to several reasons. First, outcome numbers in bingers and/or CAGE-positives were
relatively low (especially in women), which did not allow the performance of
adequately powered analyses. Second, classical risk factors, such as SBP and TCH,
could partly explain the elevated CVD risk in hazardous drinkers. Adjusting for these
conventional risk determinants could have decreased the magnitude of the association
between drinking and fatal CVD.272;280;290;400 Third, differential misclassification317,
when participants with more hazardous drinking patterns and at a higher cardiovascular
risk would under-report their alcohol consumption to a greater extent than non-
hazardous drinkers, might also have weakened the link between drinking and
atherosclerotic CVD mortality. Finally, the magnitude of the alcohol effect on
cardiovascular risk could be, to a considerable extent, influenced by the recent episodes
of hazardous drinking, and, hence, be larger in case-control vs. cohort studies.392;416
In summary, the adjusted positive link to cardiovascular mortality was significant for
SCORE in all HAPIEE samples, although it did not reach statistical significance for
hazardous drinking, which agrees with the evidence from some, but not all, CEE/FSU
studies. In this thesis, the assessment of the associations between SCORE, hazardous
drinking, and cardiovascular mortality was a preliminary step towards investigating the
prognostic performance of SCORE extended by bingeing and/or positive CAGE, in
order to address the fourth research hypothesis. However, the absence of a clear link
between alcohol and fatal CVD risk suggested that such an extension was unlikely to
result in improved SCORE performance.
b) Calibration and discrimination of the SCORE model extended by alcohol
consumption parameters
The evaluation of the alcohol-extended SCORE performance across male and female
HAPIEE samples demonstrated that adding either binge drinking, or positive CAGE, or
both, to the high-risk SCORE did not markedly affect Hosmer-Lemeshow χ2 values, as
a measure of model calibration (Section 8.2). Moreover, it was impossible to identify a
single model, original or extended, that would demonstrate better calibration across all
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HAPIEE samples. SCORE extension by hazardous drinking parameters also failed to
show a substantial improvement in the model discrimination, as assessed by Harrell’s
C-statistic, Royston’s R2, and LRT p-values. Alcohol-extended SCORE could explain
up to 50% of the outcome variation, and the overall discrimination improvement,
denoted by IDI, was <1%. These results disagreed with the fourth research hypothesis,
although they did not reject it completely. The current HAPIEE follow-up is less than
10 years, which limited the outcome numbers. Moreover, the self-reported prevalence of
hazardous drinking in HAPIEE women (particularly in Poland) was low, which
restricted the power of the alcohol-extended analyses. On the other hand, the current
absence of considerable improvement in SCORE performance after the model extension
by hazardous drinking parameters was similar to the results for the SCORE instrument
enriched by socioeconomic characteristics (Section 7.2). These findings suggest that, at
the moment, the original SCORE could be the algorithm of choice for cardiovascular
risk assessment in CEE/FSU populations.
Despite the wealth of data on alcohol as a cardiovascular risk factor (Background,
Section 2.3.3), no studies in CEE/FSU or Western populations, to the best of my
knowledge, have investigated the prognostic performance of SCORE, or any other
cardiovascular risk instrument, after extending it by alcohol consumption measures.
Moreover, no cardiovascular risk scale developed thus far includes any drinking
parameters. This lack of evidence not only complicates the comparison of HAPIEE
findings with other data, but also points to the important knowledge gap, which should
be addressed in future studies (Section 10.4.3).
To summarise Section 10.3, SCORE demonstrated a significant association with
atherosclerotic CVD mortality, as well as satisfactory discrimination, across most
MONICA and HAPIEE samples, which agreed with the existing external evidence. At
the same time, SCORE markedly under-predicted the fatal CVD risk in Russian
MONICA. The estimated 10-year SCORE calibration in HAPIEE suggested that in
contemporary CEE/FSU populations, different versions of this instrument could be used
(low-risk for the Czech Republic and Poland, and high-risk for Russia). These results, as
well as the data from numerous Western studies, emphasize the importance of a regular
reassessment of SCORE performance across populations and over time and, if
necessary, its recalibration. Despite some evidence of the association between CVD
mortality and socioeconomic parameters or hazardous drinking characteristics in
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selected MONICA and HAPIEE samples, which agrees with the findings of other
studies, the improvement in calibration and discrimination of the extended SCORE was
modest. A marginal improvement in the prognostic performance of extended
cardiovascular risk models has also been shown in other studies. While these results
suggest that the original SCORE instrument could be used as effectively as its extended
versions, they do not deny the possibility of further improvement of the SCORE-based
cardiovascular risk prediction.
10.4. Future directions of CVD risk assessment and reduction
This section discusses the areas for optimisation of cardiovascular risk prediction and
reduction and debates such topics as SCORE recalibration and “evolution” as a
prognostic model, the potential of socioeconomic parameters and alcohol consumption
characteristics as CVD risk determinants, the extension of cardiovascular risk models
with novel risk predictors, and the importance of targeting lifestyle risk factors in
cardiovascular prevention.
In the field of CVD risk prediction and reduction, research and practice are closely
related. For example, the development of effective risk assessment instruments requires
routine collection of local data on cardiovascular risk factors and outcomes, while the
CVD burden reduction involves accurate risk evaluation and identification of the
individuals, groups, and populations at the highest risk, i.e. those most likely to benefit.
Therefore, the research and policy-related aspects of further development of CVD risk
prediction and management are presented together.
10.4.1. SCORE recalibration
Recalibrated, or locally adjusted, cardiovascular risk scales, such as SCORE, typically
demonstrate better prognostic performance in local populations than original, non-
calibrated instruments; however, even recalibrated scales might become less accurate
over time (e.g.141-143). This emphasises the need for continuous revision, update, and
readjustment of risk assessment instruments, particularly in populations with rapidly
changing levels of cardiovascular risk factors and fatal CVD, such as CEE/FSU.
Country-specific SCORE models, which were introduced in the Czech Republic175 and
Poland176 in the mid-2000s, are very close to the original high-risk SCORE. Presently,
these scales lack a description of recalibration procedure and/or comparison of their
predictive performance with the original instrument, and it is possible that they over-
estimate the risk in contemporary Czech and Polish populations. The analysis of the
248
estimated 10-year SCORE calibration in HAPIEE samples (Section 6.3) demonstrated
that the low-risk SCORE might predict CVD mortality in Czech and Polish participants
more accurately than the high-risk SCORE.
In this thesis, it was not possible to recalibrate SCORE to the contemporary Czech,
Polish, or Russian settings, as HAPIEE samples represented selected urban
communities, rather than populations of the whole countries. This, together with non-
response, affected the generalizability of the observed levels of risk factors and CVD
mortality. The information on background risk levels, which were assessed in 2002-
2004, was somewhat out-dated; and the current follow-up length was under 10 years.
Nonetheless, this study is an important first step towards SCORE recalibration and,
hence, the improvement of its prognostic accuracy in the CEE/FSU context.
Essentially, SCORE recalibration requires two local sources of updated information: the
current national statistics on cardiovascular mortality and representative surveys of
conventional risk factor levels in the population.9;13 While fatal CVD rates are available
for CEE/FSU, albeit with varying time lags, obtaining the local representative data on
risk factors is a more challenging task, due to the lack of extensive epidemiological
research expertise and preventive infrastructure in these countries.24;146;417 An obvious
option is to use local prospective individual-level studies as a source of information on
CVD mortality and risk factors, required for SCORE recalibration. However, due to
such issues as limited sample representativeness and/or follow-up time, these studies are
unlikely to be an adequate substitute for a national system of health and disease
surveillance. If the enormous burden of CVD in CEE/FSU is to be reduced, the current
focus of healthcare systems, health research communities, and policy-makers needs to
be gradually extended from treatment of the patients with already developed circulatory
pathology to primordial and primary prevention and, hence, to routine monitoring and
management of cardiovascular risk factors.
One of the possible mid-term solutions to the problem of data availability for the
recalibration of cardiovascular risk scales, such as SCORE, is to use the data routinely
collected in general practice. Probably the best-known example of this strategy is the
UK QRISK/QRISK2 Project (for details, see Section 2.1.2). In large cohorts of British
general practice patients, the eponymous prognostic algorithm has been shown to
predict CVD risk more accurately than the Framingham model.105;107;108 Another
example is PREDICT-CVD, a web-based clinical decision support programme,
249
operating in the Auckland region, New Zealand.418-420 This programme provides
cardiovascular risk assessment and management advice to primary care patients with or
without manifested CVD. Since its implementation in 2002, it has generated
comprehensive data on individual cardiovascular risk for large numbers of patients.
Such data could also be linked to national hospital discharge database and mortality
registers, providing a unique opportunity to study the CVD risk continuum in a large
community cohort. In some CEE/FSU countries, the general practice data on
conventional cardiovascular risk factors and outcomes are also routinely collected and
typically computerised. These data can potentially be analysed on the national or
regional level and used for the development and validation of relevant, context-specific
SCORE versions. However, the major obstacle is the issue of data confidentiality, as the
possibility of individual-level data linkage is restricted by local legislation.
Importantly, not only will the research on CVD risk prediction benefit from using
clinically derived data, but also the routine use of reliable cardiovascular risk
instruments will provide numerous benefits in clinical practice settings. It will increase
physicians’ trust in risk scales, stimulate doctors’ compliance with cardiovascular
prevention guidelines and risk assessment implementation, enhance the accuracy of risk
prediction, and, ultimately, improve clinical outcomes.16;55;189;346;421 Cardiovascular risk
prediction provides clinicians with an opportunity to discuss with their patients the
potential impact of lifestyle changes and treatment on both short and long-term risk.
Such a discussion might help the patients better understand their risk at earlier disease
stages and, hence, improve their motivation for early, prolonged risk
reduction.7;17;53;54;422;423 The repeated provision of information on total CVD risk to
patients appears to reduce predicted risk levels slightly but significantly (by up to 2%
over 10 years in the studies using the Framingham scale).424 This highlights the
importance of a routine, consistent, sustainable, and repeated cardiovascular risk
assessment, which should be incorporated into the healthcare structure and function, as
a part of the general framework for surveillance, monitoring, prevention, and treatment
of chronic non-communicable disease.2;24;44;417
10.4.2. Post-recalibration SCORE “evolution”
Recalibration is an important step in the risk model “evolution”, which reflects the
process of statistical validation – measuring calibration and discrimination of the model
(ideally, in external populations, as addressed in this thesis) and updating the risk
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prediction algorithm, if necessary. While this first step is particularly important for
CEE/FSU countries, due to their high but heterogeneous CVD rates, these populations
also require clinical validation of cardiovascular risk instruments, such as SCORE.
Clinical validation of the risk model involves assessing its uptake by physicians and the
subsequent effects on clinical decisions, outcomes, and treatment cost-effectiveness, in
datasets of adequate size.39;76;350;394;423;425 The clinical impact of “upgrading” SCORE
from a prediction rule to a decision rule should be evaluated in terms of both efficacy
and effectiveness, or, respectively, potential and actual impact.426 As these parameters
can differ substantially across clinical settings even within one country, not to mention
the potential discrepancies between European populations, they need to be thoroughly
investigated in future studies.
Since the SCORE model is expected to guide clinical decisions on the initiation of the
pharmacological primary CVD prevention, it is necessary to investigate its decision
analytic measures, such as the net benefit-plotting decision curves.83;427;428 The
relatively inexpensive and time-saving method of decision-analysis modelling could be
used to simulate both health outcomes (comparative effectiveness modelling) and
economic outcomes (cost-effectiveness modelling), to systematically compare the
efficiency and effectiveness of all preventive strategies across all relevant subgroups,
and to generate actionable information for clinicians and policy-makers. As the quality
of its results depends on how well a simplified model captures the relevant trade-offs,
and how much data are available to base the key model assumptions on422, decision-
analysis modelling also identifies the main areas of uncertainty, which require more
clinical evidence from randomised controlled trials (RCTs) and other studies.86;346;422
Although RCTs are considered the best approach to directly evaluate the health impact
of cardiovascular risk measurement39;348;422;429, thus far they have not demonstrated that
assessing CVD risk substantially changes clinical management, reduces the levels of
individual risk factors and/or total risk, or improves the outcomes.9;31;54;424 This is an
important area for further research, which should first define a conceptual framework
for the impact of total risk assessment and explicitly measure the potential mediators of
outcome improvement. Relevant to both Western and CEE/FSU populations, the key
points to address are: whether clinicians and patients accurately interpret and use risk
scores; how exactly doctors calculate risk levels in clinical practice settings; whether the
presentation of additional information, for example, about specific risk factors, can
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affect the outcomes; and what are the acceptable measures of success in the total CVD
risk assessment.54;350
Preliminary information could be obtained from observational studies, and one such
example is the international collaborative project EURIKA (European Study on
Cardiovascular Risk Prevention and Management in Daily Practice).430-432 It is aimed at
determining the degree of cardiovascular risk factor control in the current clinical
practice across 12 European countries, assessing physicians’ knowledge of and attitudes
towards CVD prevention, and identifying barriers for the implementation of the ESC
guidelines on cardiovascular prevention. EURIKA results are not completely
representative for Europe (e.g., Russia is the only CEE/FSU country included), or even
for the participating countries, and no analysis of the outcome impact is possible due to
cross-sectional design. Nonetheless, it is an important step towards the ambitious goal
of evaluating the risk factor control across the whole spectrum of primary CVD
prevention settings.
10.4.3. Socioeconomic characteristics and hazardous drinking parameters as
cardiovascular risk predictors
Although this thesis did not demonstrate any substantial improvement in SCORE
performance after adding socioeconomic measures or alcohol consumption parameters
to the model, it does not mean that people experiencing socioeconomic disadvantage or
hazardous drinking are not at increased CVD risk in CEE/FSU or elsewhere. As shown
in Section 2.3.2 (Background), the social gradient in cardiovascular risk is only partly
explained by classical risk factors in both Western and CEE/FSU populations. Using
SCORE, or any other scale which excludes socioeconomic characteristics, might
potentially lead to the relative under-treatment of deprived individuals and over-
treatment of their more privileged peers, exacerbating the existing inequalities in
cardiovascular mortality and morbidity.205;258-260;395;433
The analysis of the 15-year follow-up data from the Whitehall Study demonstrated that
when applied population-wide, the so-called best-practice interventions (reducing SBP
by 10 mm Hg, TCH by 2 mmol/l, and blood glucose by 1 mmol/l; halving the
prevalence of Type 2 DM; and achieving complete smoking cessation) could not only
reduce CHD mortality by 57%, but also decrease the mortality difference between high
and low employment grade groups by 69%. Achieving primordial (ideal) levels of risk
factors could reduce coronary mortality and mortality difference by 73% and 86%,
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respectively.434 Of note, such an improvement requires equal implementation and
similar effectiveness of the intervention across socioeconomic groups, which, in turn,
entails comparable accuracy of CVD risk assessment. Therefore, new risk scales which
include socioeconomic characteristics (such as the UK-oriented QRISK/QRISK2 and
ASSIGN) may be more equitable, even if their statistical performance is only
moderately better than that for traditional instruments.106;395;435
Education and marital status are only two of the multitude of socioeconomic parameters
that independently affect cardiovascular risk levels. Adding other measures to the risk
scales, such as SCORE, could, therefore, demonstrate an improvement in the model’s
prognostic performance. While these additional socioeconomic parameters could be
problematic to assess in routine clinical settings, they deserve further investigation, as
they might facilitate better identification of individuals and groups at higher risk, as well
as implementation of complex, multilevel preventive interventions. For example, during
the second wave of the HAPIEE study (2005-2006), a wide range of data on individual
and household income and wealth was collected. In future, this information could be
linked to the cause-specific mortality records and used for a more extensive
modification of the SCORE instrument.
A link between area-level socioeconomic deprivation, operationalized via
unemployment rate and overcrowding, and higher levels of selected cardiovascular risk
factors was demonstrated for Czech HAPIEE participants.436 Although area-level
deprivation could potentially act as an independent predictor of atherosclerotic fatal
CVD in both MONICA and HAPIEE, and its measures are relatively easy to obtain in
some populations (and can potentially be used as a substitute for individual-level
socioeconomic characteristics), it was not assessed in all MONICA samples and most
HAPIEE samples. Moreover, it is known that the impact of the neighbourhood-level
socioeconomic deprivation on cardiovascular risk is relatively small after adjustment for
individual-level socioeconomic characteristics.437-440 Presently, the contextual
socioeconomic predictors of CVD mortality remain understudied for CEE/FSU. This
issue should be addressed by future research, in order to provide the evidence base for
more effective and efficient multilevel policies, practices, and interventions aimed at
cardiovascular risk reduction.
Marital strain, or the level of stress associated with marital factors, appears to be linked
to higher CVD morbidity and mortality, via such physiological mechanisms as
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excessive cardiovascular reactivity, endocrine dysfunction, and immune
disregulation.267;269;271 If unhappy marriage was related to increased cardiovascular risk
in MONICA and HAPIEE participants, it would have weakened the association between
non-married status and CVD mortality. However, only the data on formal categories of
marital status, rather than marital strain levels, were available for MONICA and
HAPIEE. Future studies, employing more detailed assessment of not only marital status
per se, but also its “quality”, might provide a better estimation of the underlying link
between marital status and fatal CVD.
It has been shown that cardiovascular care quality and psychosocial factors are
important and socioeconomically patterned determinants of CVD mortality in
CEE/FSU. Across international MONCA Project centres, coronary treatment scores
partly explained the cross-sectional differences in case fatality and CHD mortality
between CEE/FSU and Western Europe149, as well as the 10-year trends in CHD event
rates and mortality.322 This could be due to the fact that treatment quality not only
influences CVD rates directly, but also reflects a major underlying determinant of
cardiovascular risk – socioeconomic circumstances of individuals and populations.149;441
In addition, it has been demonstrated that psychosocial factors, such as depression,
perceived control, job strain, and hopelessness, are distributed less favourably in
CEE/FSU than in Western Europe, which might be linked to both adverse
socioeconomic characteristics and increased CVD risk (e.g.149;442-447). Since the
availability of the data on cardiovascular care quality and psychosocial factors was
limited for MONICA and HAPIEE samples, these parameters were not analysed in the
thesis. Nonetheless, future studies should also address the possible prognostic value of
these factors as additional predictors in the cardiovascular risk models.
More research is also necessary on alcohol consumption, and hazardous drinking in
particular, in relation to cardiovascular risk in CEE/FSU. Adequately powered future
studies, focusing on the association between various, repeatedly measured
characteristics of drinking amount and patterns (including surrogate/non-beverage
alcohol intake and novel biomarkers200;391;392;448;449), and, possibly, involving CEE/FSU
subpopulations with higher prevalence of hazardous alcohol consumption, might reveal
the role of alcohol as an important component of cardiovascular risk assessment in
specific populations or population groups.
254
In this thesis, the investigation of the simultaneous effects of socioeconomic factors and
hazardous drinking on fatal CVD would not be informative. Such an analysis would be
restricted to HAPIEE samples, since compatible data on alcohol consumption were not
available for all MONICA samples. It would also result in very low outcome numbers
across the subgroups defined by both socioeconomic measures and alcohol consumption
characteristics (Methods, Section 4.5.4). Moreover, the aim of the present study was to
investigate the general possibility of extending SCORE in the CEE/FSU context, and it
first required a separate assessment of selected extra risk determinants, before adding
them to SCORE as a combination. Since neither socioeconomic disadvantage nor
hazardous drinking markedly improved the prognostic performance of the SCORE
model in MONICA and HAPIEE samples, it was highly unlikely that their combination
could achieve this goal. Nevertheless, future studies of adequate power could
demonstrate that SCORE-comprising classical risk factors, socioeconomic measures,
and alcohol consumption parameters might each be significantly associated with CVD
mortality and provide an incremental prognostic value to the cardiovascular risk
assessment model.
Although in this thesis, socioeconomic factors or hazardous drinking did not
substantially improve SCORE performance, it neither denotes their irrelevance for
cardiovascular risk prediction, nor denies the important role of tackling socioeconomic
disadvantage and hazardous alcohol consumption in decreasing the overall burden of
disease and, specifically, CVD burden.241;415 At the same time, socioeconomic
disadvantage and hazardous drinking are important, but not exclusive additional
determinants of total CVD risk. The issue of extending cardiovascular risk scales by
other risk predictors is discussed below.
10.4.4. Other cardiovascular risk predictors
The already extensive and constantly growing panel of cardiovascular risk markers
currently includes: laboratory markers of inflammation, endothelial dysfunction, or
oxidative stress (such as hsCRP, homocysteine, folate, IL-6, vascular and cellular
adhesion molecules, matrix metalloproteinase 1, E-selectin, leptin, and antibodies to
infectious agents – e.g., cytomegalovirus and chlamydia), cardiac injury (troponins),
neurohormonal activation (brain natriuretic peptide, aldosterone), renal injury (cystatin
C, urinary albumin/creatinine ratio), procoagulation (for instance, fibrinogen,
thromboxane A2, D-dimer, plasminogen activator inhibitor type 1), dyslipidaemia
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(lipoprotein (a), apolipoprotein B/apolipoprotein A1 ratio, lipoprotein-associated
phospholipase, small dense LDL, oxidised LDL), and hyperglycaemia (glycated
haemoglobin); genetic biomarkers (such as single nucleotide polymorphisms from
chromosomes 9p21.3, 1p13.3, 2q36.3, or 10q11.21); imaging biomarkers (for example,
coronary calcification or carotid intima-media thickness); vascular function markers
(such as aortic pulse wave velocity, ankle-brachial index, or brachial artery flow-
mediated dilation); and various abnormalities at exercise stress electrocardiography,
stress echocardiography, or stress myocardial perfusion (e.g.26;28-32;40;86;177;450-454).
There have been several attempts to extend the original SCORE model by adding HDL-
CH (overall improvement in AUROC by 0.01; NRI 2%)192, resting heart rate (AUROC
improvement <0.01; NRI 0.3%)193, or markers of subclinical organ damage, such as left
ventricular mass index, atherosclerotic carotid plaques, carotid/femoral pulse wave
velocity, and urine albumin/creatinine ratio (increase in C-statistic 0.02; NRI 9%).194
These studies have demonstrated statistically significant, but modest from a clinical
perspective, changes in the prognostic performance. It should be taken into account that
the more predictors the model includes, the more expensive their measurement, and the
less focused the quality control.10;76;394 Presently, there is no evidence that reducing the
levels of novel risk determinants could effectively reduce total cardiovascular
risk.32;33;180;185
On the other hand, the continuous search for new cardiovascular risk predictors is
justified by the fact that the share of additional risk determinants in the population-
attributable risk of CVD and, hence, their preventive potential is unrestrictedly large.
Given the unlimited number of possible combinations of component causes which
would result in CVD development, the maximal sum of disease fractions attributable to
all the component causes is infinite, as well as the potential number of risk
determinants.8;455 Adding several new predictors to the risk model appears to be more
beneficial for the prognostic performance measures, compared to individual extra risk
determinants. This so-called multiple biomarker, or multimarker, approach supports
extending the model by a number of predictors which reflect different pathogenetic
pathways and, hence, provide additional prognostic information.32-34;41;86;186;456 The
essential condition is that these novel risk markers provide incremental prognostic value
beyond standard risk factors, and/or can assist in the treatment selection, and/or improve
clinical outcomes via altered management.8;31;39;40;75;86;180;188;457 Ultimately, the extended
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instruments need to undergo all the steps of the complex risk scale “evolution” (Section
10.4.2(b)), which must also include test standardisation and validation of population
norms; evaluation of observer bias and reliability; investigation of the model
generalizability to external populations; and assessment of potential harms, costs, and
benefits of additional testing.31;86;346
The most appropriate and cost-effective strategy for applying extended risk models
could be their use for individuals at intermediate risk, since in the traditionally
established low-risk group, even abnormal results of additional testing may not justify
further investigation or treatment. At the same time, in the conventionally identified
high-risk group, even normal results of extra tests could not lead to discontinuation of
preventive treatment.10;13;31;34;39-41;180;188;347 Introduction of an additional “intermediate
risk” category, which has a particular need for collecting extra prognostic information,
to the SCORE instrument could enable a better representation of the well-established
concept of cardiovascular risk continuum, without sacrificing SCORE clarity and user-
friendliness. Potentially, this “grey” category would benefit the most from extending the
original SCORE instrument by additional risk determinants, and may demonstrate not
only statistically, but also clinically significant improvement in the model performance.
The adequate assessment of extended cardiovascular risk models requires large outcome
numbers, in order to achieve adequate EPV values (Section 10.2.5), and large samples
drawn from diverse populations. One of the promising approaches might be the meta-
analysis based on individual participant data (IPD).458-461 Despite numerous logistic and
methodological difficulties, it provides an opportunity to perform data analyses in a
consistent, standardised way, including the data from both published and unpublished
studies. Pooling the information across studies requires extensive data harmonisation,
which is a challenging, but rewarding task, as demonstrated by the example of the
collaborative multidisciplinary DataSHaPER (DataSchema and Harmonization Platform
for Epidemiological Research) Project.462;463 For CEE/FSU countries, it is particularly
important to participate in such collaborations, since they produce valid, generalizable,
and context-relevant results even if the sample sizes of individual studies are
understandably limited.
10.4.5. Lifestyle-oriented CVD risk assessment and risk reduction
The area of cardiovascular risk assessment is currently developing in two opposite, but
complementary directions: the search for more complex models, extended by novel risk
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determinants (see previous section) vs. the simplification of risk scales and
minimisation of risk predictors. Recently, it has been demonstrated that the number of
variables in CVD risk models can be successfully reduced to the core, easily measurable
risk factors, such as age, gender, TCH, SBP, and smoking. For instance, this so-called
low-information approach was proven successful in contemporary Chinese
populations.23 After recalibration, based on the data from non-Chinese Asian cohorts,
discrimination and calibration of the “low-information” Framingham model were
adequate.
The low-information approach can be simplified even further, involving only the
assessment of demographic characteristics (age and gender) and non-laboratory
parameters (such as smoking status, SBP, BMI, waist-to-hip ratio, self-reported DM,
AH, current antihypertensive treatment, or family history). For example, non-laboratory
models have shown satisfactory calibration and discrimination among middle-aged
participants of the Framingham Heart Study and Framingham Offspring Study48,
American men and women participating in the NHANES Follow-up Study464, middle-
aged Finnish men and women465, EPIC-Norfolk Study subjects466, and participants of
the well-known case-control INTERHEART study.467 Moreover, the performance of the
CVD risk algorithms that were derived exclusively from questionnaire data is only
slightly worse than that for the models including data from questionnaires, physical
examination, and blood tests, as demonstrated, for example, for middle-aged
participants of the Norwegian Tromsø Study330, or members of the nine European
cohorts participating in the MORGAM Project.468
These findings are particularly promising for transitional, developing, low and middle-
income countries, including CEE/FSU populations, due to the limited resources of their
healthcare systems.24;52 In all settings, evaluating CVD risk with laboratory-based scales
means the individuals have to return for a fasting blood test, which compromises their
compliance and the potential for risk reduction, while non-laboratory risk assessment
can be performed during the same clinical visit, in 5-10 minutes, using non-invasive
routine procedures.12;156;464 In addition, simplified, non-laboratory CVD risk scales
could be used as a pre-stratification test in the stepwise population screening, prior to
visiting the clinic466;469, and potentially even be self-administered.13
As a clinical reflection of this non-laboratory paradigm, the updated version of
HeartScore, an interactive tool calculating individual SCORE risk levels, features the
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“fast track” calculator which replaces BP and TCH inputs with BMI values. While this
approach might be useful when instrumental measures are not available, it is
recommended only for preliminary risk assessment.139 The comparative prognostic
performance of this simplified algorithm across Western and CEE/FSU populations
deserves to be addressed in future studies, since the relationship between BMI and SBP,
or between BMI and TCH, was demonstrated to be rather different in Russia and
Western Europe.470
The important role of conventional risk factors not only for CVD risk assessment, but
also for risk reduction has been re-emphasized by the INTERHEART study. Across 52
participating countries, only nine potentially modifiable and largely lifestyle-determined
factors (smoking, dyslipidaemia, AH, DM, abdominal obesity, physical activity, diet,
alcohol, and psychosocial stress) explained over 90% of population-attributable risk
(PAR) of the first MI, while four of them – smoking, dyslipidaemia, AH, and DM –
accounted for 76% of PAR.49 Since classical risk factors explain the vast majority of
cardiovascular events across populations, even modest downward shifts in the
population levels of BP, TCH, and smoking prevalence could result in a substantial
reduction of total cardiovascular risk and CVD rates, without additional costs or
increased risk of adverse effects associated with pharmacological risk
management.237;396;471-480
Although pharmacological treatments are important for managing some classical risk
determinants, such as AH, dyslipidaemia, or DM, there is also a need for addressing
lifestyle as the underlying cause, via rebalancing the current research, clinical care, and
health policy priorities. Specifically, more research is needed on the “upstream”
lifestyle risk factors (smoking, obesity, physical inactivity, and unhealthy diet), their
personal and environmental determinants, and effective, early interventions to control
these factors.7;44;475;481-485 The importance of the so-called primordial prevention, or
prevention of risk factors, is highlighted by the fact that patients receiving
antihypertensive, lipid-lowering, and glucose-lowering drugs are still at a higher
cardiovascular risk than people without AH, dyslipidaemia, or DM; moreover, in the
real-world clinical practice, even treated CVD patients often have uncontrolled lifestyle
risk determinants.329;432;472;481;486;487 While lifestyle changes are the cornerstone of
primary prevention, due to their population-wide benefits and minimization of adverse
drug effects, they also provide similar relative impacts in secondary prevention and,
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hence, result in an even greater reduction of absolute risk. In addition, the preventive
programmes promoting healthy lifestyle are able to lower the costs to individuals,
healthcare systems, and societies as a whole.44;471;473;475;480;481;487-490
Targeting classical risk factors in order to reduce CVD risk levels is particularly
important for the CEE/FSU populations, which currently demonstrate the lowest control
rates even among individuals with already developed cardiovascular pathology. For
example, among treated middle-aged outpatients from 12 European countries, examined
in 2009 as a part of the international EURIKA study, Russia had a lower than average
prevalence of achieving target levels of BP (36%), TCH and LDL-CH (24%), glycated
haemoglobin (4%), and BMI (1%).430;431 Therefore, lifestyle interventions in CEE/FSU
populations, such as more effective smoking cessation strategies and advice on healthy
diet, weight reduction, and physical activity, may result in substantially improved
control of total cardiovascular risk.
This thesis has focused on the SCORE risk assessment and identification of individuals
and groups at higher risk. However, this strategy alone is unlikely to substantially
reduce the overall CVD prevalence, since the “low-risk” population, due to its larger
size, will comprise more events.7;40;47;53;197;471;491 At the same time, a substantial
proportion of cardiovascular events occur in patients with established CVD, who should
be the highest priority for comprehensive, aggressive risk management.6;14;418;492;493
Therefore, in order to curb the worldwide CVD epidemic and, in particular, to reduce
the high burden of disease in CEE/FSU populations, a combination of population-level
and high-risk approaches is necessary. The first strategy is targeted at reducing the CVD
incidence, by shifting the distribution of risk factors in the entire population through
community-based interventions. The second strategy aims to identify and treat the
individuals at the highest risk, who gain the most from aggressive risk factor
modification, while low-risk individuals avoid unnecessary
medicalization.4;7;10;13;17;24;52;147;177;197;347;433;471;483;484;494;495
As demonstrated by the widely used IMPACT model of coronary mortality, the recent
CHD decline in developed countries is partly explained by the changes in major risk
factors (approximately 60%), which mostly reflect the population-level risk reduction,
and partly by specific cardiovascular treatments (approximately 40%), which typically
represent the high-risk approach.203;474;475;496;497 To my knowledge, the IMPACT model
has only recently been applied to some CEE/FSU populations, and the preliminary data
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suggest that the relative impact of risk factor reduction and treatment is similar to that in
Western populations. For example, in the Polish adult population, aged 25-74 years,
coronary mortality halved from 1991 to 2005 (over 26,000 fewer CHD deaths), which
was explained by beneficial dynamics in risk factors (54%) and the increased uptake of
cardiovascular treatments (37%).158
The recent modelling studies suggest that both population and high-risk approaches can
be effective for Europe as a whole and for individual CEE/FSU countries. For instance,
in the selected SCORE Project cohorts from the “high-risk” European countries, a 10-
year reduction of TCH levels by 10%, SBP levels by 10%, and smoking prevalence by
10% could save 9,125 lives per million of adult population, while treating all high-risk
individuals with statins, antihypertensive agents, and aspirin would save up to 7,452
lives per million.471 Another modelling study showed that a sustained reduction in the
mean SBP levels by 5 mm Hg, either pharmacological or non-pharmacological, could
avert up to 69.4, 83.4, and 100.7 cardiovascular deaths per 100,000 person-years among
30-69-year-old people from the Czech Republic, Poland, and Lithuania, respectively,
and that the higher the baseline CVD risk in the population, the greater the benefits of
risk reduction.498
Therefore, to effectively reduce the high levels of CVD in CEE/FSU, as well as to avoid
the reversal of declining CVD rates in other countries, the complementary population-
level and high-risk strategies of cardiovascular prevention should be based on robust,
accurate, up-to-date risk prediction instruments, together with the effective control of
conventional, lifestyle-related risk factors and, possibly, novel risk determinants.
10.5. Study implications and conclusions
Cardiovascular risk prediction and reduction is an extensive, multidisciplinary, dynamic
field, with numerous scientific and practical directions for further development. This
section focuses on the research and policy implications of the thesis and outlines how
the data on SCORE performance in CEE/FSU populations could be used for both the
optimisation of cardiovascular risk assessment and the effective management of this
risk, in order to reduce the CVD burden. The conclusion summarises how the key
findings of this thesis help to address the existing gaps in knowledge and to expand the
evidence base of cardiovascular risk assessment.
261
10.5.1. Research implications
This thesis has focused on the prognostic performance of the high-risk SCORE version,
as the use of this scale is recommended for CEE/FSU countries.17;20 It was shown that
the high-risk SCORE was a significant predictor of fatal atherosclerotic CVD in all
MONICA and HAPIEE samples, both before and after the adjustment for
socioeconomic characteristics and hazardous drinking parameters. At the same time, the
high-risk SCORE under-predicted the risk in Russian MONICA participants, and could
over-estimate the risk in Czech and Polish HAPIEE samples. These findings have
several research implications.
First, the high-risk SCORE could be effectively used for the populations of interest
which still face high levels of cardiovascular mortality, such as Russia. However, in the
countries which have experienced a decline in fatal CVD, such as the Czech Republic
and Poland, the low-risk SCORE might be the instrument of choice. A longer-term
solution for the task of further improvement of SCORE performance in the region of
interest should be the recalibration of this scale for respective CEE/FSU populations,
using local levels of cardiovascular mortality and risk factors.139 The possible sources of
information on CVD risk determinants are local epidemiological studies, clinical
practice databases, and national systems of health and disease surveillance.
Second, the next step in the “evolution” of recalibrated SCORE versions should be their
clinical validation, such as the investigation of the scale uptake by health professionals
and the impact on clinical decisions, health outcomes, and healthcare costs. This
research step is especially important for CEE/FSU populations, as they might face
additional barriers to the implementation of cardiovascular risk assessment and its
translation into effective risk reduction.
Third, this thesis did not demonstrate a marked improvement in SCORE performance
after extending the model by socioeconomic parameters or hazardous drinking
characteristics. However, this does not necessarily negate the need for further
investigation of these additional cardiovascular risk factors, which are particularly
relevant to CEE/FSU populations. Future studies may show that other measures of
socioeconomic disadvantage (such as area-level deprivation or individual and household
income and wealth), or hazardous alcohol consumption (for example, surrogate/non-
beverage drinking), when added to SCORE separately or in combination, could be
independently related to the fatal CVD risk and provide incremental prognostic value.
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Fourth, the findings of the thesis stressed the importance of assessing the improvement
in discrimination of extended models, as, for example, IDI values for the extended
SCORE were under 1% across most MONICA and HAPIEE samples. In future, other
novel predictors may provide a clinically significant improvement in the performance of
the expanded SCORE instrument, most likely in people with intermediate risk levels.
New SCORE versions, therefore, may progress from the current “dichotomous”
approach (risk levels ≥5% have been regarded as “increased risk”, which implies that 
levels <5% denote “non-increased risk”) and introduce an intermediate risk category.
Fifth, in the CEE/FSU context, the data on novel risk factors are not routinely collected
in epidemiological studies or in the clinical practice. An alternative is to employ the
“low-information” approach, which uses non-laboratory measurements and self-
reported characteristics for the assessment of cardiovascular risk. Future studies need to
compare the prognostic performance and the cost-effectiveness of the original SCORE
vs. the recently introduced modified SCORE instrument, in which SBP and TCH are
substituted with BMI139, across the CEE/FSU populations.
Finally, the findings of this thesis, consistently with the WHO data on cardiovascular
mortality trends and the results of international and local studies, demonstrate that some
CEE countries, such as the Czech Republic and Poland, have experienced a recent
reduction in fatal CVD rates. The relative impact of the risk factor dynamics and
cardiovascular treatments on this decline should be compared across populations of
interest (for example, using the IMPACT model), in order to identify the context-
specific priorities for both population-level and high-risk strategies of cardiovascular
prevention.
10.5.2. Policy implications
The development of recalibrated local SCORE instruments in CEE/FSU is essential for
improving the accuracy of cardiovascular risk prediction in these populations,
characterised by high but heterogeneous risk levels. This task requires a major shift in
health policy, as the priorities of healthcare systems need to expand from treatment to
prevention. In particular, the adequate assessment and effective management of
cardiovascular risk, which follows the current ESC recommendations17, should be
incorporated into routine clinical practice and supported by sufficient organisational,
educational, and material resources.
263
The availability of an accurate, context-specific SCORE version could increase the
physicians’ uptake of this instrument and their compliance with the clinical guidelines
on CVD prevention, and, hopefully, improve both the clinical effectiveness and the
cost-effectiveness of cardiovascular risk reduction. The real-world performance of
SCORE should be constantly monitored, and health policy decisions should take this
evidence into account.
This thesis has re-emphasised the importance of classical risk factors, captured by
SCORE, for the prediction of cardiovascular risk in CEE/FSU settings. Moreover, these
conventional risk factors and their lifestyle determinants should be the main target of
cardiovascular prevention. Controlling their levels both across whole populations and in
higher-risk groups and individuals (identified with risk assessment instruments, such as
SCORE) will help to reduce the burden of CVD in CEE/FSU.
10.5.3. Conclusions
The global burden of CVD, which remains one of the leading public health problems, is
not evenly distributed. Some countries, such as CEE/FSU states, face particularly high
albeit heterogeneous levels of cardiovascular mortality, morbidity, and disability. To
address this problem, future CVD cases should be prevented via accurate assessment of
cardiovascular risk and its effective management, with a specific focus on individuals
and groups at higher risk. The risk scale which is officially recommended by the ESC
for the use in CEE/FSU populations is the high-risk SCORE version. However, this
instrument, which was developed without using any local data, has not been properly
recalibrated to local settings, and thus far, its prognostic performance has not been
investigated in the region of interest. Moreover, the SCORE-comprising classical risk
factors are important, but not exclusive, determinants of cardiovascular risk. Previous
attempts to expand the SCORE model did not employ socioeconomic parameters or
hazardous drinking, as additional determinants of cardiovascular risk which might be
particularly important in CEE/FSU settings.
In order to address these gaps, the thesis used prospective individual-level data from
Czech, Polish, Lithuanian, and Russian samples of two large international studies,
MONICA and HAPIEE. It was shown that the high-risk SCORE was a significant,
independent predictor of fatal atherosclerotic CVD both across individual study-,
country-, and gender-specific samples and in random-effects meta-analyses. While this
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SCORE version demonstrated satisfactory discrimination in most MONICA and
HAPIEE samples, it substantially under-predicted the 10-year risk of CVD death in
Russian MONICA. In HAPIEE, 10-year calibration estimates suggested that the high-
risk SCORE could adequately reflect the risk in contemporary Russian settings,
although the low-risk SCORE might be better fitted for Czech and Polish populations.
SCORE extension by socioeconomic characteristics or hazardous drinking parameters
did not substantially improve the prognostic performance of the model in MONICA and
HAPIEE.
These findings demonstrate that, in order to optimise cardiovascular risk prediction in
CEE/FSU populations, SCORE should be recalibrated to local settings, which will
better reflect recent heterogeneous trends in fatal CVD across the region of interest.
Accurate cardiovascular risk assessment and effective risk management should be
incorporated into routine clinical practice and established as one of the priorities of
healthcare systems. While the search for novel risk predictors should continue,
preventive measures need to be focused primarily on conventional, lifestyle-determined
risk factors. As demonstrated by a steady decline in cardiovascular mortality rates
across most Western populations over the last 50 years and, more recently, by the
positive dynamic of CVD trends in the Czech Republic and Poland, the task of reducing
CVD burden in CEE and particularly FSU is challenging but nonetheless feasible.
265
Addendum
As this thesis went to press (May 2012), the Fifth Joint Task Force of the European
Society of Cardiology and other societies published the latest guidelines on CVD
prevention in clinical practice.499 The references to the current CVD prevention
guidelines throughout the thesis reflect the information presented in the respective 2007
document by the Fourth Joint Task Force.17
The major updates in the newest guidelines499 include modifications to the list of high
and low-risk European countries. In particular, while the high-risk SCORE version is
still recommended for the Czech Republic and Poland, it is now expected to under-
estimate the risk in Russia and Lithuania, which have become “very-high-risk
countries”. However, no SCORE modification for the populations at very high risk is
presented, and no evidence supporting this division of CEE and FSU countries is given,
apart from the 2008 national rates of CVD and DM mortality. At the same time, the
differentiation of CEE/FSU populations in terms of background risk levels (and, hence,
the locally appropriate SCORE versions) agrees with the findings of this thesis.
The change in SCORE calibration over time, demonstrated for MONICA vs. HAPIEE
samples, is consistent with the fact that the 2012 guidelines no longer consider countries
such as Austria, Germany, Iceland, the Netherlands, or Norway as “high-risk”. This also
confirms that it is feasible to reduce the CVD burden in a relatively short period and
across different populations.
Finally, one of the research implications of this thesis – the assessment of extra risk
factors in the intermediate risk group – is mirrored in the new recommendations which
suggest the measurement of novel biomarkers and the employment of cardiovascular
imaging methods among asymptomatic adults at “moderate risk” (SCORE levels ≥1% 
and <5%).
Therefore, the results of the present research, obtained and summarised prior to May
2012, should be regarded as generally consistent with the latest European guidelines on
CVD prevention.
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Appendix I. SCORE-predicted 10-year risk of fatal CVD in populations at high and low CVD risk
Table A4.3.1. SCORE-predicted 10-year risk of fatal CVD in populations at high CVD risk17;20
Age,
years
SBP
(mm
Hg)
Women Men
Non-smoker Smoker Non-smoker Smoker
TCH (mmol/l) TCH (mmol/l) TCH (mmol/l) TCH (mmol/l)
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
65 180 7 8 9 10 12 13 15 17 19 22 14 16 19 22 26 26 30 35 41 47
160 5 5 6 7 8 9 10 12 13 16 9 11 13 15 16 18 21 25 29 34
140 3 3 4 5 6 6 7 8 9 11 6 8 9 11 13 13 15 17 20 24
120 2 2 3 3 4 4 5 5 6 7 4 5 6 7 9 9 10 12 14 17
60 180 4 4 5 6 7 8 9 10 11 13 9 11 13 15 18 18 21 24 28 33
160 3 3 3 4 5 5 6 7 8 9 6 7 9 10 12 12 14 17 20 24
140 2 2 2 3 3 3 4 5 5 6 4 5 6 7 9 8 10 12 14 17
120 1 1 2 2 2 2 3 3 4 4 3 3 4 5 6 6 7 8 10 12
55 180 2 2 3 3 4 4 5 5 6 7 6 7 8 10 12 12 13 16 19 22
160 1 2 2 2 3 3 3 4 4 5 4 5 6 7 8 8 9 11 13 16
140 1 1 1 1 2 2 2 2 3 3 3 3 4 5 6 5 6 8 9 11
120 1 1 1 1 1 1 1 2 2 2 2 2 3 3 4 4 4 5 6 8
50 180 1 1 1 2 2 2 2 3 3 4 4 4 5 6 7 7 8 10 12 14
160 1 1 1 1 1 1 2 2 2 3 2 3 3 4 5 5 6 7 8 10
140 0 1 1 1 1 1 1 1 1 2 2 2 2 3 3 3 4 5 6 7
120 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3 4 5
40 180 0 0 0 0 0 0 0 0 1 1 1 1 1 2 2 2 2 3 3 4
160 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 2 2 2 3
140 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 2 2
120 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1
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Table A4.3.2. SCORE-predicted 10-year risk of fatal CVD in populations at low CVD risk17;20
Age,
years
SBP
(mm
Hg)
Women Men
Non-smoker Smoker Non-smoker Smoker
TCH (mmol/l) TCH (mmol/l) TCH (mmol/l) TCH (mmol/l)
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
65 180 4 5 6 6 7 9 9 11 12 14 8 9 10 12 14 15 17 20 23 26
160 3 3 4 4 5 6 6 7 8 10 5 6 7 8 10 10 12 14 16 19
140 2 2 2 3 3 4 4 5 6 7 4 4 5 6 7 7 8 9 11 13
120 1 1 2 2 2 3 3 3 4 4 2 3 3 4 5 5 5 6 8 9
60 180 3 3 3 4 4 5 5 6 7 8 5 6 7 8 9 10 11 13 15 18
160 2 2 2 2 3 3 4 4 5 5 3 4 5 5 6 7 8 9 11 13
140 1 1 1 2 2 2 2 3 3 4 2 3 3 4 4 5 5 6 7 9
120 1 1 1 1 1 1 2 2 2 3 2 2 2 3 3 3 4 4 5 6
55 180 1 1 2 2 2 3 3 3 4 4 3 4 4 5 6 6 7 8 10 12
160 1 1 1 1 1 2 2 2 3 3 2 2 3 3 4 4 5 6 7 8
140 1 1 1 1 1 1 1 1 2 2 1 2 2 2 3 3 3 4 5 6
120 0 0 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3 4
50 180 1 1 1 1 1 1 1 2 2 2 2 2 3 3 4 4 4 5 6 7
160 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3 4 5
140 0 0 0 0 0 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3
120 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 2 2 2
40 180 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 2 2
160 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
140 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1
120 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
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APPENDIX II. SCORE performance in MONICA and HAPIEE: additional tables and figures
Table A6.1.1. Dichotomous and continuous low-risk SCORE and 10-year atherosclerotic CVD mortality in MONICA men and women:
hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
4.29 (2.13-8.63) 4.76 (3.12-7.27) 3.76 (2.28-6.20) 2.45 (1.42-4.24) 3.04 (2.25-4.10)
Continuous SCORE
(per 1% increase)
1.16 (1.11-1.22) 1.18 (1.13-1.23) 1.20 (1.14-1.26) 1.15 (1.08-1.23) 1.20 (1.17-1.24)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
too few observations 5.19 (1.75-15.43) too few observations too few observations 6.30 (3.26-12.17)
Continuous SCORE
(per 1% increase)
1.39 (1.09-1.76) 1.34 (1.15-1.55) 1.54 (1.24-1.93) 1.47 (1.28-1.69) 1.56 (1.44-1.70)
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Table A6.1.2. Dichotomous and continuous high-risk SCORE and 10-year atherosclerotic CVD mortality in MONICA men and women:
hazard ratios and 95% confidence intervals obtained by standard Cox analysis (1st line), competing-risks Cox analysis (2nd line),
and Weibull analysis (3rd line)
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
5.32 (2.30-12.30)
5.00 (2.16-11.54)
5.33 (2.30-12.32)
4.50 (2.68-7.56)
4.24 (2.52-7.13)
4.50 (2.67-7.56)
3.06 (1.77-5.29)
3.00 (1.73-5.19)
3.06 (1.77-5.29)
3.99 (2.24-7.10)
3.79 (2.13-6.73)
3.97 (2.23-7.06)
2.66 (1.96-3.62)
2.54 (1.87-3.45)
2.66 (1.96-3.62)
Continuous SCORE
(per 1% increase)
1.09 (1.06-1.12)
1.09 (1.06-1.12)
1.09 (1.06-1.12)
1.10 (1.07-1.12)
1.09 (1.07-1.12)
1.10 (1.07-1.12)
1.11 (1.08-1.14)
1.11 (1.07-1.14)
1.11 (1.08-1.14)
1.08 (1.05-1.12)
1.08 (1.05-1.11)
1.08 (1.05-1.12)
1.11 (1.09-1.13)
1.11 (1.09-1.12)
1.11 (1.09-1.13)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
5.02 (1.64-15.36)
4.98 (1.63-15.15)
5.06 (1.66-15.47)
1.70 (0.57-5.06)
1.65 (0.55-4.90)
1.71 (0.58-5.08)
4.15 (1.49-11.52)
3.97 (1.43-11.01)
4.15 (1.49-11.52)
5.07 (2.20-11.66)
4.94 (2.15-11.33)
5.02 (2.18-11.54)
6.32 (4.08-9.79)
6.14 (3.97-9.50)
6.30 (4.07-9.76)
Continuous SCORE
(per 1% increase)
1.23 (1.06-1.43)
1.23 (1.11-1.36)
1.23 (1.06-1.43)
1.21 (1.10-1.33)
1.20 (1.10-1.32)
1.21 (1.10-1.33)
1.33 (1.16-1.53)
1.32 (1.21-1.45)
1.33 (1.16-1.53)
1.27 (1.16-1.39)
1.27 (1.19-1.37)
1.27 (1.16-1.39)
1.34 (1.27-1.41)
1.33 (1.27-1.41)
1.34 (1.27-1.41)
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Table A6.1.3. Dichotomous and continuous low-risk SCORE and 10-year atherosclerotic CVD mortality in MONICA men and women:
hazard ratios and 95% confidence intervals obtained by standard Cox analysis (1st line), competing-risks Cox analysis (2nd line),
and Weibull analysis (3rd line)
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
4.29 (2.13-8.63)
3.97 (1.98-7.97)
4.30 (2.14-8.64)
4.76 (3.12-7.27)
4.31 (2.82-6.57)
4.76 (3.12-7.27)
3.76 (2.28-6.20)
3.63 (2.20-5.98)
3.77 (2.28-6.21)
2.45 (1.42-4.24)
2.34 (1.35-4.05)
2.44 (1.41-4.21)
3.04 (2.25-4.10)
2.87 (2.13-3.87)
3.04 (2.26-4.10)
Continuous SCORE
(per 1% increase)
1.16 (1.11-1.22)
1.16 (1.10-1.22)
1.16 (1.11-1.22)
1.18 (1.13-1.23)
1.17 (1.13-1.22)
1.18 (1.13-1.23)
1.20 (1.14-1.26)
1.20 (1.13-1.26)
1.20 (1.14-1.26)
1.15 (1.08-1.23)
1.14 (1.09-1.20)
1.15 (1.08-1.22)
1.20 (1.17-1.24)
1.20 (1.16-1.23)
1.20 (1.17-1.24)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
too few observations 5.19 (1.75-15.43)
5.06 (1.70-15.07)
5.22 (1.76-15.51)
too few observations too few observations 6.30 (3.26-12.17)
6.16 (3.23-11.76)
6.29 (3.25-12.16)
Continuous SCORE
(per 1% increase)
1.39 (1.09-1.76)
1.39 (1.19-1.62)
1.39 (1.09-1.76)
1.34 (1.15-1.55)
1.33 (1.15-1.53)
1.34 (1.15-1.55)
1.54 (1.24-1.93)
1.53 (1.33-1.76)
1.54 (1.24-1.93)
1.47 (1.28-1.69)
1.47 (1.31-1.65)
1.47 (1.28-1.69)
1.56 (1.44-1.70)
1.55 (1.42-1.69)
1.56 (1.44-1.70)
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Table A6.1.4. Dichotomous and continuous low-risk SCORE and atherosclerotic CVD
mortality in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
6.55 (3.09-13.88) 3.24 (1.64-6.42) 5.52 (3.45-8.84)
Continuous SCORE
(per 1% increase)
1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
2.39 (0.55-10.33) 9.15 (3.18-26.33) 6.91 (3.75-12.74)
Continuous SCORE
(per 1% increase)
1.34 (1.11-1.62) 1.56 (1.38-1.76) 1.56 (1.40-1.73)
Table A6.1.5. Dichotomous and continuous high-risk SCORE and atherosclerotic CVD
mortality in HAPIEE men and women: hazard ratios and 95% confidence intervals
obtained by standard Cox analysis (1st line), competing-risks Cox analysis (2nd line),
and Weibull analysis (3rd line)
Czech Republic Poland Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
10.51 (2.53-43.71)
10.35 (2.49-43.09)
10.52 (2.53-43.73)
2.56 (1.11-5.87)
2.50 (1.09-5.74)
2.55 (1.11-5.86)
7.63 (3.35-17.40)
7.50 (3.30-17.08)
7.61 (3.34-17.34)
Continuous SCORE
(per 1% increase)
1.10 (1.07-1.13)
1.10 (1.07-1.12)
1.10 (1.07-1.13)
1.10 (1.06-1.13)
1.10 (1.07-1.13)
1.10 (1.06-1.13)
1.08 (1.06-1.10)
1.08 (1.06-1.09)
1.08 (1.06-1.10)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
3.59 (1.44-8.91)
3.56 (1.44-8.84)
3.57 (1.44-8.88)
8.79 (3.19-24.18)
8.67 (3.15-23.83)
8.79 (3.20-24.19)
7.36 (3.77-14.38)
7.34 (3.75-14.35)
7.49 (3.83-14.62)
Continuous SCORE
(per 1% increase)
1.20 (1.06-1.35)
1.20 (1.10-1.30)
1.20 (1.06-1.35)
1.32 (1.22-1.43)
1.32 (1.24-1.41)
1.32 (1.22-1.43)
1.32 (1.24-1.41)
1.32 (1.24-1.41)
1.32 (1.24-1.42)
Table A6.1.6. Dichotomous and continuous low-risk SCORE and atherosclerotic CVD
mortality in HAPIEE men and women: hazard ratios and 95% confidence intervals
obtained by standard Cox analysis (1st line), competing-risks Cox analysis (2nd line),
and Weibull analysis (3rd line)
Czech Republic Poland Russia
Men
Dichotomous SCORE
(≥5% vs. <5%) 
6.55 (3.09-13.88)
6.43 (3.04-13.63)
6.56 (3.09-13.89)
3.24 (1.64-6.42)
3.16 (1.60-6.25)
3.24 (1.64-6.42)
5.52 (3.45-8.84)
5.41 (3.38-8.66)
5.50 (3.44-8.80)
Continuous SCORE
(per 1% increase)
1.19 (1.13-1.25)
1.18 (1.14-1.23)
1.19 (1.13-1.25)
1.18 (1.12-1.25)
1.18 (1.12-1.24)
1.18 (1.12-1.25)
1.14 (1.11-1.18)
1.14 (1.11-1.17)
1.14 (1.11-1.18)
Women
Dichotomous SCORE
(≥5% vs. <5%) 
2.39 (0.55-10.33)
2.36 (0.55-10.25)
2.36 (0.55-10.21)
9.15 (3.18-26.33)
8.97 (3.12-25.80)
9.19 (3.19-26.44)
6.91 (3.75-12.74)
6.90 (3.74-12.74)
6.99 (3.79-12.88)
Continuous SCORE
(per 1% increase)
1.34 (1.11-1.62)
1.34 (1.17-1.53)
1.34 (1.11-1.62)
1.56 (1.38-1.76)
1.55 (1.41-1.71)
1.55 (1.38-1.75)
1.56 (1.40-1.73)
1.55 (1.40-1.72)
1.56 (1.41-1.74)
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Table A6.2.1. Predicted (P) by low-risk SCORE and observed (O) 10-year atherosclerotic CVD mortality by age groups
and SCORE level in MONICA men
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
P O P/O P O P/O P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole
sample
2.71
(3.06)
N=17.2
5.03
N=32
0.54 3.00
(3.04)
N=37.6
6.68
N=86
0.45 2.82
(2.63)
N=35.7
4.89
N=62
0.58 2.58
(2.69)
N=42.6
3.51
N=58
0.74 2.78
(2.69)
N=71.6
7.03
N=181
0.40
Age groups, years
40-44.9 0.42
(0.51)
N=0.7
1.16
N=2
0.36 0.39
(0.50)
N=1.1
3.32
N=9
0.12 0.39
(0.51)
N=0.9
2.71
N=6
0.14 0.30
(0.46)
N=1.2
1.02
N=4
0.29 0.33
(0.47)
N=1.5
3.96
N=18
0.08
45-49.9 1.94
(1.12)
N=2.8
4.20
N=6
0.46 1.87
(1.00)
N=4.9
3.85
N=10
0.49 1.74
(0.88)
N=4.6
2.28
N=6
0.76 1.61
(0.96)
N=5.1
1.57
N=5
1.03 1.68
(0.91)
N=9.8
4.12
N=24
0.41
50-54.9 2.72
(1.74)
N=3.7
5.22
N=7
0.52 2.56
(1.75)
N=6.4
5.98
N=15
0.43 2.42
(1.60)
N=6.6
5.47
N=15
0.44 2.10
(1.39)
N=6.3
2.68
N=8
0.78 2.28
(1.45)
N=12.2
6.92
N=37
0.33
55-59.9 4.19
(2.65)
N=4.2
4.95
N=5
0.85 4.44
(2.52)
N=12.5
9.57
N=27
0.46 3.83
(2.34)
N=11.3
5.78
N=17
0.66 3.88
(2.49)
N=14.7
6.08
N=23
0.64 3.94
(2.40)
N=23.5
7.55
N=45
0.52
60-64.9 6.84
(4.79)
N=5.9
13.95
N=12
0.49 6.73
(4.15)
N=12.7
13.23
N=25
0.51 5.76
(3.31)
N=12.4
8.37
N=18
0.69 5.83
(3.27)
N=15.3
6.87
N=18
0.85 6.06
(3.40)
N=24.7
14.00
N=57
0.43
SCORE level
<5% 1.65
(1.23)
N=8.7
3.42
N=18
0.48 1.74
(1.23)
N=17.1
4.17
N=41
0.42 1.81
(1.19)
N=18.6
3.31
N=34
0.55 1.59
(1.23)
N=21.7
2.86
N=39
0.56 1.73
(1.17)
N=36.1
2.86
N=39
0.61
≥5% 7.84 
(3.95)
N=8.6
12.84
N=14
0.61 7.59
(3.25)
N=20.4
16.73
N=45
0.45 7.12
(2.72)
N=17.2
11.62
N=28
0.61 7.24
(2.81)
N=20.9
6.62
N=19
1.09 7.24
(2.72)
N=35.6
6.62
N=19
1.09
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Table A6.2.2. Predicted (P) by low-risk SCORE and observed (O) 10-year atherosclerotic CVD mortality by age groups
and SCORE level in MONICA women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
P O P/O P O P/O P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole
sample
0.99
(1.34)
N=7.0
1.85
N=13
0.54 1.13
(1.58)
N=13.0
1.82
N=21
0.62 0.97
(1.26)
N=14.2
1.30
N=19
0.75 0.88
(1.25)
N=14.5
1.58
N=26
0.56 0.92
(1.29)
N=24.6
3.21
N=86
0.29
Age groups, years
40-44.9 0.00
(0.00)
N=0.0
0.59
N=1
N/A 0.00
(0.00)
N=0.0
0.00
N=0
N/A 0.00
(0.00)
N=0.0
0.37
N=1
N/A 0.00
(0.00)
N=0.0
0.25
N=1
N/A 0.00
(0.00)
N=0.0
0.38
N=2
N/A
45-49.9 0.33
(0.51)
N=0.6
0.00
N=0
N/A 0.27
(0.47)
N=0.7
2.01
N=5
0.13 0.25
(0.44)
N=0.8
0.32
N=1
0.78 0.17
(0.39)
N=0.6
0.29
N=1
0.59 0.12
(0.32)
N=0.7
2.04
N=12
0.06
50-54.9 0.80
(0.61)
N=1.0
2.42
N=3
0.33 0.83
(0.83)
N=2.0
0.00
N=0
N/A 0.63
(0.56)
N=2.0
0.32
N=1
1.97 0.64
(0.59)
N=2.1
0.62
N=2
1.03 0.60
(0.56)
N=3.4
1.61
N=9
0.37
55-59.9 1.61
(0.97)
N=2.1
3.13
N=4
0.51 1.87
(1.21)
N=4.5
3.33
N=8
0.56 1.51
(0.94)
N=4.7
3.25
N=10
0.47 1.54
(0.87)
N=4.9
2.82
N=9
0.55 1.43
(0.86)
N=7.9
4.74
N=26
0.30
60-64.9 3.07
(1.66)
N=3.3
4.63
N=5
0.66 3.31
(2.16)
N=5.8
4.55
N=8
0.73 2.63
(1.57)
N=6.8
2.33
N=6
1.13 2.73
(1.59)
N=7.0
5.10
N=13
0.54 2.77
(1.63)
N=12.8
8.01
N=37
0.35
SCORE level
<5% 0.87
(1.08)
N=6.0
1.89
N=13
0.46 0.88
(1.08)
N=9.7
1.55
N=17
0.57 0.84
(1.00)
N=12.0
1.33
N=19
0.63 0.79
(1.03)
N=12.8
1.60
N=26
0.49 0.80
(1.03)
N=20.9
2.90
N=76
0.28
≥5% 6.19 
(1.28)
N=1.0
0.00
N=0
N/A 6.25
(1.71)
N=3.3
7.55
N=4
0.83 5.68
(0.58)
N=2.2
0.00
N=0
N/A 6.14
(1.35)
N=1.7
0.00
N=0
N/A 6.12
(0.97)
N=3.6
16.95
N=10
0.36
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Table A6.2.3. Predicted (P) by low-risk SCORE and observed (O) atherosclerotic CVD mortality by age groups
and SCORE level in HAPIEE men
Czech Republic Poland Russia
P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole sample 4.00 (3.32)
N=106.4
1.39
N=37
2.88 3.92 (3.26)
N=135.5
0.98
N=34
4.00 4.84 (4.07)
N=157.1
3.23
N=105
1.50
Age groups, years
<50 1.56 (0.87)
N=7.2
0.22
N=1
7.09 1.64 (0.97)
N=11.6
0.28
N=2
5.86 1.78 (0.96)
N=10.9
0.65
N=4
2.74
50-54.9 2.10 (1.36)
N=11.0
0.38
N=2
5.53 2.16 (1.49)
N=16.2
0.93
N=7
2.32 2.52 (1.66)
N=17.4
1.59
N=11
1.59
55-59.9 3.41 (2.18)
N=18.8
1.63
N=9
2.09 3.68 (2.23)
N=27.2
0.81
N=6
4.54 4.38 (2.80)
N=30.7
3.14
N=22
1.40
60-64.9 5.53 (3.48)
N=31.7
2.09
N=12
2.65 5.68 (3.28)
N=36.0
0.79
N=5
7.19 7.43 (4.35)
N=43.9
4.06
N=24
1.83
65 6.82 (3.78)
N=37.7
2.35
N=13
2.90 7.11 (3.91)
N=44.7
2.23
N=14
3.19 8.31 (4.50)
N=54.0
6.77
N=44
1.23
SCORE level
<5% 2.21 (1.09)
N=39.4
0.51
N=9
4.33 2.20 (1.08)
N=52.2
0.59
N=14
3.73 2.26 (1.01)
N=43.4
1.14
N=22
1.98
≥5% 7.64 (3.35) 
N=67.0
3.19
N=28
2.40 7.71 (3.25)
N=83.5
1.85
N=20
4.17 8.58 (3.93)
N=113.6
6.27
N=83
1.37
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Table A6.2.4. Predicted (P) by low-risk SCORE and observed (O) atherosclerotic CVD mortality by age groups
and SCORE level in HAPIEE women
Czech Republic Poland Russia
P O P/O P O P/O P O P/O
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Whole sample 1.46 (1.54)
N=49.0
0.57
N=19
2.56 1.39 (1.56)
N=52.2
0.43
N=16
3.23 1.77 (1.83)
N=71.6
1.04
N=42
1.70
Age groups, years
<50 0.17 (0.39)
N=1.1
0.00
N=0
N/A 0.17 (0.39)
N=1.5
0.23
N=2
0.74 0.20 (0.41)
N=1.7
0.12
N=1
1.67
50-54.9 0.55 (0.58)
N=3.9
0.28
N=2
1.96 0.56 (0.61)
N=4.9
0.11
N=1
5.09 0.66 (0.62)
N=5.6
0.36
N=3
1.83
55-59.9 1.27 (0.87)
N=7.8
0.33
N=2
3.85 1.34 (0.87)
N=10.4
0.26
N=2
5.15 1.45 (0.88)
N=12.8
0.23
N=2
6.30
60-64.9 2.28 (1.50)
N=18.2
0.75
N=6
3.04 2.47 (1.48)
N=16.4
0.30
N=2
8.23 3.11 (1.77)
N=21.6
1.44
N=10
2.16
65 3.09 (1.66)
N=18.0
1.55
N=9
1.99 3.28 (1.84)
N=19.1
1.55
N=9
2.12 3.76 (1.81)
N=29.9
3.27
N=26
1.15
SCORE level
<5% 1.22 (1.13)
N=39.0
0.53
N=17
2.30 1.15 (1.12)
N=41.1
0.31
N=11
3.71 1.31 (1.20)
N=47.9
0.66
N=24
1.99
≥5% 6.09 (1.25) 
N=9.9
1.23
N=2
4.95 6.12 (1.44)
N=11.2
2.73
N=5
2.24 6.05 (0.96)
N=23.4
4.65
N=18
1.30
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Table A6.3.1. Estimation of 10-year atherosclerotic CVD mortality in HAPIEE men
and women, based on the exponential survival model
Czech Republic Poland Russia
Men Women Men Women Men Women
Observed HAPIEE
deaths, N (%)
37
(1.39)
19
(0.57)
34
(0.98)
16
(0.43)
105
(3.23)
42
(1.04)
Current mean
HAPIEE follow-up,
complete years
6 5 4
Estimated HAPIEE
deaths in 10 years,
N (%)
61.4
(2.31)
31.9
(0.95)
67.4
(1.95)
32.3
(0.86)
255.8
(7.88)
104.3
(2.58)
Table A6.3.2. Predicted (P) by high-risk SCORE and exponentially estimated (E)
atherosclerotic CVD mortality in HAPIEE men and women
Czech Republic Poland Russia
P E P/E P E P/E P E P/E
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Men 7.51
(5.99)
N=199.7
2.31
N=61.4
3.25 7.37
(5.89)
N=254.7
1.95
N=67.4
3.78 9.07
(7.27)
N=294.4
7.88
N=255.8
1.15
Women 2.53
(2.39)
N=85.0
0.95
N=31.9
2.66 2.45
(2.41)
N=92.0
0.86
N=32.3
2.85 3.08
(2.90)
N=124.6
2.58
N=104.3
1.19
Table A6.3.3. Predicted (P) by low-risk SCORE and exponentially estimated (E)
atherosclerotic CVD mortality in HAPIEE men and women
Czech Republic Poland Russia
P E P/E P E P/E P E P/E
%(SD),N %,N %(SD),N %,N %(SD),N %,N
Men 4.00
(3.32)
N=106.4
2.31
N=61.4
1.73 3.92
(3.26)
N=135.5
1.95
N=67.4
2.01 4.84
(4.07)
N=157.1
7.88
N=255.8
0.61
Women 1.46
(1.54)
N=49.0
0.95
N=31.9
1.54 1.39
(1.56)
N=52.2
0.86
N=32.3
1.62 1.77
(1.83)
N=71.6
2.58
N=104.3
0.69
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Table A6.4.1. Discrimination characteristics of the 5% cut-off for low-risk SCORE predicting 10-year atherosclerotic CVD mortality
in MONICA men and women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Sensitivity 14/32=0.4375 45/86=0.5233 28/62=0.4516 19/58=0.3276 71/181=0.3923
Specificity 509/604=0.8427 943/1167=0.8081 992/1205=0.8232 1324/1593=0.8311 1974/2395=0.8242
LR+
(sensitivity/
1-specificity)
43.75/15.73=2.78 52.33/19.19=2.73 45.16/17.68=2.55 32.76/16.89=1.94 39.23/17.58=2.23
LR-
((1-sensitivity)/
specificity)
56.25/84.27=0.67 47.67/80.81=0.59 54.84/82.32=0.67 67.24/83.11=0.81 60.77/82.42=0.74
PPV 14/109=0.1284 45/269=0.1673 28/241=0.1162 19/288=0.0660 71/492=0.1443
NPV 509/527=0.9658 943/984=0.9583 992/1026=0.9669 1324/1363=0.9714 1974/2084=0.9472
AUROC (95% CI) 0.64 (0.55-0.73) 0.67 (0.61-0.72) 0.64 (0.57-0.70) 0.58 (0.52-0.64) 0.61 (0.57-0.65)
Harrell’s C 0.6429 0.6680 0.6341 0.5797 0.6084
Women
Sensitivity 0/13=0 4/21=0.1905 0/19=0 0/26=0 10/86=0.1163
Specificity 675/691=0.9769 1081/1130=0.9566 1405/1443=0.9737 1596/1624=0.9828 2542/2591=0.9811
LR+
(sensitivity/
1-specificity)
0/2.31=0 19.05/4.34=4.39 0/2.63=0 0/1.72=0 11.63/1.89=6.15
LR-
((1-sensitivity)/
specificity)
100.00/97.69=1.02 80.95/95.66=0.85 100.00/97.37=1.03 100.00/98.28=1.02 88.37/98.11=0.90
PPV 0/16=0 4/53=0.0755 0/38=0 0/28=0 10/59=0.1695
NPV 675/688=0.9811 1081/1098=0.9845 1405/1424=0.9867 1596/1622=0.9840 2542/2618=0.9710
AUROC (95% CI) 0.49 (0.48-0.49) 0.57 (0.49-0.66) 0.49 (0.48-0.49) 0.49 (0.49-0.50) 0.55 (0.52-0.58)
Harrell’s C 0.5115 0.5745 0.5122 0.5086 0.5474
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Table A6.4.2. Discrimination of low-risk SCORE estimated by Royston’s R2 in MONICA men and women
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Dichotomous
SCORE
0.2432
(0.0319, 0.5382)
0.3100
(0.1513, 0.4812)
0.2163
(0.0650, 0.4120)
0.0830
(0.0000, 0.2606)*
0.1503
(0.0716, 0.2504)
Continuous
SCORE
0.3442
(0.1148, 0.6315)
0.2896
(0.1562, 0.4498)
0.2777
(0.1289, 0.4794)
0.1382
(0.0403, 0.2805)
0.2666
(0.1638, 0.3850)
Women
Dichotomous
SCORE
0.0185
(0.0000, 0.0057)*
0.1448
(0.0000, 0.5332)*
0.0021
(0.0000, 0.0132)*
0.0023
(0.0000, 0.0074)*
0.1246
(0.0179, 0.2905)
Continuous
SCORE
0.1858
(0.0000, 0.4919)*
0.2407
(0.0000, 0.6219)*
0.2988
(0.0835, 0.5617)
0.3393
(0.1672, 0.5511)
0.4339
(0.2809, 0.5914)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A6.4.3. Discrimination characteristics of the 5% cut-off for low-risk SCORE predicting atherosclerotic CVD mortality
in HAPIEE men and women
Czech Republic Poland Russia
Men
Sensitivity 28/37=0.7568 20/34=0.5882 83/105=0.7905
Specificity 1773/2622=0.6762 2359/3422=0.6894 1900/3141=0.6049
LR+ (sensitivity/1-specificity) 75.68/32.38=2.34 58.82/31.06=1.89 79.05/39.51=2.00
LR- ((1-sensitivity)/specificity) 24.32/67.62=0.36 41.18/68.94=0.60 20.95/60.49=0.35
PPV 28/877=0.0319 20/1083=0.0185 83/1324=0.0627
NPV 1773/1782=0.9950 2359/2373=0.9941 1900/1922=0.9886
AUROC (95% CI) 0.72 (0.65-0.79) 0.64 (0.56-0.72) 0.70 (0.66-0.74)
Harrell’s C 0.7178 0.6446 0.6925
Women
Sensitivity 2/19=0.1053 5/16=0.3125 18/42=0.4286
Specificity 3180/3340=0.9521 3559/3737=0.9524 3633/4002=0.9078
LR+ (sensitivity/1-specificity) 10.53/4.79=2.20 31.25/4.76=6.57 42.86/9.22=4.65
LR- ((1-sensitivity)/specificity) 89.47/95.21=0.94 68.75/95.24=0.72 57.14/90.78=0.63
PPV 2/162=0.0124 5/183=0.0273 18/387=0.0465
NPV 3180/3197=0.9947 3559/3570=0.9969 3633/3657=0.9934
AUROC (95% CI) 0.53 (0.46-0.60) 0.63 (0.52-0.75) 0.67 (0.59-0.74)
Harrell’s C 0.5192 0.6415 0.6656
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Table A6.4.4. Discrimination of low-risk SCORE estimated by Royston’s R2 in HAPIEE men and women
Czech Republic Poland Russia
Men
Dichotomous SCORE 0.4122
(0.1888, 0.6380)
0.1810
(0.0114, 0.4313)
0.3364
(0.1965, 0.4790)
Continuous SCORE 0.4201
(0.2079, 0.6432)
0.3509
(0.1033, 0.6172)
0.3143
(0.1916, 0.4658)
Women
Dichotomous SCORE 0.00260
(0.0000, 0.3033)*
0.3664
(0.0000, 0.7914)*
0.3905
(0.1493, 0.6438)
Continuous SCORE 0.1813
(0.0000, 0.4760)*
0.7197
(0.2618, 0.9449)
0.5904
(0.3606, 0.7862)
* Lower confidence limits calculated as negative were regarded as 0.
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APPENDIX III. Education, marital status, and SCORE performance in MONICA and HAPIEE:
additional tables
Table A7.1.1. Continuous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality
in MONICA men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.09 (1.06-1.12) 1.10 (1.07-1.12) 1.11 (1.08-1.14) 1.08 (1.05-1.12) 1.11 (1.09-1.13)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.09 (1.06-1.13) 1.10 (1.07-1.12) 1.10 (1.07-1.14) 1.08 (1.04-1.12) 1.10 (1.08-1.12)
Lower education (vs. higher) 1.44 (0.68-3.06) 1.63 (1.06-2.51) 1.28 (0.67-2.45) 1.39 (0.82-2.38) 1.58 (1.16-2.14)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.10 (1.07-1.14) N/A N/A 1.08 (1.05-1.12) 1.11 (1.09-1.13)
Non-married (vs. married) 5.80 (2.74-12.29) 1.84 (0.83-4.05) 1.72 (1.11-2.67)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.11 (1.07-1.14) N/A N/A 1.08 (1.04-0.12) 1.10 (1.08-1.13)
Lower education (vs. higher) 1.34 (0.63-2.88) 1.38 (0.81-2.36) 1.54 (1.14-2.10)
Non-married (vs. married) 5.77 (2.72-12.20) 1.81 (0.82-4.00) 1.74 (1.12-2.69)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.23 (1.06-1.43) 1.21 (1.10-1.33) 1.33 (1.16-1.53) 1.27 (1.16-1.39) 1.34 (1.27-1.41)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.23 (1.05-1.43) 1.21 (1.10-1.34) 1.34 (1.16-1.54) 1.22 (1.10-1.34) 1.33 (1.26-1.40)
Lower education (vs. higher) 1.65 (0.46-6.01) 4.39 (1.61-12.00) 0.68 (0.22-2.10) 3.92 (1.52-10.12) 1.48 (0.94-2.31)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.23 (1.05-1.43) N/A N/A 1.28 (1.16-1.40) 1.34 (1.27-1.41)
Non-married (vs. married) 2.07 (0.68-6.33) 1.37 (0.55-3.42) 1.18 (0.75-1.84)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.22 (1.04-1.43) N/A N/A 1.22 (1.10-1.34) 1.33 (1.26-1.40)
Lower education (vs. higher) 1.63 (0.45-5.95) 3.91 (1.52-1.10) 1.43 (0.91-2.24)
Non-married (vs. married) 2.07 (0.68-6.33) 1.09 (0.41-2.91) 1.18 (0.75-1.85)
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Table A7.1.2. Dichotomous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality
in MONICA men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 4.29 (2.13-8.63) 4.76 (3.12-7.27) 3.76 (2.28-6.20) 2.45 (1.42-4.24) 3.04 (2.25-4.10)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 4.31 (2.14-8.67) 4.54 (2.97-6.96) 3.57 (2.15-5.93) 2.21 (1.26-3.88) 2.75 (2.03-3.73)
Lower education (vs. higher) 1.17 (0.57-2.43) 1.53 (0.99-2.36) 1.41 (0.75-2.68) 1.51 (0.89-2.56) 1.72 (1.27-2.34)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 4.09 (2.00-8.37) N/A N/A 2.46 (1.42-4.26) 3.08 (2.28-4.16)
Non-married (vs. married) 4.53 (2.22-9.26) 1.81 (0.82-3.99) 1.63 (1.05-2.53)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 4.10 (2.00-8.38) N/A N/A 2.22 (1.26-3.90) 2.80 (2.06-3.81)
Lower education (vs. higher) 1.09 (0.52-2.27) 1.49 (0.88-2.54) 1.69 (1.25-2.30)
Non-married (vs. married) 4.52 (2.21-9.24) 1.79 (0.81-3.94) 1.66 (1.07-2.58)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) too few observations 5.19 (1.75-15.43) too few observations too few observations 6.30 (3.26-12.17)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) too few observations 4.40 (1.47-13.12) too few observations too few observations 5.02 (2.57-9.83)
Lower education (vs. higher) 1.86 (0.51-6.77) 4.24 (1.55-11.60) too few observations 5.46 (2.18-13.68) 2.13 (1.38-3.29)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) too few observations N/A N/A too few observations 5.95 (3.06-11.59)
Non-married (vs. married) 2.24 (0.73-6.83) 1.40 (0.56-3.49) 1.39 (0.89-2.17)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) too few observations N/A N/A too few observations 4.86 (2.47-9.58)
Lower education (vs. higher) 1.84 (0.51-6.70) 5.45 (2.18-13.65) 2.04 (1.31-3.17)
Non-married (vs. married) 2.24 (0.73-6.83) 1.11 (0.42-2.95) 1.34 (0.85-2.10)
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Table A7.1.3. Continuous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality
in MONICA men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.16 (1.11-1.22) 1.18 (1.13-1.23) 1.20 (1.14-1.26) 1.15 (1.08-1.23) 1.20 (1.17-1.24)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.17 (1.11-1.23) 1.18 (1.13-1.23) 1.19 (1.13-1.26) 1.14 (1.07-1.22) 1.19 (1.15-1.23)
Lower education (vs. higher) 1.43 (0.67-3.03) 1.65 (1.07-2.53) 1.28 (0.67-2.45) 1.41 (0.82-2.40) 1.58 (1.16-2.14)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.19 (1.13-1.26) N/A N/A 1.15 (1.08-1.23) 1.21 (1.17-1.25)
Non-married (vs. married) 5.87 (2.77-12.47) 1.84 (0.84-4.06) 1.72 (1.11-2.66)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.20 (1.14-1.27) N/A N/A 1.14 (1.07-1.22) 1.20 (1.15-1.24)
Lower education (vs. higher) 1.34 (0.63-2.88) 1.39 (0.81-2.38) 1.55 (1.14-2.10)
Non-married (vs. married) 5.85 (2.76-12.41) 1.82 (0.82-4.00) 1.74 (1.12-1.69)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.39 (1.09-1.76) 1.34 (1.15-1.55) 1.54 (1.24-1.93) 1.47 (1.28-1.69) 1.56 (1.44-1.70)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.38 (1.08-1.77) 1.34 (1.15-1.57) 1.56 (1.25-1.96) 1.37 (1.17-1.60) 1.53 (1.40-1.67)
Lower education (vs. higher) 1.66 (0.46-6.03) 4.36 (1.60-11.91) 0.70 (0.23-2.14) 3.89 (1.51-10.04) 1.47 (0.93-2.30)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.38 (1.08-1.76) N/A N/A 1.48 (1.28-1.70) 1.56 (1.43-1.70)
Non-married (vs. married) 2.05 (0.67-6.28) 1.40 (0.56-3.49) 1.17 (0.75-1.84)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.37 (1.07-1.77) N/A N/A 1.37 (1.17-1.60) 1.53 (1.40-1.68)
Lower education (vs. higher) 1.64 (0.45-5.96) 3.88 (1.50-10.02) 1.42 (0.90-2.23)
Non-married (vs. married) 2.05 (0.67-6.29) 1.11 (0.41-2.95) 1.17 (0.75-1.84)
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Table A7.1.4. Continuous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality
in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.09)
Lower education (vs. higher) 2.69 (1.10-6.59) 2.29 (0.99-5.29) 1.67 (1.03-2.69)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.10 (1.07-1.14) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
Non-married (vs. married) 1.89 (0.86-4.17) 2.60 (1.21-5.58) 2.26 (1.43-3.56)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
Lower education (vs. higher) 2.54 (1.04-6.23) 2.19 (0.95-5.07) 1.62 (1.00-2.61)
Non-married (vs. married) 1.86 (0.84-4.15) 2.52 (1.18-5.41) 2.22 (1.40-3.50)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.20 (1.06-1.35) 1.32 (1.22-1.43) 1.32 (1.24-1.41)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.19 (1.05-1.35) 1.32 (1.21-1.44) 1.31 (1.22-1.40)
Lower education (vs. higher) 2.00 (0.76-5.29) 2.57 (0.89-7.40) 1.60 (0.77-3.32)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.19 (1.06-1.34) 1.32 (1.21-1.44) 1.32 (1.23-1.41)
Non-married (vs. married) 1.87 (0.76-4.62) 1.03 (0.36-2.99) 2.61 (1.38-4.97)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.18 (1.05-1.34) 1.32 (1.21-1.44) 1.31 (1.22-1.40)
Lower education (vs. higher) 1.96 (0.74-5.19) 2.57 (0.89-7.39) 1.45 (0.70-3.03)
Non-married (vs. married) 1.85 (0.75-4.57) 1.03 (0.36-2.95) 2.55 (1.34-4.86)
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Table A7.1.5. Dichotomous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality
in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 6.55 (3.09-13.88) 3.24 (1.64-6.42) 5.52 (3.45-8.84)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 7.05 (3.21-15.51) 3.03 (1.52-6.03) 5.20 (3.23-8.35)
Lower education (vs. higher) 3.16 (1.31-7.62) 2.44 (1.05-5.63) 1.68 (1.05-2.70)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 6.65 (3.14-14.10) 3.14 (1.59-6.23) 5.49 (3.43-8.78)
Non-married (vs. married) 1.73 (0.79-3.78) 2.50 (1.17-5.36) 2.26 (1.43-3.57)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 7.14 (3.24-15.70) 2.96 (1.49-5.89) 5.19 (3.23-8.35)
Lower education (vs. higher) 2.93 (1.19-7.20) 2.35 (1.02-5.42) 1.63 (1.02-2.63)
Non-married (vs. married) 1.57 (0.70-3.51) 2.43 (1.13-5.21) 2.22 (1.41-3.51)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 2.39 (0.55-10.33) 9.15 (3.18-26.33) 6.91 (3.75-12.74)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 2.24 (0.52-9.72) 7.89 (2.69-23.09) 6.07 (3.23-11.42)
Lower education (vs. higher) 2.23 (0.85-5.89) 2.83 (0.97-8.27) 2.09 (1.00-4.35)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 2.31 (0.53-10.02) 8.65 (2.97-25.18) 6.38 (3.46-11.79)
Non-married (vs. married) 2.01 (0.82-4.94) 1.43 (0.53-3.87) 2.74 (1.44-5.21)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 2.17 (0.50-9.43) 7.50 (2.53-22.21) 5.73 (3.05-10.76)
Lower education (vs. higher) 2.19 (0.83-5.77) 2.77 (0.95-8.14) 1.92 (0.92-3.99)
Non-married (vs. married) 1.98 (0.80-4.87) 1.38 (0.51-3.74) 2.65 (1.39-5.05)
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Table A7.1.6. Continuous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality
in HAPIEE men and women: hazard ratios and 95% confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.18 (1.12-1.24) 1.17 (1.11-1.24) 1.14 (1.10-1.17)
Lower education (vs. higher) 2.70 (1.10-6.61) 2.28 (0.99-5.27) 1.66 (1.03-2.69)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
Non-married (vs. married) 1.90 (0.86-4.20) 2.62 (1.22-5.61) 2.23 (1.42-3.53)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.17 (1.11-1.25) 1.14 (1.10-1.17)
Lower education (vs. higher) 2.55 (1.04-6.25) 2.18 (0.94-5.04) 1.62 (1.00-2.61)
Non-married (vs. married) 1.88 (0.84-4.18) 2.54 (1.18-5.44) 2.20 (1.39-3.47)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.34 (1.11-1.62) 1.56 (1.38-1.76) 1.56 (1.40-1.73)
Model 2 (SCORE and education)
SCORE 5% (vs. <5%) 1.33 (1.09-1.61) 1.56 (1.37-1.77) 1.53 (1.37-1.71)
Lower education (vs. higher) 2.00 (0.76-5.29) 2.56 (0.89-7.37) 1.61 (0.78-3.35)
Model 3 (SCORE and marital status)
SCORE 5% (vs. <5%) 1.32 (1.10-1.60) 1.56 (1.36-1.78) 1.54 (1.38-1.72)
Non-married (vs. married) 1.86 (0.75-4.59) 0.99 (0.34-2.90) 2.57 (1.35-4.89)
Model 4 (SCORE, education, and marital status)
SCORE 5% (vs. <5%) 1.31 (1.08-1.59) 1.56 (1.36-1.79) 1.52 (1.36-1.70)
Lower education (vs. higher) 1.96 (0.74-5.19) 2.56 (0.89-7.36) 1.46 (0.70-3.05)
Non-married (vs. married) 1.83 (0.74-4.53) 0.99 (0.34-2.85) 2.51 (1.32-4.78)
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Table A7.2.1. Continuous low-risk SCORE, education, marital status, and 10-year
atherosclerotic CVD mortality in MONICA men and women: Hosmer-Lemeshow (HL)
test results
Czech
Republic
Poland
(Warsaw)
Poland
(Tarnobrzeg)
Lithuania Russia
HL χ2 (p)
Men
Model 1
(SCORE
only)
10.92
(0.0530)
9.26
(0.0991)
4.33
(0.5025)
14.93
(0.0106)
3.83
(0.5753)
Model 2
(SCORE and
education)
13.02
(0.1110)
10.94
(0.1412)
14.95
(0.0207)
14.92
(0.0371)
6.05
(0.5344)
Model 3
(SCORE and
marital status)
10.45
(0.1070)
N/A N/A 9.96
(0.1264)
4.43
(0.6190)
Model 4
(SCORE,
education,
and marital
status)
16.68
(0.0336)
N/A N/A 10.00
(0.1885)
8.37
(0.3011)
Women
Model 1
(SCORE
only)
6.19
(0.1028)
8.25
(0.0411)
6.61
(0.0367)
17.46
(0.0002)
12.38
(0.0062)
Model 2
(SCORE and
education)
5.13
(0.2739)
8.41
(0.1350)
7.66
(0.1047)
16.01
(0.0068)
7.33
(0.1974)
Model 3
(SCORE and
marital status)
10.92
(0.0275)
N/A N/A 19.84
(0.0005)
12.74
(0.0259)
Model 4
(SCORE,
education,
and marital
status)
13.59
(0.0589)
N/A N/A 4.75
(0.4466)
13.35
(0.0203)
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Table A7.2.2. Continuous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.7597 0.7245 0.7114 0.6981 0.6789
R2 0.3540
(0.1214, 0.6471)
0.2878
(0.1533, 0.4374)
0.2802
(0.1267, 0.4681)
0.1421
(0.0353, 0.3008)
0.2813
(0.1751, 0.3995)
Model 2 (SCORE and education)
Harrell’s C 0.7464 0.7289 0.7112 0.6892 0.6896
R2 0.3491
(0.1187, 0.6572)
0.3119
(0.1825, 0.4808)
0.2768
(0.1238, 0.4815)
0.1467
(0.0536, 0.3184)
0.3007
(0.1993, 0.4234)
LRT p value 0.4078 0.0239 0.2437 0.2253 0.0053
IDI (p value) 0.00030
(0.86057)
0.00311
(0.27529)
0.00006
(0.93754)
0.00059
(0.50166)
0.00149
(0.34840)
Model 3 (SCORE and marital status)
Harrell’s C 0.8085 N/A N/A 0.6957 0.6907
R2 0.5856
(0.3140, 0.8391)
0.1518
(0.0480, 0.3298)
0.2936
(0.1826, 0.4152)
LRT p value <0.0001 0.1587 0.0218
IDI (p value) 0.03975
(0.01224)
0.00092
(0.43458)
0.00290
(0.10363)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7892 N/A N/A 0.6949 0.6989
R2 0.5809
(0.2885, 0.8261)
0.1553
(0.0589, 0.3346)
0.3015
(0.1201, 0.4350)
LRT p value 0.0001 0.1877 0.0014
IDI (p value) 0.04051
(0.01247)
0.00132
(0.32030)
0.00423
(0.07949)
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Table A7.2.3. Continuous high-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.7465 0.7244 0.7848 0.8101 0.7898
R2 0.1843
(0.0000, 0.5052)*
0.2526
(0.0000, 0.6580)*
0.3248
(0.0865, 0.5771)
0.3314
(0.1646, 0.5435)
0.4872
(0.3230, 0.6548)
Model 2 (SCORE and education)
Harrell’s C 0.7487 0.7830 0.7877 0.8085 0.7861
R2 0.1686
(0.0000, 0.5614)*
0.4589
(0.1204, 0.7802)
0.3094
(0.0713, 0.6148)
0.4809
(0.2508, 0.7251)
0.4947
(0.3293, 0.6490)
LRT p value 0.4259 0.0015 0.7249 0.0024 0.1117
IDI (p value) 0.00028
(0.87199)
0.00776
(0.33194)
0.00066
(0.00108)
0.00773
(0.00133)
-0.00037
(0.84053)
Model 3 (SCORE and marital status)
Harrell’s C 0.7662 N/A N/A 0.8065 0.7935
R2 0.2073
(0.0000, 0.6274)*
0.3133
(0.1576, 0.5582)
0.4851
(0.3279, 0.6513)
LRT p value 0.2142 0.7652 0.4492
IDI (p value) 0.00234
(0.45472)
0.00005
(0.82733)
-0.00088
(0.19522)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7685 N/A N/A 0.8064 0.7909
R2 0.1905
(0.0000, 0.6560)*
0.4647
(0.2392, 0.7313)
0.4923
(0.3395, 0.6638)
LRT p value 0.3421 0.0097 0.2194
IDI (p value) 0.00304
(0.46620)
0.00780
(0.00132)
-0.00103
(0.63172)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.4. Dichotomous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.6341 0.6680 0.6341 0.5796 0.6124
R2 0.2168
(0.0189, 0.4942)
0.3100
(0.1695, 0.4852)
0.2163
(0.0730, 0.4034)
0.0825
(0.0000, 0.2527)*
0.1604
(0.0787, 0.2648)
Model 2 (SCORE and education)
Harrell’s C 0.6344 0.6970 0.6654 0.6197 0.6523
R2 0.2008
(0.0031, 0.5017)
0.3261
(0.1760, 0.5083)
0.2180
(0.0863, 0.4226)
0.0958
(0.0012, 0.2801)
0.1933
(0.1046, 0.3039)
LRT p value 0.7626 0.0521 0.2747 0.1286 0.0007
IDI (p value) 0.00005
(0.79410)
0.00319
(0.17150)
0.00012
(0.92540)
0.00099
(0.35148)
0.00401
(0.01099)
Model 3 (SCORE and marital status)
Harrell’s C 0.7118 N/A N/A 0.6018 0.6266
R2 0.4350
(0.1241, 0.7490)
0.0917
(0.0018, 0.2579)
0.1710
(0.0902, 0.2729)
LRT p value 0.0001 0.1670 0.0372
IDI (p value) 0.03700
(0.00729)
0.00080
(0.47051)
0.00208
(0.11622)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.6817 N/A N/A 0.6396 0.6600
R2 0.4214
(0.1520, 0.7521)
0.1036
(0.0188, 0.2876)
0.2042
(0.1200, 0.3243)
LRT p value 0.0006 N/A N/A 0.1291 0.0003
IDI (p value) 0.03603
(0.00713)
0.00156
(0.24537)
0.00599
(0.00388)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.5. Dichotomous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.5116 0.5745 0.5122 0.5086 0.5488
R2 0.0184
(0.0000, 0.0042)*
0.1448
(0.0000, 0.5264)*
0.0021
(0.0000, 0.0130)*
0.0031
(0.0000, 0.0078)*
0.1297
(0.0206, 0.2972)
Model 2 (SCORE and education)
Harrell’s C 0.5725 0.7126 0.5148 0.7024 0.6435
R2 0.0190
(0.0000, 0.3819)*
0.3571
(0.0893, 0.7183)
0.0342
(0.0000, 0.1637)*
0.3311
(0.0894, 0.6212)
0.1949
(0.0795, 0.3752)
LRT p value 0.3206 0.0021 0.9521 0.0001 0.0010
IDI (p value) 0.00137
(0.28955)
0.00962
(0.02027)
<0.00001
(0.96014)
0.01005
(0.00001)
0.00257
(0.25090)
Model 3 (SCORE and marital status)
Harrell’s C 0.5940 N/A N/A 0.5206 0.6054
R2 0.0218
(0.0000, 0.4170)*
0.0250
(0.0000, 0.1275)*
0.1375
(0.0295, 0.2969)
LRT p value 0.1726 0.7434 0.1431
IDI (p value) 0.00304
(0.23549)
0.00006
(0.77713)
-0.00088
(0.37901)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.6253 N/A N/A 0.6998 0.6635
R2 0.0197
(0.0000, 0.5173)*
0.3120
(0.0800, 0.6326)
0.1985
(0.0838, 0.3634)
LRT p value 0.0933 0.0001 0.0022
IDI (p value) 0.00469
(0.14434)
0.01016
(0.00001)
0.00227
(0.37337)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.6. Continuous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.7648 0.7254 0.7116 0.6943 0.6763
R2 0.3483
(0.0872, 0.6393)
0.2896
(0.1503, 0.4441)
0.2777
(0.1197, 0.4718)
0.1376
(0.0419, 0.2938)
0.2780
(0.1626, 0.3971)
Model 2 (SCORE and education)
Harrell’s C 0.7521 0.7268 0.7113 0.6854 0.6877
R2 0.3420
(0.1082, 0.6433)
0.3147
(0.1913, 0.4807)
0.2741
(0.1268, 0.4628)
0.1430
(0.0447, 0.3039)
0.2977
(0.2002, 0.4123)
LRT p value 0.4159 0.0218 0.4473 0.2137 0.0051
IDI (p value) 0.00042
(0.80506)
0.00326
(0.26091)
-0.0003
(0.96810)
0.00068
(0.44709)
0.00151
(0.34182)
Model 3 (SCORE and marital status)
Harrell’s C 0.8059 N/A N/A 0.6949 0.6875
R2 0.5835
(0.2789, 0.8350)
0.1474
(0.0434, 0.3165)
0.2903
(0.1903, 0.4111)
LRT p value <0.0001 0.1577 0.0220
IDI (p value) 0.04096
(0.00911)
0.00085
(0.45800)
0.00294
(0.09707)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7819 N/A N/A 0.6938 0.6962
R2 0.5790
(0.2868, 0.8529)
0.1516
(0.0593, 0.3208)
0.3100
(0.2043, 0.4320)
LRT p value 0.0001 0.1803 0.0014
IDI (p value) 0.04187
(0.00927)
0.00133
(0.31031)
0.00430
(0.07373)
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Table A7.2.7. Continuous low-risk SCORE, education, marital status, and 10-year atherosclerotic CVD mortality in MONICA women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland (Warsaw) Poland (Tarnobrzeg) Lithuania Russia
Model 1 (SCORE only)
Harrell’s C 0.7465 0.7066 0.7755 0.8092 0.7661
R2 0.1859
(0.0000, 0.4538)*
0.2407
(0.0000, 0.6000)*
0.2988
(0.0700, 0.5702)
0.3419
(0.1604, 0.5709)
0.4500
(0.2848, 0.6064)
Model 2 (SCORE and education)
Harrell’s C 0.7507 0.7796 0.7822 0.8088 0.7729
R2 0.1706
(0.0000, 0.5491)*
0.4475
(0.1441, 0.7525)
0.2819
(0.0558, 0.5874)
0.4871
(0.2542, 0.7346)
0.4571
(0.3063, 0.5425)
LRT p value 0.4227 0.0016 0.5410 0.0026 0.1233
IDI (p value) 0.00042
(0.79908)
0.00699
(0.37111)
0.00053
(0.54904)
0.00744
(0.00290)
-0.00019
(0.91063)
Model 3 (SCORE and marital status)
Harrell’s C 0.7622 N/A N/A 0.8057 0.7742
R2 0.2074
(0.0000, 0.5719)*
0.3243
(0.1512, 0.5665)
0.4478
(0.2974, 0.6051)
LRT p value 0.2195 0.7402 0.4522
IDI (p value) 0.00215
(0.46860)
0.00006
(0.81194)
-0.00079
(0.18946)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7739 N/A N/A 0.8069 0.7754
R2 0.1910
(0.0000, 0.6671)*
0.4711
(0.2310, 0.7349)
0.4544
(0.3024, 0.6247)
LRT p value 0.3466 0.0105 0.2395
IDI (p value) 0.00298
(0.45103)
0.00752
(0.00289)
-0.00076
(0.69457)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.8. Continuous low-risk SCORE, education, marital status, and
atherosclerotic CVD mortality in HAPIEE men and women: Hosmer-Lemeshow (HL)
test results
Czech Republic Poland Russia
HL χ2 (p)
Men
Model 1
(SCORE only)
6.61
(0.3581)
7.18
(0.3042)
36.52
(<0.0001)
Model 2 (SCORE and
education)
6.40
(0.3802)
9.09
(0.1688)
20.94
(0.0039)
Model 3 (SCORE and
marital status)
7.54
(0.3747)
6.58
(0.3616)
27.83
(0.0002)
Model 4 (SCORE,
education, and marital
status)
8.01
(0.3315)
13.43
(0.0622)
22.98
(0.0017)
Women
Model 1
(SCORE only)
3.79
(0.2847)
2.55
(0.4658)
3.00
(0.5586)
Model 2 (SCORE and
education)
2.05
(0.7268)
3.18
(0.5281)
4.08
(0.3955)
Model 3 (SCORE and
marital status)
4.59
(0.5971)
2.71
(0.8442)
6.94
(0.3260)
Model 4 (SCORE,
education, and marital
status)
7.56
(0.3726)
1.87
(0.9310)
6.56
(0.3630)
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Table A7.2.9. Continuous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7848 0.7181 0.7387
R2 0.4385
(0.2015, 0.6691)
0.3497
(0.1010, 0.6470)
0.3154
(0.1885, 0.4645)
Model 2 (SCORE and education)
Harrell’s C 0.7891 0.7338 0.7423
R2 0.4725
(0.2549, 0.7037)
0.3804
(0.1163, 0.6805)
0.3295
(0.2057, 0.4678)
LRT p value 0.0497 0.0415 0.0460
IDI (p value) 0.00198
(0.50455)
0.00292
(0.27913)
-0.00044
(0.73991)
Model 3 (SCORE and marital status)
Harrell’s C 0.7827 0.7144 0.7497
R2 0.4566
(0.2469, 0.7074)
0.4064
(0.1401, 0.7320)
0.3595
(0.2355, 0.4994)
LRT p value 0.1135 0.0258 0.0012
IDI (p value) 0.00192
(0.32185)
0.00739
(0.08068)
0.00404
(0.10852)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7888 0.7324 0.7539
R2 0.4848
(0.2587, 0.7428)
0.4313
(0.1392, 0.7652)
0.3711
(0.2547, 0.5191)
LRT p value 0.0518 0.0123 0.0009
IDI (p value) 0.00362
(0.25584)
0.00898
(0.01096)
0.00353
(0.20136)
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Table A7.2.10. Continuous high-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.6946 0.8034 0.7983
R2 0.1727
(0.0000, 0.4388)*
0.6903
(0.2143, 0.9431)
0.6003
(0.3511, 0.8113)
Model 2 (SCORE and education)
Harrell’s C 0.7020 0.8007 0.8006
R2 0.1947
(0.0000, 0.5262)*
0.7173
(0.2711, 0.9455)
0.6041
(0.3613, 0.8048)
LRT p value 0.1852 0.1601 0.2251
IDI (p value) 0.00054
(0.43688)
-0.00362
(0.43566)
0.00114
(0.55238)
Model 3 (SCORE and marital status)
Harrell’s C 0.7025 0.8083 0.8047
R2 0.1963
(0.0000, 0.5471)*
0.6729
(0.1753, 0.9337)
0.6620
(0.4231, 0.8414)
LRT p value 0.1784 0.5909 0.0024
IDI (p value) 0.00096
(0.16772)
0.00019
(0.23286)
0.00716
(0.03613)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7040 0.8058 0.8090
R2 0.2156
(0.0053, 0.6000)
0.7013
(0.2737, 0.9500)
0.6615
(0.4377, 0.8483)
LRT p value 0.1756 0.3338 0.0062
IDI (p value) 0.00162
(0.15442)
-0.00347
(0.43917)
0.00811
(0.03843)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.11. Dichotomous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7307 0.6444 0.6925
R2 0.4498
(0.2003, 0.6723)
0.1804
(0.0176, 0.4305)
0.3364
(0.2093, 0.4662)
Model 2 (SCORE and education)
Harrell’s C 0.7470 0.6755 0.7074
R2 0.4988
(0.2615, 0.7402)
0.2227
(0.0514, 0.5069)
0.3510
(0.2303, 0.4956)
LRT p value 0.0222 0.0569 0.0417
IDI (p value) 0.00511
(0.11836)
0.00151
(0.21992)
0.00141
(0.24670)
Model 3 (SCORE and marital status)
Harrell’s C 0.7438 0.6712 0.7182
R2 0.4612
(0.2173, 0.7243)
0.2399
(0.0389, 0.5555)
0.3799
(0.2553, 0.5275)
LRT p value 0.1618 0.0300 0.0012
IDI (p value) 0.00180
(0.18280)
0.00273
(0.05785)
0.00406
(0.05477)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7569 0.6973 0.7300
R2 0.5002
(0.2717, 0.7584)
0.2763
(0.0714, 0.5977)
0.3920
(0.2674, 0.5283)
LRT p value 0.0418 0.0177 0.0008
IDI (p value) 0.00629
(0.08426)
0.00381
(0.04394)
0.00537
(0.03235)
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Table A7.2.12. Dichotomous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.5193 0.6414 0.6656
R2 0.0028
(0.0000, 0.3073)*
0.3654
(0.0000, 0.7954)*
0.3905
(0.1417, 0.6600)
Model 2 (SCORE and education)
Harrell’s C 0.5822 0.7048 0.7025
R2 0.0453
(0.0000, 0.4027)*
0.4256
(0.0560, 0.8218)
0.4168
(0.1648, 0.6880)
LRT p value 0.1262 0.0789 0.0644
IDI (p value) 0.00062
(0.33274)
0.00061
(0.76520)
0.00160
(0.38632)
Model 3 (SCORE and marital status)
Harrell’s C 0.5666 0.6611 0.7228
R2 0.0422
(0.0000, 0.4890)*
0.3498
(0.0000, 0.8130)*
0.4854
(0.2363, 0.7376)
LRT p value 0.1345 0.4883 0.0015
IDI (p value) 0.00106
(0.08709)
0.00048
(0.49403)
0.00567
(0.00868)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.6079 0.7287 0.7380
R2 0.0807
(0.0000, 0.5240)*
0.4082
(0.0348, 0.8257)
0.5021
(0.2558, 0.7507)
LRT p value 0.1067 0.1764 0.0016
IDI (p value) 0.00334
(0.02211)
0.00059
(0.69555)
0.00669
(0.01593)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A7.2.13. Continuous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7938 0.7215 0.7406
R2 0.4359
(0.2134, 0.6457)
0.3505
(0.0997, 0.6307)
0.3143
(0.1794, 0.4571)
Model 2 (SCORE and education)
Harrell’s C 0.7962 0.7376 0.7440
R2 0.4702
(0.2456, 0.7030)
0.3805
(0.1226, 0.6775)
0.3282
(0.2068, 0.4672)
LRT p value 0.0491 0.0765 0.0476
IDI (p value) 0.00196
(0.49770)
0.00297
(0.28428)
-0.00049
(0.71332)
Model 3 (SCORE and marital status)
Harrell’s C 0.7905 0.7178 0.7491
R2 0.4545
(0.2325, 0.6859)
0.4080
(0.1151, 0.7139)
0.3575
(0.2247, 0.5054)
LRT p value 0.1107 0.0231 0.0014
IDI (p value) 0.00209
(0.30298)
0.00736
(0.08661)
0.00406
(0.10660)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7960 0.7364 0.7532
R2 0.4831
(0.2655, 0.7183)
0.4321
(0.1548, 0.7650)
0.3690
(0.2499, 0.5133)
LRT p value 0.0500 0.0184 0.0010
IDI (p value) 0.00378
(0.230580)
0.00893
(0.01099)
0.00351
(0.20257)
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Table A7.2.14. Continuous low-risk SCORE, education, marital status, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7052 0.8236 0.7953
R2 0.1833
(0.0000, 0.4544)*
0.7191
(0.2575, 0.9348)
0.5904
(0.3482, 0.7756)
Model 2 (SCORE and education)
Harrell’s C 0.7017 0.8193 0.7966
R2 0.2054
(0.0000, 0.5513)*
0.7436
(0.3369, 0.9528)
0.5947
(0.3750, 0.8025)
LRT p value 0.1845 0.1048 0.2166
IDI (p value) 0.00049
(0.47953)
-0.00351
(0.45686)
0.00105
(0.57809)
Model 3 (SCORE and marital status)
Harrell’s C 0.6993 0.8226 0.8006
R2 0.2055
(0.0000, 0.5528)*
0.7031
(0.2312, 0.9432)
0.6512
(0.4251, 0.8323)
LRT p value 0.1841 0.9883 0.0028
IDI (p value) 0.00104
(0.15199)
0.00003
(0.27314)
0.00687
(0.03072)
Model 4 (SCORE, education, and marital status)
Harrell’s C 0.7022 0.8170 0.8042
R2 0.2247
(0.0119, 0.6192)
0.7289
(0.2671, 0.9571)
0.6508
(0.4313, 0.8376)
LRT p value 0.1793 0.2682 0.0072
IDI (p value) 0.00159
(0.13932)
-0.00349
(0.45704)
0.00773
(0.03433)
* Lower confidence limits calculated as negative were regarded as 0.
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APPENDIX IV. Alcohol consumption parameters and
SCORE performance in HAPIEE: additional tables
Table A8.1.1. Continuous high-risk SCORE, binge drinking, CAGE, and
atherosclerotic CVD mortality in HAPIEE men and women: hazard ratios and 95%
confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 1.10 (1.07-1.14) 1.10 (1.07-1.14) 1.08 (1.06-1.10)
Binge drinking (vs. no
binge drinking)
1.00 (0.41-2.39) 0.75 (0.23-2.48) 1.08 (0.73-1.61)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 1.10 (1.07-1.13) 1.10 (1.06-1.13) 1.08 (1.06-1.10)
CAGE 2 (vs. <2) 1.03 (0.36-2.94) 1.74 (0.67-4.49) 1.06 (0.67-1.68)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 1.10 (1.07-1.14) 1.10 (1.07-1.14) 1.08 (1.06-1.10)
Binge drinking (vs. no
binge drinking)
0.83 (0.31-2.22) 0.59 (0.17-2.08) 1.07 (0.70-1.64)
CAGE 2 (vs. <2) 1.17 (0.39-3.44) 2.05 (0.75-5.62) 1.03 (0.64-1.68)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.20 (1.06-1.35) 1.32 (1.22-1.43) 1.32 (1.24-1.41)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 1.22 (1.09-1.37) 1.32 (1.22-1.43) 1.33 (1.24-1.42)
Binge drinking (vs. no
binge drinking)
1.89 (0.25-14.23) too few observations 6.75 (1.60-28.53)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 1.22 (1.08-1.37) 1.32 (1.22-1.43) 1.33 (1.24-1.43)
CAGE 2 (vs. <2) 3.27 (0.44-24.57) too few observations 6.84 (1.61-29.08)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 1.22 (1.08-1.37) 1.32 (1.22-1.43) 1.33 (1.25-1.43)
Binge drinking (vs. no
binge drinking)
1.37 (0.15-12.72) too few observations 3.62 (0.57-22.89)
CAGE 2 (vs. <2) 2.89 (0.31-26.76) too few observations 3.67 (0.58-23.33)
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Table A8.1.2. Dichotomous low-risk SCORE, binge drinking, CAGE, and
atherosclerotic CVD mortality in HAPIEE men and women: hazard ratios and 95%
confidence intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 6.55 (3.09-13.88) 3.24 (1.64-6.42) 5.52 (3.45-8.84)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 6.38 (3.00-13.58) 3.24 (1.64-6.42) 5.52 (3.45-8.83)
Binge drinking (vs. no
binge drinking)
0.98 (0.41-2.35) 0.92 (0.28-3.00) 1.18 (0.80-1.76)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 7.27 (3.30-16.02) 3.30 (1.66-6.53) 5.53 (3.46-8.85)
CAGE 2 (vs. <2) 1.31 (0.46-3.71) 1.78 (0.69-4.61) 1.16 (0.74-1.83)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 7.02 (3.18-15.53) 3.30 (1.66-6.54) 5.53 (3.45-8.85)
Binge drinking (vs. no
binge drinking)
0.79 (0.29-2.13) 0.73 (0.21-2.56) 1.15 (0.76-1.76)
CAGE 2 (vs. <2) 1.44 (0.49-4.29) 1.98 (0.72-5.45) 1.10 (0.68-1.79)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 2.39 (0.55-10.33) 9.15 (3.18-26.33) 6.91 (3.75-12.74)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 2.51 (0.58-10.95) 9.20 (3.20-26.49) 7.26 (3.92-13.46)
Binge drinking (vs. no
binge drinking)
1.72 (0.23-12.96) too few observations 5.23 (1.25-21.93)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 2.51 (0.58-10.93) 9.11 (3.16-26.21) 7.29 (3.93-13.54)
CAGE 2 (vs. <2) 3.05 (0.41-22.91) too few observations 5.17 (1.23-21.74)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 2.48 (0.57-10.81) 9.08 (3.15-26.13) 7.48 (4.02-13.94)
Binge drinking (vs. no
binge drinking)
1.34 (0.16-11.54) too few observations 3.37 (0.65-17.66)
CAGE 2 (vs. <2) 2.79 (0.33-23.97) too few observations 3.32 (0.63-17.41)
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Table A8.1.3. Continuous low-risk SCORE, binge drinking, CAGE, and atherosclerotic
CVD mortality in HAPIEE men and women: hazard ratios and 95% confidence
intervals
Czech Republic Poland Russia
Men
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
Binge drinking (vs. no
binge drinking)
0.99 (0.41-2.39) 0.76 (0.23-2.50) 1.09 (0.73-1.62)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 1.18 (1.13-1.25) 1.18 (1.12-1.25) 1.14 (1.11-1.18)
CAGE 2 (vs. <2) 1.04 (0.36-2.97) 1.76 (0.68-4.54) 1.07 (0.68-1.68)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 1.19 (1.13-1.25) 1.19 (1.12-1.26) 1.14 (1.10-1.18)
Binge drinking (vs. no
binge drinking)
0.83 (0.31-2.21) 0.59 (0.17-2.09) 1.07 (0.70-1.64)
CAGE 2 (vs. <2) 1.18 (0.40-3.48) 2.07 (0.76-5.68) 1.04 (0.64-1.69)
Women
Model 1 (SCORE only)
SCORE 5% (vs. <5%) 1.34 (1.11-1.62) 1.56 (1.38-1.76) 1.56 (1.40-1.73)
Model 2 (SCORE and binge drinking)
SCORE 5% (vs. <5%) 1.37 (1.14-1.65) 1.56 (1.38-1.76) 1.57 (1.41-1.75)
Binge drinking (vs. no
binge drinking)
1.89 (0.25-14.18) too few observations 6.47 (1.54-27.18)
Model 3 (SCORE and CAGE)
SCORE 5% (vs. <5%) 1.37 (1.14-1.65) 1.55 (1.37-1.76) 1.57 (1.41-1.75)
CAGE 2 (vs. <2) 3.28 (0.44-24.69) too few observations 6.48 (1.53-27.44)
Model 4 (SCORE, binge drinking, and CAGE)
SCORE 5% (vs. <5%) 1.37 (1.14-1.64) 1.55 (1.37-1.75) 1.58 (1.42-1.76)
Binge drinking (vs. no
binge drinking)
1.36 (0.15-12.70) too few observations 3.54 (0.57-22.08)
CAGE 2 (vs. <2) 2.91 (0.31-27.21) too few observations 3.53 (0.56-22.14)
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Table A8.2.1. Continuous low-risk SCORE, binge drinking, CAGE, and atherosclerotic
CVD mortality in HAPIEE men and women: Hosmer-Lemeshow (HL) test results
Czech Republic Poland Russia
HL χ2 (p)
Men
Model 1
(SCORE only)
6.92
(0.3286)
7.13
(0.3089)
36.52
(<0.0001)
Model 2 (SCORE
and binge drinking)
6.88
(0.3318)
5.15
(0.5250)
36.28
(<0.0001)
Model 3 (SCORE
and CAGE)
7.46
(0.4874)
9.51
(0.1470)
36.29
(<0.0001)
Model 4 (SCORE,
binge drinking, and
CAGE)
12.97
(0.0435)
9.85
(0.1311)
35.06
(<0.0001)
Women
Model 1
(SCORE only)
5.90
(0.1168)
2.56
(0.4643)
3.00
(0.5586)
Model 2 (SCORE
and binge drinking)
6.61
(0.0856)
2.58
(0.4615)
5.45
(0.2443)
Model 3 (SCORE
and CAGE)
4.32
(0.2293)
3.42
(0.3315)
2.87
(0.5792)
Model 4 (SCORE,
binge drinking, and
CAGE)
6.97
(0.1375)
3.42
(0.3316)
6.87
(0.1432)
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Table A8.2.2. Continuous high-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7818 0.7187 0.7387
R2 0.4249
(0.1950, 0.6748)
0.3511
(0.1053, 0.6352)
0.3154
(0.1865, 0.4558)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.7877 0.7143 0.7399
R2 0.4130
(0.1950, 0.6628)
0.3399
(0.1023, 0.6456)
0.3113
(0.1905, 0.4549)
LRT p value 0.7497 0.6379 0.7000
IDI (p value) -0.00002
(0.94580)
0.00044
(0.11387)
0.00032
(0.36090)
Model 3 (SCORE and CAGE)
Harrell’s C 0.7844 0.7225 0.7387
R2 0.4121
(0.2146, 0.6543)
0.3532
(0.1146, 0.6749)
0.3109
(0.1823, 0.4711)
LRT p value 0.8543 0.2838 0.7992
IDI (p value) -0.00015
(0.50627)
0.00047
(0.60970)
0.00007
(0.68504)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.7915 0.7246 0.7395
R2 0.4006
(0.1896, 0.6728)
0.3599
(0.1220, 0.6564)
0.3066
(0.1939, 0.4706)
LRT p value 0.9159 0.3838 0.9207
IDI (p value) -0.00023
(0.46984)
0.00134
(0.22561)
0.00032
(0.36797)
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Table A8.2.3. Continuous high-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7348 0.8032 0.7983
R2 0.2192
(0.0140, 0.4860)
0.6890
(0.1618, 0.9412)
0.6003
(0.3665, 0.8008)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.7428 0.8041 0.8229
R2 0.1989
(0.0169, 0.4910)
0.6742
(0.1923, 0.9298)
0.6246
(0.4362, 0.8149)
LRT p value 0.5658 too few observations 0.0425
IDI (p value) 0.00001
(0.96040)
-0.00002
(0.58128)
0.00068
(0.36079)
Model 3 (SCORE and CAGE)
Harrell’s C 0.7298 0.8046 0.8158
R2 0.2178
(0.0000, 0.5649)*
0.6752
(0.1657, 0.9353)
0.6249
(0.3973, 0.8126)
LRT p value 0.3293 0.6497 0.0417
IDI (p value) 0.00063
(0.49880)
-0.00004
(0.47808)
0.00100
(0.26596)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.7406 0.8051 0.8263
R2 0.1895
(0.1451, 0.5896)
0.6587
(0.1123, 0.9299)
0.6292
(0.4373, 0.8258)
LRT p value 0.5993 0.8633 0.0574
IDI (p value) 0.00049
(0.52914)
-0.00011
(0.37014)
0.00121
(0.26346)
* Lower confidence limits calculated as negative were regarded as 0.
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Table A8.2.4. Dichotomous low-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7266 0.6445 0.6925
R2 0.4340
(0.1907, 0.6771)
0.1808
(0.0111, 0.4400)
0.3364
(0.2142, 0.4794)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.7358 0.6469 0.7044
R2 0.4223
(0.2038, 0.6780)
0.1646
(0.0000, 0.4480)*
0.3350
(0.2139, 0.4762)
LRT p value 0.7536 0.9085 0.4082
IDI (p value) -0.00008
(0.76183)
-0.00001
(0.96207)
0.00027
(0.59758)
Model 3 (SCORE and CAGE)
Harrell’s C 0.7338 0.6589 0.6967
R2 0.4246
(0.1836, 0.6728)
0.1855
(0.0126, 0.4832)
0.3336
(0.2124, 0.4707)
LRT p value 0.6006 0.2573 0.5252
IDI (p value) 0.00025
(0.62409)
0.00067
(0.33253)
0.00022
(0.52834)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.7380 0.6701 0.7045
R2 0.4144
(0.1946, 0.6848)
0.1734
(0.0016, 0.4611)
0.3309
(0.2160, 0.4879)
LRT p value 0.7791 0.4610 0.6618
IDI (p value) 0.00022
(0.76092)
0.00062
(0.30812)
0.00035
(0.51307)
* Lower confidence limits calculated as negative were regarded as 0.
342
Table A8.2.5. Dichotomous low-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.5216 0.6415 0.6656
R2 0.0063
(0.000, 0.2928)*
0.3668
(0.0000, 0.7891)*
0.3905
(0.1370, 0.6363)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.5372 0.6440 0.6883
R2 0.0193
(0.0000, 0.3396)*
0.3434
(0.0000, 0.7822)*
0.4154
(0.1707, 0.6778)
LRT p value 0.6213 0.6365 0.0696
IDI (p value) 0.00006
(0.77643)
0.00004
(0.02697)
0.00086
(0.32862)
Model 3 (SCORE and CAGE)
Harrell’s C 0.5438 0.6449 0.6826
R2 0.0017
(0.0000, 0.3952)*
0.3453
(0.0000, 0.7789)*
0.4150
(0.1832, 0.6873)
LRT p value 0.3525 0.5940 0.0714
IDI (p value) 0.00033
(0.55147)
0.00003
(0.02704)
0.00078
(0.33912)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.5617 0.6467 0.6946
R2 0.0300
(0.0000, 0.3824)*
0.3183
(0.0000, 0.7674)*
0.4220
(0.1844, 0.6857)
LRT p value 0.6281 too few observations 0.0816
IDI (p value) 0.00029
(0.55086)
0.00003
(0.02718)
0.00155
(0.28912)
* Lower confidence limits calculated as negative were regarded as 0.
343
Table A8.2.6. Continuous low-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE men:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7891 0.7220 0.7406
R2 0.4217
(0.2193, 0.6617)
0.3520
(0.0951, 0.6170)
0.3143
(0.1855, 0.4521)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.7930 0.7173 0.7424
R2 0.4098
(0.1873, 0.6617)
0.3407
(0.0998, 0.6539)
0.3103
(0.1861, 0.4564)
LRT p value 0.7508 0.6479 0.6855
IDI (p value) 0.00002
(0.94933)
0.00043
(0.10636)
0.00035
(0.34028)
Model 3 (SCORE and CAGE)
Harrell’s C 0.7919 0.7260 0.7408
R2 0.4090
(0.2117, 0.6690)
0.3547
(0.1084, 0.6473)
0.3099
(0.1812, 0.4691)
LRT p value 0.8380 0.2749 0.7853
IDI (p value) -0.00016
(0.47032)
0.00045
(0.62326)
0.00009
(0.63340)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.7974 0.7298 0.7423
R2 0.3975
(0.2010, 0.6528)
0.3512
(0.0975, 0.6903)
0.3056
(0.1926, 0.4575)
LRT p value 0.9108 0.3786 0.9121
IDI (p value) -0.00020
(0.50788)
0.00130
(0.22622)
0.00036
(0.34481)
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Table A8.2.7. Continuous low-risk SCORE, binge drinking, CAGE, and atherosclerotic CVD mortality in HAPIEE women:
Harrell’s C, Royston’s R2, LRT p value, and IDI
Czech Republic Poland Russia
Model 1 (SCORE only)
Harrell’s C 0.7406 0.8233 0.7953
R2 0.2281
(0.0259, 0.4985)
0.7177
(0.2813, 0.9482)
0.5904
(0.3361, 0.7859)
Model 2 (SCORE and binge drinking)
Harrell’s C 0.7512 0.8241 0.8178
R2 0.2078
(0.0235, 0.5271)
0.7039
(0.2120, 0.9457)
0.6142
(0.3938, 0.8063)
LRT p value 0.5667 0.7071 0.0460
IDI (p value) -0.00001
(0.98969)
-0.00004
(0.41919)
0.00065
(0.40645)
Model 3 (SCORE and CAGE)
Harrell’s C 0.7465 0.8245 0.8080
R2 0.2269
(0.0124, 0.5710)
0.7048
(0.1697, 0.9356)
0.6142
(0.4070, 0.8021)
LRT p value 0.3267 0.6566 0.0462
IDI (p value) 0.00063
(0.50396)
-0.00006
(0.40785)
0.00112
(0.26535)
Model 4 (SCORE, binge drinking, and CAGE)
Harrell’s C 0.7446 0.8250 0.8202
R2 0.1988
(0.0247, 0.6160)
0.6896
(0.1800, 0.9367)
0.6184
(0.4224, 0.8250)
LRT p value 0.5977 0.8684 0.0635
IDI (p value) 0.00048
(0.54117)
-0.00014
(0.34798)
0.00137
(0.28866)
